Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K
(Mark One)
☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023
OR
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
COMMISSION FILE NUMBER: 001-36279
CARA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of
incorporation or organization)
400 Atlantic Street
Suite 500
Stamford, Connecticut
(Address of principal executive offices)
75-3175693
(I.R.S. Employer
Identification No.)
06901
(Zip Code)
Registrant’s telephone number, including area code: (203) 406-3700
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Common Stock, par value $0.001 per share
Trading Symbol
CARA
Name of each exchange on which registered
The Nasdaq Stock Market LLC
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ⌧
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ⌧
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes ⌧ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§
232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ⌧ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth
company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
Non-accelerated filer
☐
☒
Accelerated filer
Smaller Reporting Company
Emerging growth company
☐
☒
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial
reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒
Indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.
Yes ☐ No ⌧
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the
registrant’s executive officers during the relevant recovery period pursuant to § 240.10D-1(b). Yes ☐ No ⌧
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ⌧
The aggregate market value of the registrant’s Common Stock (the only common equity of the registrant) held by non-affiliates, based on the closing sales price of the
stock on the Nasdaq Global Market for the last business day of the registrant’s most recently completed second fiscal quarter, was $130,943,146. For purposes of this calculation,
shares of common stock held by directors and officers and their affiliated entities at June 30, 2023 were excluded. Exclusion of shares held by any person should not be
construed to indicate that the person possesses the power, direct or indirect, to direct or cause the direction of the management or policies of the registrant, or that the person is
controlled by or under common control with the registrant.
The number of shares outstanding of the registrant’s Common Stock, par value $0.001 per share, as of March 1, 2024 was 54,656,413.
Portions of the registrant’s Proxy Statement for its 2024 Annual Meeting of Stockholders, to be filed with the Securities and Exchange Commission no later than 120
days after December 31, 2023, are incorporated by reference in Part III of this Annual Report on Form 10-K.
Documents Incorporated By Reference
Table of Contents
CARA THERAPEUTICS, INC.
2023 ANNUAL REPORT ON FORM 10-K
TABLE OF CONTENTS
Item 1.
Business.
Item 1A.
Risk Factors.
Item 1B.
Unresolved Staff Comments.
Item 1C.
Cybersecurity.
Item 2.
Properties.
Item 3.
Legal Proceedings.
Item 4.
Mine Safety Disclosures.
PART I
PART II
Item 5.
Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity
Securities.
Item 6.
[Reserved]
Item 7.
Management’s Discussion and Analysis of Financial Condition and Results of Operations.
Item 7A.
Quantitative and Qualitative Disclosures About Market Risk.
Item 8.
Financial Statements and Supplementary Data.
Item 9.
Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.
Item 9A.
Controls and Procedures.
Item 9B.
Other Information.
Item 9C.
Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.
Item 10.
Directors, Executive Officers and Corporate Governance.
Item 11.
Executive Compensation.
PART III
Item 12.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.
Item 13.
Certain Relationships and Related Transactions, and Director Independence.
Item 14.
Principal Accountant Fees and Services.
PART IV
Item 15.
Exhibit and Financial Statement Schedules.
Item 16.
Form 10-K Summary.
PAGE
4
23
61
62
63
63
63
64
65
66
87
89
145
145
146
146
146
146
146
146
146
147
150
Table of Contents
PART I
In this Annual Report on Form 10-K, the terms “we,” “us” and “our” refer to Cara Therapeutics, Inc.
Cautionary Note Regarding Forward-Looking Statements
This Annual Report on Form 10-K contains forward-looking statements, within the meaning of the Private Securities
Litigation Reform Act of 1995, that involve substantial risks and uncertainties. The forward-looking statements are
contained principally in the sections of this Annual Report on Form 10-K titled “Risk Factors,” “Management’s Discussion
and Analysis of Financial Condition and Results of Operations” and “Business,” but are also contained elsewhere in this
Annual Report on Form 10-K. In some cases, you can identify forward-looking statements by the words “aim”,
“anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,”
“plan,” “predict,” “project,” “potential,” “seek,” “should,” “will,” or “would,” and or the negative of these terms, or other
comparable terminology intended to identify statements about the future. These statements involve known and unknown
risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be
materially different from the information expressed or implied by these forward-looking statements. Although we believe
that we have a reasonable basis for each forward-looking statement contained in this Annual Report on Form 10-K, we
caution you that these statements are based on a combination of facts and factors currently known by us and our
expectations of the future, about which we cannot be certain.
The forward-looking statements in this Annual Report on Form 10-K include, among other things, statements about:
● our plans to develop and commercialize oral difelikefalin for the treatment of pruritus associated with notalgia
paresthetica, or NP, and any potential future product candidates;
● our ability to execute on our strategic plans, including efforts to focus our resources on the development of oral
difelikefalin for the treatment of chronic pruritus associated with NP and significantly reduce our operating
expenses;
● the timing of our clinical trials and reporting of our results from these trials, including our clinical trial programs
for oral difelikefalin in chronic pruritus associated with NP;
● the potential results of ongoing and planned preclinical studies and clinical trials and future regulatory and
development milestones for our product candidates;
● the performance of third-party manufacturers, clinical research organizations, or CROs, and other vendors;
● the size and growth of the potential markets for pruritus management, including the treatment of chronic pruritus
associated with NP;
● the rate and degree of market acceptance of any other future approved indications or products;
● our ability to obtain and maintain additional regulatory approval of our product candidate, and the labeling under
any approval we may obtain;
● the anticipated use of Enteris Biopharma, Inc.’s, or Enteris’s, Peptelligence® technology to develop, manufacture
and commercialize oral difelikefalin;
● our ability to establish additional collaborations for our product candidates;
● the continued service of our key scientific or management personnel;
1
Table of Contents
● our ability to establish commercialization and marketing capabilities for any approved products;
● regulatory developments in the United States and foreign countries;
● our ability to obtain and maintain coverage and adequate reimbursement from third-party payers and governments
for any other future approved indications or products;
● our planned use of our cash and cash equivalents and marketable securities and the clinical milestones we expect
to fund with such proceeds;
● the accuracy of our estimates regarding expenses, future revenues and capital requirements;
● our ability to obtain funding for our operations;
● our ability to obtain and maintain intellectual property protection for our product candidates and our ability to
operate our business without infringing on the intellectual property rights of others;
● our ability to maintain proper and effective internal controls, especially due to our high dependence on CSL Vifor
for timely and accurate information;
● the success of competing drugs that are or may become available;
● the potential effects of any public pandemics or future global health crises, geopolitical tensions and
macroeconomic conditions on our business, operations and clinical development and regulatory timelines and
plans; and
● the performance of our current and future collaborators and licensees, including CSL Vifor, Maruishi
Pharmaceuticals Co. Ltd., or Maruishi, and Chong Kun Dang Pharmaceutical Corp., or CKDP, as well as sub-
licensees, including Winhealth Pharma and Kissei Pharmaceutical Co. Ltd., or Kissei, and our ability to maintain
such collaborations.
You should refer to Part I Item 1A. “Risk Factors” of this Annual Report on Form 10-K for a discussion of material
factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking
statements. As a result of these factors, we cannot assure you that the forward-looking statements in this Annual Report on
Form 10-K will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy
may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these
statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any
specified time frame or at all. We undertake no obligation to publicly update any forward-looking statements, whether as a
result of new information, future events or otherwise, except as required by law.
You should read this Annual Report on Form 10-K and the documents that we reference in this Annual Report on
Form 10-K and have filed as exhibits to this Annual Report on Form 10-K completely and with the understanding that our
actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by
these cautionary statements.
Risk Factors Summary
Investing in our common stock involves a high degree of risk because our business is subject to numerous risks and
uncertainties, as fully described below. The principal factors and uncertainties that make investing in our common stock
risky include, among others:
● We are substantially dependent on the success of oral difelikefalin for the treatment of NP, which is our only
current product candidate. If we are unable to successfully complete clinical development, obtain regulatory
2
Table of Contents
approvals and successfully commercialize oral difelikefalin, or experience significant delays in doing so, our
business will be materially harmed.
● We recently engaged in a strategic prioritization of our pipeline. We may be unable to successfully execute our
strategic prioritization plans, including efforts to reduce our costs.
● We rely, and expect to continue to rely, on third parties to conduct our preclinical and clinical studies, and those
third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials.
● If the manufacturers upon whom we rely fail to produce our product candidate or any potential future product in
the volumes that we require on a timely basis, or to comply with stringent regulations applicable to
pharmaceutical drug manufacturers, we may face delays in the development of our product candidate.
● Even if we obtain additional regulatory approvals for our product candidate or any potential future product
candidate, they may never be successfully launched or become profitable, in which case our business, prospects,
operating results and financial condition may be materially harmed.
● If we or our collaborators are unable to establish sufficient and effective marketing and sales capabilities, or if we
are unable to enter into or maintain agreements with third parties to market and sell our products and product
candidate, if it is approved, we may be unable to generate product revenues.
● Any collaboration arrangements that we enter into in the future may not be successful, which could adversely
affect our ability to develop and commercialize our product candidate.
● We face significant competition from other pharmaceutical and biotechnology companies, academic institutions,
government agencies and other research and development organizations. Our operating results will suffer if we
fail to compete effectively.
● If we experience continuous delays or difficulties in the enrollment of patients in clinical trials, our receipt of
necessary regulatory approvals could be delayed or prevented.
● The regulatory approval processes of the U.S. Food and Drug Administration, or FDA, and comparable foreign
authorities are lengthy, time consuming and inherently unpredictable. If we are not able to obtain, or if there are
delays in obtaining, required additional regulatory approvals, we will not be able to commercialize our product
candidate as expected, and our ability to generate revenue will be materially impaired.
● Our product candidate may have serious adverse events or undesirable side effects that may limit dosing during
development, or delay or prevent regulatory or marketing approval.
● We have incurred significant losses since inception, and we anticipate that we may incur losses in the foreseeable
future. We may never achieve profitability.
● Failure or perceived failure to comply with laws, regulations, contracts, notices, and other obligations related to
data privacy and security (including security incidents) could harm our business. Compliance or the actual or
perceived failure to comply with such obligations could increase our business costs, limit adoption of our
products, and otherwise negatively affect our operating results and business.
● We may need to license certain intellectual property from third parties, and such licenses may not be available or
may not be available on commercially reasonable terms.
3
Table of Contents
Item 1. Business.
Overview
We are a development-stage biopharmaceutical company driving innovation in sizable, yet underserved diseases and
conditions. Specifically, we are focused on leading a new treatment paradigm to improve the lives of patients suffering
from chronic pruritus. We are developing an oral formulation of difelikefalin, a selective, predominantly peripherally
acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with
Notalgia Paresthetica, a common, underdiagnosed neuropathy affecting the upper back. We are conducting a Phase 2/3
program with topline results of the dose-finding portion expected in the third quarter of 2024. We also developed an IV
formulation of the same molecule, which is approved for the treatment of moderate-to-severe pruritus associated with
advanced chronic kidney disease in adults undergoing hemodialysis in the United States, EU and multiple other countries.
The IV formulation is out-licensed worldwide.
Chronic Pruritus – Overview
Pruritus, or itch, is defined as an unpleasant sensation that provokes the desire to scratch, which can range from a
mild annoyance to an intractable, disabling condition. Chronic pruritus, defined as an itch lasting longer than 6 weeks, has
a variety of etiologies including inflammatory, metabolic and neuropathic, the latter being caused by direct damage to the
nerve itself. Chronic pruritus represents a significant unmet need with few if any robustly efficacious or pruritus-specific
treatment options. Because chronic pruritus is often not amenable to currently available treatments, it can result in a
debilitating course, including the development of symptoms of depression, global distress, and impairment of sleep.
Multiple studies have demonstrated this significant impact of chronic pruritus on health-related quality of life, some
suggesting an impact similar to chronic pain. In contrast to pain, chronic pruritus is often under-reported by patients and
therefore under-treated by providers. Overall, it is estimated that about one in every eight people globally suffer from
chronic pruritus.
Chronic Neuropathic Pruritus - Overview
Chronic neuropathic pruritus is a common subcategory of chronic pruritus representing approximately 8% of all
chronic pruritus cases. Chronic neuropathic pruritus can be caused by local nerve fiber compression (e.g., notalgia
paresthetica, brachioradial pruritus) or localized or generalized nerve fiber degeneration (e.g., small fiber neuropathy)
affecting different neuronal structures in the peripheral or central nervous system. Chronic neuropathic pruritus can be
divided into localized and generalized forms with localized forms occurring on almost any area of the body (e.g., notalgia
paresthetica affecting the upper back). Chronic neuropathic pruritus is often accompanied by sensory damage experienced
as pain, allodynia, paresthesia, allokinesis, hyperesthesia, or hypothesia. There are no approved treatments for chronic
neuropathic pruritus and off-label use of other therapies, frequently treatments indicated for neuropathic pain, are mostly
ineffective or associated with significant side effects. Hence, there is a significant unmet need for an effective, safe, and
well tolerated treatment for chronic neuropathic pruritus.
Role of Difelikefalin in Chronic Pruritus
Recent advancements in the understanding of the biology of pruritus have led to the discovery of novel targets in
the central nervous system, or CNS, and a unique pathway central to chronic pruritus. Pruritus, commonly referred to as
itch, originates in the epidermis and dermal–epidermal junction and is transmitted by itch-selective sensory neuron C
fibers, or pruriceptors. Some of these fibers are sensitive to histamine while others are not, and there is evidence for
histamine-insensitive C fibers that are activated by numerous itch-inducing substances or pruritogens, many of which
initiate signals through interaction with specific G-protein-coupled receptors. In addition, there is increasing evidence for
the differential involvement of these systems in various forms of itch which may involve disease-specific pruritogens.
Different peripheral cell types express kappa opioid receptors, or KORs, which can regulate the release of these
pruritogenic substances, while the KORs on C fibers are thought to regulate their response to these pruritogens. Because
KORs are expressed in peripheral tissues, there is a potential to modulate itch signals peripherally without impacting the
central KORs. The itch-sensitive sensory nerve fibers transmit signals to the cell bodies in the dorsal root ganglia (that
4
Table of Contents
also have KORs), which send fibers to enter the spinal cord. Itch signals then ascend via the spinothalamic tract to multiple
brain areas for sensory processing and interactions with cognitive and other systems. Additionally, the activation of kappa
receptors via an agonist is thought to reduce itching by functionally counteracting increased mu opioid receptor activity
which is suggested to be associated with some chronic forms of pruritus. Activation of the mu opioid receptor in the brain
and in the peripheral nerve endings results in itching while non-selective mu opioid antagonists can inhibit itching. KOR
stimulation inhibits the effects of mu receptor activation both centrally and peripherally.
Our novel compound, difelikefalin, is a highly selective, predominantly peripherally acting KOR agonist. Its design
includes specific characteristics that limit entry into the CNS. As a KOR agonist, difelikefalin’s mechanism of action turns
off the itch sensation by acting on the peripheral neurons responsible for sensing pruritus. In other words, difelikefalin
disrupts the itch sensation of chronic pruritus at the nerve level. In addition, difelikefalin acts on KORs expressed on a
range of activated immune cells to subsequently block the release of pruritogenic cytokines. A central hypothesis driving
our development work is that by acting on peripheral nerves that sense pruritus, difelikefalin may be able to address
pruritus regardless of the underlying disease.
Our Strategy
Cara Therapeutics is a development stage biotechnology company with the mission to drive innovation in sizable, yet
underserved diseases and conditions. We are focused on chronic pruritus, a condition associated with many diseases across
multiple therapeutic areas. Due to its mechanism of action, our unique compound difelikefalin, a selective, predominantly
peripherally acting, non-scheduled Kappa opioid receptor agonist, has broad applicability for the treatment of chronic
pruritus.
We are developing an oral formulation of difelikefalin for pruritus associated with Notalgia Paresthetica (NP). NP is
a common but under-recognized and consequently undertreated neuropathic disorder characterized by chronic pruritus
affecting the upper back. NP is challenging to manage and there are currently no FDA-approved therapies or therapies in
development. NP represents a sizable patient population with an estimated addressable market of 650,000 patients in
the United States who are under the care of a healthcare provider, not accounting for those who are undiagnosed. We are
conducting a Phase 2/3 program with the intent to develop the first treatment indicated for pruritus associated NP.
We believe our strategy to focus on NP, which is anchored in the favorable preclinical and clinical profile and benefit
of difelikefalin, will lead to sustainable, long-term growth for our company.
5
Table of Contents
Our Product Portfolio
Product Candidate
Indication
Oral difelikefalin
Pruritus NP
KORSUVA
(difelikefalin)
injection/Kapruvia
Pruritus CKD -
Hemodialysis
Status
Phase 2/3 KOURAGE 1
ongoing
Phase 3 KOURAGE 2
planned
Approved in the U.S.
(08/2021)
Approved in EU incl. UK
(04/2022)
Approved in Japan (09/2023)
Other approvals: Switzerland,
Canada, Singapore, Australia,
Kuwait, Israel, UAE, Saudi
Arabia
Next Milestone
Phase 2
KOURAGE 1
Topline 3Q2024
Commercialization Rights
Cara (Worldwide excl. South
Korea)
CSL Vifor (Worldwide excl.
Japan and South Korea)*;
Maruishi (Japan);
CKDP (South Korea)
*We are party to two collaborations for the commercialization of KORSUVA (difelikefalin) injection/Kapruvia with a joint venture between CSL Vifor and
Fresenius Medical Care. In this Annual Report, unless the context otherwise requires, “CSL Vifor” refers to CSL Vifor and its affiliated entities, including,
where applicable, the joint venture.
Oral Difelikefalin, Our Development Stage Product Candidate
Notalgia Paresthetica and Associated Pruritus
Notalgia paresthetica (NP) is a common chronic cutaneous neuropathy primarily characterized by localized pruritus
in the upper back and associated dysesthesias, including sensations of pain, numbness, and tingling. While the exact
pathophysiology remains unknown, the sensory neuropathy characteristic of NP is thought to result from spinal nerve
entrapment possibly caused by degenerative changes in the spine or musculoskeletal compression. The symptomatic area
may be associated with a hyperpigmented patch, most often secondary to chronic scratching and rubbing to relieve the
discomfort.
There are no FDA-approved treatments and the management of NP is challenging as conventional treatments for
pruritus, such as antihistamines and topical steroids, are largely ineffective. It is estimated that chronic pruritus affects up
to 13% of the U.S. population. NP falls within the subcategory of chronic neuropathic pruritus which comprises
approximately 8% of all cases of chronic pruritus.
We estimate that approximately 650,000 adult patients with NP associated pruritus are in the care of a healthcare
provider, not accounting for mis- or undiagnosed patients.
Oral Difelikefalin for Treatment of Moderate-to-Severe Pruritus Associated with Notalgia Paresthetica (NP)
In June 2022, we announced positive top-line results from the proof-of-concept Phase 2 KOMFORT trial of oral
difelikefalin for the treatment of pruritus in patients with NP.
KOMFORT was a Phase 2 randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and
safety of oral difelikefalin for moderate-to-severe pruritus in 125 adult patients with NP and moderate-to-severe pruritus.
Patients were randomized to receive oral difelikefalin 2 mg twice daily (BID) vs. matching placebo for eight weeks
followed by a 4-week open-label active extension period and follow-up visit approximately 14 days after the last dose of
the study drug.
6
Table of Contents
KOMFORT’s primary efficacy endpoint was the change from baseline in the weekly mean of the daily 24-hour worst
itch NRS score at week 8 of the treatment period. Patients treated with oral difelikefalin achieved the primary endpoint
(-4.0 difelikefalin vs. -2.4 placebo, p=0.001) with statistically significant improvement observed as early as Day 1 and
sustained through Week 8.
Other endpoints included a ≥4-point improvement in worst itch NRS, complete response in worst itch NRS, and
safety assessments. A statistically significantly greater proportion of patients treated with oral difelikefalin achieved a ≥4-
point improvement in worst itch NRS score at Week 8 vs. placebo (41% difelikefalin vs. 18% placebo, p=0.007). In
addition, oral difelikefalin met the complete response endpoint, defined as a worst itch NRS score of 0 or 1 for 70% of the
daily non-missing worst itch NRS scores for the week. At Week 8, a significantly greater proportion of patients receiving
oral difelikefalin vs. placebo achieved a complete response (22% difelikefalin vs. 5% placebo, p<0.01).
Oral difelikefalin was generally well tolerated, with all adverse events, or AEs, in difelikefalin-treated patients
reported as mild or moderate in severity. Nausea, headache, dizziness, constipation, and increased urine output were more
commonly reported in patients on difelikefalin.
In November 2022, we had a positive interaction with the FDA leading to the initiation of a Phase 2/3 program for
the treatment of chronic pruritus associated with NP. In February 2023, the results of our KOMFORT Phase 2 trial were
published in the New England Journal of Medicine.
In the first quarter of 2023, we initiated a Phase 2/3 program for the treatment of moderate-to-severe pruritus in NP.
The Phase 2/3 program for difelikefalin in NP will comprise two studies: KOURAGE 1 and KOURAGE 2. The
KOURAGE 1 study will be composed of two parts: Part A and Part B.
Part A of KOURAGE 1, the dose finding portion of the study, is a double-blind, placebo-controlled, 8-week study. In
the first quarter of 2024, we completed enrollment with 214 patients who were randomized equally to four arms (0.25 mg
BID, 1.0 mg BID, 2.0 mg BID, placebo BID). Part A is not powered for statistical significance. We expect to have topline
efficacy and safety results from KOURAGE 1 Part A in the third quarter of 2024. This readout will provide key
information, specifically the dose and the sample size, to initiate the pivotal Phase 3 portions of the program - Part B of
KOURAGE 1 and the second study KOURAGE 2.
Part B of KOURAGE 1 and KOURAGE 2, the pivotal studies, will be identical in design. They will likely be
double-blind, placebo-controlled, 8-week studies with patients allowed to roll over into open label 52-week extensions.
Patients will be randomized 1:1 to either difelikefalin or matching placebo. The primary endpoint will likely be the
proportion of patients with a ≥4-point improvement at Week 8 from baseline in the worst itch NRS.
KOURAGE 1 and KOURAGE 2 will include adult patients with NP who have had chronic pruritus of moderate-to-
severe intensity for ≥6 months (worst itch NRS of ≥ 5).
We expect to release final topline results from the first pivotal study KOURAGE 1 Part B by the end of 2025 with
the second pivotal study KOURAGE 2 results in early 2026.
KORSUVA (difelikefalin) injection – Our Commercial Stage Product
Overview
We have out-licensed to CSL Vifor the commercialization of KORSUVA injection/Kapruvia in dialysis patients
with advanced CKD-aP worldwide, excluding Japan (licensed to Maruishi/sub-licensee Kissei), and South Korea (licensed
to CKDP).
On August 23, 2021, KORSUVA injection was approved by the FDA for the treatment of moderate-to-severe
pruritus associated with advanced CKD in adults undergoing hemodialysis. In December 2021, CMS granted Transition
Drug Add-on Payment Adjustment, or TDAPA, to KORSUVA injection in the anti-pruritic functional category. TDAPA
went into effect on April 1, 2022 for a minimum of two years. The commercial launch of KORSUVA injection
7
Table of Contents
commenced in April 2022 and we began recording the associated profit-sharing revenues in the second quarter of 2022. On
October 27, 2023, CMS published the final CY 2024 rule, which finalized the post-TDAPA add-on payment as proposed in
the draft CY 2024 rule. Under the final rule, TDAPA drugs in existing functional categories will receive a post-TDAPA
add-on payment set at 65 percent of the total trailing 12-months expenditure levels for the given renal dialysis drug or
biological product. The post-TDAPA add-on payment will be applied to all ESRD PPS payments and paid for 3 years,
adjusted annually. The add-on payments for KORSUVA injection will commence on April 1, 2024. The anticipated
unfavorable CMS reimbursement codified in the final CY2024 rule resulted in a lack of sequential revenues growth for
KORSUVA injection since its launch. For the years ended December 31, 2023 and 2022, CSL Vifor recorded net sales of
KORSUVA injection in the United States of approximately $26.5 million and $35.0 million, respectively, and we recorded
associated collaborative revenue of $12.4 million and $16.6 million, respectively, which represented our share of the profit
from these sales. We expect no meaningful revenue contribution from KORSUVA injection post its TDAPA expiration.
In April 2022, the European Commission granted a marketing authorization to difelikefalin injection under the brand
name Kapruvia for the treatment of moderate-to-severe pruritus associated with advanced CKD in adult hemodialysis
patients. The marketing authorization approves Kapruvia for use in all member states of the European Union, or EU, as
well as Iceland, Liechtenstein, and Norway. Difelikefalin injection was also approved in the United Kingdom, or UK,
(04/2022) and Switzerland (08/2022) under the brand name Kapruvia as well as Singapore (08/2022), Canada (08/2022),
Australia (11/2022), UAE (01/2023), Kuwait (05/2023), Israel (06/2023) and Saudi Arabia (01/2024) under the brand name
KORSUVA injection. For the years ended December 31, 2023 and 2022, we recorded royalty revenue of approximately
$415,000 and $72,000 respectively, which represented our royalties on net sales of Kapruvia and KORSUVA injection.
During the fourth quarter of 2023, we entered into a Purchase and Sale Agreement with HCRX Investments Holdco, L.P.
and Healthcare Royalty Partners IV, L.P., or collectively HCR, where we sold our future royalties and milestones for
Kapruvia and KORSUVA injection to HCR. For the period of October 1, 2023 through December 31, 2023, we recorded
other revenue of $699,000, of which approximately $284,000 related to royalties to be paid to HCR under this agreement
(see “Royalty Purchase and Sale Agreement” below).
We have out-licensed to Maruishi and its sub-licensee Kissei the commercialization of KORSUVA injection in
Japan. In September 2023, Maruishi received manufacturing and marketing approval from Japan’s Ministry of Health,
Labour and Welfare for KORSUVA IV Injection Syringe for the treatment of pruritus in hemodialysis patients. In
conjunction with the approval, we earned a $1.4 million milestone payment per the terms of the licensing agreement during
the year ended December 31, 2023. During the fourth quarter of 2023, we entered into the Purchase and Sale Agreement
with HCR where we sold our future royalties and milestones for KORSUVA in Japan to HCR. For the period of October 1,
2023 through December 31, 2023, we recorded other revenue of $699,000, of which approximately $415,000 related to
royalties and milestones to be paid to HCR under this agreement (see “Royalty Purchase and Sale Agreement” below).
KORSUVA Injection U.S. Commercialization
In April 2022, our partner CSL Vifor initiated the commercialization of KORSUVA injection in the United States.
The launch was initially driven by independent and mid-size dialysis organizations coupled with product stocking at the
wholesaler level. In the third quarter of 2022, large dialysis organizations, or LDOs, came on-line driving a significant
quarter-to-quarter increase in order volume from the wholesaler. This stocking at the clinic level, particularly from
Fresenius Medical Care (FMC), resulted in significant subsequent quarterly revenue fluctuations. In the third quarter of
2023, FMC decided to reallocate all remaining clinic level inventory within its network of clinics resulting in limited
revenues in the fourth quarter of 2023. During the years ended December 31, 2023 and 2022, KORSUVA injection
generated net sales of approximately $26.5 million and $35.0 million, respectively, and we recorded collaborative revenue
of $12.4 million and $16.6 million, respectively, which represented our share of the profit from sales of KORSUVA
injection.
8
Table of Contents
KORSUVA Injection and Kapruvia Revenue and Other Metrics
We generate revenue from our lead products KORSUVA injection and Kapruvia primarily through our collaboration
agreements with CSL Vifor:
● Collaborative revenue from our share of the profit generated by KORSUVA injection sales in the United States.
For the years ended December 31, 2023 and 2022, we recorded collaborative revenue of $12.4 million and $16.6
million, respectively.
● Commercial supply revenue from our sales of commercial product to CSL Vifor, which is subsequently sold to
wholesalers. For the years ended December 31, 2023 and 2022, we recorded commercial supply revenue of $5.8
million and $10.2 million, respectively.
Royalty revenue in conjunction with the launch of Kapruvia. For the years ended December 31, 2023 and 2022, we
recorded approximately $415,000 and $72,000, respectively, which represented royalty payments earned by us.
During the fourth quarter of 2023, we entered into the Purchase and Sale Agreement with HCR where we sold our
royalties for Kapruvia and KORSUVA injection to HCR. For the period of October 1, 2023 through December 31, 2023,
we recorded other revenue of $699,000, of which approximately $284,000 related to CSL Vifor royalties and
approximately $415,000 related to Maruishi royalties to be paid to HCR under this agreement (see “Royalty Purchase and
Sale Agreement” below).
● Sales-based or regulatory milestone payments, which could be earned in the future in accordance with certain
licensing agreements. For the year ended December 31, 2023, we earned regulatory milestone revenue of $1.4
million related to the manufacturing and marketing approval in Japan under the Maruishi Agreement, but we did
not record any sales-based milestone revenue.
Additional metrics that we have reported in the past:
● Net sales of KORSUVA injection in the United States. This amount is the net sales amount recorded by CSL
Vifor to reflect shipments of KORSUVA injection vials from CSL Vifor to wholesalers. For the years ended
December 31, 2023 and 2022, CSL Vifor recorded net sales of KORSUVA injection in the United States of
approximately $26.5 million and $35.0 million, respectively.
● Shipments of KORSUVA injection vials from wholesalers in the United States to the dialysis clinics. 314,100 and
207,096 KORSUVA injection vials were shipped from wholesalers to the dialysis clinics for the years ended
December 31, 2023 and 2022, respectively. Of the vials shipped to the FMC dialysis centers for the year ended
December 31, 2023, a significant portion was reallocated product by FMC within its network of clinics.
Royalty Purchase and Sale Agreement
During the fourth quarter of 2023, we, through our wholly-owned subsidiary Cara Royalty Sub LLC, or Cara Royalty
Sub, entered into the Purchase and Sale Agreement with HCR, or the HCR Agreement, pursuant to which Cara Royalty
Sub sold to HCR certain of its rights to receive future royalties and milestone payments, or the Royalties, due and payable
to Cara Royalty Sub (as our assignee) under our agreements with Maruishi and CSL Vifor, collectively the Covered
License Agreements, in exchange for up to $40.0 million. We have retained all of our right, title and interest in, to and
under the Covered License Agreements that relate to any non-intravenous formulation of difelikefalin.
Under the terms of the HCR Agreement, Cara received an initial payment of $17.5 million less certain transaction
costs in November 2023. In December 2023, we received an additional $20.0 million less certain advisory fees, upon
satisfying the milestone event for pricing of Kapruvia® (difelikefalin) in Germany being approved above a certain
threshold amount per dose. The terms of the HCR Agreement also provide for an additional $2.5 million milestone
payment to Cara Royalty Sub upon achievement of a 2024 sales milestone of KORSUVA in Japan.
9
Table of Contents
The HCR Agreement will automatically expire, and the payment of Royalties to HCR will cease, when HCR has
received payments of Royalties equal to two times the aggregate amount of payments made by HCR under the HCR
Agreement if achieved on or prior to December 31, 2029, or 2.8 times the aggregate amount of payments made by HCR
under the HCR Agreement, if not achieved on or prior to December 31, 2029. In the event of a change of control, Cara
Royalty Sub will pay to HCR an amount equal to 2.8 times the aggregate amount of payments made by HCR less the total
net amounts paid by Cara Royalty Sub to HCR as of the effective date of control. In certain situations, Cara Royalty Sub
would not be obligated to pay the change of control payment to HCR. After the HCR Agreement expires, all rights to
receive the Royalties return to Cara Royalty Sub.
Difelikafilin Development in Pruritus
Difelkefalin, our selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, acts on
the peripheral neurons responsible for sensing pruritus. Given this unique mechanism of action, difelikfelin is thought to
work broadly independent of the origin of itch. To date, we have studied difelikefalin for pruritus associated with systemic,
inflammatory, and neuropathic diseases. The IV formulation is approved in the United States, EU and other countries
around the world for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in
adults undergoing hemodialysis (HD). We have studied the oral formulation at multiple dosage strengths in moderate-to-
severe pruritus associated with advanced kidney disease (5 trials/over 430 patients on DFK), atopic dermatitis (2 trials/over
590 patients on DFK), and notalgia paresthetica (2 trials/over 270 patients on DFK, 1 trial ongoing) with positive efficacy
signals across all completed mono therapy studies. In these studies, oral difelikefalin was generally well tolerated with all
AEs in difelikefalin-treated patients reported as mild or moderate in severity.
In December 2023, we announced the outcome from the dose-finding Part A of the KIND 1 study evaluating the
efficacy and safety of oral difelikefalin in moderate-to-severe pruritus associated with atopic dermatitis as an adjunct to
topical corticosteroids. In the study, oral difelikefalin did not demonstrate a meaningful clinical benefit., which resulted in
our decision to discontinue the clinical program in atopic dermatitis.
In January 2024, following a review of our strategic priorities, we announced a strategic prioritization to focus our
resources on our late-stage clinical program evaluating oral difelikefalin in chronic pruritus associated with NP, which we
believe is the therapeutic indication with the greatest commercial potential for oral difelikefalin. As part of this strategic
focus, we made the decision to terminate our Phase 3 clinical program evaluating oral difelikefalin in pruritus associated
with advanced chronic kidney disease, including the ongoing KICK 1 and KICK 2 Phase 3 clinical trials.
Sales and Marketing
In executing our strategy, our goal is to continue to commercialize KORSUVA injection and Kapruvia in the dialysis
setting by out-licensing, and to maintain significant control over the development process and commercial execution for
the oral formulation of difelikefalin, if approved.
We have executed out-licensing agreements on KORSUVA injection and Kapruvia in the dialysis setting in the
United States and the rest of the world. Per the terms of the associated licensing agreements, CSL Vifor will commercialize
KORSUVA injection and Kapruvia in the United States and worldwide (excluding Japan and South Korea), Maruishi will
commercialize KORSUVA in Japan, and we will not be incurring costs for commercializing in the United States or outside
of the United States as we will be relying on sales and marketing infrastructure support from our partners.
For oral difelikefalin, we plan to develop and commercialize our drug candidate in chronic pruritus associated with
NP on our own in the United States, while exploring partnerships for development and commercialization in geographical
territories outside the United States.
Intellectual Property
We strive to protect the proprietary technologies that we believe are important to our business, including seeking and
maintaining patent protection intended to cover the composition of matter of our product candidate, its methods of
10
Table of Contents
use, related technology and other inventions that are important to our business. As more fully described below, patent
applications have been filed covering compositions and novel formulations of these compositions, as well as methods of
using difelikefalin and related compounds. We own the patent portfolio of eighteen issued U.S. patents covering KOR
agonists, sixteen of which cover composition of matter of difelikefalin and its uses; six of these include composition of
matter claims directed to difelikefalin, and ten patents include claims to its uses. All of these U.S. patents covering
difelikefalin and its uses are expected to expire no earlier than November 12, 2027. Additionally, three U.S. patents have
been granted with claims to difelikefalin-like dimer compounds and their uses. We have filed patent applications in the
United States and internationally claiming novel oral formulations of difelikefalin. Two U.S. patents with claims to oral
formulations of difelikefalin that are not currently under development have been granted and are expected to expire no
earlier than September 13, 2039. Related U.S. and foreign applications, if granted, would also be expected to expire no
earlier than September 13, 2039. We also rely on trade secrets and careful monitoring of our proprietary information to
protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection.
Our success will depend significantly on our ability to obtain and maintain patent and other proprietary protection for
commercially important technology, inventions and know-how related to our business, defend and enforce our patents,
maintain our licenses to use intellectual property owned by third parties, preserve the confidentiality of our trade secrets
and operate without infringing valid and enforceable patents and other proprietary rights of third parties. We also rely on
know-how, and continuing technological innovation to develop, strengthen, and maintain our proprietary position in the
field of chronic pruritus.
A third party may hold intellectual property, including patent rights, which are important or necessary to the
development of our products. It may be necessary for us to use the patented or proprietary technology of third parties to
commercialize our products, in which case we would be required to obtain a license from these third parties on
commercially reasonable terms, or our business could be harmed, possibly materially. If we were not able to obtain a
license or were not able to obtain a license on commercially reasonable terms, our business could be harmed, possibly
materially.
We plan to continue to expand our intellectual property estate by filing patent applications directed to novel
formulations and novel uses of our proprietary compounds. We anticipate seeking patent protection in the United States
and internationally for the chemistries and processes for manufacturing these novel formulations and uses of these
compounds in a variety of therapies.
The patent positions of biopharmaceutical companies like us are generally uncertain and involve complex legal,
scientific and factual questions. In addition, the coverage claimed in a patent application can be significantly reduced
before the patent is issued, and the patent’s scope can be modified after issuance by later judicial decisions. Consequently,
we do not know whether our product candidates will be adequately protectable or remain protected by enforceable patents.
We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular
jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors.
Any patents that we hold may be challenged, circumvented or invalidated by third parties.
Because patent applications in the United States and certain other jurisdictions are maintained in secrecy for up to
18 months, and since publication of discoveries in the scientific or patent literature often lags behind actual discoveries, we
cannot be certain of our entitlement to the inventions covered by pending patent applications. Moreover, although unlikely,
we may have to participate in interference proceedings declared by the United States Patent and Trademark Office, or
USPTO, to determine priority of invention, or in post-grant challenge proceedings in the USPTO, or a foreign patent office
such as oppositions, inter-partes review, post grant review, or a derivation proceeding, that challenge our entitlement to an
invention or the patentability of one or more claims in our patent applications or issued patents. Such proceedings could
result in substantial cost, even if the eventual outcome is favorable to us.
The patent portfolios for our most advanced programs are summarized below.
11
Table of Contents
Difelikefalin
Our synthetic peptide amide kappa opioid agonist patent portfolio is wholly owned by us. The portfolio includes
eighteen issued U.S. patents (U.S. Patent Nos. 7,402,564; 7,713,937; 7,727,963; 7,842,662; 8,217,007; 8,236,766;
8,486,894; 8,536,131; 8,906,859; 8,951,970; 9,321,810; 9,334,305; 9,359,399; 10,017,536; 10,138,270; 10,793,596;
10,913,769 and 11,033,629) with claims to compositions of a wide range of synthetic peptide amide kappa opioid agonists,
including difelikefalin and related molecules, as well as formulations containing and methods of using these compounds.
These patents claiming difelikefalin compositions are due to expire November 12, 2027. U.S. Patent No. 11,033,629 with
claims to oral formulations of difelikefalin that are not currently under development is due to expire September 13, 2039.
We have listed twelve of the patents claiming difelikefalin acetate and/or its uses in the Orange Book, a listing of
patents relating to approved drug products maintained by the FDA. Difelikefalin acetate has been awarded a five-year data
exclusivity from the approval date, i.e. until August 23, 2026, prohibiting the FDA from accepting an application for
approval of a difelikefalin product from a generic manufacturer until after the exclusivity period expires. In addition, we
have also submitted an application for a patent term extension of one of our difelikefalin U.S. patents, which if granted for
the additional full five-year extension requested, would extend the patent term to November 12, 2032.
Foreign applications relating to difelikefalin and related molecules, as well as formulations containing and methods
of using these compounds, were filed in more than 40 foreign countries. National patents have been granted in 27 European
countries, as well as in Australia, Brazil, Canada, China, Hong Kong, India, Israel, Japan, Malaysia, Mexico, New Zealand,
Russian Federation, Singapore, South Africa and South Korea. These granted foreign patents with claims to difelikefalin
are due expire no earlier than November 12, 2027. We have applied for supplementary patent certificates (“SPCs”) for the
basic product patent in Europe, including the five major European markets (France, Spain, Italy, Germany, and the UK). In
the five major European markets, the SPC has been granted in France and Italy, (extending the patent term to November
12, 2032) and is pending in Germany, Spain, and the UK. We have also applied for a patent term extension in Japan, which
is pending.
We also own pending U.S. continuation and foreign patent applications with claims to oral formulations containing
difelikefalin and medium chain fatty acid glycerides as absorption enhancers that are not currently under development in
Australia, Brazil, Canada, China, Europe, Japan, Hong Kong, Israel, India, South Korea, Malaysia, Mexico, New Zealand,
Philippines, Russian Federation, Saudi Arabi, UAE, and South Africa. If granted, these patents would expire no earlier
than September 13, 2039.
In addition, we own pending U.S. and foreign patent applications with claims to oral formulations containing
difelikefalin and oligosaccharides not currently under development in Australia, Brazil, Canada, China, Europe, Japan,
Hong Kong, Israel, India, South Korea, Malaysia, Mexico, New Zealand, Philippines, Russian Federation, Saudi Arabi,
UAE, and South Africa. If granted, these patents would expire no earlier than March 18, 2041.
Other Cara Patents and Patent Applications
The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained.
In most countries in which we file, the patent term is 20 years from the earliest date of filing a PCT application or a non-
provisional patent application. The term of a patent in the United States can be adjusted and extended due to the failure of
the USPTO following certain statutory and regulation deadlines for progressing prosecution and issuing a patent.
In the United States, the patent term of a patent that covers an FDA-approved drug may also be eligible for patent
term extension, which permits patent term restoration as compensation for a portion of the patent term lost during the FDA
regulatory review process. The Hatch-Waxman Act permits a patent term extension of up to five years beyond the
expiration of the patent. The length of the patent term extension is related to the length of time the drug is under regulatory
review. Patent extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product
approval and only one patent applicable to an approved drug may be extended. Similar provisions are available in Europe
and other non-United States jurisdictions to extend the term of a patent that covers an approved drug.
12
Table of Contents
In the future, if and when our pharmaceutical products receive FDA approval, we expect to apply for patent term
extensions on patents covering those products. Although we intend to seek patent term extensions to any of our issued
patents in any jurisdiction where these are available there is no guarantee that the applicable authorities, including the FDA
in the United States, will agree with our assessment of whether such extensions should be granted, and even if granted, the
length of such extensions.
Cara Trademark Applications and Registrations
We rely on our U.S. and foreign trademarks for authentication of our current and future products and for protection
against counterfeits. In the United States, trademarks may be reserved under an “Intent to Use” designation but may only
be registered upon a showing of actual use in the stream of commerce. Many countries permit registration without such a
showing of actual use. However, such registrations become vulnerable to cancellation after a designated period of non-use.
For example, a trademark registered in EU States may be cancelled for non-use after five years from the date of
registration. Trademark registrations can in principle last for as long as the owner uses the trademark and pays the
maintenance fees due at regular intervals (every ten years in most jurisdictions after complying with filing requirements for
confirmations of use and paying the designated fees during the first ten years from the registration date).
We own the registered trademark “KORSUVA” in the United States and in fourteen foreign countries (Australia,
Brazil, Canada, China, India, Israel, Japan, Kuwait, Mexico, New Zealand, Norway, South Korea, Switzerland, and the
UK). In addition, we own three registered Japanese trademarks for Katakana versions of “KORSUVA” as may be
pronounced in the Japanese language: “KORSUVA” Katakana version 1: “ko-ru-su-ba” コルスバ; Katakana version 2:
“ko-ru-su-o-ba” コルスーバ; and Katakana version 3 “ko-o-su-ba” コースバ.
Additionally, we own the U.S. trademark application for “KAPRUVIA” currently pending under an “Intent to Use”
designation, as well as the “KAPRUVIA” trademark registered in all twenty-seven EU States (Austria, Belgium, Bulgaria,
Croatia, Republic of Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland,
Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain and
Sweden) and fourteen additional countries: Albania, Australia, China, Iceland, Israel, Monaco, New Zealand, North
Macedonia, Norway, Russian Federation, Serbia, Switzerland, Turkey and the UK.
We rely on trade secret protection for our confidential and proprietary information. Although we take steps to protect
our proprietary information and trade secrets, including through contractual means with our employees and consultants,
third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain
access to our trade secrets or disclose our technology. Thus, we may not be able to adequately protect our trade secrets to
prevent harm to our business. It is our policy to require our employees, consultants, outside scientific collaborators,
sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or
consulting relationships with us. These agreements provide that all confidential information concerning our business or
financial affairs developed or made known to the individual during the course of the individual’s relationship with us is to
be kept confidential and not disclosed to third parties except in specific circumstances. In the case of employees, the
agreements provide that all inventions conceived by the individual, and which are related to our current or planned
business or research and development, or R&D, or made during normal working hours, on our premises or using our
equipment or proprietary information, are our exclusive property.
Competition
The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense
competition and a strong emphasis on proprietary products. While we believe that our technology, knowledge, experience
and scientific resources provide us with competitive advantages, we face potential competition from many different
sources, including large pharmaceutical and biotechnology companies, specialty pharmaceutical and generic drug
companies, and medical technology companies. Any product candidates that we successfully develop and commercialize
will compete with existing therapies and new therapies that may become available in the future.
13
Table of Contents
There are no FDA-approved treatments for chronic pruritus associated with NP. The management of NP is
challenging and conventional treatments for pruritus, such as antihistamines and topical steroids, are largely ineffective.
However, there are a number of companies developing or marketing therapies for different pruritic indications. We believe
that the late-stage nature of our oral difelikefalin clinical program, along with our substantial safety database developed
over years of testing difelikefalin in different clinical settings, would give us an advantage over any competitor seeking to
develop a competitive product candidate for neuropathic pruritus associated with NP. Accordingly, it is possible that one or
more companies could elect to develop a product candidate for chronic pruritus associated with NP that could compete
with oral difelikefalin. We also compete with these companies in recruiting and retaining qualified scientific personnel and
establishing clinical trial sites and patient recruitment for clinical trials.
We believe the key competitive factors that will affect the development and commercial success of our product
candidate, if approved for marketing, are likely to be its safety, efficacy and tolerability profile, reliability, convenience of
dosing, price and reimbursement from government and third-party payers. Our commercial opportunity could be reduced
or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less
severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also
may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which
could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our
ability to compete may be affected in many cases by insurers or other third-party payers seeking to encourage the use of
generic products. Generic products currently on the market are often tried off-label for the indication that we are pursuing,
and additional products are expected to become available on a generic basis over the coming years. If our product
candidate achieves marketing approval, we expect that it will be priced at a significant premium over generic products.
Manufacturing
We do not have any manufacturing facilities. We currently rely, and expect to continue to rely, on third parties for the
manufacture of our product candidate for preclinical and clinical testing, as well as for commercial manufacture for
KORSUVA injection and if our product candidate receives marketing approval. We have negotiated long-term
commitments with at least one primary supplier for our primary manufacturing and distribution functions. We have entered
into a commercial manufacturing agreement with Patheon for KORSUVA injection, a commercial supply agreement with
PPL to produce API, and a commercial packaging agreement with PCI Pharma Services. During 2023, we negotiated to
reduce our commitment based on much lower-than-expected demand going forward for KORSUVA injection in the United
States.
Our product candidate is a small peptide and is manufactured in reliable and reproducible synthetic processes from
available starting materials. The chemistry is amenable to scale up and does not require any special equipment or
technology in the manufacturing process. We expect to continue to develop our product candidate that can be produced
cost-effectively at contract manufacturing facilities.
Government Regulation and Product Approval
Government authorities in the United States, at the federal, state and local level, and in other countries extensively
regulate, among other things, the research, development, testing, manufacture, packaging, storage, recordkeeping, labeling,
advertising, promotion, distribution, marketing, import and export of pharmaceutical products. The processes for obtaining
regulatory approvals in the United States and in foreign countries, along with subsequent compliance with applicable
statutes and regulations, require the expenditure of substantial time and financial resources.
FDA Regulation
In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and its
implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate
federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources.
Failure to comply with the applicable United States requirements at any time during the product development process,
approval process or after approval, may subject an applicant to a variety of administrative or
14
Table of Contents
judicial sanctions, such as the FDA’s refusal to approve pending NDAs, withdrawal of an approval, imposition of a clinical
hold, issuance of warning or untitled letters, product recalls, product seizures, total or partial suspension of production or
distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties.
The process required by the FDA before a drug may be marketed in the United States generally involves the
following:
●
●
●
●
●
●
●
completion of preclinical laboratory tests, animal studies and formulation studies in compliance with the
FDA’s good laboratory practice, or GLP, regulations;
submission to the FDA of an IND which must become effective before human clinical trials may begin;
approval by an independent institutional review board, or IRB, at each clinical site before each trial may be
initiated;
performance of human clinical trials, including adequate and well-controlled clinical trials, in accordance with
good clinical practices, or cGCP, to establish the safety and efficacy of the proposed drug product for each
indication;
submission to the FDA of an NDA;
satisfactory completion of an FDA advisory committee review, if applicable;
satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is
produced to assess compliance with current good manufacturing practices, or cGMP, and to assure that the
facilities, methods and controls are adequate to preserve the drug’s identity, strength, quality and purity, as well
as satisfactory completion of an FDA inspection of selected clinical sites to determine cGCP compliance; and
●
FDA review and approval of the NDA.
Preclinical Studies. Preclinical studies include laboratory evaluation of drug substance chemistry, toxicity and drug
product formulation, as well as animal studies to assess potential safety and efficacy. An IND sponsor must submit the
results of the preclinical tests, together with manufacturing information, analytical data and any available clinical data or
literature, among other things, to the FDA as part of an IND. Manufacture of drug substance, drug product and the labeling
and distribution of clinical supplies must all comply with cGMP standards. Some preclinical testing may continue even
after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that
time the FDA raises concerns or questions related to one or more proposed clinical trials and places the trial on a clinical
hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can
begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence.
Clinical Trials. Clinical trials involve the administration of the investigational new drug to human subjects under the
supervision of qualified investigators in accordance with cGCP requirements, which include the requirement that all
research subjects provide their informed consent in writing for their participation in any clinical trial. Clinical trials are
conducted under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring
safety and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol
amendments must be submitted to the FDA as part of the IND. In addition, an IRB at each institution participating in the
clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB
must continue to oversee the clinical trial while it is being conducted. Information about certain clinical trials must be
submitted within specific timeframes to the National Institutes of Health, or NIH, for public dissemination on their
ClinicalTrials.gov website.
15
Table of Contents
Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined. In Phase
1, the drug is initially introduced into healthy human subjects or patients with the target disease or condition and tested for
safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an initial indication of its
effectiveness. In Phase 2, the drug typically is administered to a limited patient population to identify possible adverse
effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine
dosage tolerance and optimal dosage. In Phase 3, the drug is administered to an expanded patient population, generally at
geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate
the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product and to provide
adequate information for the labeling of the product.
Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more
frequently if serious adverse events occur. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully
within any specified period, or at all. Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any
time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk.
Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being
conducted in accordance with the IRB’s requirements or if the drug has been associated with unexpected serious harm to
patients.
Marketing Approval. Assuming successful completion of the required clinical testing, the results of the preclinical
and clinical studies, together with detailed information relating to the product’s chemistry, manufacture, controls and
proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the
product for one or more indications. In most cases, the submission of an NDA is subject to a substantial application user
fee.
Under the Pediatric Research Equity Act, or PREA, an NDA or supplement to an NDA must contain data that are
adequate to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric
subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and
effective. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or
all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data
requirements.
The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them
for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request
additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the
additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the
submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA reviews an NDA to determine,
among other things, whether the drug is safe and effective and whether the facility in which it is manufactured, processed,
packaged or held meets standards designed to assure the product’s continued safety, quality and purity.
The FDA may refer an application for a novel drug to an external advisory committee. An advisory committee is a
panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a
recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by
the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.
The FDA also may require submission of a risk evaluation and mitigation strategy, or REMS, to mitigate any
identified or suspected serious risks and ensure safe use of the drug. The REMS plan could include medication guides,
physician communication plans, assessment plans, and elements to assure safe use, such as restricted distribution methods,
patient registries or other risk minimization tools.
Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured,
referred to as a Pre-Approval Inspection. The FDA will not approve an application unless it determines that the
manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure
16
Table of Contents
consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA will
typically inspect one or more clinical trial sites to assure compliance with cGCP.
The testing and approval process for an NDA requires substantial time, effort and financial resources, and each may
take several years to complete. Data obtained from preclinical and clinical testing are not always conclusive and may be
susceptible to varying interpretations, which could delay, limit or prevent regulatory approval. The FDA may not grant
approval of an NDA on a timely basis, or at all.
After evaluating the NDA and all related information, including the advisory committee recommendation, if any, and
inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in
some cases, a complete response letter. A complete response letter generally contains a statement of specific conditions that
must be met in order to secure final approval of the NDA and may require additional clinical or preclinical testing in order
for FDA to reconsider the application. Even with submission of this additional information, the FDA ultimately may decide
that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the
FDA’s satisfaction, the FDA may issue an approval letter. An approval letter authorizes commercial marketing of the drug
with specific prescribing information for specific indications.
Even if the FDA approves a product, it may limit the approved indications for use of the product, require that
contraindications, warnings or precautions be included in the product labeling, including a boxed warning, require that
post-approval studies, including Phase 4 clinical trials, be conducted to further assess a drug’s safety after approval, require
testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including
distribution restrictions or other risk management mechanisms under a REMS which can materially affect the potential
market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results
of post-marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as
adding new indications, manufacturing changes, and additional labeling claims, are subject to further testing requirements
and FDA review and approval.
Post-Approval Requirements. Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive
and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic
reporting, product sampling and distribution, advertising and promotion, reporting of adverse experiences with the product,
and compliance with any post-approval requirements imposed as a condition of approval, such as Phase 4 clinical trials and
surveillance to assess safety and effectiveness after commercialization. After approval, most changes to the approved
product, such as adding new indications or other labeling claims are subject to prior FDA review and approval. There also
are continuing, annual program user fee requirements for any marketed products, as well as new application fees for
supplemental applications with clinical data. In addition, drug manufacturers and other entities involved in the manufacture
and distribution of approved drugs are required to register their establishments with the FDA and state agencies and are
subject to periodic announced and unannounced inspections by the FDA and these state agencies for compliance with
cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval
before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and
impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor
may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production
and quality control to maintain cGMP compliance.
Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and
standards is not maintained or if problems occur after the product reaches the market.
Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity
or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory
revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to
assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential
consequences include, among other things:
●
restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the
market or product recalls;
17
Table of Contents
●
●
●
●
fines, warning letters or holds on post-approval clinical trials;
refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation
of product license approvals;
product seizure or detention, or refusal to permit the import or export of products; or
injunctions or the imposition of civil or criminal penalties.
The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market.
Although physicians, in the practice of medicine, may prescribe approved drugs for unapproved indications,
pharmaceutical companies are required to promote their drug products only for the approved indications and in accordance
with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations
prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may
be subject to significant liability. However, physicians may, in their independent medical judgment, prescribe legally
available products for off-label uses. The FDA does not regulate the behavior of physicians in their choice of treatments
but the FDA does restrict manufacturer’s communications on the subject of off-label use of their products.
In addition, the distribution of prescription pharmaceutical products is subject to the Drug Supply Chain Security Act
and state laws that limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure
accountability in distribution.
Fraud and Abuse, Data Privacy and Security and Transparency Laws and Regulations
In addition to FDA restrictions on marketing of pharmaceutical products, federal and state health care regulatory
laws restrict business practices in the biopharmaceutical industry. These laws include, among other things, anti-kickback
and false claims laws and regulations, physician payment transparency laws and regulations, as well as data privacy and
security laws and regulations.
The federal Anti-Kickback Statute prohibits, among other things, any person or entity, from knowingly and willfully
offering, paying, soliciting or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to
induce or in return for purchasing, leasing, ordering, or arranging for or recommending the purchase, lease, or order of any
item or service reimbursable under Medicare, Medicaid or other federal healthcare programs. The term “remuneration” has
been interpreted broadly to include anything of value. The Anti-Kickback Statute has been interpreted to apply to
arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers, and formulary managers on
the other. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from
prosecution. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases, or
recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the
requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se
illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis
based on a cumulative review of all of its facts and circumstances.
Additionally, the intent standard under the federal Anti-Kickback Statute was amended by the Patient Protection and
Affordable Care Act, as amended by the Health Care Education Reconciliation Act (collectively, the “Health Care Reform
Law”), to a stricter standard such that a person or entity no longer needs to have actual knowledge of the statute or specific
intent to violate it in order to have committed a violation. In addition, the Health Care Reform Law provided that the
government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback
Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act.
Federal false claims laws, including the federal civil False Claims Act prohibit, among other things, any person or
entity from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment to, or approval by, the
federal government or knowingly making, using, or causing to be made or used a false record or statement material
18
Table of Contents
to a false or fraudulent claim to the federal government. A claim includes “any request or demand” for money or property
presented to the U.S. government. The federal civil False Claims Act has been used to assert liability on the basis of
kickbacks and other improper referrals, improperly reported government pricing metrics such as Best Price or Average
Manufacturer Price, improper use of Medicare provider or supplier numbers when detailing a provider of services,
improper promotion of off-label uses not expressly approved by FDA in a drug’s label, and allegations as to
misrepresentations with respect to the services rendered. Additionally, the civil monetary penalties statute, which, among
other things, imposes fines against any person or entity who is determined to have presented, or caused to be presented,
claims to a federal healthcare program that the person knows, or should know, is for an item or service that was not
provided as claimed or is false or fraudulent. The federal Health Insurance Portability and Accountability Act of 1996, or
HIPAA, created additional federal criminal statutes that prohibit knowingly and willfully executing, or attempting to
execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations, or promises, any of
the money or property owned by, or under the custody or control of, any healthcare benefit program, including private
third-party payers and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device a material
fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for
healthcare benefits, items or services relating to healthcare matters. Also, many states have similar fraud and abuse statutes
or regulations that apply to items and services reimbursed under Medicaid and other state programs, or, in several states,
apply regardless of the payer.
In addition, we may be subject to data privacy and security regulation by both the U.S. federal government and the
states in which we conduct our business. HIPAA, as amended by the Health Information Technology for Economic and
Clinical Health Act, or HITECH, and their respective implementing regulations, including the Final HIPAA Omnibus
Rule published on January 25, 2013, imposes specified requirements on certain types of individuals and entities subject to
the law, known as covered entities, such as certain healthcare providers, health plans, and healthcare clearinghouses, as
well as their business associates that process individually identifiable health information on their behalf, relating to the
privacy, security and transmission of individually identifiable health information as well as their covered subcontractors.
Among other things, HITECH makes security standards and certain privacy standards directly applicable to the business
associates of covered entities that perform services for them that involve the creation, use, maintenance or disclosure of,
individually identifiable health information. HITECH also created four new tiers of civil monetary penalties, amended
HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new
authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek
attorney’s fees and costs associated with pursuing federal civil actions. In addition, we are or may become subject to U.S.
state laws (such as the California Consumer Privacy Act of 2018 (“CCPA”) and foreign laws (such as the EU’s General
Data Protection Regulation 2016/679 (“EU GDPR”), the EU GDPR as it forms part of UK law by virtue of section 3 of the
European Union (Withdrawal) Act 2018 (“UK GDPR”) that govern data privacy, security and protection. These and other
similar laws govern the privacy and security of personal data. Many of these laws differ from each other in significant ways
and may not have the same effect, both of which complicate compliance efforts to the extent we are or may become subject
to these laws.
Additionally, federal transparency laws, including the federal Physician Payments Sunshine Act created under
Section 6002 of the Health Care Reform Law and its implementing regulations, require that manufacturers of drugs,
devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health
Insurance Program (with certain exceptions) report annually to the Centers for Medicare & Medicaid Services, or CMS,
information related to payments or other transfers of value made or distributed to physicians (defined to include doctors of
medicine, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physician assistants
and nurse practitioners), and teaching hospitals, or to entities or individuals at their request or designation. Additionally,
applicable manufacturers and applicable group purchasing organizations are required to report annually to CMS certain
ownership and investment interests held by physicians (as defined above) and their immediate family members.
There are also an increasing number of analogous state laws that require manufacturers to file reports with states on
pricing and marketing information, such as tracking and reporting of gifts, compensations, other remuneration and items of
value provided to healthcare professionals and healthcare entities. For example, several states have enacted legislation
requiring pharmaceutical companies to, among other things, establish and implement commercial compliance programs,
file periodic reports with the state, make periodic public disclosures on sales, marketing, pricing, clinical trials
19
Table of Contents
and other activities and/or register their sales representatives. Certain state laws also regulate manufacturers’ use of
prescriber-identifiable data. These laws may affect our sales, marketing and other promotional activities by imposing
administrative and compliance burdens. In addition, given the lack of clarity with respect to these laws and their
implementation, our reporting actions could be subject to the penalty provisions of the pertinent state and federal
authorities.
If our operations are found to be in violation of any of the health regulatory laws described above or any other laws
that apply to us, we may be subject to penalties, including significant criminal, civil and administrative penalties, damages,
fines, imprisonment, exclusion from participation in government healthcare programs, contractual damages, reputational
harm, diminished profits and future earnings, additional reporting requirements and/or oversight if we become subject to a
corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and the
curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and
our results of operations. To the extent that any of our products are sold in a foreign country, we may be subject to similar
foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety
surveillance, anti-fraud and abuse laws, and implementation of corporate compliance programs and reporting of payments
or transfers of value to healthcare professionals.
Coverage and Reimbursement Generally
The commercial success of KORSUVA injection and our ability to commercialize any approved product candidate
successfully will depend in part on the extent to which governmental payer programs at the federal and state levels,
including Medicare and Medicaid, private health insurers and other third-party payers provide coverage for and establish
adequate reimbursement levels. In the United States, private health insurers and other third-party payers often provide
reimbursement for products and services based on the level at which the government provides reimbursement through the
Medicare or Medicaid programs for such products and services.
Patients who are prescribed treatments for their conditions and providers performing the prescribed services
generally rely on third-party payers to reimburse all or part of the associated healthcare costs. Sales of KORSUVA injection
and our product candidate to the extent approved will therefore depend substantially, both domestically and abroad, on the
extent to which the costs of our products will be paid by health maintenance, managed care, pharmacy benefit and similar
healthcare management organizations, or reimbursed by government health administration authorities, such as Medicare
and Medicaid, private health insurers and other third-party payers. Further, assuming coverage is approved, the resulting
reimbursement payment rates might not be adequate. KORSUVA injection is expected to be designated as a component of
the government’s bundled reimbursement for ESRD treatment.
Our U.S. commercial partner, CSL Vifor, submitted the payment reimbursement application for TDAPA and HCPCS
to CMS in September 2021. In December 2021, CMS granted TDAPA to KORSUVA injection in the anti-pruritic
functional category. TDAPA will apply to KORSUVA injection beginning April 1, 2022 for two years. On October 27,
2023, CMS published the final CY 2024 rule, which finalized the post-TDAPA add-on payment as proposed in the draft
CY 2024 rule. Under the final rule, TDAPA drugs in existing functional categories will receive a post-TDAPA add-on
payment set at 65 percent of the total trailing 12-months expenditure levels for the given renal dialysis drug or biological
product. The post-TDAPA add-on payment will be applied to all ESRD PPS payments and paid for 3 years, adjusted
annually. The add-on payments for KORSUVA injection will commence on April 1, 2024.
Third-party payers are increasingly imposing additional requirements and restrictions on coverage and limiting
reimbursement levels for medical products, including pharmaceuticals. For example, federal and state governments
reimburse covered prescription drugs at varying rates generally below average wholesale price. These restrictions and
limitations influence the purchase of healthcare services and products. Third-party payers may limit coverage to specific
drug products on an approved list, or formulary, which might not include all of the FDA-approved drug products for a
particular indication. Additionally, third-party payers are increasingly challenging the price and examining the medical
necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. Therefore, we
may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-
effectiveness of our products, in addition to the costs required to obtain the FDA approvals. KORSUVA injection and
20
Table of Contents
our product candidate, to the extent it receives approval, may not be considered medically necessary or cost-effective.
Moreover, a payer’s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate
will be approved, and one payer’s determination to provide coverage for a product does not assure that other payers will
also provide coverage. Adequate third-party reimbursement may not be available to enable us to maintain price levels
sufficient to realize an appropriate return on our investment in drug development. Legislative proposals to reform
healthcare or reduce costs under government insurance programs may result in lower reimbursement for our products and
product candidates or exclusion of our products and product candidates from coverage. The cost containment measures that
healthcare payers and providers are instituting and any healthcare reform could significantly reduce our revenues from the
sale of KORSUVA injection and any approved product candidate.
Healthcare Regulatory Developments
In the United States and some foreign jurisdictions, the legislative landscape with respect to healthcare continues to
evolve. There have been a number of legislative and regulatory changes to the healthcare system that could affect our
ability to sell our products profitably. Among policy makers and payers in the United States and elsewhere, there is
significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs,
improving quality and expanding access. In the United States, the pharmaceutical industry has been a particular focus of
these efforts and has been significantly affected by major legislative initiatives.
For example, the Health Care Reform Law was passed in March 2010 and includes provisions that have substantially
changed healthcare financing by both governmental and private insurers. Among other provisions that could have an
impact on our business, the Health Care Reform Law revised the methodology by which rebates owed by manufacturers to
the state and federal government for covered outpatient drugs under the Medicaid Drug Rebate Program are calculated,
increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program, extended
the Medicaid Drug Rebate program to utilization of prescriptions of individuals enrolled in Medicaid managed care
organizations, subjected manufacturers to new annual fees and taxes for certain branded prescription drugs, and provided
incentives to programs that increase the federal government’s comparative effectiveness research. Additionally, the Health
Care Reform Law implemented a new Medicare Part D coverage gap discount program in which manufacturers must now
agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during
their coverage gap period as a condition for the outpatient drugs being covered under Medicare Part D.
There have been executive, judicial and Congressional challenges to certain aspects of the Health Care Reform Law.
For example, the Tax Cuts and Jobs Act of 2017, or TCJA, included a provision that repealed, effective January 1, 2019,
the tax-based shared responsibility payment imposed by the Health Care Reform Law on certain individuals who fail to
maintain qualifying health coverage for all or part of a year that is commonly referred to as the “individual mandate”. On
June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the Health Care Reform
Law is unconstitutional in its entirety because the “individual mandate” was repealed by Congress. Thus, the Health Care
Reform Law will remain in effect in its current form. Prior to the U.S. Supreme Court ruling, on January 28, 2021,
President Biden issued an executive order to initiate a special enrollment period from February 15, 2021 through August
15, 2021 for purposes of obtaining health insurance coverage through the Health Care Reform Law marketplace. The
executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that
limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that
include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage
through Medicaid or the Health Care Reform Law. In addition, on August 16, 2022, President Biden signed the Inflation
Reduction Act of 2022, or IRA, into law, which among other things, extends enhanced subsidies for individuals purchasing
health insurance coverage in Health Care Reform Law marketplaces through plan year 2025. The IRA also eliminates the
“donut hole” under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum
out-of-pocket cost and creating a new manufacturer discount program. It is possible that the Health Care Reform Law will
be subject to judicial or Congressional challenges in the future. It is unclear how such challenges and the healthcare reform
measures of the Biden administration will impact the Health Care Reform Law and our business.
21
Table of Contents
In addition, other legislative changes have been proposed and adopted since the Health Care Reform Law was
enacted. In August 2011, President Obama signed into law the Budget Control Act of 2011, as amended, which, among
other things, created the Joint Select Committee on Deficit Reduction to recommend proposals in spending reductions to
Congress. The Joint Select Committee on Deficit Reduction did not achieve its targeted deficit reduction of at least $1.2
trillion for the years 2013 through 2021, triggering the legislation’s automatic reductions to several government programs.
These reductions include aggregate reductions to Medicare payments to providers of up to 2% per fiscal year starting in
2013 and, due to subsequent legislative amendments, will remain in effect until 2032, unless additional Congressional
action is taken. Additionally, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law,
which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug’s average manufacturer price, for
single source and innovator multiple source drugs, beginning January 1, 2024. Congress is considering additional health
reform measures.
In the United States, the EU, and other potentially significant markets for our product candidates, government
authorities and third-party payers are increasingly attempting to limit or regulate the price of medical products and services,
particularly for new and innovative products and therapies, which often has resulted in average selling prices lower than
they would otherwise be. Further, the increased emphasis on managed healthcare in the United States and on country and
regional pricing and reimbursement controls in the EU will put additional pressure on product pricing, reimbursement and
utilization, which may adversely affect our future product sales and results of operations. For example, there have been
several recent U.S. Presidential executive orders, Congressional inquiries and proposed and enacted federal and state
legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between
pricing and manufacturer patient programs, reduce the cost of drugs under Medicare, and reform government program
reimbursement methodologies for drugs. At the federal level, in July 2021, the Biden administration released an executive
order, “Promoting Competition in the American Economy,” with multiple provisions aimed at prescription drugs. In
response to Biden’s executive order, on September 9, 2021, the U.S. Department of Health and Human Services, or HHS,
released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets
out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can
take to advance these principles. No legislation or administrative actions have been finalized to implement these principles.
It is unclear whether these or similar policy initiatives will be implemented in the future. In addition, the IRA, among other
things, (1) directs HHS to negotiate the price of certain single-source drugs and biologics covered under Medicare and (2)
imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. These
provisions take effect progressively starting in fiscal year 2023. On August 29, 2023, HHS announced the list of the first
ten drugs that will be subject to price negotiations, although the Medicare drug price negotiation program is currently
subject to legal challenges. It is unclear how the IRA will be implemented but is likely to have a significant impact on the
pharmaceutical industry. In response to the Biden administration’s October 2022 executive order, on February 14, 2023,
HHS released a report outlining three new models for testing by the CMS Innovation Center which will be evaluated on
their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models
will be utilized in any health reform measures in the future. Further, on December 7, 2023, the Biden administration
announced an initiative to control the price of prescription drugs through the use of march-in rights under the Bayh-Dole
Act. On December 8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency
Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes the price of a
product as one factor an agency can use when deciding to exercise march-in rights. While march-in rights have not
previously been exercised, it is uncertain if that will continue under the new framework. At the state level, legislatures have
increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product
pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and
marketing cost disclosure and transparency measures, and, in some cases, to encourage importation from other countries
and bulk purchasing. For example, on January 5, 2024, the FDA approved Florida’s Section 804 Importation Program
(SIP) proposal to import certain drugs from Canada for specific state healthcare programs. It is unclear how this program
will be implemented, including which drugs will be chosen, and whether it will be subject to legal challenges in the United
States or Canada. Other states have also submitted SIP proposals that are pending review by the FDA. Any such approved
importation plans, when implemented, may result in lower drug prices for products covered by those programs. These
pressures can arise from rules and practices of managed care groups, judicial decisions and laws and regulations related to
Medicare, Medicaid and healthcare reform, pharmaceutical coverage and reimbursement policies and pricing in general.
22
Table of Contents
These and other healthcare reform initiatives may result in additional reductions in Medicare payments and other
healthcare funding, which could have a material adverse effect on our financial operations. We expect that additional state
and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and
state governments will pay for healthcare products and services, which could further limit the prices we are able to charge,
or the amounts of reimbursement available, for KORSUVA injection and our product candidate once they are approved.
Foreign Regulation
In order to market any product outside of the United States, we would need to comply with numerous and varying
regulatory requirements of other countries regarding safety and efficacy. Individual countries govern, among other things,
clinical trials, marketing authorization, commercial sales and distribution of our products. For example, in the EU, we must
obtain authorization of a clinical trial application, or CTA, through the Clinical Trials Registration process in each member
state in which we intend to conduct a clinical trial. Whether or not we obtain FDA marketing approval for a product, we
would need to obtain the necessary approvals by the comparable regulatory authorities of foreign countries before we can
commence marketing of the product in those countries. The approval process varies from country to country and can
involve additional product testing and varying administrative review periods. The time required to obtain approval in other
countries might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country
does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may
negatively impact the regulatory outcome in others.
Employees and Human Capital
On January 22, 2024, we announced a planned workforce reduction of up to 50% of our employees in order to reduce
our operating expenses and focus our efforts on development of oral difelikefalin in chronic pruritus associated with NP. As
of March 1, 2024, we had 55 employees, of whom 15 hold PharmD, PhD or MD degrees or the foreign equivalent. All of
these employees are located in the United States. None of our employees are represented by a labor union or covered by a
collective bargaining agreement. We consider our relationship with our employees to be good.
Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing, and
integrating our existing and new employees, advisors, and consultants. The principal purposes of our equity and cash
incentive plans are to attract, retain and reward personnel through the granting of stock-based and cash-based
compensation awards, in order to increase stockholder value and the success of our company by motivating such
individuals to perform to the best of their abilities and achieve our objectives.
Website Access to Reports
Our website is www.caratherapeutics.com. We are subject to the informational requirements of the Exchange Act and
file or furnish reports, including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on
Form 8-K, and amendments to reports filed pursuant to Sections 13(a) and 15(d) of the Exchange Act, proxy statements
and other information with the SEC. We make copies of these reports and other information available free of charge
through our website (under the heading “SEC Filings”) as soon as reasonably practicable after we file or furnish them with
the SEC. The SEC maintains a website that contains reports, proxy and information statements and other information
regarding issuers that file electronically with the SEC at www.sec.gov. The information contained on the websites
referenced in this Annual Report on Form 10-K is not incorporated by reference into this filing, and the website addresses
are provided only as inactive textual references.
Item 1A. Risk Factors
In addition to other information contained in this Annual Report on Form 10-K, the following risks should be
considered in evaluating our business and future prospects and an investment in our common stock. The risks and
uncertainties described below are not the only ones we face. If any of the following risks and uncertainties develops into
actual events, our business, financial condition, results of operations and cash flows could be materially adversely
affected. In that case, the price of our common stock could decline and you may lose all or part of your investment.
23
Table of Contents
Risks Related to Our Business and the Development and Commercialization of Our Product and Product Candidate
We are substantially dependent on the success of oral difelikefalin for the treatment of NP, which is our only current
product candidate. If we are unable to successfully complete clinical development, obtain regulatory approvals and
commercialize oral difelikefalin, or experience significant delays in doing so, our business will be materially harmed.
Our business depends on the successful development, regulatory approval, and commercialization of our product
candidate. In January 2024, we announced a prioritization of our pipeline to focus our resources on our late-stage clinical
program evaluating oral difelikefalin in chronic pruritus associated with NP and terminate our Phase 3 clinical program
evaluating oral difelikefalin in pruritus associated with advanced chronic kidney disease, including our KICK 1 and KICK
2 Phase 3 clinical trials. After this prioritization, we have a single product candidate in clinical development, oral
difelikefalin for the treatment of chronic pruritus associated with NP, which we are currently evaluating in a Phase 2/3
clinical trial. We cannot be certain that oral difelikefalin or any future product candidates will be successful in clinical trials
or receive regulatory approval. Regulatory authorities may interpret our data differently than we have. We are not permitted
to market or promote any of our product candidates before we receive regulatory approval from the FDA or comparable
foreign regulatory authorities, and we may never receive such regulatory approval for oral difelikefalin or any future
product candidates.
The success of our product candidate will depend on many factors, including but not limited to:
● successful enrollment in, and completion of, clinical trials, as well as completion of preclinical studies;
● favorable efficacy and acceptable safety data from our clinical trials and other studies;
● receipt of additional regulatory approvals;
● managing our reliance on sole-source third parties such as our third-party vendors, suppliers, and manufacturers;
● the performance by CROs or other third parties and consultants we may retain of their duties to us in a manner
that complies with our protocols and applicable laws and that protects the integrity of the resulting data;
● obtaining and maintaining patent, trade secret and other intellectual property protection and regulatory
exclusivity;
● ensuring we do not infringe, misappropriate or otherwise violate the valid patent, trade secret or other intellectual
property rights of third parties;
● successfully launching, either alone or with a commercial partner, any product candidate for which regulatory
approval is received;
● obtaining and maintaining favorable reimbursement from third-party payers and governments for products and
product candidate;
● competition with other products;
● post-marketing commitments, if any, to regulatory agencies following regulatory approval of our product
candidate;
● continued acceptable safety profile following regulatory approval; and
24
Table of Contents
● manufacturing or obtaining sufficient supplies of our products and product candidate that may be necessary for
use in clinical trials for evaluation of our product candidate and commercialization of any approved product.
If we do not achieve and maintain one or more of these factors in a timely manner or at all, we could experience
significant delays in our ability to, or be unable to obtain regulatory approvals for, and/or to successfully commercialize our
products and product candidate, which would materially harm our business and we may not be able to generate sufficient
revenues and cash flows to continue our operations.
We recently engaged in a strategic prioritization of our pipeline. We may be unable to successfully execute our strategic
prioritization plans, including efforts to reduce our costs.
On January 22, 2024, following a review of our strategic goals, we announced a prioritization of our pipeline to focus
our resources on our late-stage clinical program evaluating oral difelikefalin in chronic pruritus associated with NP and
terminate our Phase 3 clinical program evaluating oral difelikefalin in pruritus associated with advanced chronic kidney
disease, including our KICK 1 and KICK 2 Phase 3 clinical trials. As part of this strategic update, in the first quarter of
2024, we reduced our global workforce by approximately 50%. We cannot guarantee that we will successfully implement
this strategic prioritization or that the benefits, including reduction of operating expenses, even if achieved, will be
adequate to meet our medium- or long-term financial and operational expectations. We may also experience additional
unexpected costs and negative impacts on our cash flows from operations and liquidity, employee attrition and adverse
effects on employee morale, diversion of management attention, and adverse effects to our reputation as an employer,
which could make it more difficult for us to hire new employees in the future.
Further, pursuant to this strategic prioritization and because we have limited financial and managerial resources, we
may forgo or delay the pursuit of opportunities with other product candidates or other indications that could have had
greater commercial potential or likelihood of success. Our resource allocation decisions may cause us to fail to capitalize
on viable commercial products or profitable market opportunities. Our spending on current and future research and
development programs and product candidates for specific indications may not yield any commercially viable products. If
we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may
relinquish valuable rights to that product candidate through future collaborations, licenses, and other similar arrangements
in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to
such product candidate.
Clinical and preclinical drug development involves a lengthy and expensive process with uncertain timelines and
outcomes, and the results of preclinical studies and early clinical trials are not necessarily predictive of future results.
Oral difelikefalin or any potential future product candidate may not achieve favorable results in clinical trials or
preclinical studies or receive regulatory approval on a timely basis, if at all.
Drug development is expensive and can take many years to complete, and its outcome is inherently uncertain. We
cannot guarantee that any clinical trials or preclinical studies will be conducted as planned, including whether we are able
to meet expected timeframes for data readouts, or complete on schedule, if at all, and failure can occur at any time during
the trial or study process, including due to factors that are beyond our control. Despite promising preclinical or clinical
results, oral difelikefalin or any potential future product candidate can unexpectedly fail at any stage of clinical or
preclinical development.
The results from preclinical studies or clinical trials of oral difelikefalin, any potential future product candidate, or a
competitor’s product candidate in the same class may not predict the results of later clinical trials, and interim, topline or
preliminary results of a clinical trial are not necessarily indicative of final results. Oral difelikefalin or any future product
candidate in later stages of clinical trials may fail to show the desired characteristics despite having progressed through
preclinical studies and initial clinical trials. It is not uncommon to observe results in clinical trials that are unexpected
based on preclinical studies and early clinical trials, and many product candidates fail in clinical trials despite very
promising early results.
25
Table of Contents
Moreover, preclinical and clinical data may be susceptible to varying interpretations and analyses. A number of
companies in the biopharmaceutical and biotechnology industries have suffered significant setbacks in clinical
development even after achieving promising results in earlier studies. Such setbacks have occurred and may occur for
many reasons, including, but not limited to: clinical sites and investigators may deviate from clinical trial protocols,
whether due to lack of training or otherwise, and we may fail to detect any such deviations in a timely manner; patients
may fail to adhere to any required clinical trial procedures, including any requirements for post-treatment follow-up; our
product candidates may fail to demonstrate safety, potency (or efficacy) in certain patient subpopulations, which has not
been observed in earlier trials due to limited sample size, lack of analysis or otherwise; or our clinical trials may not
adequately represent the patient populations we intend to treat, whether due to limitations in our trial designs or otherwise,
such as where one patient subgroup is overrepresented in the clinical trial. There can be no assurance that we will not suffer
similar setbacks despite the data we observed in earlier or ongoing studies. Based upon negative or inconclusive results, we
or any current or any future collaborator may decide, or regulators may require us, to conduct additional preclinical studies
or clinical trials, which would cause us to incur additional operating expenses and delays and may not be sufficient to
support regulatory approval on a timely basis or at all.
As a result, we cannot be certain that our ongoing and planned clinical trials or preclinical studies will be successful.
Any safety concerns observed in any one of our clinical trials in chronic pruritus associated with NP could limit the
prospects for regulatory approval of oral difelikefalin in NP or other indications, which could have a material adverse effect
on our business, financial condition, results of operations and prospects.
If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory
approvals could be delayed or prevented.
We may not be able to initiate or continue conducting clinical trials for our product candidate if we are unable to
locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar
regulatory authorities outside the United States. Some of our competitors have ongoing clinical trials for product
candidates that treat the same indications as our product candidate, and patients who would otherwise be eligible for our
clinical trials may instead enroll in clinical trials of our competitors’ product candidates. Patient enrollment is affected by
other factors including:
·
·
·
·
·
·
·
·
·
·
the size and nature of the patient population;
the severity of the disease under investigation;
the eligibility criteria for, and design of, the trial in question;
the perceived risks and benefits of the product candidate under study;
competition in recruiting and enrolling patients in clinical trials;
the efforts to facilitate timely enrollment in clinical trials;
the patient referral practices of physicians;
the ability to monitor patients adequately during and after treatment;
the proximity and availability of clinical trial sites for prospective patients; and
delays or difficulties due to public health crises, such as pandemics or other similar outbreaks.
For example, we experienced a delay in patient enrollment for our Phase 2 clinical trial of oral difelikefalin for the
treatment of pruritus in patients with hepatic impairment due to PBC that led to our decision to discontinue and unblind
26
Table of Contents
this trial. We could in the future experience similar delays in our ongoing oral difelikefalin program in chronic pruritus
associated with NP or potential future product candidates.
Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays and
could require us to abandon one or more clinical trials altogether. We may encounter difficulties and/or delays in
completing our planned enrollments. Enrollment delays in our clinical trials may result in increased development costs for
our product candidate, or the inability to complete development of our product candidate, which would cause the value of
our company to decline, limit our ability to obtain additional financing, and materially impair our ability to generate
revenues.
We rely, and expect to continue to rely, on third parties to conduct our preclinical studies and clinical trials, and those
third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials.
We rely on third-party CROs to conduct our clinical trials for oral difelikefalin, and do not plan to independently
conduct preclinical studies or clinical trials of any other potential product candidates. We expect to continue to rely on third
parties, such as CROs, clinical data management organizations, medical institutions and clinical investigators, to conduct
our preclinical studies and clinical trials. These agreements might terminate for a variety of reasons, including a failure to
perform by the third parties. If we need to enter into alternative arrangements, that would delay our product development
activities and adversely affect our business.
Our reliance on these third parties for development activities will reduce our control over these activities.
Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable
protocol, legal, regulatory and scientific standards and our reliance on the CROs does not relieve us of our regulatory
responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in
accordance with the general investigational plan and protocols for the trial and for ensuring that our preclinical trials are
conducted in accordance with FDA’s good laboratory practice, or GLP, as appropriate. Moreover, the FDA and comparable
foreign regulatory authorities require us to comply with standards, commonly referred to as good clinical practices, or
GCPs, for conducting, recording and reporting the results of clinical trials to assure that data and reported results are
credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. Regulatory
authorities enforce these requirements through periodic inspections of trial sponsors, clinical investigators and trial sites. If
we or any of our CROs fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be
deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical
trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory
authority, such regulatory authority will determine that any of our clinical trials complies with GCP regulations. In
addition, our clinical trials must be conducted with product produced, under current good manufacturing practices, or
cGMP, regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay
the regulatory approval process. We also are required to register certain clinical trials and post the results of certain
completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within specified timeframes. Failure to
do so can result in fines, adverse publicity and civil and criminal sanctions.
Our CROs may also have relationships with other entities, some of which may be our competitors. In addition, our
CROs are not our employees, and except for remedies available to us under our agreements with such CROs, we cannot
control whether or not they devote sufficient time and resources to our on-going clinical, non-clinical and preclinical
programs. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct
our preclinical studies or clinical trials in accordance with regulatory requirements or our stated protocols, if they need to
be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our
clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated
and we may not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidate and will
not be able to, or may be delayed in our efforts to, successfully commercialize our products and product candidate. As a
result, our results of operations and the commercial prospects for our products and product candidates would be harmed,
our costs could increase and our ability to generate revenues could be delayed.
If any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with
alternative CROs or to do so on commercially reasonable terms. Switching or adding additional CROs involves
27
Table of Contents
additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO
commences work. As a result, delays could occur, which could compromise our ability to meet our desired development
timelines. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not
encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse
impact on our business, financial condition and prospects.
If the manufacturers upon whom we rely fail to produce our product candidate or any potential future product
candidate in the volumes that we require on a timely basis, or to comply with stringent regulations applicable to
pharmaceutical drug manufacturers, we may face delays in the development of our product candidate.
We do not manufacture oral difelikefalin, and we do not currently plan to develop any capacity to do so. We currently
rely, and expect to continue to rely, on third parties for the manufacture of oral difelikefalin and any potential future
product candidate for preclinical and clinical testing. If we were to experience an unexpected loss of supply of our product
candidate or any of our future product candidates for any reason, whether as a result of manufacturing, supply or storage
issues or otherwise, we could experience delays, disruptions, suspensions or terminations of, or be required to restart or
repeat, any pending or ongoing clinical studies.
It is our intention that, by the time of any regulatory approvals for commercialization of oral difelikefalin, we will
have negotiated long-term commitments with at least one primary supplier for each manufacturing and distribution
function. Any problems or delays we experience in preparing for commercial-scale manufacturing of a product or product
candidate may result in a delay in FDA approval of the product or product candidate or may impair our ability to
manufacture commercial quantities, which would adversely affect our business. For example, our manufacturers will need
to produce specific batches of our product or product candidate to demonstrate acceptable stability under various
conditions and for commercially viable lengths of time. We and our contract manufacturers will need to demonstrate to the
FDA and other regulatory authorities this acceptable stability data for our product or product candidate, as well as validate
methods and manufacturing processes, in order to receive and maintain regulatory approval to commercialize any approved
product candidates. Furthermore, if our commercial manufacturers fail to deliver the required commercial quantities of
bulk drug substance or finished product on a timely basis and at commercially reasonable prices, we would likely be unable
to meet demand for our product and we would lose potential revenues.
The manufacture of pharmaceutical products requires significant expertise and capital investment, including the
development of advanced manufacturing techniques and process controls. Manufacturers of pharmaceutical products often
encounter difficulties in production, particularly in scaling up initial production. These problems include difficulties with
production costs and yields, quality control, including stability of the products and product candidate and quality assurance
testing, shortages of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations.
Our manufacturers may not perform as agreed. If our manufacturers were to encounter any of these difficulties, our ability
to provide products for commercialization and product candidates to patients in our clinical trials would be jeopardized.
This could, among other things, lead to increased costs, lost revenue, damage to customer relationships, time and expense
spent investigating the cause and, depending on the cause, similar losses with respect to other batches or products. If
problems are not discovered before the product is released to the market, recall and product liability costs may also be
incurred.
Further, we may rely on proprietary technology developed by our contract manufacturers for purposes of
manufacturing certain of our products and product candidate and our failure to negotiate or maintain the long-term use of
any such proprietary technology or the inability for our contract manufacturers to produce our products and product
candidate or components of our products and product candidate in the volumes that we require on a timely basis, may lead
to delays or interruptions in the regulatory approval or commercialization process, as well as increased costs. For example,
in August 2019, we entered into the Enteris License Agreement and intend to use Enteris’s Peptelligence® technology to
develop, manufacture and commercialize oral difelikefalin. If we experience any interruptions in the manufacture, delivery
or scale-up of the Enteris formulation technology, we may experience delays in the development and commercialization of
oral difelikefalin. Further, if we are unable to maintain our relationship with Enteris, we may be forced to reformulate oral
difelikefalin which could result in significantly delaying commercializing oral difelikefalin and require us to incur
additional costs in connection with such reformulation and potentially needed to seek additional approvals from the FDA.
The operations of our third-party manufacturers have been and may in the future be
28
Table of Contents
constrained or disrupted and their operating capacity may be reduced by public health crises, such as pandemics or other
similar outbreaks, which could negatively impact our clinical development and commercialization timelines.
In addition, all manufacturers of our products and product candidate must comply with cGMP requirements enforced
by the FDA through its facilities inspection program. These requirements include quality control, quality assurance and the
maintenance of records and documentation. Manufacturers of our products and product candidate may be unable to comply
with these cGMP requirements and with other FDA, state and foreign regulatory requirements. If our contract
manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory
requirements of the FDA or other regulatory authorities, they will not be able to secure and/or maintain regulatory approval
for their manufacturing facilities. In addition, regulatory agencies subject an approved product, its manufacturer and the
manufacturer’s facilities to continual review and inspections, including periodic unannounced inspections. The subsequent
discovery of previously unknown problems with our current or any future approved products, including adverse events of
unanticipated severity or frequency, or problems with the facilities where our current or any future approved products are
manufactured, may result in restrictions on the marketing of our current or any such future approved products, up to and
including withdrawal of the affected product from the market. We have little control over our manufacturers’ compliance
with these regulations and standards. If the FDA or a comparable foreign regulatory authority does not approve these
facilities for the manufacture of our products and product candidate or if it withdraws any such approval in the future, we
may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain
regulatory approval for or market our products and product candidate, if approved. A failure to comply with these
requirements may result in fines and civil penalties, suspension of production, suspension, delay or denial of product
approval, product seizure or recall, or withdrawal of product approval. If the safety of any quantities supplied is
compromised due to our manufacturers’ failure to adhere to applicable laws or for other reasons, we may not be able to
obtain regulatory approval for or successfully commercialize our products and product candidate.
Even if we obtain regulatory approvals for our product candidate or any potential future product candidate, they may
never be successfully launched or become profitable, in which case our business, prospects, operating results and
financial condition may be materially harmed.
In order to successfully launch a product and have it become profitable, we anticipate that we will have to dedicate
substantial time and resources. Our ability to generate revenues from our commercialized products will depend on a
number of factors, including, but not limited to:
● achievement of broad market acceptance and coverage by government and third-party payers for our product;
● our or our partners’ effectiveness in marketing and selling our product;
● our ability to have manufactured commercial quantities of our product at acceptable cost levels and in compliance
with regulatory requirements;
● our ability to maintain a cost-efficient organization and, to the extent we seek to do so, to collaborate successfully
with additional third parties;
● our ability to expand and maintain intellectual property protection for our product successfully;
● the efficacy and safety of our product; and/or
● our ability to comply with regulatory requirements, which are subject to change.
Because of the numerous risks and uncertainties associated with our commercialization efforts, we may not be able
to achieve profitability. For example, we previously successfully developed KORSUVA injection through regulatory
approval, for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing
hemodialysis. However, this product failed to achieve meaningful commercial success.
29
Table of Contents
Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual
basis. A failure to become and remain profitable would depress the value of our company and could impair our ability to
raise capital, expand our business, diversify our product offerings or continue our operations. A decline in the value of our
company could also cause you to lose all or part of your investment.
If we or our collaborators are unable to establish effective marketing and sales capabilities, or if we are unable to enter
into or maintain agreements with third parties to market and sell our product and product candidate, if they are
approved, we may be unable to generate product revenues.
We currently do not have an internal commercial infrastructure for the marketing, sale, and distribution of
pharmaceutical products, but we intend to develop this infrastructure if oral difelikefalin or any future product candidate is
approved for marketing in the United States. In order to commercialize oral difelikefalin or any potential future product
candidate (if approved) in the United States, we will need to build our marketing, sales and distribution capabilities. We
have no prior experience in the marketing, sale and distribution of pharmaceutical products, and there are significant risks
involved in the building and managing of a commercial infrastructure to the extent we choose to do so in the future. The
establishment and development of our own sales force and related plans to market any products in the United States we
may develop will be expensive and time-consuming and could delay any product launch, and we may not be able to
successfully develop this capability. If oral difelikefalin or any future product candidate is approved for marketing outside
of the United States, we intend to make and maintain arrangements with third parties to perform these services.
We, or our partners or collaborators, will have to compete with other pharmaceutical and biotechnology companies to
recruit, hire, train, manage and retain marketing and sales personnel. In the event that we or our partners or our
collaborators are unable to develop a marketing and sales infrastructure, we may not be able to commercialize oral
difelikefalin or any potential future product candidate, which would limit our ability to generate product revenues. Factors
that may inhibit our or our partners’ or collaborators’ efforts to commercialize oral difelikefalin, if approved, or any
potential future product candidate include:
● inability to recruit, train, manage and retain adequate numbers of effective sales and marketing personnel;
● inability of sales personnel to obtain access to physicians and other providers or educate adequate numbers of
physicians and other providers on the benefits of prescribing the product;
● inability to effectively oversee a geographically dispersed sales and marketing team;
● the lack of complementary products to be offered by sales personnel, which may put us at a competitive
disadvantage relative to companies with more extensive product lines; and
● unforeseen costs and expenses associated with creating an independent sales and marketing organization.
Our or our partners’ or our collaborators’ sales force and marketing teams may not be successful in commercializing
any approved product candidate that may receive regulatory approval. For example, we previously partnered with CSL
Vifor for the commercialization of KORSUVA injection, but that product has not achieved meaningful commercial success.
In the event that we are unable to successfully collaborate with a third-party marketing and sales organization to
commercialize any approved product candidate outside the United States, our ability to generate product revenues may be
limited. To the extent that we rely on third parties to commercialize products for which we obtain regulatory approval, we
may receive less revenues than if we commercialized these products ourselves. In addition, we would have less control
over the sales efforts of any other third parties involved in our commercialization efforts.
30
Table of Contents
We face significant competition from other pharmaceutical and biotechnology companies, academic institutions,
government agencies and other research organizations. Our operating results will suffer if we fail to compete effectively.
The development and commercialization of new drug products is highly competitive. We face competition with
respect to our current product, KORSUVA injection, and our product candidate, and will face competition with respect to
any product candidates that we may seek to develop or commercialize in the future, from major pharmaceutical companies,
specialty pharmaceutical companies and biotechnology companies worldwide. There are a number of large pharmaceutical
and biotechnology companies that currently market and sell products or are pursuing the development of products for the
treatment of pruritus. Potential competitors also include academic institutions, government agencies and other public and
private research organizations that conduct research, seek patent protection and establish collaborative arrangements for
research, development, manufacturing and commercialization.
Among the companies that currently market or are developing therapies in the pruritus space that, if approved, our
oral difelikefalin may potentially compete with include: Pfizer, AbbVie, Eli Lilly, Amgen, Regeneron, Leo Pharma,
Galderma, Chugai, Incyte and others.
Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products
that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than our
products or our current or future product candidates. Our competitors also may obtain FDA or other regulatory approval for
their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a
strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many
cases by insurers or other third-party payers seeking to encourage the use of generic products. Generic products are
approved or used in clinical practice in some markets for the indication that our product candidate is intended to treat. We
expect that oral difelikefalin and any potential future product candidates, if approved, would be priced at a significant
premium over competitive generic products, if any.
Many of the companies against which we are competing or against which we may compete in the future have
significantly greater financial resources and expertise in R&D, manufacturing, preclinical testing, conducting clinical trials,
obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the
pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller
number of our competitors. Early-stage companies may also prove to be significant competitors, particularly through
collaborative arrangements with large and established companies. These third parties compete with us in recruiting and
retaining qualified scientific and management personnel, establishing clinical trial sites and patient recruitment for clinical
trials, as well as in acquiring technologies complementary to, or necessary for, our programs.
We face potential product liability exposure, and if successful claims are brought against us, we may incur substantial
liability and may have to limit commercialization of our product candidate.
We face an inherent risk of product liability lawsuits related to the sale of our products to, use of our products by, and
testing of our product candidate in, seriously ill patients. For example, product liability claims might be brought against us
by consumers, healthcare providers or others using, administering or selling our products. We may be sued if any product
we develop allegedly causes injury or is found to be otherwise unsuitable during clinical testing, manufacturing, marketing
or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure
to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. If we cannot successfully
defend ourselves against these claims, we will incur substantial liabilities. Regardless of merit or eventual outcome,
liability claims may result in:
● loss of revenue from decreased demand for our products and/or product candidate;
● impairment of our business reputation or financial stability;
● costs of related litigation;
31
Table of Contents
● substantial monetary awards to patients or other claimants;
● diversion of management attention and scientific resources from our business operations;
● withdrawal of clinical trial participants and potential termination of clinical trial sites or entire clinical programs;
● the inability to successfully commercialize our products and/or product candidate;
● significant negative media attention;
● initiation of investigations by regulators or increased regulatory scrutiny;
● product recalls, withdrawals or labeling, marketing or promotional restrictions; and
● the inability to commercialize our product candidate.
For any product candidate that is approved for commercial sale, we will be highly dependent upon healthcare
provider and patient perceptions of us and the safety and quality of our products. We could be adversely affected if we are
subject to negative publicity. We could also be adversely affected if any of our products or any similar products distributed
by other companies prove to be, or are asserted to be, harmful to patients. Because of our dependence upon consumer
perceptions, any adverse publicity associated with illness or other adverse effects resulting from patients’ use or misuse of
our products or any similar products distributed by other companies could have a material adverse impact on our financial
condition or results of operations.
We have obtained limited product liability insurance coverage for our products and our clinical trials with a $15.0
million annual aggregate coverage limit in the United States and various other coverage limits outside of the United States.
However, our insurance coverage may not reimburse us or may not be sufficient to reimburse us for any expenses or losses
we may suffer. Moreover, insurance coverage is becoming increasingly expensive, and, in the future, we may not be able to
maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. We
intend to expand our insurance coverage to include the sale of commercial products for our product candidate in
development, but we may be unable to obtain commercially reasonable product liability insurance for any products
approved for marketing, or at all. On occasion, large judgments have been awarded in class action lawsuits based on drugs
that had unanticipated side effects. A successful product liability claim or series of claims brought against us could cause
our stock price to fall and, if judgments exceed our insurance coverage, could decrease our cash and adversely affect our
business.
We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on our
product candidate or indications that may be more profitable or for which there is a greater likelihood of success.
Because we have limited financial and managerial resources, we focus on developing product candidates for specific
indications that we identify as most likely to succeed, in terms of both its regulatory approval and commercialization. As
such, we are currently focused on the development of oral difelikefalin for NP. As a result, we may have foregone or
delayed, or may in the future forgo or delay, pursuit of opportunities with other product candidates or for other indications
that may prove to have greater commercial potential. For example, in 2023, we terminated the atopic dermatitis program as
part of our strategy to focus on our advanced chronic kidney disease and NP programs. Further, in January 2024, we
announced a prioritization of our pipeline to focus our resources on our late-stage clinical program evaluating oral
difelikefalin in chronic pruritus associated with NP and terminate our Phase 3 clinical program evaluating oral difelikefalin
in pruritus associated with advanced chronic kidney disease. Our resource allocation decisions may cause us to fail to
capitalize on viable commercial products or profitable market opportunities. Our spending on current and future R&D
programs and product candidates for specific indications may not yield any commercially viable products. If we do not
accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish
valuable rights to that product candidate through collaboration, licensing, or other
32
Table of Contents
royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and
commercialization rights to such product candidate.
Our future growth may depend on our ability to identify and develop products and if we do not successfully identify and
develop product candidates or integrate them into our operations, we may have limited growth opportunities.
One component of our business strategy is to continue to develop a product that we believe is a strategic fit with our
focus on pruritus therapeutics. However, these business activities may entail numerous operational and financial risks,
including:
● difficulty or inability to secure financing to fund development activities for such development;
● disruption of our business and diversion of our management’s time and attention;
● higher than expected development costs;
● exposure to unknown liabilities;
● difficulty in managing multiple clinical trials; and
● inability to successfully develop new products or clinical failure.
We have limited resources to identify and execute the development of products. Moreover, we may devote resources
to potential developments that are never completed, or we may fail to realize the anticipated benefits of such efforts. If we
do not successfully develop and commercialize product candidates, we may not be able to obtain product revenues in
future periods.
The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and
inherently unpredictable. If we are not able to obtain, or if there are delays in obtaining, required additional regulatory
approvals, we will not be able to commercialize our product candidates as expected, and our ability to generate revenue
will be materially impaired.
The time required to obtain approval by the FDA and comparable foreign authorities is unpredictable but typically
takes many years following the commencement of clinical trials and depends upon numerous factors, including the
substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of
clinical data necessary to gain approval may change during the course of a product candidate’s clinical development and
may vary among jurisdictions. It is possible that neither oral difelikefalin, nor any potential product candidates we may
seek to develop in the future, will ever obtain regulatory approval.
Our product candidates and the activities associated with their development and commercialization, including their
design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale and
distribution, are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and by
the EMA, and similar regulatory authorities in other countries. Failure to obtain marketing approval for a product candidate
will prevent us from commercializing that product candidate. We expect to continue to rely on third-party CROs, other
vendors, and consultants to assist us in filing and supporting the applications necessary to gain marketing approvals.
Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information
to regulatory authorities for each therapeutic indication to establish the product candidate’s safety and efficacy for that
indication. Securing marketing approval also requires the submission of information about the product manufacturing
process to, and inspection of manufacturing facilities by, the regulatory authorities.
Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure
can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of our
product candidates may not be predictive of the results of later-stage clinical trials. Product candidates in later stages of
33
Table of Contents
clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies
and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in
advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials.
Our future clinical trial results may not be successful. We may also experience numerous unforeseen events during, or as a
result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product
candidates, including:
● regulators or institutional review boards may not authorize us or our investigators to commence a clinical trial or
conduct a clinical trial at a prospective trial site;
● we may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts or clinical
trial protocols with prospective trial sites;
● clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or
regulators may require us, to conduct additional clinical trials or abandon product development programs;
● the number of patients required for clinical trials of our product candidates may be larger than we anticipate,
enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical
trials at a higher rate than we anticipate;
● our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations
to us in a timely manner, or at all;
● we may have to suspend clinical trials, or terminate clinical trials of our product candidate for various reasons,
including a finding that the participants are being exposed to unacceptable health risks;
● regulators or institutional review boards may require that we or our investigators suspend or terminate clinical
research for various reasons, including noncompliance with regulatory requirements or a finding that the
participants are being exposed to unacceptable health risks;
● changes in marketing approval policies during the development period;
● changes in or the enactment of additional statutes or regulations;
● changes in regulatory review for each submitted product application;
● the cost of clinical trials of our product candidate may be greater than we anticipate;
● the supply or quality of our product candidate or other materials necessary to conduct clinical trials of our product
candidate may be insufficient or inadequate; and
● our product candidate may have undesirable side effects or other unexpected characteristics, causing us or our
investigators, regulators or institutional review boards to suspend or terminate the trials.
In addition, unfavorable changes in our industry or the global economy, including as a result of macroeconomic
factors related to inflation, rising interest rates, political turmoil, or public health crises such as pandemics or other similar
outbreaks, could contribute to some of the events listed above and further impact our ability to progress our clinical trials,
submit for marketing approval or commercialize our product candidates, if approved, as planned. Further, if and to the
extent, global health concerns prevent the FDA or other regulatory authorities from conducting their regular inspections,
reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to
timely review and process our additional regulatory submissions, which could affect our ability to obtain marketing
approval for our product candidate.
34
Table of Contents
Moreover, if we are required to conduct additional clinical trials or other testing of our product candidate beyond
those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidate or
other testing, if the results of these trials or tests are not positive or are only modestly positive or if there are safety
concerns, we may:
● be delayed in obtaining marketing approval for our product candidate;
● not obtain marketing approval at all;
● obtain approval for indications or patient populations that are not as broad as intended or desired;
● obtain approval with labeling that includes significant use or distribution restrictions or safety warnings;
● be subject to additional post-marketing testing requirements; or
● have the product removed from the market after obtaining marketing approval.
Furthermore, regulatory authorities have substantial discretion in the approval process and may refuse to accept any
application or may decide that our data is insufficient for approval and require additional preclinical, clinical or other
studies, including with respect to third-party technology used in any of our product candidates such as the excipient we
intend to use for oral difelikefalin. In addition, varying interpretations of the data obtained from preclinical and clinical
testing could delay, limit or prevent marketing approval of a product candidate. Any marketing approval we ultimately
obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not
commercially viable.
Finally, even if we were to obtain approval, regulatory authorities may approve our product candidate for fewer or
more limited indications than we request, may grant approval contingent on the performance of costly post-marketing
clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or
desirable for the successful commercialization of that product candidate. Any of these scenarios could compromise the
commercial prospects for our product candidate to assure safe use of the product candidate, either as a condition of product
candidate approval or on the basis of new safety information.
If we experience delays in obtaining approval, if we fail to obtain approval of a product candidate or if the label for a
product candidate does not include the labeling claims necessary or desirable for the successful commercialization of that
product candidate, the commercial prospects for such product candidate may be harmed and our ability to generate
revenues will be materially impaired.
Our product candidate or any future product candidate, if approved, could be subject to labeling and other restrictions
and market withdrawal and we may be subject to penalties if we fail to comply with regulatory requirements or
experience unanticipated problems with our product.
Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the
indicated uses for which the product may be marketed or to the conditions of approval, including any requirement to
implement a Risk Evaluation and Mitigation Strategies, or REMS. If our product candidate receives marketing approval,
the accompanying label may limit the approved use of our drug, which could limit sales of the product.
The FDA or other regulatory authorities may also impose requirements for costly post-marketing studies or clinical
trials and surveillance to monitor the safety or efficacy of the product. The FDA and other regulatory authorities closely
regulate the post-approval marketing and promotion of drugs to ensure drugs are marketed only for the approved
indications and in accordance with the provisions of the approved labeling. The FDA and other regulatory authorities
impose stringent restrictions on manufacturers’ communications regarding off-label use and if we do not market our
products for their approved indications, we may be subject to enforcement action for off-label marketing. Violations of the
Federal Food, Drug, and Cosmetic Act or equivalent regulations outside the United States relating to the promotion
35
Table of Contents
of prescription drugs may lead to investigations alleging violations of federal and state health care fraud and abuse laws, as
well as state consumer protection laws.
In addition, later discovery of previously unknown AEs or other problems with our products, manufacturers or
manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including:
● restrictions on the products, manufacturers, manufacturing facilities or manufacturing process;
● imposition of restrictions on operations, including costly new manufacturing requirements;
● restrictions on the labeling or marketing of a product;
● restrictions on product distribution or use;
● requirements to conduct post-marketing studies or clinical trials;
● warning letters;
● withdrawal of the products from the market;
● refusal to approve pending applications or supplements to approved applications that we submit;
● recall of products and publicity requirements;
● fines, restitution or disgorgement of profits or revenues;
● suspension or withdrawal of marketing or regulatory approvals;
● refusal to permit the import or export of our products;
● product seizure, detentions or import bans; or
● injunctions or the imposition of civil or criminal penalties.
The FDA’s or other regulatory authorities’ policies may change and additional government regulations may be
enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt
to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain
regulatory compliance, we may lose any marketing approval that we may have obtained.
Regulatory approval is limited by the FDA and other regulatory authorities to those specific indications and conditions
for which clinical safety and efficacy have been demonstrated, and we may be subject to fines, penalties or injunctions if
we are determined to be promoting the use of our products for unapproved or “off-label” uses, resulting in damage to
our reputation and business.
When the FDA or comparable foreign regulatory authorities issue regulatory approval for a product candidate, the
regulatory approval is limited to those specific indications for which a product is approved. If we are not able to obtain
FDA approval for any desired future indications for our products and product candidates, our ability to effectively market
and sell our products may be reduced and our business may be adversely affected.
While physicians may choose to prescribe drugs for uses that are not described in the product’s labeling and for uses
that differ from those tested in clinical studies and approved by the regulatory authorities, we are prohibited from
marketing and promoting the products for indications that are not specifically approved by the FDA or other regulatory
36
Table of Contents
authorities. These “off-label” uses are common across medical specialties and may constitute an appropriate treatment for
some patients in varied circumstances. Regulatory authorities in the United States and other countries generally do not
restrict or regulate the behavior of physicians in their choice of treatment within the practice of medicine. Regulatory
authorities do, however, restrict communications by pharmaceutical companies on off-label use. If the FDA or other
regulatory authorities determine that our or our commercial partners’ promotional activities constitute promotion of an off-
label use, it could request that we modify our promotional materials. Further, off-label promotion could subject us to
regulatory or enforcement actions by the FDA and other authorities, including issuance of warning letters or untitled
letters, suspension or withdraw an approved product from the market, mandatory or voluntary recalls, civil fines,
disgorgement of money, operating restrictions, additional reporting requirements and/or oversight if we become subject to a
corporate integrity agreement or similar agreement, injunctions or criminal prosecution, any of which could significantly
harm our business.
Failure to obtain marketing approval in international jurisdictions would prevent our product candidate from being
marketed abroad.
In order to market and sell our products in the EU and many other jurisdictions, we or our collaborators or partners
must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. Even if we
obtain FDA approval of a product candidate, the regulatory approval procedure varies among countries and can involve
additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval.
The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA
approval. In addition, in many countries outside the United States, it is required that the product be approved for
reimbursement before the product can be approved for sale in that country. We or these third parties may not obtain
approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not
ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority
outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the
FDA. However, the failure to obtain approval in one jurisdiction may compromise our or our collaborators’ or partners’
ability to obtain approval elsewhere. We or our collaborators or partners may not be able to file for marketing approvals
and may not receive necessary approvals to commercialize our products in any market.
Our agreements with HCR contain various covenants and other provisions, which, if violated, could materially
adversely affect our financial condition.
During the fourth quarter of 2023, we, through Cara Royalty Sub, entered into the HCR Agreement with HCR,
pursuant to which Cara Royalty Sub sold, or agreed to sell, to HCR the Royalties under the Covered License Agreements,
in exchange for up to $40.0 million. We have retained all of our right, title and interest in, to and under the Covered
License Agreements that relate to any non-intravenous formulation of difelikefalin.
Under the terms of the HCR Agreement, Cara received an initial payment of $17.5 million in November 2023. In
December 2023, we received an additional $20.0 million less certain advisory fees, upon satisfying the milestone event for
pricing for Kapruvia® (difelikefalin) in Germany being approved above a certain threshold amount per dose. The terms of
the HCR Agreement also provide for an additional $2.5 million milestone payment to Cara Royalty Sub upon achievement
of a 2024 sales milestone of KORSUVA in Japan.
The HCR Agreement will automatically expire, and the payment of Royalties to HCR will cease, when HCR has
received payments of Royalties equal to two times the aggregate amount of payments made by HCR under the HCR
Agreement if achieved on or prior to December 31, 2029, or 2.8 times the aggregate amount of payments made by HCR
under the HCR Agreement, if the 2029 Threshold is not achieved on or prior to December 31, 2029. In the event of a
change of control, Cara Royalty Sub will pay to HCR an amount equal to 2.8 times the aggregate amount of payments
made by HCR less the total net amounts paid by Cara Royalty Sub to HCR as of the effective date of control. In certain
situations, Cara Royalty Sub would not be obligated to pay the change of control payment to HCR. After the HCR
Agreement expires, all rights to receive the Royalties return to Cara Royalty Sub.
In connection with the HCR Agreement, we entered into a Contribution and Servicing Agreement which contains
various representations and warranties, covenants, indemnification obligations and other provisions related to the
37
Table of Contents
contribution of the Covered License Agreement to Cara Royalty Sub and our maintenance and servicing obligations with
respect to the Royalties and the Covered License Agreements. In the event we violate these covenants or provisions, we
may lose the right to act as the servicer of Cara Royalty Sub and a third-party servicer may be appointed at Cara Royalty
Sub’s expense. Our replacement as servicer, if it were to occur, could have a material adverse effect on our financial
condition as HCR, by virtue of owning Cara Royalty Sub, would own the Royalties.
In connection with the HCR Agreement we also entered into a Pledge and Security Agreement containing various
representations, warranties and covenants, and a limited recourse guaranty of Cara Royalty Sub’s obligations under the
Purchase and Sale Agreement which is secured by the pledge in favor of HCR all of the capital stock of Cara Royalty Sub.
HCR is entitled to foreclose on the capital stock of Cara Royalty Sub following the occurrence of certain remedies events,
including, without limitation, a bankruptcy of us or the failure of us to perform our obligations under the Contribution and
Servicing Agreement. Such foreclosure, if it were to occur, could have a material adverse effect on our financial condition
as HCR, by virtue of owning Cara Royalty Sub, would own the Royalties.
Our information systems, or those of others upon whom we rely (such as our CROs, contract manufacturers,
contractors, consultants, service providers, collaborators and others) may fail or suffer cybersecurity breaches, loss or
leakage of data or other disruptions, which could result in a material disruption of our development programs,
compromise sensitive information related to our business, or prevent us from accessing critical information, potentially
exposing us to liability that could adversely affect our business.
We are increasingly dependent upon information systems, infrastructure and data to operate our business. In the
ordinary course of business, we collect, store, transmit and otherwise process confidential information (including but not
limited to intellectual property, proprietary business information and personal data). We also have outsourced elements of
our operations to third parties, and as a result we manage a number of service providers who have access to our data and
information systems and infrastructure. Our reliance on service providers could introduce new cybersecurity risks and
vulnerabilities, including supply-chain attacks, and other threats to our business operations. We rely on service providers
and technologies to operate critical business systems to process sensitive data in a variety of contexts, including, without
limitation, cloud-based infrastructure, data center facilities, encryption and authentication technology, personnel email, and
other functions. We also rely on third-party service providers to provide other products, services, parts, or otherwise to
operate our business. Our ability to monitor these third parties’ information security practices is limited, and these third
parties may not have adequate information security measures in place. If our third-party service providers experience a
security incident or other interruption, we could experience adverse consequences. While we may be entitled to damages if
our third-party service providers fail to satisfy their privacy or security-related obligations to us, any award may be
insufficient to cover our damages, or we may be unable to recover such award. In addition, supply-chain attacks have
increased in frequency and severity, and we cannot guarantee that third parties’ infrastructure in our supply chain or our
third-party partners’ supply chains have not been compromised.
Cybersecurity risks have significantly increased in recent years in part because of the proliferation of new
technologies, the use of the internet and telecommunication technologies to conduct financial transactions, especially as
personnel are working remotely, and the increased sophistication and activities of organized crime, hackers, terrorists,
nation-states and other external parties. To the extent that any disruption or cybersecurity breach were to result in a loss of,
or damage to, our data or information systems, or inappropriate disclosure of confidential or proprietary information, we
could incur liability and reputational damage and the further development of our product candidates could be delayed.
Some actors now engage and are expected to continue to engage in cyberattacks, including without limitation nation-
state actors for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war
and other major conflicts, we, and the third parties upon which we rely, may be vulnerable to a heightened risk of these
attacks, including retaliatory cyberattacks, that could materially disrupt our systems and operations, supply chain, and
ability to produce, sell and distribute our goods and services. In particular, severe ransomware attacks are becoming
increasingly prevalent and can lead to significant interruptions in our operations, ability to provide our products or services,
loss of sensitive data and income, reputational harm, and diversion of funds. Extortion payments may alleviate the
negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example,
applicable laws or regulations prohibiting such payments.
38
Table of Contents
We and the third parties upon which we rely are subject to a variety of evolving threats, including but not limited to
social-engineering attacks (including through deep fakes, which may be increasingly more difficult to identify as fake, and
phishing attacks), malicious code (such as viruses and worms), malware (including as a result of advanced persistent threat
intrusions), denial-of-service attacks, credential stuffing, credential harvesting, personnel misconduct or error, ransomware
attacks, supply-chain attacks, software bugs, server malfunctions, software or hardware failures, loss of data or other
information technology assets, adware, attacks enhanced or facilitated by AI, telecommunications failures, earthquakes,
fires, floods, and other similar threats. Additionally, future or past business transactions (such as acquisitions or
integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively
affected by vulnerabilities present in acquired or integrated entities’ systems and technologies. Furthermore, we may
discover security issues that were not found during due diligence of such acquired or integrated entities, and it may be
difficult to integrate companies into our information technology environment and security program.
While we have implemented security measures designed to protect against security incidents, there can be no
assurance that these measures will be effective. We take steps designed to detect, mitigate, and remediate vulnerabilities in
our information systems (such as our hardware and/or software, including that of third parties upon which we rely). We
may not, however, detect and remediate all such vulnerabilities including on a timely basis. Further, we may experience
delays in developing and deploying remedial measures and patches designed to address identified vulnerabilities.
Vulnerabilities could be exploited and result in a security incident.
Any of the previously identified or similar threats could cause a security incident or other interruption that could
result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure
of, or access to our sensitive data or our information technology systems, or those of the third parties upon whom we rely.
A security incident or other interruption could disrupt our ability (and that of third parties upon whom we rely) to provide
our services.
We may expend significant resources or modify our business activities to try to protect against security incidents.
Additionally, certain data privacy and security obligations may require us to implement and maintain specific security
measures or industry-standard or reasonable security measures to protect our information technology systems and sensitive
data.
Applicable data privacy and security obligations may require us to notify relevant stakeholders, including affected
individuals, customers, regulators, and investors, of security incidents. Such disclosures are costly, and the disclosure or
the failure to comply with such requirements could lead to adverse consequences.
If we (or a third party upon whom we rely) experience a security incident or are perceived to have experienced a
security incident, we may experience adverse consequences, such as government enforcement actions (for example,
investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on
processing sensitive data (including personal data); litigation (including class claims); indemnification obligations;
negative publicity; reputational harm; monetary fund diversions; diversion of management attention; interruptions in our
operations (including development and commercialization of oral difelikefalin, if approved, and availability of data);
financial loss; and other similar harms. Security incidents and attendant consequences may prevent or cause customers to
stop using our services, deter new customers from using our services, and negatively impact our ability to grow and operate
our business.
Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that
limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data
privacy and security obligations. We cannot be sure that our insurance coverage will be adequate or sufficient to protect us
from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be
available on commercially reasonable terms or at all, or that such coverage will pay future claims.
39
Table of Contents
Risks Related to Our Financial Condition and Capital Requirements
We have incurred significant losses from our inception, and we anticipate that we may incur losses in the foreseeable
future.
We are a development-stage biopharmaceutical company. Until recently, we had focused our efforts primarily on
developing KORSUVA injection, Kapruvia and oral difelikefalin for a number of indications with the goal of achieving
regulatory approval and, more recently, commercializing KORSUVA injection and Kapruvia. However, the commercial
launches of KORSUVA injection and Kapruvia did not achieve meaningful success and, in January 2024, we made the
strategic decision to focus our efforts on developing oral difelikefalin for the treatment of pruritus associated with NP.
Since inception, we have incurred significant operating and net losses. We incurred net losses of $118.5 million, $85.5
million and $88.4 million for the years ended December 31, 2023, 2022 and 2021, respectively. As of December 31, 2023,
we had an accumulated deficit of $684.7 million, and we expect to continue to incur significant expenses and operating and
net losses in the foreseeable future, as we continue to develop and seek regulatory approval for oral difelikefalin and any
potential future product candidates.
Our financial results may fluctuate significantly from year to year, depending on the timing of our clinical trials, the
receipt of payments under any future agreements we may enter into, and our expenditures on other R&D activities as well
as any payments owed under the License Agreement with Enteris and any future similar agreements.
As a result, we expect to continue to incur significant losses for the foreseeable future as we:
● continue the development of oral difelikefalin for NP;
● seek regulatory approvals for any other product candidate that successfully completes clinical trials;
● establish a sales, marketing and distribution infrastructure in the United States and scale up external
manufacturing capabilities to commercialize any products for which we may obtain regulatory approval;
● maintain, expand and protect our global intellectual property portfolio;
● hire additional clinical, quality control and scientific personnel; and
● add operational, financial and management information systems and personnel, including personnel to support
our drug development and potential future commercialization efforts.
Revenues from KORSUVA injection will not be sufficient to enable us to reach profitability. To become and remain
profitable from product sales, we must succeed in developing and eventually commercializing one or more products that
generate significant revenue. In order to commercialize any product candidate, we will need to be successful in a range of
challenging activities, including successful registration of oral difelikefalin, discovering, developing, licensing or acquiring
additional product candidates and completing preclinical testing and clinical trials for those product candidates, potentially
entering into collaboration and license agreements, obtaining regulatory approval for product candidates and
manufacturing, marketing and selling approved products and product candidates for which we may obtain regulatory
approval. We may never succeed in these activities and, even if we do, may never achieve profitability.
Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable
to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. If
we are required by the FDA or foreign regulatory authorities, to perform studies in addition to those currently expected, or
if there are any delays in completing our clinical trials or the development of our product candidate, our expenses could
increase.
40
Table of Contents
Even if we do achieve profitability from product sales, we may not be able to sustain or increase profitability on a
quarterly or annual basis. Our failure to become and remain profitable would depress the value of our company and could
impair our ability to raise capital, expand our business, maintain our R&D efforts, diversify our product offerings or even
continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.
We may need additional funding and may be unable to raise capital when needed, which would force us to delay, reduce
or eliminate our product development programs.
Conducting clinical trials, pursuing regulatory approvals, establishing outsourced manufacturing relationships, and
successfully manufacturing and commercializing our product and product candidate is expensive. We may need to raise
additional capital to continue the development of oral difelikefalin for NP and potentially in-license or acquire other
product candidates.
In January 2024, we announced a prioritization of our pipeline to focus our resources on our late-stage clinical
program evaluating oral difelikefalin in chronic pruritus associated with NP and terminate our Phase 3 clinical program
evaluating oral difelikefalin in pruritus associated with advanced chronic kidney disease, including our KICK 1 and KICK
2 Phase 3 clinical trials. As part of this strategic update, in the first quarter of 2024, we reduced our global workforce by
approximately 50%.
After taking into account our strategic prioritization and reduction in workforce, we expect that our current
unrestricted cash and cash equivalents and available-for-sale marketable securities will be sufficient to fund our currently
anticipated operating plan into 2026. Our anticipated operating expenses include contractually committed costs as well as
non-contractually committed clinical trial costs for trials that may be delayed or not initiated and other non-committed
controllable costs. Because the process of testing product candidates in clinical trials is costly and the timing of progress in
these trials is uncertain, it is possible that the assumptions upon which we have based this estimate may prove to be wrong,
and we could use our capital resources sooner than we presently expect.
Our future funding requirements will depend on many factors, including, but not limited to:
● the rate of progress and costs related to Phase 2 and Phase 3 development of oral difelikefalin and any trials for
future product candidates;
● the rate of progress and costs for any product candidates that we may in-license or acquire in the future;
● the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights
associated with our product candidate, including any such costs we may be required to expend if our licensors are
unwilling or unable to do so;
● the effect of competing technological and market developments; and
● the terms and timing of any collaborative, licensing, co-promotion or other arrangements that we may establish.
Future capital requirements will also depend on the extent to which we acquire or invest in additional complementary
businesses, products and technologies. Until we can generate a sufficient amount of product revenue, if ever, we expect to
finance future cash needs through public or private equity offerings, debt financings, milestone and royalty payments from
corporate collaboration and licensing arrangements, as well as through interest income earned on cash and investment
balances. We cannot be certain that additional funding will be available on acceptable terms, or at all, and our ability to
raise additional capital may be adversely impacted by potential worsening global economic conditions, including high rates
of inflation and interest rates, the continuing disruptions to and volatility in the credit and financial markets in the United
States and worldwide, including resulting from the ongoing conflicts between Russia and the Ukraine, conflicts in the
Middle East, and increasing tensions between China and Taiwan. If adequate funds are not available, we may be required
to delay, reduce the scope of, or eliminate, our development program.
41
Table of Contents
Risks Related to Our Dependence on Third Parties
Any collaboration arrangements that we are a party to or may enter into in the future may not be successful, which
could adversely affect our ability to develop and ultimately commercialize our product candidate or any potential future
product candidate.
Our business model is to develop and commercialize our product candidate in the United States and generally to seek
collaboration arrangements with pharmaceutical or biotechnology companies for the development or commercialization of
our product candidate in the rest of the world. We currently have license agreements with Maruishi and CKDP for the
intravenous and oral formulations of difelikefalin, as well as license agreements with respect to our commercially approved
products, KORSUVA Injection and Kapruvia with CSL Vifor. In addition to our existing agreements, we may enter into
additional collaboration arrangements in the future on a selective basis. Our existing collaborations and future collaboration
arrangements may not be successful. The success of our existing and future collaboration arrangements will depend heavily
on the efforts and activities of our collaborators.
Collaborators generally have significant discretion in determining the efforts and resources that they will apply to
these collaboration arrangements. Disagreements between parties to a collaboration arrangement regarding clinical
development and commercialization matters can lead to delays in the development process or commercializing the
applicable product candidate and, in some cases, termination of the collaboration arrangement. These disagreements can be
difficult to resolve if neither of the parties has final decision-making authority.
Collaborations with pharmaceutical companies and other third parties often are terminated or allowed to expire by
the other party. Maruishi may terminate its agreement with us at will, and CKDP may terminate its agreement with us in
certain circumstances relating to patent invalidity or unenforceability or generic entry by a third party, as further described
in the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations -
Collaboration and License Agreements”. Any such termination or expiration could adversely affect us financially and
could harm our business reputation. Our current collaborations and any future collaborations we might enter into may pose
a number of risks, including the following:
● collaborators may not perform their obligations as expected;
● collaborators may not pursue development and commercialization of our product or product candidate that
achieves regulatory approval or may elect not to continue or renew development or commercialization programs
based on clinical trial results, changes in the collaborators’ strategic focus or available funding that divert
resources or create competing priorities;
● collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial
or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product
candidate for clinical testing;
● collaborators could fail to make timely regulatory submissions for a product or product candidate;
● collaborators may not comply with all applicable regulatory requirements or may fail to report safety data in
accordance with all applicable regulatory requirements;
● collaborators could independently develop, or develop with third parties, products that compete directly or
indirectly with our products or product candidates if the collaborators believe that competitive products are more
likely to be successfully developed or can be commercialized under terms that are more economically attractive
than ours;
● product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with
their own product candidates or products, which may cause collaborators to cease to devote resources to the
commercialization of our product candidate;
42
Table of Contents
● a collaborator with marketing and distribution rights to one or more of our products or product candidate that
achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such
product or products;
● disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the
preferred course of development, might cause delays or termination of the research, development or
commercialization of products and product candidate, might lead to additional responsibilities for us with respect
to products and product candidate, or might result in litigation or arbitration, any of which would be time-
consuming and expensive;
● collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary
information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or
proprietary information or expose us to potential litigation;
● collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and
potential liability; and
● collaborations, including our collaboration with Maruishi, may be terminated for the convenience of the
collaborator and, if terminated, we could be required to raise additional capital to pursue further development or
commercialization of the applicable product candidate.
If our current collaborations or any other collaborations we might enter into in the future do not result in the
successful development and commercialization of products or if one of our collaborators terminates its agreement with us,
we may not receive any future research funding or milestone or royalty payments under the collaboration. If we do not
receive the funding we expect under these agreements, our development of our product candidate could be delayed and we
may need additional resources to develop our product candidate and our product platform. All of the risks relating to our
product development, regulatory approval and commercialization described in this Annual Report on Form 10-K also apply
to the activities of our collaborators in their respective jurisdictions.
Additionally, if any current or future collaborator of ours is involved in a business combination, the collaborator
might deemphasize or terminate development or commercialization of any product candidate licensed to it by us. If one of
our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators and our
reputation in the business and financial communities could be adversely affected.
If we determine to collaborate in the future with additional pharmaceutical or biotechnology companies for the
development and potential commercialization of oral difelikefalin or any potential future product candidate, we would face
significant competition in seeking appropriate collaborators. Our ability to reach a definitive agreement for collaboration
will depend, among other things, upon our assessment of the collaborator’s resources and expertise, the terms and
conditions of the proposed collaboration and the proposed collaborator’s evaluation of a number of factors. If we are
unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to
curtail the development of a product candidate, reduce or delay its development program or one or more of our other
development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or
increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to
fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise
and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations
and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we
may not be able to further develop our product candidates or bring them to market or continue to develop our product
platform or successfully commercialize our products and our business may be materially and adversely affected.
43
Table of Contents
Risks Related to Legal and Compliance Matters
If we fail to comply with federal and state healthcare laws, including fraud and abuse, and transparency laws, we could
face substantial penalties and our business, results of operations, financial condition and prospects could be adversely
affected.
As a pharmaceutical company, even though we do not and will not control referrals of healthcare services or bill
directly to Medicare, Medicaid or other third-party payers, certain federal and state healthcare laws and regulations
pertaining to fraud and abuse, transparency and patients’ rights may be applicable to our business. The healthcare laws and
regulations that may affect our ability, and our partners’ and collaborators’ ability, to operate include, but are not limited to:
● the federal Anti-Kickback Statute, which regulates, among other things, our marketing practices, educational
programs, pricing policies, and relationships with healthcare providers or other entities, by prohibiting, among
other things, any person or entity from knowingly and willfully soliciting, receiving, offering or paying any
remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, the purchase,
recommendation, lease, order or furnishing of an item or service reimbursable, in whole or in part, under a federal
healthcare program, such as the Medicare and Medicaid programs;
● federal civil and criminal false claims laws, including without limitation the federal civil False Claims Act, and
civil monetary penalties law, which prohibit, among other things, individuals or entities from knowingly
presenting, or causing to be presented, false or fraudulent claims for payment or approval from a federal health
care program (including Medicare and Medicaid);
● Federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional federal
criminal statutes that prohibit, among other things, knowingly and willfully executing, or attempting to execute, a
scheme to defraud any healthcare benefit program or to obtain, by means of false or fraudulent pretenses,
representations, or promises, any of the money or property owned by, or under the custody or control of, any
health care benefit program, regardless of the payer (e.g., public or private) and knowingly and willfully
falsifying, concealing, or covering up by any trick, scheme or device a material fact or making any materially
false statements in connection with the delivery of, or payment for, health care benefits, items or services relating
to healthcare matters;
● federal transparency laws, including the federal Physician Payments Sunshine Act, that requires certain
manufacturers of drugs, devices, biologics, and medical supplies for which payment is available under Medicare,
Medicaid, or the Children’s Health Insurance Program to report annually to CMS information related to payments
and other transfers of value provided to physicians (defined to include doctors of medicine, dentists, optometrists,
podiatrists and chiropractors), other healthcare professionals (such as physician assistants and nurse
practitioners), and teaching hospitals, and applicable manufacturers and group purchasing organizations to report
annually to CMS ownership and investment interests held by physicians and their immediate family members;
● state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may
apply to items or services reimbursed by any third-party payer, including commercial insurers; and
● state laws that require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary
compliance guidelines and the relevant compliance guidance promulgated by the federal government, or
otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state
laws that require drug manufacturers to report information related to the pricing of certain drugs, as well as
payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and
state and local laws that require the registration of pharmaceutical sales representatives, many of which differ
from each other in significant ways and may not have the same effect, thus complicating compliance efforts.
44
Table of Contents
Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors
available under these laws, it is possible that some of our business activities could be subject to challenge under one or
more of such laws. Pharmaceutical and other healthcare companies continue to be prosecuted under the federal false claims
laws for numerous activities, including those related to research, sales, marketing and promotional programs. In addition,
recent health care reform legislation has strengthened these laws. For example, the Patient Protection and Affordable Care
Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, or the Health Care Reform Law,
among other things, amends the intent requirement of the federal Anti-Kickback Statute and certain other criminal
healthcare fraud statutes. As a result, a person or entity no longer needs to have actual knowledge of these statutes or
specific intent to violate them in order to commit a violation. Moreover, the Health Care Reform Law provides that the
government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback
Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. To the extent that any
product we make is sold in a foreign country, we may be subject to similar foreign laws and regulations. If we or our
operations are found to be in violation of any of the laws described above or any other governmental regulations that apply
to us, we may be subject to significant penalties, including administrative, civil and criminal penalties, damages, fines,
disgorgement, exclusion from participation in U.S. federal or state health care programs, contractual damages, reputational
harm, imprisonment, diminished profits and future earnings, additional reporting requirements and/or oversight if we
become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these
laws, and the curtailment or restructuring of our operations, any of which could materially adversely affect our ability to
operate our business and our financial results. Although an effective compliance program can mitigate the risk of
investigation and prosecution for violations of these laws, the risks cannot be entirely eliminated. Any action against us for
violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and
divert our management’s attention from the operation of our business. Moreover, achieving and sustaining compliance with
applicable federal and state transparency and fraud and abuse laws may prove costly. If any of the physicians or other
healthcare providers or entities with whom we do business, including our partners or collaborators, is found not to be in
compliance with applicable laws, it may be subject to significant criminal, civil or administrative sanctions, including but
not limited to, exclusions from participation in government healthcare programs, which could also materially affect our
business.
We are subject to stringent and evolving U.S. and foreign laws, regulations and standards, contracts, industry standards,
policies and other obligations related to data privacy and security. Our actual or perceived failure to comply with such
obligations could lead to regulatory investigations or actions, litigation (including class claims) and mass arbitration
demands, fines and penalties, disruptions of our business operations, reputational harm, loss of revenue and profits,
and otherwise adversely affect our business, operations and financial performance.
We are subject to or affected by numerous domestic (both federal and state) and foreign laws and regulations, as well
as regulatory guidance, contracts, industry standards, policies and other obligations governing the collection, use,
disclosure, retention, security and other processing of personal data, such as information that we collect about participants
and healthcare providers in connection with clinical trials in the United States and abroad. Obligations related to data
privacy and security (and consumers’ data privacy expectations) are quickly changing, becoming increasingly stringent,
and creating uncertainty. Additionally, these obligations may be subject to differing applications and interpretations, which
may be inconsistent or conflict among jurisdictions. This evolving global data protection landscape may create uncertainty
in our business, affect our or our service providers’ ability to operate in certain jurisdictions or to collect, store, transfer
use, share and otherwise personal data, result in liability or impose additional costs on us. The cost of compliance with
these obligations is high and is likely to increase in the future and may necessitate changes to our operations and to those of
third parties that process personal data on our behalf. In many jurisdictions, enforcement actions and consequences for
noncompliance are rising.
In the United States, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health
Act of 2009, or HITECH, imposes certain requirements relating to the privacy, security and transmission of individually
identifiable health information without appropriate authorization by entities subject to the rule, including health plans,
healthcare clearinghouses, certain healthcare providers, and their business associates and covered subcontractors that
perform services for them that involve the creation, use, maintenance or disclosure of, individually identifiable health
information. In the event we are subject to HIPAA and we or our business associates or subcontractors fail to properly
maintain the privacy and security of certain individually identifiable health information,
45
Table of Contents
or we or our business associates or subcontractors are responsible for an inadvertent disclosure or security breach of such
individually identifiable health information, we could be subject to enforcement measures, including civil and criminal
penalties and fines for violations of state and federal privacy or security standards, such as HIPAA and HITECH, and their
respective implementing regulations.
Additionally, certain states have adopted their own privacy and security laws and regulations for health information,
some of which may be more stringent than HIPAA.
In the past few years, numerous U.S. states, following California’s enactment of the CCPA — including Virginia,
Colorado, Connecticut, and Utah—have enacted comprehensive privacy laws that impose certain obligations on covered
businesses, including providing specific disclosures in privacy notices and affording residents with certain rights
concerning their personal data. As applicable, such rights may include the right to access, correct, or delete certain personal
data, and to opt-out of certain data processing activities, such as targeted advertising, profiling, and automated decision-
making. To the extent that we are or may become subject to these laws, the exercise of these rights may impact our
business and ability to provide our products and services. Similar laws are being considered in several other states, as well
as at the federal and local levels, and we expect more states to pass similar laws in the future. These state laws may allow
for statutory fines for noncompliance (for example, under the CCPA, fines can be levied up to $7,500 per intentional
violation) and private rights of action. While some of these laws may exempt some data processed in the context of clinical
trials, these developments further complicate compliance efforts, and increase legal risk and compliance costs for us, and
the third parties upon whom we rely. For example, Washington’s My Health My Data Act (“MHMD”) broadly defines
consumer health data, places restrictions on processing consumer health data (including imposing stringent consent
requirements), provides consumers certain rights with respect to their health data, and creates a private right of action to
allow individuals to sue for violations of the law.
Outside the United States, an increasing number of laws, regulations, and industry standards govern data privacy and
security. For example, the EU GDPR and the UK GDPR impose strict requirements for processing personal data. GDPR
may increase compliance burdens on us, including by mandating potentially burdensome documentation requirements and
granting certain rights to individuals to control how we collect, use, disclose, retain and otherwise process personal data.
The processing of sensitive personal data, such as physical health conditions, may also be subject to heightened compliance
burdens under the GDPR. Under the GDPR, companies may face temporary or definitive bans on data processing and other
corrective actions; fines of up to 20 million Euros under the EU GDPR, 17.5 million pounds sterling under the UK GDPR
or, in each case, 4% of annual global revenue, whichever is greater; or private litigation related to processing of personal
data brought by classes of data subjects or consumer protection organizations authorized at law to represent their interests.
In addition, we may be unable to transfer personal data from Europe and other jurisdictions to the United States or
other countries due to data localization requirements or limitations on cross-border data flows. Europe and other
jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal data to other countries. In
particular, the European Economic Area (EEA) and the United Kingdom (UK) have significantly restricted the transfer of
personal data to the United States and other countries whose privacy laws it generally believes are inadequate. Other
jurisdictions may adopt similarly stringent interpretations of their data localization and cross-border data transfer laws.
Although there are currently various mechanisms that may be used to transfer personal data from the EEA and UK to the
United States in compliance with law, such as the EEA’s standard contractual clauses, the UK’s International Data Transfer
Agreement/Addendum, and the EU-U.S. Data Privacy Framework and the UK extension thereto (which allows for
transfers to relevant U.S.-based organizations who self-certify compliance and participate in the Framework), these
mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to
lawfully transfer personal data to the United States. If there is no lawful manner for us to transfer personal data from the
EEA, the UK, or other jurisdictions to the United States, or if the requirements for a legally-compliant transfer are too
onerous, we could face significant adverse consequences, including the interruption or degradation of our operations, the
need to relocate part of or all of our business or data processing activities to other jurisdictions (such as Europe) at
significant expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data
and work with partners, vendors and other third parties, and injunctions against our processing or transferring of personal
data necessary to operate our business. Additionally, companies that transfer personal data out of the EEA and UK to other
jurisdictions, particularly to the United States, are subject to increased scrutiny from regulators, individual litigants,
46
Table of Contents
and activities groups. Some European regulators have ordered certain companies to suspend or permanently cease certain
transfers of personal data out of Europe for allegedly violating the GDPR’s cross-border data transfer limitations.
In addition to data privacy and security laws, we are or may become contractually subject to industry standards
adopted by industry groups. We are also bound by other contractual obligations related to data privacy and security, and
our efforts to comply with such obligations may not be successful.
We publish privacy policies, marketing materials, and other statements, such as compliance with certain certifications
or self-regulatory principles, regarding data privacy and security. If these policies, materials or statements are found to be
deficient, lacking in transparency, deceptive, unfair, or misrepresentative of our practices, we [may] be subject to
investigation, enforcement actions by regulators, or other adverse consequences.
We may at times fail (or be perceived to have failed) in our efforts to comply with our data privacy and security
obligations. Moreover, despite our efforts, our personnel or third parties on whom we rely may fail to comply with such
obligations, which could negatively impact our business operations. If we or the third parties on which we rely fail, or are
perceived to have failed, to address or comply with applicable data privacy and security obligations, we could face
significant consequences, including but not limited to: government enforcement actions (e.g., investigations, fines,
penalties, audits, inspections, and similar); litigation (including class-action claims) and mass arbitration demands;
additional reporting requirements and/or oversight; bans on processing personal data; orders to destroy or not use personal
data; and imprisonment of company officials. In particular, plaintiffs have become increasingly more active in bringing
privacy-related claims against companies, including class claims and mass arbitration demands. Some of these claims
allow for the recovery of statutory damages on a per violation basis, and, if viable, carry the potential for monumental
statutory damages, depending on the volume of data and the number of violations. Any of these events could have a
material adverse effect on our reputation, business, or financial condition, including but not limited to: loss of customers;
interruptions or stoppages in our business operations (including, as relevant, clinical trials); inability to process personal
data or to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and
resources to defend any claim or inquiry; adverse publicity; or substantial changes to our business model or operations.
We are subject to recent legislation, regulatory proposals and healthcare payer initiatives that may increase our costs of
compliance and adversely affect our ability to market our products, obtain collaborators and raise capital.
In March 2010, President Obama signed the Health Care Reform Law, which includes provisions that have changed,
and likely will continue to change, health care financing and the delivery of health care in the United States. The Health
Care Reform Law, among other things, increased the minimum level of Medicaid rebates payable by manufacturers of
brand name drugs, required collection of rebates for drugs paid by Medicaid managed care organizations, required
manufacturers to participate in a coverage gap discount program, under which they must agree to offer point-of-sale
discounts (increased to 70 percent, effective as of January 1, 2019) off negotiated prices of applicable brand drugs to
eligible beneficiaries during their coverage gap period, as a condition for the manufacturer’s outpatient drugs to be covered
under Medicare Part D; imposed a non-deductible annual fee on pharmaceutical manufacturers or importers who sell
certain “branded prescription drugs” to specified federal government programs, implemented a new methodology by which
rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused,
instilled, implanted, or injected expanded the types of entities eligible for the 340B drug discount program; expanded
eligibility criteria for Medicaid programs; created a new Patient-Centered Outcomes Research Institute to oversee, identify
priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and established
a Center for Medicare Innovation at CMS to test innovative payment and service delivery models to lower Medicare and
Medicaid spending, potentially including prescription drug spending.
There have been executive, judicial, and Congressional challenges to certain aspects of the Health Care Reform Law.
For example, on June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the
Health Care Reform Law is unconstitutional in its entirety because the “individual mandate” was repealed by Congress.
Further, prior to the Supreme Court ruling, on January 28, 2021, President Biden issued an executive order that initiated a
special enrollment period for purposes of obtaining health insurance coverage through the Health Care Reform Law
marketplace, which began on February 15, 2021, and remained open through August 15, 2021. The executive order also
instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to
healthcare, including among others, reexamining Medicaid demonstration projects and waiver
47
Table of Contents
programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health
insurance coverage through Medicaid or the Health Care Reform Law. In addition, on August 16, 2022, President Biden
signed the Inflation Reduction Act of 2022, or IRA, into law, which among other things, extends enhanced subsidies for
individuals purchasing health insurance coverage in Health Care Reform Law marketplaces through plan year 2025. The
IRA also eliminates the “donut hole” under the Medicare Part D program beginning in 2025 by significantly lowering the
beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program. It is also unclear how any
such challenges and the healthcare reform measures of the Biden administration will impact the Health Care Reform Law
and our business.
In addition, other legislative changes have been proposed and adopted since the Health Care Reform Law was
enacted. These changes include, among other things, aggregate reductions to Medicare payments to providers of up to 2%
per fiscal year, which went effective on April 1, 2013, and, due to subsequent legislative amendments, will remain in effect
until 2032, unless additional Congressional action is taken. In January 2013, President Obama signed into law the
American Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare payments to several
providers and increased the statute of limitations period for the government to recover overpayments to providers from
three to five years. Additionally, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into
law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug’s average manufacturer price,
for single source and innovator multiple source drugs, beginning January 1, 2024. Congress is considering additional health
reform measures. These new laws may result in additional reductions in Medicare and other healthcare funding, which
could have a material adverse effect on customers for our drugs, if approved, and, accordingly, our financial operations.
Further, Congress is considering additional health reform measures.
We expect that the Health Care Reform Law, as well as other federal and state healthcare reform measures that may
be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price
that we receive for KORSUVA injection or any approved product candidate. Any reduction in reimbursement from
Medicare or other government healthcare programs may result in a similar reduction in payments from private payers. In
addition, there have been several recent U.S. Presidential executive orders, Congressional inquiries and proposed and
enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the
relationship between pricing and manufacturer patient programs, reduce the cost of drugs under Medicare, and reform
government program reimbursement methodologies for drugs. At the federal level, on March 11, 2021, President Biden
signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently
set at 100% of a drug’s average manufacturer price, for single source and innovator multiple source drugs, beginning
January 1, 2024. Further, in July 2021, the Biden administration released an executive order that included multiple
provisions aimed at prescription drugs. In response to Biden’s executive order, on September 9, 2021, HHS released a
Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform. The plan sets out a
variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take
to advance these principles. In addition, the IRA, among other things, (1) directs HHS to negotiate the price of certain
single-source drugs and biologics covered under Medicare and (2) imposes rebates under Medicare Part B and Medicare
Part D to penalize price increases that outpace inflation. These provisions take effect progressively starting in fiscal year
2023. On August 29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations, although
the Medicare drug price negotiation program is currently subject to legal challenges. It is unclear how the IRA will be
implemented but is likely to have a significant impact on the pharmaceutical industry. In response to the Biden
administration’s October 2022 executive order, on February 14, 2023, HHS released a report outlining three new models
for testing by the CMS Innovation Center which will be evaluated on their ability to lower the cost of drugs, promote
accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in
the future. Further, on December 7, 2023, the Biden administration announced an initiative to control the price of
prescription drugs through the use of march-in rights under the Bayh-Dole Act. On December 8, 2023, the National
Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering
the Exercise of March-In Rights which for the first time includes the price of a product as one factor an agency can use
when deciding to exercise march-in rights. While march-in rights have not previously been exercised, it is uncertain if that
will continue under the new framework. At the state level, legislatures have increasingly passed legislation and
implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient
reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency
measures, and, in some cases, to encourage importation from other
48
Table of Contents
countries and bulk purchasing. For example, on January 5, 2024, the FDA approved Florida’s Section 804 Importation
Program (SIP) proposal to import certain drugs from Canada for specific state healthcare programs. It is unclear how this
program will be implemented, including which drugs will be chosen, and whether it will be subject to legal challenges in
the United States or Canada. Other states have also submitted SIP proposals that are pending review by the FDA. Any such
approved importation plans, when implemented, may result in lower drug prices for products covered by those programs.
The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate
revenue, attain profitability or commercialize our drugs.
Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and
promotional activities for drugs. We cannot be sure whether additional legislative changes will be enacted, or whether the
FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing
approvals of our product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA’s
approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product
labeling and post-marketing testing and other requirements. Moreover, the Drug Supply Chain Security Act imposes
obligations on manufacturers of pharmaceutical products, among others, related to product tracking and tracing.
Legislation and regulations that, among other things, reduce drug prices or require the implementation of costly
compliance measures could result in decreased net revenues from our pharmaceutical products and decrease potential
returns from our development efforts, and we cannot predict what legislation will be enacted in the future.
Governments outside the United States tend to impose strict price controls, which may adversely affect our revenues, if
any.
In international markets, reimbursement and health care payment systems vary significantly by country, and many
countries have instituted price ceilings on specific products and therapies. In some countries, particularly the countries of
the EU, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing
negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product.
To obtain coverage and reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial
that compares the cost-effectiveness of our product candidate to other available therapies. There can be no assurance that
our products will be considered cost-effective by third-party payers, that an adequate level of reimbursement will be
available or that the third-party payers’ reimbursement policies will not adversely affect our ability to sell our products
profitably. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at
unsatisfactory levels, our business could be harmed, possibly materially.
Our employees, independent contractors, consultants, and commercial partners may engage in misconduct or other
improper activities, including noncompliance with regulatory standards and requirements, which could have a material
adverse effect on our business.
We are exposed to the risk of fraud or other misconduct by our employees, independent contractors, consultants and
commercial partners. Misconduct by such individuals could include inadvertent or intentional failures to:
● comply with FDA regulations and other similar foreign regulations;
● provide true, complete and accurate information to the FDA;
● comply with manufacturing standards;
● comply with federal and state data privacy, security, fraud and abuse and other healthcare laws and regulations in
the United States and similar foreign laws;
● report financial information or data accurately; or
● disclose unauthorized activities to us.
49
Table of Contents
In particular, the promotion, sales and marketing of healthcare items and services, as well as certain business
arrangements in the healthcare industry, are subject to extensive laws and regulations intended to prevent fraud,
misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide
range of pricing, discounting, marketing and promotion, including off label uses of our products, structuring and
commission(s), certain customer incentive programs, patient assistance programs, and other business arrangements
generally. Third party misconduct could also involve the improper use or misrepresentation of information obtained in the
course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always
possible to identify and deter such misconduct, and the precautions we take to detect and prevent this activity may not be
effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or
other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are
instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a
significant impact on our business and financial results, including the imposition of civil, criminal and administrative
penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid and other
federal healthcare programs, individual imprisonment, contractual damages, reputational harm, diminished profits and
future earnings, additional reporting requirements and/or oversight if we become subject to a corporate integrity agreement
or similar agreement to resolve allegations of non-compliance with these laws, and curtailment or restructuring of our
operations, any of which could adversely affect our ability to operate our business and our results of operations.
Our business involves the use of hazardous materials and we and our third-party manufacturers and suppliers must
comply with environmental laws and regulations, which can be expensive and restrict how we do business.
Our third-party manufacturers’ and suppliers’ activities involve the controlled storage, use and disposal of hazardous
materials owned by us, including the components of oral difelikefalin and other hazardous compounds. We and any third-
party manufacturers and suppliers we engage are subject to numerous federal, state and local environmental, health and
safety laws, regulations and permitting requirements, including those governing laboratory procedures; the generation,
handling, use, storage, treatment, and disposal of hazardous and regulated materials and wastes; the emission and discharge
of hazardous materials into the ground, air and water; and employee health and safety. Our partners’ operations involve the
use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce
hazardous waste. In some cases, these hazardous materials and various wastes resulting from their use are stored at our
contract manufacturers’ facilities pending their use and disposal. We generally contract with third parties for the disposal of
these materials and wastes. We cannot eliminate the risk of contamination, which could cause an interruption of our
commercialization efforts, research and development efforts and business operations, environmental damage resulting in
costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of
these materials and specified waste products. In addition, we cannot entirely eliminate the risk of accidental injury or
contamination from these materials or wastes.
Although we believe that the safety procedures utilized by our third-party manufacturers for handling and disposing
of these materials generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that
this is the case or eliminate the risk of accidental contamination or injury from these materials. Under certain
environmental laws, we could be held responsible for costs relating to any contamination at our current or past facilities
and at third-party facilities. In such an event, we may be held liable for any resulting damages and such liability could
exceed our resources and state or federal or other applicable authorities may curtail our use of certain materials and/or
interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently and
have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future
compliance.
Compliance with applicable environmental laws and regulations may be expensive, and current or future
environmental laws and regulations may impair our research, product development and manufacturing efforts.
50
Table of Contents
Risks Related to Intellectual Property
It is difficult and costly to protect our proprietary rights and as a result we may not be able to ensure their protection
and all patents will eventually expire.
Our commercial success will depend in part on obtaining and maintaining patent protection and trade secret
protection for difelikefalin and for any other product candidates that we may develop, license or acquire and the methods
we use to manufacture them, as well as successfully defending these patents and trade secrets against third-party
challenges. We will only be able to protect our technologies from unauthorized use by third parties to the extent that valid
and enforceable patents or trade secrets cover them.
The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute to
issuance all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we
may fail to identify patentable aspects of our R&D output before it is too late to obtain patent protection. Moreover, should
we enter into additional collaborations we may be required to consult with or cede control to collaborators regarding the
prosecution, maintenance and enforcement of our patents. Therefore, these patents and applications may not be
successfully prosecuted to issuance and enforced in a manner consistent with the best interests of our business. The patent
positions of pharmaceutical and biotechnology companies can be highly uncertain and involve complex legal and factual
questions for which important legal principles remain unresolved. No consistent policy regarding the breadth of claims
allowed in pharmaceutical or biotechnology patents has emerged to date in the United States. The patent situation outside
the United States is also uncertain. Changes in either the patent laws or in interpretations of patent laws in the United States
and other countries may diminish the value of our intellectual property. Accordingly, we cannot predict the breadth of
claims that may be allowed or enforced in our patents or in third-party patents. The degree of future protection for our
proprietary rights is uncertain, because legal means afford only limited protection and may not adequately protect our
rights or permit us to gain or keep our competitive advantage. Moreover, the patent application process is also subject to
numerous risks and uncertainties, and there can be no assurance that we or any of our future development partners will be
successful in protecting difelikefalin and any other product candidates that we may develop, license or acquire by obtaining
and defending patents. For example:
● we may not have been the first to make the inventions covered by each of our pending patent applications and
issued patents;
● we may not have been the first to file patent applications for these inventions;
● others may independently develop similar or alternative technologies or duplicate any of our product candidates
or technologies;
● it is possible that none of the pending patent applications will result in issued patents;
● the issued patents covering our product candidates may not provide a basis for commercially viable active
products, may not provide us with any competitive advantages, or may be challenged by third parties;
● we may not develop additional proprietary technologies that are patentable;
● patents of others may have an adverse effect on our business;
● competitors may file trademark infringement claims or challenges to the validity of our trademark(s);
● noncompliance with governmental patent agencies requirements can result in abandonment or lapse of a patent or
patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction, potentially
allowing competitors to enter the market earlier than would otherwise have been the case;
51
Table of Contents
● our competitors, many of whom have substantially greater resources than we do and many of whom have made
significant investments in competing technologies, may seek or may have already obtained patents that will limit,
interfere with, or eliminate our ability to make, use, and sell our potential product candidates; or
● there may be significant pressure on the U.S. government and international governmental bodies to limit the
scope of available patent protection both inside and outside the United States for disease treatments that prove
successful, as a matter of public policy regarding worldwide health concerns.
Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent
applications and the enforcement or defense of our issued patents. On September 16, 2011, the Leahy-Smith America
Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes
to U.S. patent law. These include provisions that affect the way patent applications are prosecuted and may also affect
patent litigation. The U.S. Patent Office has developed new regulations and procedures to govern administration of the
Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, including and
in particular, the first to file provisions, became effective on March 16, 2013. The Leahy-Smith Act and its implementation
could increase the uncertainties and costs surrounding the prosecution of our currently pending and future patent
applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our
business and financial condition.
Patent applications in the United States are generally maintained in confidence for at least 18 months after their
earliest effective filing date and in certain circumstances not until granted when no foreign counterpart patent applications
are filed. Furthermore, published patent applications may issue at a later date with new and/or amended claims
substantially different from those published earlier. Consequently, we cannot be certain we were the first to invent or the
first to file patent applications on difelikefalin or any other product candidates that we may develop, license or acquire.
Until recent changes to the U.S. Patent Laws, patents and patent applications relating to substantially similar claimed
inventions were potentially subject to interference proceedings to determine the first applicant to invent the claimed subject
matter. For an interference to be declared against our patents and patent applications, any such interference would be under
the 1952 law which was eliminated by the America Invents Act, or AIA, enacted in 2011 and fully effective in 2013. Such
an interference would therefore have to relate to a patent or application with an effective filing date before March 16, 2013.
No interference with such a patent or application has been declared to date. Therefore, it seems extremely unlikely that we
may have to participate in interference proceedings declared by the USPTO to determine priority of invention in the United
States against one or more parties claiming the same or similar invention. However, in the unlikely event that such
interference was to be declared, the costs of these proceedings could be substantial and it is possible that our efforts would
be unsuccessful, resulting in a material adverse effect on our U.S. patent position. The results of these types of proceedings
could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products
and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products
without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and
patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or
commercialize current or future product candidates. Such results could have a material adverse effect on our results of
operations.
In addition, the patentability of claims in pending patent applications covering KORSUVA injection or other
difelikefalin-based product can be challenged by third parties during prosecution in the USPTO under the new AIA law of
2013, for example by third party observations and derivation proceedings, and the validity of claims in issued patents can
be challenged by third parties in various post-grant proceedings such as Post-Grant Review, Inter-partes Reexamination,
and Inter-partes Review proceedings.
Furthermore, we may not have identified all U.S. and foreign patents or published applications that affect our
business either by blocking our ability to commercialize our drugs or by covering similar technologies that affect our drug
market. In addition, some countries, including many in Europe, do not grant patent claims directed to methods of treating
humans, and in these countries patent protection may not be available at all to protect our product candidates.
52
Table of Contents
Even if patents issue, we cannot guarantee that the claims of those patents will be valid and enforceable or provide us with
any significant protection against competitive products, or otherwise be commercially valuable to us.
We also rely on trade secrets to protect our technology, particularly where we do not believe patent protection is
appropriate or obtainable. However, trade secrets are difficult to protect. While we use reasonable efforts to protect our
trade secrets, our licensors, employees, consultants, contractors, outside scientific collaborators and other advisors may
unintentionally or willfully disclose our information to competitors. Enforcing a claim that a third party illegally obtained
and is using our trade secrets is expensive and time consuming, and the outcome is unpredictable. In addition, courts
outside the United States are sometimes less willing to protect trade secrets. Moreover, our competitors may independently
develop equivalent knowledge, methods and know-how.
If we fail to obtain or maintain patent protection or trade secret protection for difelikefalin or any other product
candidate that we may develop, license or acquire, third parties could use our proprietary information, which could impair
our ability to compete in the market and adversely affect our ability to generate revenues and achieve profitability.
Even if our patent applications issue as patents, they may not issue in a form that will provide us with any
meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive
advantage. Our competitors may be able to circumvent our owned or licensed patents by developing similar or alternative
technologies or products in a non-infringing manner.
The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and
licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may
result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in
whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology
and products, or limit the duration of the patent protection of our technology and products. Given the amount of time
required for the development, testing and regulatory review of new product candidates, patents protecting such product
candidates might expire before or shortly after such product candidates are commercialized. As a result, our owned and
licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar
or identical to ours.
If we or any current or future collaboration partner are sued for infringing intellectual property rights of third parties,
it will be costly and time consuming, and an unfavorable outcome in any litigation would harm our business.
Our ability to develop, manufacture, market and sell difelikefalin or any potential future product candidate will
depend upon our ability to avoid infringing the proprietary rights of third parties, and our commercial success will depend
upon our ability, and the ability of our collaborators, to develop, manufacture, market and sell our product candidates and
use our proprietary technologies without infringing the proprietary rights of third parties. There is considerable intellectual
property litigation in the biotechnology and pharmaceutical industries. Numerous U.S. and foreign issued patents and
pending patent applications, which are owned by third parties, exist in the general field of pain management and cover the
use of numerous compounds and formulations in our targeted markets. Third parties may assert infringement claims against
us based on existing patents or patents that may be granted in the future. Because of the uncertainty inherent in any patent
or other litigation involving proprietary rights, we and our licensors may not be successful in defending intellectual
property claims by third parties, which could have a material adverse effect on our results of operations. Regardless of the
outcome of any litigation, defending the litigation may be expensive, time-consuming and distracting to management. In
addition, because patent applications can take many years to issue, there may be currently pending applications, unknown
to us, which may later result in issued patents that current or potential future product candidates may infringe. There could
also be existing patents of which we are not aware that our current or potential future product candidates may inadvertently
infringe.
53
Table of Contents
There is a substantial amount of litigation involving patent and other intellectual property rights in the biotechnology
and biopharmaceutical industries generally. If a third-party claims that we infringe on their products or technology, we
could face a number of issues, including:
● infringement and other intellectual property claims which, with or without merit, can be expensive and time
consuming to litigate and can divert management’s attention from our core business;
● substantial damages for past infringement which we may have to pay if a court decides that our product infringes
on a competitor’s patent;
● a court prohibiting us from selling or licensing our product unless the patent holder licenses the patent to us,
which it would not be required to do;
● if a license is available from a patent holder, we may have to pay substantial royalties or grant cross licenses to
our patents; and
● redesigning our processes so they do not infringe, which may not be possible or could require substantial funds
and time.
If we are found to infringe on a third party’s intellectual property rights, we could be required to obtain a license
from such third party to continue developing and marketing our products and technology. However, we may not be able to
obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be
non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We could be forced,
including by court order, to cease commercializing the infringing technology or product. In addition, we could be found
liable for monetary damages, including treble damages and attorneys’ fees if we are found to have willfully infringed a
patent. A finding of infringement could prevent us from commercializing our product candidate or force us to cease some
of our business operations, which could materially harm our business. Claims that we have misappropriated the
confidential information or trade secrets of third parties could have a similar negative impact on our business.
We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be
expensive, time consuming and may ultimately be unsuccessful.
Competitors may infringe on our issued patents or other intellectual property. To counter infringement or
unauthorized use, we may be required to file infringement claims, which can be expensive and time consuming. Any
claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we
infringe their patents. In addition, in a patent infringement proceeding, a court may decide that a patent of ours is invalid or
unenforceable, in whole or in part, construe the patent’s claims narrowly or refuse to stop the other party from using the
technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any
litigation proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly. Furthermore,
because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk
that some of our confidential information could be compromised by disclosure during this type of litigation.
Most of our competitors are larger than we are and have substantially greater resources. They are, therefore, likely to
be able to sustain the costs of complex patent litigation longer than we could. In addition, the uncertainties associated with
litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials,
continue our internal research programs, in-license needed technology, or enter into development partnerships that would
help us bring our product candidate to market.
54
Table of Contents
We may need to license certain intellectual property from third parties, and such licenses may not be available or may
not be available on commercially reasonable terms.
A third party may hold intellectual property, including patent rights that are important or necessary to the
development or commercialization of our products. It may be necessary for us to use the patented or proprietary technology
of third parties to commercialize our products, in which case we would be required to obtain a license from these third
parties. Such a license may not be available on commercially reasonable terms or at all, which could materially harm our
business.
We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former
employers.
As is common in the biotechnology and pharmaceutical industry, we employ individuals who were previously
employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors.
Although no claims against us are currently pending, we may be subject to claims that these employees, or we have
inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers.
Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims,
litigation could result in substantial costs and be a distraction to management.
We may not be able to protect our intellectual property rights throughout the world.
Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be
prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less
extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual
property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to
prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing
products made using our inventions in and into the United States or other jurisdictions. Competitors may use our
technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may
export otherwise infringing products to territories where we have patent protection, but enforcement rights are not as strong
as those in the United States. These products may compete with our product candidate and our patents or other intellectual
property rights may not be effective or sufficient to prevent them from competing.
Many companies have encountered significant problems in protecting and defending intellectual property rights in
foreign jurisdictions. The legal systems of certain countries do not favor the enforcement of patents and other intellectual
property protection, which could make it difficult for us to stop the infringement of our patents generally. Proceedings to
enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from
other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent
applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any
lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful.
Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a
significant commercial advantage from the intellectual property that we develop or license.
The validity and enforceability of the patents and applications that cover difelikefalin can be challenged by competitors.
In the event that oral difelikefalin or any potential future product candidate is approved by the FDA, one or more
third parties may challenge the patents covering these products and product candidates, which could result in the
invalidation of, or render unenforceable, some or all of the relevant patent claims. For example, if a third party files an
Abbreviated New Drug Application, or ANDA, for a generic drug product containing difelikefalin, and relies in whole or
in part on studies conducted by or for us, the third party will be required to certify to the FDA that either: (1) the patents
listed in the Orange Book have expired; (2) the listed patents have not expired, but will expire on a particular date and
approval is sought after patent expiration; or (3) the listed patents are invalid or will not be infringed by the manufacture,
use or sale of the third-party’s generic drug product. A certification that the new product will not infringe the Orange Book-
listed patents for difelikefalin, or that such patents are invalid, is called a paragraph IV certification. If
55
Table of Contents
the third party submits a paragraph IV certification to the FDA, a notice of the paragraph IV certification must also be sent
to us once the third-party’s ANDA is accepted for filing by the FDA. We may then initiate a lawsuit to defend the patents
identified in the notice. The filing of a patent infringement lawsuit within 45 days of receipt of the notice automatically
prevents the FDA from approving the third-party’s ANDA until the earliest of 30 months or the date on which the patent
expires, the lawsuit is settled, or the court reaches a decision in the infringement lawsuit in favor of the third party. If we do
not file a patent infringement lawsuit within the required 45-day period, the third-party’s ANDA will not be subject to the
30-month stay. Litigation or other proceedings to enforce or defend intellectual property rights are often very complex in
nature, may be very expensive and time-consuming, may divert our management’s attention from our core business, and
may result in unfavorable results that could adversely impact our ability to prevent third parties from competing with our
products.
Risks Related to Employee Matters and Managing Growth
We depend on skilled personnel to operate our business effectively in a rapidly changing market, and if we are unable to
retain existing or hire additional personnel when needed, our ability to develop and sell our products could be harmed.
In January 2024, as part of our pipeline prioritization, we reduced our headcount by approximately 50%, including
the separation of our former Chief Scientific Officer and SVP of Research & Development. Although we believe these
employee transitions are in the best interest of our company and our stockholders, these transitions may result in the loss of
personnel with deep institutional or technical knowledge. Further, the transition could potentially disrupt our operations
and relationships with employees, suppliers, and partners and, as a result, create added costs, operational inefficiencies,
decreased employee morale and productivity and increased turnover. In addition, our competitors may seek to use these
transitions and the related potential disruptions to gain a competitive advantage over us. Furthermore, these changes
increase our dependency on the other members of our leadership team and clinical and preclinical operations teams that
remain with us, who are not contractually obligated to remain employed with us and may leave at any time. Any such
departure could be particularly disruptive and, to the extent we experience additional turnover, competition for top talent is
high such that it may take some time to find a candidate that meets our requirements. We may not be able to attract or
retain qualified management and commercial, scientific, and clinical personnel due to the intense competition for qualified
personnel among biotechnology, pharmaceutical and other businesses. If we are not able to attract and retain necessary
personnel to accomplish our business objectives, we may experience constraints that will significantly impede the
achievement of our development objectives, our ability to raise additional capital and our ability to implement our business
strategy.
If we lose additional members of our senior management team, our ability to successfully implement our business
strategy could be seriously harmed. Replacing these employees may be difficult and may take an extended period of time
because of the limited number of individuals in our industry with the breadth of skills and experience required to develop,
gain regulatory approval of and commercialize products successfully. Competition to hire from this limited pool is intense,
and we may be unable to hire, train, retain or motivate additional key personnel. We do not maintain “key person”
insurance for any of our executives or other employees.
If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a
timely basis could be impaired.
We are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, the Sarbanes-
Oxley Act of 2002 and the rules and regulations of The Nasdaq Global Market. Pursuant to Section 404 of the Sarbanes-
Oxley Act of 2002, or Section 404, we are required to perform system and process evaluation and testing of our internal
control over financial reporting to allow our management to report on the effectiveness of our internal control over
financial reporting and, in the past, we have also been required to have our independent registered public accounting firm
issue an opinion on the effectiveness of our internal control over financial reporting on an annual basis as a large
accelerated filer. However, based on our public float as of June 30, 2023, we qualified as a non-accelerated filer at the end
of 2023, which would allow us to forgo the auditor attestation requirement for the fiscal year ended December 31, 2023.
However, we have determined to voluntarily comply with the auditor attestation requirement for the fiscal year ended
December 31, 2023.
56
Table of Contents
During the evaluation and testing process, if we identify one or more material weaknesses in our internal control over
financial reporting, we will be unable to assert that our internal control over financial reporting is effective. Further, we
may in the future discover weaknesses in our system of internal financial and accounting controls and procedures that
could result in a material misstatement of our financial statements. Moreover, our internal controls over financial reporting
will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide
only reasonable, not absolute, assurance that the control system’s objectives will be met. Because of the inherent
limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error
or fraud will not occur or that all control issues and instances of fraud will be detected. Moreover, we are aware that the
increased prevalence of remote working arrangements potentially presents additional areas of risk, including cyber and
privacy risks, and we are carefully monitoring any impact to our internal controls and procedures.
If we are unable to assert that our internal control over financial reporting is effective, or if our independent
registered public accounting firm is unable to express an opinion on the effectiveness of our internal control over financial
reporting, investors could lose confidence in the reliability of our financial statements, the market price of our stock could
decline and we could be subject to sanctions or investigations by The Nasdaq Global Market, the SEC or other regulatory
authorities.
Risks Related to Ownership of Our Common Stock
If we fail to meet all applicable requirements of Nasdaq and Nasdaq determines to delist our common stock, the
delisting could adversely affect the market liquidity of our common stock and the market price of our common stock
could decrease.
On February 1, 2024, we received a letter from Nasdaq, notifying us that, for the previous 30 consecutive business
day period prior to the date of the letter, the closing bid price for our common stock was below $1.00. In accordance with
Nasdaq Listing Rule 5810(c)(3)(A) we have been provided an initial period of 180 calendar days, or until July 30, 2024, to
regain compliance with Nasdaq’s bid price requirement. If, at any time before July 30, 2024, the bid price for our common
stock closes at $1.00 or more for a minimum of 10 consecutive business days, we will regain compliance with the bid price
requirement, unless Nasdaq staff exercised its discretion to extend this 10-day period pursuant to Nasdaq rules.
If we are unable to satisfy the Nasdaq criteria for continued listing, our common stock would be subject to delisting.
A delisting of our common stock could negatively impact us by, among other things, reducing the liquidity and market
price of our common stock; reducing the number of investors willing to hold or acquire our common stock, which could
negatively impact our ability to raise equity financing; decreasing the amount of news and analyst coverage of us; and
limiting our ability to issue additional securities or obtain additional financing in the future. In addition, delisting from
Nasdaq may negatively impact our reputation and, consequently, our business.
The market price of our common stock has been, and is likely to continue to be, highly volatile, and you may not be able
to resell your shares at or above the price you paid for them.
Since our initial public offering in January 2014, our stock price has been volatile and it is likely that the trading
price of our common stock will continue to be volatile. As a result of this volatility, investors may not be able to sell their
common stock at or above the price paid for the shares. The market price for our common stock may be influenced by
many factors, including:
● actual or anticipated variations in quarterly or annual operating results;
● delays in the commencement, enrollment and ultimate completion of our clinical trials, including our planned
trials for oral difelikefalin;
● results of clinical trials of oral difelikefalin for the treatment of pruritus in patients with NP, or any potential
future product candidate or those of our competitors;
57
Table of Contents
● any delay or refusal on the part of the FDA or other regulatory authorities in approving marketing authorization
for oral difelikefalin or any potential future product candidate;
● failure to meet or exceed financial projections we provide to the public;
● failure to meet or exceed the estimates and projections of the investment community, including securities
analysts;
● introduction of competitive products or technologies;
● changes or developments in laws or regulations applicable to product candidate;
● the perception of the pharmaceutical industry by the public, legislatures, regulators and the investment
community;
● general trends in our industry or economic and market conditions and overall fluctuations in U.S. equity markets;
● developments concerning our sources of manufacturing supply, warehousing and inventory control;
● disputes or other developments relating to patents or other proprietary rights;
● additions or departures of key scientific or management personnel;
● announcements of investigations or regulatory scrutiny of our operations or lawsuits filed against us;
● capital commitments;
● investors’ general perception of our company and our business;
● announcements and expectations of additional financing efforts, including the issuance of debt, equity or
convertible securities or other security instruments;
● sales of our common stock, including sales by our directors and officers or significant stockholders;
● changes in the market valuations of companies similar to us;
● announcements by us or our competitors of significant acquisitions, strategic partnerships, or divestitures;
● changes in the structure of healthcare payment systems; and
● the other factors described in this “Risk Factors” section.
In addition, the stock market in general, and the market for small pharmaceutical and biotechnology companies in
particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to
the operating performance of these companies. Broad market and industry factors, such as those related to high rates of
inflation and interest rates and concerns of a recession in the United States or other major markets, the recent disruptions to
and volatility in the credit and financial markets in the United States and worldwide, and geopolitical instability, including
resulting from the ongoing conflicts between Russia and the Ukraine, conflicts in the Middle East, and increasing tensions
between China and Taiwan, may negatively affect the market price of our common stock, regardless of our actual operating
performance.
58
Table of Contents
Further, in the past, stockholders have initiated class action lawsuits against pharmaceutical and biotechnology
companies following periods of volatility in the market prices of these companies’ stock. Such litigation, if instituted
against us, could cause us to incur substantial costs and divert management’s attention and resources from our business.
If equity research analysts cease to publish research or reports about us or if they publish unfavorable research or
reports about us, our business or our market, our stock price and trading volume could decline.
The trading market for our common stock is likely to be influenced by the research and reports that equity research
analysts publish about us and our business. We do not have any control over the analysts or the content and opinions
included in their reports. The price of our stock could decline if one or more equity research analysts downgrade our stock
or issue other unfavorable commentary or research. Certain equity research analysts who covered us have ceased coverage,
and if further analysts who cover us were to cease coverage of our company or fail to publish reports on us regularly,
demand for our stock could decrease, which in turn could cause our stock price or trading volume to decline.
Our quarterly operating results may fluctuate significantly.
We expect our operating results to be subject to quarterly fluctuations. Our operating results will be affected by
numerous factors, including:
● the successful progress of our clinical trials for oral difelikefalin and other potential future product candidates;
● variations in the level of expenses related to our future development programs;
● whether the FDA or other regulatory authorities require us to complete additional, unanticipated studies, tests or
other activities prior to approving our other current or future product candidates, which would likely further delay
any such approval;
● our ability to identify, enter into and maintain third party manufacturing arrangements capable of manufacturing
oral difelikefalin or any potential future product candidate in commercial quantities;
● our execution of other collaborative, licensing or similar arrangements and the timing of payments we may make
or receive under these arrangements;
● any product liability or intellectual property infringement lawsuit in which we may become involved;
● regulatory developments affecting oral difelikefalin, any potential future product candidates, or the product
candidates of our competitors; and
● if oral difelikefalin or any potential future product candidates receives regulatory approval, the level of
underlying demand for such product and wholesaler buying patterns.
If our quarterly or annual operating results fall below the expectations of investors or securities analysts, the price of
our common stock could decline substantially. Furthermore, any quarterly or annual fluctuations in our operating results
may, in turn, cause the price of our stock to fluctuate substantially. We believe that quarterly comparisons of our financial
results are not necessarily meaningful and should not be relied upon as an indication of our future performance.
Raising additional funds by issuing securities may cause dilution to existing stockholders and raising funds through
lending and licensing arrangements may restrict our operations or require us to relinquish proprietary rights.
Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs
through a combination of equity offerings, debt financings, royalty arrangements, grants, license and development
agreements in connection with any collaborations, and other financial instruments. We do not yet have any committed
external source of funds. To the extent that we raise additional capital by issuing equity securities, our existing
59
Table of Contents
stockholders’ ownership will be diluted, and the terms of these securities may include liquidation or other preferences that
adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available, may
involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring
additional debt, making capital expenditures or declaring dividends.
If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing
arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams,
research programs, product candidate or grant licenses on terms that may not be favorable to us. Any debt financing that
we enter into may involve covenants that restrict our operations. These restrictive covenants may include limitations on
additional borrowing and specific restrictions on the use of our assets as well as prohibitions on our ability to create liens,
pay dividends, redeem our stock or make investments. If we are unable to raise additional funds through equity or debt
financings when needed, we may be required to delay, limit, reduce or terminate our product development or future
commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to
develop and market ourselves.
The use of our net operating loss carryforwards and research tax credits may be limited.
A portion of our net operating loss, or NOL, carryforwards and R&D tax credits may expire and not be used. As of
December 31, 2023, we had federal and state NOL carryforwards of approximately $467.0 million and $473.3 million,
respectively, and we also had federal and state R&D tax credit carryforwards of approximately $27.5 million and $4.5
million, respectively. Our NOL carryforwards will begin expiring in 2026 for federal purposes (to the extent such federal
NOLs are generated in taxable years beginning on or before December 31, 2017) and 2027 for state purposes if we have
not used them prior to that time, and our federal R&D tax credits will begin expiring in 2025 unless previously used. The
federal NOLs arising in 2018 and forward have an unlimited carryforward period and losses from 2018-2020 may be
carried back five years due to the Coronavirus Aid, Relief, and Economic Security Act of 2020, or the CARES Act. It is
uncertain if and to what extent various states will conform to the TCJA, as modified by the CARES Act. To the extent that
we have not exchanged our Connecticut R&D tax credits for a tax refund, those tax credits carry forward indefinitely.
Additionally, our ability to use any NOL and R&D tax credit carryforwards to offset taxable income or tax, respectively, in
the future will be limited under Internal Revenue Code Sections 382 and 383, respectively, if we have a cumulative change
in ownership of our stock of more than 50% within a three-year period. The completion of our initial public offering in
2014 and our follow-on public offerings in 2015, 2017, 2018 and 2019, together with private placements and other
transactions that have occurred, may have triggered such ownership changes. We conducted a 382 analysis in the first
quarter of 2021. This analysis showed a limited change of ownership had occurred, and the amount of NOL carryforwards
and R&D tax credits that could be utilized annually in the future to offset taxable income or tax, respectively. In addition,
since we will need to raise substantial additional funding to finance our operations, we may undergo ownership changes in
the future. Any such annual limitation may significantly reduce the utilization of the NOL carryforwards and R&D tax
credits before they expire. In addition, certain states have in the past suspended use of NOL carryforwards for certain
taxable years (including Connecticut which currently limits the use of NOL carryforwards by 50% and without limitation
legislation enacted by California in June 2020 that suspends the use of California NOLs and limits the use of California
R&D tax credits for certain years), and other states are considering similar measures. As a result, we may incur higher state
income tax expense in the future. Depending on our future tax position, limitations on our ability to use NOL
carryforwards in states in which we are subject to income tax could have an adverse impact on our results of operations and
financial condition.
New or future changes to tax laws could materially adversely affect our company.
On December 22, 2017, President Trump signed into law the TCJA, which significantly amends the Internal Revenue
Code of 1986, which was modified by the CARES Act. We continue to examine the impact these changes may have on our
business. Notwithstanding the reduction in the corporate income tax rate, the overall impact of the TCJA and CARES Act,
or any other future changes in tax laws, is uncertain and our business and financial condition could be adversely affected.
For example, proposals have recently been made in Congress (which have not yet been enacted) that include tax law
changes that could have a material adverse impact on us. The impact of the TCJA and CARES Act and any future changes
in tax laws on holders of our common stock is also uncertain and could be adverse.
60
Table of Contents
Further, beginning in our tax year ending December 31, 2022, as a result of the TCJA, current R&D expenditures
incurred in the United States must be capitalized for tax purposes, and amortized over a period of five years (fifteen years
in the case of R&D performed outside the United States). As such, the deferred tax asset for intangible assets will
materially increase in lieu of NOL carryforwards, offset by a change in valuation allowance.
Because we do not intend to pay dividends on our common stock, your returns will be limited to any increase in the
value of our stock.
We have never declared or paid any cash dividends on our capital stock. We currently intend to retain all available
funds and any future earnings to support our operations and finance the growth and development of our business and do not
anticipate declaring or paying any cash dividends on our common stock for the foreseeable future. Any return to
stockholders will therefore be limited to the appreciation of their stock, if any. Investors seeking cash dividends should not
purchase our common stock.
Provisions in our corporate charter documents and under Delaware law may prevent or frustrate attempts by our
stockholders to change our management and hinder efforts to acquire a controlling interest in us, and the market price
of our common stock may be lower as a result.
There are provisions in our certificate of incorporation and bylaws, as amended, that may make it difficult for a third
party to acquire, or attempt to acquire, control of our company, even if a change in control was considered favorable by you
and other stockholders. For example, our Board of Directors has the authority to issue up to 5,000,000 shares of preferred
stock and to fix the price, rights, preferences, privileges, and restrictions of the preferred stock without any further vote or
action by our stockholders. The issuance of shares of preferred stock may delay or prevent a change in control transaction.
As a result, the market price of our common stock and the voting and other rights of our stockholders may be adversely
affected. An issuance of shares of preferred stock may result in the loss of voting control to other stockholders.
Our charter documents also contain other provisions that could have an anti-takeover effect, including:
● our Board of Directors are divided into three classes, with only one class of directors elected each year;
● our stockholders are entitled to remove directors only for cause upon a 66 2/3% vote;
● our stockholders are not permitted to take actions by written consent;
● our stockholders are not permitted to call a special meeting of stockholders; and
● our stockholders must give us advance notice of their intent to nominate directors or submit proposals for
consideration at stockholder meetings.
In addition, we are subject to the anti-takeover provisions of Section 203 of the Delaware General Corporation Law,
which regulates corporate acquisitions by prohibiting Delaware corporations from engaging in specified business
combinations with particular stockholders of those companies. These provisions could discourage potential acquisition
proposals and could delay or prevent a change in control transaction. They could also have the effect of discouraging others
from making tender offers for our common stock, including transactions that may be in your best interests. These
provisions may also prevent changes in our management or limit the price that investors are willing to pay for our stock.
Item 1B. Unresolved Staff Comments.
None.
61
Table of Contents
Item 1C. Cybersecurity.
Risk Management and Strategy
We implement and maintain various information security processes designed to identify, assess and manage material
risks from cybersecurity threats to our critical computer networks, third party hosted services, communications systems,
hardware and software, products and our critical data (including intellectual property and confidential information that is
proprietary, strategic or competitive in nature, and clinical trial data) (collectively, “Information Systems and Data”).
Our Executive Director of Information Technology, or IT, and other relevant personnel help identify, assess and
manage our cybersecurity threats and risks. We identify and assess risks from cybersecurity threats by monitoring and
evaluating our threat environment. We (including the Executive Director of IT) use various methods designed to
accomplish this task including, for example: manual tools, automated tools, subscribing to reports and services that identify
cybersecurity threats, analyzing reports of threats and threat actors, conducting scans of the threat environment, evaluating
our and our industry’s risk profile, evaluating threats reported to us, coordinating with law enforcement concerning threats,
conducting internal audits, conducting threat assessments, conducting third-party threat assessments, conducting
vulnerability assessments, and arranging a managed detection and response process with a third-party vendor.
Depending on the relevant information systems environment, we implement and maintain various technical, physical,
and organizational measures, processes, standards and policies designed to manage and mitigate material risks from
cybersecurity threats to our Information Systems and Data, including, for example: an incident response policy, incident
detection and response measures, a vulnerability management policy, disaster recovery/business continuity plans, risk
assessments, implementation of security standards/certifications, encryption of certain data, network security controls, data
segregation, access controls, physical security, asset management (such as tracking and disposal of our information
systems), systems monitoring, a vendor risk management program, personnel training, and cybersecurity insurance.
Our assessment and management of material risks from cybersecurity threats are integrated into our overall risk
management processes. For example, the Executive Director of IT works with executive management to prioritize our risk
management processes and mitigate cybersecurity threats that are more likely to lead to a material impact to our business.
Our Executive Director of IT and executive management also evaluate material risks from cybersecurity threats against our
overall business objectives and reports to the Audit Committee of our Board of Directors, or the Board.
We use service providers in an effort to identify, assess, and manage material risks from cybersecurity threats. These
service providers may provide services related to: threat intelligence, cybersecurity practices, cybersecurity software,
managed cybersecurity response, penetration testing, dark web monitoring, forensic investigation, and professional services
(including legal counsel).
We use service providers to perform a variety of functions throughout our business, such as application providers,
hosting companies, contract research organizations, contract manufacturing organizations, distributors, and supply chain
resources. We maintain a vendor management program designed to manage cybersecurity risks associated with our use of
these providers. The program includes conducting a risk assessment or auditing for certain vendors. Depending on the
nature of the services provided, the sensitivity of the Information Systems and Data at issue, and the identity of the
provider, our vendor management process may involve different levels of assessment designed to help identify, mitigating
and manage cybersecurity risks associated with a particular provider.
For a description of the risks from cybersecurity threats that may materially affect us and how they may do so, see
our risk factors under Part 1. Item 1A. Risk Factors in this Annual Report on Form 10-K, including the subsection titled
“Our information systems, or those of others upon whom we rely (such as our CROs, contract manufacturers, contractors,
consultants, service providers, collaborators and others) may fail or suffer cybersecurity breaches, loss or leakage of data
or other disruptions, which could result in a material disruption of our development programs,
62
Table of Contents
compromise sensitive information related to our business, or prevent us from accessing critical information, potentially
exposing us to liability that could adversely affect our business.”
Governance
Our Board performs oversight of our risk management process. The Board does not have a standing risk
management committee, but rather administers this oversight function directly through the Board as a whole, as well
as through various standing committees of the Board that address risks inherent in their respective areas of oversight.
In particular, the Board is responsible for monitoring and assessing strategic risk exposure, including a determination
of the nature and level of risk appropriate for us. The Board is also focused on emerging risks, as well as risk
mitigation strategies. As part of its risk mitigation duties, the Audit Committee monitors cybersecurity risk and
mitigation of such risks.
Our cybersecurity risk assessment and management processes are implemented and maintained by our Executive
Director of IT, who has 25 years of experience developing and deploying network and data security policy and technology.
The Executive Director of IT and Chief Financial Officer, or CFO, are responsible for hiring appropriate personnel,
helping to integrate cybersecurity risk considerations into our overall risk management strategy, and communicating key
cybersecurity priorities to relevant personnel. The Executive Director of IT is responsible for helping prepare for
cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related
reports.
Our cybersecurity incident response and vulnerability management policies are designed to escalate certain
cybersecurity incidents and threats to management members, including the CFO, depending on the circumstances. The
CFO, Executive Director of IT, and Vice President of Finance work with our incident response team in an effort to help us
mitigate and remediate cybersecurity incidents of which they are notified. In addition, our incident response and
vulnerability management policies include reporting to the Audit Committee of the Board for certain cybersecurity
incidents.
The Audit Committee receives reports from the Executive Director of IT concerning our significant cybersecurity
threats and risks, as well as the processes we have implemented that are designed to address them. The Audit Committee
also receives various reports, summaries or presentations related to cybersecurity threats, risk and mitigation.
Item 2. Properties.
On May 11, 2023, we entered into a new lease for our new principal office with an initial term of 11 years, with a
renewal option for an additional five-year term. Our new principal office occupies approximately 26,400 square feet of
office space in Stamford, Connecticut. We believe that the office space in Stamford is suitable and adequate to meet our
current needs. See Note 19 of Notes to Consolidated Financial Statements, Commitments and Contingencies, in this Annual
Report on Form 10-K.
Item 3. Legal Proceedings.
From time to time, we may become subject to arbitration, litigation or claims arising in the ordinary course of
business. We are not currently a party to any arbitration or legal proceeding that, if determined adversely to us, would have
a material adverse effect on our business, operating results or financial condition. The results of any future claims or
proceedings cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on us
because of defense and litigation costs, diversion of management resources, and other factors.
Item 4. Mine Safety Disclosures.
Not applicable.
63
Table of Contents
PART II
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity
Securities.
Market Information for Common Stock
Our common stock is traded on The Nasdaq Global Market under the ticker symbol “CARA”.
Stockholders
As of March 1, 2024, there were 34 holders of record of our common stock. This number does not reflect the
beneficial holders of our common stock who hold shares in street name through brokerage accounts or other nominees.
Dividend Policy
We have never declared or paid any cash dividends on our capital stock. We currently intend to retain all available
funds and any future earnings to support our operations and finance the growth and development of our business. We do
not intend to pay cash dividends on our common stock for the foreseeable future. Any future determination related to
dividend policy will be made at the discretion of our Board of Directors and will depend on, among other factors, our
results of operations, financial condition, capital requirements, contractual restrictions, business prospects and other factors
our Board of Directors may deem relevant.
Stock Performance
The following graph compares cumulative total return of our common stock with the cumulative total return of (i) the
Nasdaq Composite Index, and (ii) the Nasdaq Biotechnology Index. The graph assumes (a) $100 was invested on
December 31, 2018 in each of our common stock, the stocks comprising the Nasdaq Composite Index and the stocks
comprising the Nasdaq Biotechnology Index, and (b) the reinvestment of dividends. The comparisons shown in the
64
Table of Contents
graph are based on historical data and the stock price performance shown in the graph is not necessarily indicative of, or
intended to forecast, future performance of our stock.
Cumulative Total Return
Cara Therapeutics, Inc.
Nasdaq Biotechnology
Nasdaq Composite
12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023
5.72
143.60
226.24
123.92
124.41
135.23
93.69
155.37
235.78
100.00
100.00
100.00
116.38
156.36
194.24
82.62
138.42
157.74
This performance graph shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of
1934, as amended, or the Exchange Act, or incorporated by reference into any filing of ours under the Securities Act,
except as shall be expressly set forth by specific reference to such filing.
Recent Sales of Unregistered Securities
None.
Purchases of Equity Securities by the Issuer and Affiliated Purchasers
Not applicable.
Use of Proceeds
Not applicable.
Item 6. [Reserved]
65
Table of Contents
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
You should read the following discussion and analysis of our financial condition and results of operations together
with our financial statements and the related notes appearing at the end of this Annual Report on Form 10-K. Some of the
information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including
information with respect to our plans and strategy for our business and related financing, includes forward-looking
statements that involve risks and uncertainties. You should read “Cautionary Note Regarding Forward-Looking
Statements” and Item 1A. Risk Factors of this Annual Report on Form 10-K for a discussion of material factors that could
cause actual results to differ materially from the results described in or implied by the forward-looking statements
contained in the following discussion and analysis.
Overview
Introduction
We are a development-stage biopharmaceutical company driving innovation in sizable, yet underserved diseases and
conditions. Specifically, we are focused on leading a new treatment paradigm to improve the lives of patients suffering
from chronic pruritus. We are developing an oral formulation of difelikefalin, a selective, predominantly peripherally
acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic pruritus associated with NP, a common,
underdiagnosed neuropathic itch affecting the upper back. We are conducting a Phase 2/3 program with topline results of
the dose-finding portion expected in the third quarter of 2024.
Historical Development of Difelikefalin
We previously successfully developed an IV formulation of difelikefalin through regulatory approval for the
treatment of moderate-to-severe pruritus associated with advanced CKD in adults undergoing hemodialysis in the United
States, EU, and multiple other countries. The IV formulation is out-licensed to CSL Vifor for the commercialization of
KORSUVA injection/Kapruvia in dialysis patients with advanced CKD-aP worldwide, excluding Japan (Maruishi/sub-
licensee Kissei), and South Korea (CKDP).
On August 23, 2021, KORSUVA injection was approved by the FDA for the treatment of moderate-to-severe
pruritus associated with advanced CKD in adults undergoing hemodialysis. In December 2021, CMS granted TDAPA to
KORSUVA injection in the anti-pruritic functional category. TDAPA went into effect on April 1, 2022 for a minimum of
two years. The commercial launch of KORSUVA injection commenced in April 2022 and we began recording the
associated profit-sharing revenues in the second quarter of 2022. On October 27, 2023, CMS published the final CY 2024
rule, which finalized the post-TDAPA add-on payment as proposed in the draft CY 2024 rule. Under the final rule, TDAPA
drugs in existing functional categories will receive a post-TDAPA add-on payment set at 65 percent of the total trailing 12-
months expenditure levels for the given renal dialysis drug or biological product. The post-TDAPA add-on payment will be
applied to all ESRD PPS payments and paid for 3 years, adjusted annually. The add-on payments for KORSUVA injection
will commence on April 1, 2024. The anticipated unfavorable CMS reimbursement codified in the final CY2024 rule
resulted in a lack of sequential revenues growth for KORSUVA injection since its launch. For the years ended December
31, 2023 and 2022, CSL Vifor recorded net sales of KORSUVA injection in the United States of approximately $26.5
million $35.0 million, respectively, and we recorded associated collaborative revenue of $12.4 million and $16.6 million,
respectively, which represented our share of the profit from these sales. As a result of the final CY 2024 rule, we expect no
meaningful revenue contribution from KORSUVA injection following TDAPA expiration.
In April 2022, the European Commission granted a marketing authorization to difelikefalin injection under the brand
name Kapruvia for the treatment of moderate-to-severe pruritus associated with advanced CKD in adult hemodialysis
patients. The marketing authorization approves Kapruvia for use in all member states of the EU, as well as Iceland,
Liechtenstein, and Norway. Difelikefalin injection was also approved in the UK (04/2022) and Switzerland (08/2022)
under the brand name Kapruvia as well as Singapore (08/2022), Canada (08/2022), Australia (11/2022), UAE (01/2023),
Kuwait (05/2023), Israel (06/2023) and Saudi Arabia (01/2024) under the brand name KORSUVA injection. For the years
ended December 31, 2023 and 2022, we recorded royalty revenue of approximately $415,000 and $72,000, respectively,
which represented our royalties on net sales of Kapruvia.
66
Table of Contents
During the fourth quarter of 2023, we entered into the HCR Agreement where we sold our future royalties and
milestones for Kapruvia and KORSUVA to HCR. For the period of October 1, 2023 through December 31, 2023, we
recorded other revenue of $699,000, of which approximately $284,000 related to CSL Vifor royalties to be paid to HCR
under this agreement (see “Royalty Purchase and Sale Agreement” below).
We have out-licensed to Maruishi and its sub-licensee Kissei the commercialization of KORSUVA injection in
Japan. In September 2023, Maruishi received manufacturing and marketing approval from Japan’s Ministry of Health,
Labour and Welfare for KORSUVA IV Injection Syringe for the treatment of pruritus in hemodialysis patients. In
conjunction with the approval, we earned a $1.4 million milestone payment per the terms of the licensing agreement during
the year ended December 31, 2023.
During the fourth quarter of 2023, we entered into the HCR Agreement where we sold our future royalties and
milestones for KORSUVA in Japan to HCR. For the period of October 1, 2023 through December 31, 2023, we recorded
other revenue of $699,000, of which approximately $415,000 related to Maruishi royalties and milestones to be paid to
HCR under this agreement (see “Royalty Purchase and Sale Agreement” below).
As a result of our sales of the royalties and milestones for KORSUVA/Kapruvia, we expect no meaningful revenue
contribution from KORSUVA/Kapruvia royalties and milestones in the future.
KORSUVA Injection U.S. Commercialization
In April 2022, our partner CSL Vifor initiated the commercialization of KORSUVA injection in the United States.
The launch was initially driven by independent and mid-size dialysis organizations coupled with product stocking at the
wholesaler level. In the third quarter of 2022, large dialysis organizations, or LDOs, came on-line driving a significant
quarter-to-quarter increase in order volume from the wholesaler. This stocking at the clinic level, particularly from
Fresenius Medical Care (FMC), resulted in significant subsequent quarterly revenue fluctuations. In the third quarter of
2023, FMC decided to reallocate all remaining clinic level inventory within its network of clinics resulting in limited
revenues in the fourth quarter of 2023. During the years ended December 31, 2023 and 2022, KORSUVA injection
generated net sales of approximately $26.5 million and $35.0 million, respectively, and we recorded collaborative revenue
of $12.4 million and $16.6 million, respectively, which represented our share of the profit from sales of KORSUVA
injection. In addition, 314,100 and 207,096 KORSUVA injection vials were shipped from wholesalers to the dialysis
clinics for the years ended December 31, 2023 and 2022, respectively. Of the vials shipped to the FMC dialysis centers for
the year ended December 31, 2023, a significant portion was reallocated product by FMC within its network of clinics.
Strategic Prioritization and Workforce Reduction
On January 22, 2024, we announced a planned workforce reduction of up to 50% of our employees in order to reduce
our operating expenses and focus our efforts on development of oral difelikefalin in chronic pruritus associated with NP.
We expect to record a pre-tax severance expense of approximately $2.7 million during the first quarter of 2024.
Corporate History
We were incorporated and commenced operations in 2004, and our primary activities to date have been organizing
and staffing our company, developing our lead product and product candidates, including conducting preclinical studies
and clinical trials of difelikefalin-based product candidates and raising capital. To date, we have financed our operations
primarily through sales of our equity and debt securities, sales of our royalties from ex U.S. sales of our commercial
product, and payments from license agreements.
67
Table of Contents
Collaboration and License Agreements
Agreements with CSL Vifor
We are party to two separate license agreements with CSL Vifor. In October 2020, we granted CSL Vifor an
exclusive license solely in the United States to use, distribute, offer for sale, promote, sell, and otherwise commercialize
KORSUVA (difelikefalin) injection for all therapeutic uses relating to the inhibition, prevention or treatment of itch
associated with pruritus in hemodialysis and peritoneal dialysis patients in the United States.
We received an upfront payment of $100.0 million and an additional payment of $50.0 million for the purchase of an
aggregate of 2,939,552 shares of our common stock at a price of $17.0094 per share, which represented a premium over a
pre-determined average closing price of our common stock. The U.S. regulatory approval of KORSUVA injection in
August 2021 triggered an additional $50.0 million equity purchase by CSL Vifor in October 2021, in which we sold an
aggregate of 3,282,391 shares of our common stock at a price of $15.23 per share, which represented a 20% premium to
the 30-day trailing average price of our common stock. In addition, pursuant to this agreement, we are eligible to receive
payments of up to $240.0 million upon the achievement of certain sales-based milestones. However, based on the limited
commercial success of KORSUVA injection, we do not expect to achieve these sales-based milestones.
Pursuant to the agreement for commercialization of KORSUVA in the United States, we are generally entitled to
60% of the net profits from sales of KORSUVA injection in the United States and CSL Vifor is entitled to 40% of such net
profits (excluding sales to Fresenius Medical Center dialysis clinics, compensation for which is governed by a separate
agreement), subject to potential temporary adjustment in future years based on certain conditions. Under this agreement, in
consideration of CSL Vifor’s conduct of the marketing, promotion, selling and distribution of KORSUVA injection in the
United States, we pay a marketing and distribution fee to CSL Vifor based on the level of annual net sales. This fee as well
as CSL Vifor’s cost of goods sold, or COGS, are deducted from net sales in calculating the net profits that are subject to the
profit-sharing arrangement under the agreement.
Under a separate agreement with CSL Vifor, in May 2018, we granted CSL Vifor a license to seek regulatory
approval to commercialize, import, export, use, distribute, offer for sale, promote, sell and otherwise commercialize
KORSUVA (difelikefalin) injection for all therapeutic uses to prevent, inhibit or treat itch associated with pruritus in
hemodialysis and peritoneal-dialysis patients worldwide (excluding the United States, Japan and South Korea). Under the
agreement, CSL Vifor also has the right to promote KORSUVA injection in the United States in the dialysis clinics of
Fresenius Medical Care North America, or FMCNA, under a profit-sharing arrangement.
Upon entry into this agreement, we received a non-refundable, non-creditable $50.0 million upfront payment for the
purchase of an aggregate of 1,174,827 shares of our common stock at a price of $17.024 per share, which represented a
premium over a pre-determined average closing price of our common stock.
As a result of the European Commission’s regulatory approval of Kapruvia in April 2022, we received a $15.0
million regulatory milestone payment from CSL Vifor, which was recorded as license and milestone fees revenue for the
year ended December 31, 2022. After U.S. regulatory approval of KORSUVA injection in August 2021, we received a
$15.0 million regulatory milestone payment which was recorded as license and milestone fees revenue for the year ended
December 31, 2021.
We are eligible to receive from CSL Vifor commercial milestone payments in the aggregate of up to $440.0 million,
all of which milestones are sales related. We are also eligible to receive tiered double-digit royalty payments based on
annual net sales, as defined, of KORSUVA (difelikefalin) injection in the licensed territories. In the United States, CSL
Vifor will promote KORSUVA (difelikefalin) injection in the dialysis clinics of FMCNA under a profit-sharing
arrangement (subject to the terms and conditions of this agreement) based on net FMCNA clinic sales) and Vifor Fresenius
Medical Care Renal Pharma Ltd. is entitled to 50% of such net profits, subject to potential adjustments in a calendar year
based on certain conditions. During the fourth quarter of 2023, we entered into the HCR Agreement pursuant to which we
sold our future royalties and milestone payments under this agreement to HCR (see “Royalty Purchase and Sale
Agreement” below).
68
Table of Contents
Maruishi Pharmaceutical Co., Ltd., or Maruishi
In April 2013, we entered into a license agreement with Maruishi, or the Maruishi Agreement, under which we
granted Maruishi an exclusive license to develop, manufacture and commercialize drug products containing difelikefalin in
Japan in the acute pain and uremic pruritus fields. Maruishi has a right of first negotiation for any other indications for
which we develop difelikefalin and, under certain conditions, Maruishi may substitute another pruritus indication for the
uremic pruritus indication originally included in its license from us. Maruishi’s right of first negotiation has expired for the
indication of chronic pruritus associated with NP. Maruishi is required to use commercially reasonable efforts, at its
expense, to develop, obtain regulatory approval for and commercialize difelikefalin in Japan. We are required to use
commercially reasonable efforts, at our expense, to develop, obtain regulatory approval for and commercialize difelikefalin
in the United States.
In January 2022, Maruishi and its sublicensee Kissei confirmed the primary endpoint was achieved in a Japanese
Phase 3 clinical study (double-blind, placebo-controlled period) of difelikefalin injection for the treatment of pruritus in
hemodialysis patients. In the Phase 3 study, 178 patients were administered difelikefalin or placebo for 6 weeks followed
by an open-label extension period of difelikefalin administration for 52 weeks. The primary endpoint, change in itch NRS
score, and the secondary endpoint, change in itching scores of Shiratori severity criteria, were significantly improved from
baseline compared to the placebo group. Difelikefalin was well-tolerated.
Under the terms of the Maruishi Agreement, we received a non-refundable and non-creditable upfront license fee of
$15.0 million and are eligible to receive up to an aggregate of $10.5 million in clinical development and regulatory
milestones (before contractual foreign currency exchange adjustments). In January 2021, we met the milestone criteria, as
set forth in the Maruishi Agreement, for Maruishi’s first initiation of a Phase 3 trial for uremic pruritus in Japan. As a
result, we received the $2.0 million milestone payment ($1.9 million after contractual foreign currency exchange
adjustments) in May 2021.
In September 2022, Maruishi submitted a New Drug Application in Japan for approval of difelikefalin injection for
the treatment of pruritus in hemodialysis patients. In September 2023, Maruishi received manufacturing and marketing
approval from Japan’s Ministry of Health, Labour and Welfare for KORSUVA IV Injection Syringe for the treatment of
pruritus in hemodialysis patients. In conjunction with the approval, we earned a $1.4 million milestone payment per the
terms of the licensing agreement for the year ended December 31, 2023. In November 2023, we entered into an active
pharmaceutical ingredient, or API, supply agreement with Maruishi for difelikefalin.
To date, we have received $6.5 million (before contractual foreign currency exchange adjustments) of clinical
development and regulatory milestones from Maruishi. We are also eligible to receive a one-time sales milestone of one
billion Yen when a certain sales level is attained. We also receive a mid-double-digit percentage of all non-royalty
payments received by Maruishi from its sublicensees, if any, and tiered royalties based on net sales, if any, with minimum
royalty rates in the low double digits and maximum royalty rates in the low twenties. Maruishi’s obligation to pay us
royalties continues, on a product-by-product basis, until the expiration of the last-to-expire licensed patent covering such
product or the later expiration of any market exclusivity period. During the fourth quarter of 2023, we entered into the
HCR Agreement pursuant to which we sold our future royalties and milestone payments under the Maruishi Agreement to
HCR (see “Royalty Purchase and Sale Agreement” below).
Chong Kun Dang Pharmaceutical Corporation, or CKDP
In April 2012, we entered into a license agreement with CKDP, or the CKDP Agreement, under which we granted
CKDP an exclusive license to develop, manufacture and commercialize drug products containing difelikefalin in South
Korea. CKDP is required to use commercially reasonable efforts, at its expense, to develop, obtain regulatory approval for
and commercialize difelikefalin in South Korea. We are required to use commercially reasonable efforts, at our expense, to
develop, obtain regulatory approval for and commercialize difelikefalin in the United States.
Under the terms of the CKDP Agreement, we received a non-refundable and non-creditable $0.6 million upfront
payment and are eligible to receive up to an aggregate of $3.8 million in development and regulatory milestones (before
South Korean withholding taxes). To date, we have received $2.3 million (before South Korean withholding tax) of
69
Table of Contents
development and regulatory milestones. We are also eligible to receive a mid-double-digit percentage of all non-royalty
payments received by CKDP from its sublicensees, if any, and tiered royalties ranging from the high single digits to the
high teens based on net sales, if any. CKDP’s obligation to pay us royalties continues, on a product-by-product basis, until
the expiration of the last-to-expire licensed patent covering such product or the later expiration of any market exclusivity
period.
The CKDP Agreement continues until CKDP no longer has any obligation to pay us royalties on any product. Either
we or CKDP may terminate the CKDP Agreement for the other party’s breach of the CKDP Agreement or bankruptcy.
CKDP may terminate the CKDP Agreement if any of the licensed patent rights is invalid, unenforceable, is narrowed in
scope or is deemed unpatentable, except as a result of a challenge by CKDP, or a third party commercializes a product
containing a compound identical to difelikefalin without infringing any of the licensed patent rights in South Korea. We
may terminate the CKDP Agreement if CKDP challenges the licensed patent rights or if a third party in South Korea owns
an issued patent that claims difelikefalin and CKDP’s sale of products would infringe that patent. In addition, in connection
with the CKDP Agreement, CKDP made a $0.4 million equity investment in our company.
Manufacturing and License Agreements
Polypeptide Laboratories S.A., or PPL
In July 2021, we entered into an API Commercial Supply Agreement with Polypeptide Laboratories S.A., or PPL,
that defines each party’s responsibilities with respect to PPL’s manufacture and supply of API for the difelikefalin injection
product candidate. Under the API Commercial Supply Agreement, PPL shall manufacture API at its facility for sale and
supply to us, in the amounts as set forth in purchase orders to be provided by us. We will be required to purchase our
requirements of API for each year of the term of the agreement, based on internal forecasts.
The API Commercial Supply Agreement will continue until the fifth anniversary of the approval by the FDA of the
NDA for KORSUVA injection, unless the API Commercial Supply Agreement is earlier terminated, and will automatically
be extended for successive five-year periods unless either party gives notice to the other party of its intention to terminate.
Enteris Biopharma, Inc., or Enteris
In August 2019, we entered into a non-exclusive license agreement with Enteris Biopharma, Inc. (Enteris), or the
Enteris License Agreement. Pursuant to the Enteris License Agreement, Enteris granted to us a non-exclusive, royalty-
bearing license, including the right to grant sublicenses, under certain proprietary technology and patent rights related to or
covering formulations for oral delivery of peptide active pharmaceutical ingredients with functional excipients to enhance
permeability and/or solubility, known as Enteris’s Peptelligence® technology, to develop, manufacture and commercialize
products using such technology worldwide, excluding Japan and South Korea.
As consideration for the licensed rights under the Enteris License Agreement, we paid an upfront fee equal to $8.0
million, consisting of $4.0 million in cash and $4.0 million in shares of our common stock pursuant to the Enteris Purchase
Agreement described below.
We are also obligated, pursuant to the Enteris License Agreement, to pay Enteris (1) milestone payments upon the
achievement of certain development, regulatory and commercial milestones and (2) low-single digit royalty percentages on
net sales of licensed products, subject to reductions in specified circumstances. Until the second anniversary of the entry
into the Enteris License Agreement, we had the right, but not the obligation, to terminate our obligation to pay any
royalties under the Royalty Buyout. We did not exercise our Royalty Buyout right and such right expired in August 2021.
During the year ended December 31, 2023, no milestone payments or royalties were paid to Enteris by us in relation to the
Enteris License Agreement. During the years ended December 31, 2022 and 2021, we paid $5.0 million and $15.0 million,
respectively, to Enteris for milestones earned in relation to the Enteris License Agreement, which were recorded in R&D
expense for the respective periods.
70
Table of Contents
The Enteris License Agreement will expire on a country-by-country, licensed product-by-licensed product basis upon
the later of (1) the expiration (or invalidation) of all valid claims in licensed patent rights that cover such product in such
country, (2) the end of the calendar quarter in which generic competition (as defined in the Enteris License Agreement)
occurs for such product in such country and (3) ten years from the first commercial sale of such product.
Either party may terminate the Enteris License Agreement upon written notice if the other party has failed to remedy
a material breach within 60 days (or 30 days in the case of a material breach of a payment obligation). Enteris may
terminate the Enteris License Agreement upon 30 days’ written notice to us if we or any of our affiliates formally challenge
the validity of any licensed patent rights or assists a third party in doing so. We may terminate the Enteris License
Agreement for any reason or no reason (a) prior to receipt of first regulatory approval for a licensed product in the United
States for any indication upon 30 days’ prior written notice to Enteris or (b) on or after receipt of first regulatory approval
for a licensed product in the United States for any indication upon 60 days’ prior written notice to Enteris.
In August 2019, in connection with the Enteris License Agreement, we entered into the Enteris Purchase Agreement
with Enteris and its affiliate, EBP Holdco LLC, collectively referred to as Purchaser, pursuant to which we issued and sold
to Purchaser 170,793 shares of our common stock in a private placement. Such shares were issued in satisfaction of the
$4.0 million portion of the upfront fee payable in shares of our common stock pursuant to the Enteris License Agreement
and for no additional consideration, based on a purchase price of $23.42 per share, which was equal to the 30-day volume
weighted average price of our common stock on August 20, 2019. Pursuant to the Enteris Purchase Agreement, we effected
the registration and sale of the shares issued and sold to Purchaser thereunder in accordance with the applicable
requirements of the Securities Act of 1933, as amended, or the Securities Act, which included the filing of a registration
statement with the SEC on September 9, 2019. In addition, the Purchase Agreement includes customary representations,
warranties and covenants by us.
Patheon UK Limited, or Patheon
In July 2019, we entered into a Master Services Agreement, or MSA, with Patheon UK Limited, or Patheon. The
MSA governs the general terms under which Patheon, or one of its affiliates, will provide non-exclusive manufacturing
services to us for the drug products specified by us from time to time. Pursuant to the MSA, we have agreed to order from
Patheon at least a certain percentage of our commercial requirements for a product under a related Product Agreement.
Each Product Agreement that we may enter into from time to time will be governed by the terms of the MSA, unless
expressly modified in such Product Agreement.
The MSA has an initial term ending December 31, 2024, and will automatically renew after the initial term for
successive terms of two years each if there is a Product Agreement in effect, unless either party gives notice of its intention
to terminate the MSA at least 18 months prior to the end of the then current term.
Either party may terminate the MSA or a Product Agreement upon written notice if the other party (1) has failed to
remedy a material breach within a specified time or (2) is declared insolvent or bankrupt, voluntarily files a petition of
bankruptcy or assigns such agreement for the benefit of creditors. We may terminate a Product Agreement (a) upon
90 days’ prior written notice if any governmental agency takes any action that prevents us from selling the relevant product
in the relevant territory, (b) upon six months’ prior written notice if we do not intend to order manufacturing services due to
a product’s discontinuance in the market, or (c) upon 90 days’ prior written notice if we determine that the manufacture or
supply of a product likely infringes third-party rights. Patheon may terminate the MSA or a Product Agreement (i) upon
six months’ prior written notice if we assign such agreement to an assignee that is unacceptable to Patheon for certain
reasons, or (ii) upon 30 days’ prior written notice if, after the first year of commercial sales, we forecast zero volume for
12 months.
The MSA contains, among other provisions, customary representations and warranties by the parties, a grant to
Patheon of certain limited license rights to our intellectual property in connection with Patheon’s performance of the
services under the MSA, certain indemnification rights in favor of both parties, limitations of liability and customary
confidentiality provisions.
71
Table of Contents
Also in July 2019, we entered into two related Product Agreements under the MSA, one with each of Patheon and
Patheon Greenville, to govern the terms and conditions of the manufacture of commercial supplies of difelikefalin
injection. Pursuant to the Product Agreements, Patheon and Patheon Greenville will manufacture commercial supplies of
difelikefalin injection at the Monza, Italy and Greenville, North Carolina manufacturing sites, respectively, from API
supplied by us. Patheon and Patheon Greenville will be responsible for supplying the other required raw materials and
packaging components, and will also provide supportive manufacturing services such as quality control testing for raw
materials, packaging components and finished product.
In December 2023, we entered into an agreement with Patheon to reimburse Patheon approximately $1.7 million for
forecasted manufacturing commitments that are no longer needed due to the reduced demand expectations of KORSUVA
in the United States and was recorded within accounts payable and accrued expenses on our Consolidated Balance Sheet as
of December 31, 2023. In connection with the agreement with Patheon, we agreed to schedule additional manufacturing
commitments in 2024.
Royalty Purchase and Sale Agreement
During the fourth quarter of 2023, we, through our wholly-owned subsidiary Cara Royalty Sub, entered into the HCR
Agreement with HCR pursuant to which Cara Royalty Sub sold to HCR certain of its rights to receive the Royalties, due
and payable to Cara Royalty Sub (as our assignee) under the Covered License Agreements, in exchange for up to $40.0
million. We have retained all of our right, title and interest in, to and under the Covered License Agreements that relate to
any non-intravenous formulation of difelikefalin.
Under the terms of the HCR Agreement, Cara received an initial payment of $17.5 million less certain transaction
costs in November 2023. In December 2023, we received an additional $20.0 million, less certain advisory fees, upon
satisfying the milestone event for pricing for Kapruvia® (difelikefalin) in Germany being approved above a certain
threshold amount per dose. The terms of the HCR Agreement also provide for an additional $2.5 million milestone
payment to Cara Royalty Sub upon achievement of a 2024 sales milestone of KORSUVA in Japan.
The HCR Agreement will automatically expire, and the payment of Royalties to HCR will cease, when HCR has
received payments of Royalties equal to two times the aggregate amount of payments made by HCR under the HCR
Agreement if achieved on or prior to December 31, 2029, or 2.8 times the aggregate amount of payments made by HCR
under the HCR Agreement, if not achieved on or prior to December 31, 2029. In the event of a change of control, Cara
Royalty Sub will pay to HCR an amount equal to 2.8 times the aggregate amount of payments made by HCR less the total
net amounts paid by Cara Royalty Sub to HCR as of the effective date of control. In certain situations, Cara Royalty Sub
would not be obligated to pay the change of control payment to HCR. After the HCR Agreement expires, all rights to
receive the Royalties return to Cara Royalty Sub.
Components of Operating Results
The following discussion sets forth certain components of our Consolidated Statements of Comprehensive Loss as
well as factors that impact those items or could impact those items in the future.
Revenue
To date, we have generated revenue primarily from (1) collaborative revenue from our share of the profit generated
by KORSUVA injection sales in the United States; (2) commercial supply revenue from our sales of commercial product to
CSL Vifor, which is subsequently sold to wholesalers; (3) the receipt of upfront license fees and milestone payments; (4)
royalty revenue in conjunction with sales of Kapruvia in Europe through September 30, 2023; and (5) clinical compound
sales from certain license agreements. We are eligible to receive sales-based milestones in the future in accordance with
certain licensing agreements.
Beginning on October 1, 2023, the revenue received under our agreements with CSL Vifor and Maruishi for royalty
and sales-based milestone payments received in conjunction with ex-U.S. sales of KORSUVA/Kapruvia were
72
Table of Contents
recorded as other revenue and considered non-cash until we have fulfilled our obligations under HCR Agreement (see
“Royalty Purchase and Sale Agreement” above).
To date, we have earned a total of $136.8 million in clinical development or regulatory milestone payments, clinical
compound and commercial compound sales from certain license agreements, collaborative revenue from our share of the
profit generated by KORSUVA injection sales, and royalty revenue until we entered into the HCR Agreement during the
fourth quarter of 2023.
Revenue from sales of KORSUVA injection in future periods is subject to uncertainties and will depend on several
factors, including the success of our and our commercial partners’ commercialization efforts in the United States, the
number of new patients adopting or switching to KORSUVA injection, patient retention and sustained demand, the number
of physicians prescribing KORSUVA injection, the rate of monthly prescriptions, reimbursement from third-party payors
including the U.S. government, the conversion of patients from our clinical trials to commercial customers, and market
trends. More specifically, in December 2021, CMS granted TDAPA to KORSUVA injection in the anti-pruritic functional
category. TDAPA went into effect on April 1, 2022, for a minimum of two years. On October 27, 2023, CMS published the
final CY 2024 rule, which finalized the post-TDAPA add-on payment as proposed in the draft CY 2024 rule. Under the
final rule, TDAPA drugs in existing functional categories will receive a post-TDAPA add-on payment set at 65 percent of
the total trailing 12-months expenditure levels for the given renal dialysis drug or biological product. The post-TDAPA
add-on payment will be applied to all ESRD PPS payments and paid for 3 years, adjusted annually. The add-on payments
for KORSUVA injection will commence on April 1, 2024. The anticipated unfavorable CMS reimbursement codified in the
final CY2024 rule resulted in a lack of sequential revenues growth for KORSUVA injection since its launch. As a result,
we expect no meaningful revenue contribution from KORSUVA injection post its TDAPA expiration.
In addition, FMC recently decided to reallocate all remaining clinic level inventory that was shipped in the third
quarter of 2022 within its network of clinics resulting in approximately $5.0 million in net sales in the fourth quarter of
2023.
As of December 31, 2023, Vifor International owned 7,396,770, or 13.6%, of our common stock. CSL Vifor and its
affiliates are all considered related parties as of December 31, 2023, 2022 and 2021 (see Note 21 of Notes to Consolidated
Financial Statements, Related Party Transactions, in this Annual Report on Form 10-K).
Cost of Goods Sold (COGS)
COGS includes costs related to sales of our commercial product, KORSUVA injection, to CSL Vifor. Costs related to
the sales of KORSUVA injection are generally recognized upon receipt of shipment by CSL Vifor. Our COGS for
KORSUVA injection include the cost of producing commercial product that correspond with commercial supply revenue,
such as third-party supply and overhead costs, as well as certain period costs related to freight, packaging, stability, and
quality testing. The related COGS for CSL Vifor associated with the net profit share arrangement as well as the marketing
and distribution fee for the applicable period reduces our profit share revenue for the period.
For the year ended December 31, 2023, we recorded commercial supply revenue of $5.8 million, with associated
COGS of $6.2 million. For the year ended December 31, 2022, we recorded commercial supply revenue of $10.2 million,
with associated COGS of $7.3 million. In January 2022, we recorded commercial supply revenue of $2.3 million, with no
associated COGS as all inventory costs were incurred prior to receipt of regulatory approval of KORSUVA injection and,
accordingly, were expensed as incurred. For the remainder of 2022, we recorded commercial supply revenue of $7.9
million, with associated COGS of $7.3 million as these inventory costs were incurred subsequent to the receipt of
regulatory approval of KORSUVA injection and, accordingly, were capitalized as inventory. We expect our COGS to be
reflective of future KORSUVA injection sales.
Research and Development (R&D)
Our R&D expenses relate primarily to the development of difelikefalin. R&D expenses consist of expenses incurred
in performing R&D activities, including compensation and benefits for full-time R&D employees, clinical trial
73
Table of Contents
and related clinical manufacturing expenses, third-party formulation expenses or milestone payments, fees paid to CROs
and other consultants, stock-based compensation for R&D employees and consultants, and other outside expenses. Our
R&D expenses also included expenses related to preclinical activities for our earlier stage programs in prior periods and
may include such expenses in the future.
R&D costs are expensed as incurred. Non-refundable advance payments for goods or services to be received in the
future for use in R&D activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are
delivered or the services are performed. Most of our R&D costs have been external costs, which we track on a program-by
program basis. Our internal R&D costs are primarily compensation expenses for our full-time R&D employees. We do not
track internal R&D costs on a program-by-program basis.
R&D activities are central to our business model. Product candidates in later stages of clinical development generally
have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and
duration of later-stage clinical trials. Based on our current development plans, we presently expect that our R&D expenses
will decrease in the future as we focus our development efforts on the clinical trials for NP. However, it is difficult to
determine with certainty the duration and completion costs of our current studies in NP or future nonclinical and clinical
studies of our product candidates, or if, when or to what extent we will generate revenues from the commercialization and
sale of any of our product candidates that obtain regulatory approval. We may never succeed in achieving regulatory
approval for any of our product candidates.
The duration, costs and timing of clinical trials and development of our product candidate will depend on a variety of
factors including, but not limited to:
●
●
●
●
●
●
●
●
●
●
per patient trial costs;
the number of patients that participate in the trials;
the number of sites included in the trials;
the countries in which the trial is conducted;
the length of time required to enroll eligible patients;
the number of doses that patients receive;
the drop-out or discontinuation rates of patients;
potential additional safety monitoring or other studies requested by regulatory agencies;
the duration of patient follow-up; and
the efficacy and safety profile of the product candidate.
In addition, the probability of success for each product candidate will depend on numerous factors, including
competition, manufacturing capability and commercial viability. We will determine which programs to pursue and how
much to fund each program in response to the scientific and clinical success of each product candidate, as well as an
assessment of each product candidate’s commercial potential.
General and Administrative (G&A)
General and administrative, or G&A, expenses consist primarily of salaries and other related costs, including stock-
based compensation, for personnel in executive, finance, accounting, legal, business development, information technology,
or IT, human resources, project management, alliance management, and procurement functions. Other costs
74
Table of Contents
include facility costs not otherwise included in R&D expenses, legal fees, insurance costs, investor relations costs, patent
costs and fees for accounting and consulting services.
We anticipate that our G&A expenses will decrease in the future as a result of our announced reduction in workforce
in January 2024. These expenses include costs related to personnel, fees to outside consultants, lawyers, and accountants.
In addition, if oral difelikefalin or any future product candidate obtains regulatory approval for marketing, we may incur
expenses associated with building sales and marketing, commercial operations, and market access teams.
Our license agreements with CSL Vifor provide full U.S. commercialization rights of KORSUVA injection to CSL
Vifor under profit-sharing arrangements. Under these profit-sharing arrangements, in consideration of CSL Vifor’s conduct
of the marketing, promotion, selling and distribution of KORSUVA injection in the United States, we pay a marketing and
distribution fee to CSL Vifor based on the level of annual net sales. This fee as well as CSL Vifor’s COGS are deducted
from product sales in calculating the net profits that are subject to the profit-sharing arrangement (see Note 13 of Notes to
Consolidated Financial Statements, Collaboration and Licensing Arrangements, in this Annual Report on Form 10-K).
Other Income, Net
Other income, net consists of interest and dividend income earned on our cash, cash equivalents, and marketable
securities, realized gains and losses on the sale of marketable securities and property and equipment, as well as accretion of
discounts/amortization of premiums on purchases of marketable securities. In the event we record a credit loss expense on
our available-for-sale debt securities, those expenses would be offset against other income.
Non-cash Interest Expense on Liability Related to Sales of Future Royalties and Milestones
Non-cash interest expense on liability related to sales of future royalties and milestone payments, which are received
in conjunction with ex U.S. sales of KORSUVA/Kapruvia under our agreements with CSL Vifor and Maruishi, consists of
imputed interest on the carrying value of the liability and the amortization of the related issuance costs resulting from the
HCR Agreement (see “Royalty Purchase and Sale Agreement” above). This non-cash interest expense is recognized
separately on the Consolidated Statement of Comprehensive Loss for the year ended December 31, 2023.
Income Taxes
Historically, our benefit from income taxes related to state R&D tax credits exchanged for cash pursuant to the
Connecticut R&D Tax Credit Exchange Program, which permits qualified small businesses engaged in R&D activities
within Connecticut to exchange their unused R&D tax credits for a cash amount equal to 65% of the value of the
exchanged credits.
We account for income taxes using the asset and liability method. Under this method, deferred tax assets and
liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are
measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Deferred
income tax assets are reduced, as necessary, by a valuation allowance when we determine it is more likely than not that
some or all of the tax benefits will not be realized.
There were no material uncertain tax positions taken as of December 31, 2023 and 2022. We do not have any interest
or penalties accrued related to tax positions as we do not have any unrecognized tax benefits. In the event we determine
that accrual of interest or penalties are necessary in the future, the amount will be presented as a component of interest
expense.
Further, beginning in our tax year ending December 31, 2022, as a result of the TCJA, current R&D expenditures
incurred in the United States must be capitalized for tax purposes, and amortized over a period of five years (fifteen years
in the case of R&D performed outside the United States). As such, the deferred tax asset for intangible assets will
materially increase in lieu of NOL carryforwards, offset by a change in valuation allowance.
75
Table of Contents
In March 2020, former President Trump signed into law the CARES Act (H.R. 748), which was further expanded
with the signing of the Consolidation Appropriations Act of 2021 (H.R. 133) on December 27, 2020. The CARES Act (and
December expansion) included a variety of economic and tax relief measures intended to stimulate the economy, including
loans for small businesses, payroll tax credits/deferrals, and corporate income tax relief. Due to our history of tax loss
carryforwards and full valuation allowance, the CARES Act did not have a significant effect to the income tax provision
for the years ended December 31, 2023, 2022 and 2021, as the corporate income tax relief was directed towards cash
taxpayers.
Results of Operations
Comparison of the years ended December 31, 2023, 2022 and 2021
Revenue
Collaborative revenue
Commercial supply revenue
License and milestone fees
Royalty revenue
Clinical compound revenue
Other revenue
Total revenue
Collaborative Revenue
2023
$ 12,936
5,843
910
415
165
699
$ 20,968
Year Ended December 31,
2022
Dollar amounts in thousands
% change
% change
2021
(22)% $ 16,572
10,223
(43)%
15,000
(94)%
72
476 %
—
N/A
N/A
—
(50)% $ 41,867
706
2,248 % $
701
1,358 %
21,223
(29)%
—
N/A
398
(100)%
N/A
—
82 % $ 23,028
We recognized collaborative revenue of $12.9 million and $16.6 million for the years ended December 31, 2023 and
2022, respectively. Collaborative revenue was related to our share of the profit from CSL Vifor’s sales of KORSUVA
injection to third parties in the United States, which commercially launched in April 2022, as well as $0.5 million earned in
conjunction with the regulatory approval of KORSUVA injection in Japan for a milestone payment we earned in September
2023 from Maruishi that was allocated to the R&D services performance obligation under the Maruishi Agreement (see
Notes 13 and 14 of Notes to Consolidated Financial Statements, Collaboration and Licensing Agreements and Revenue
Recognition, respectively, in this Annual Report on Form 10-K).
We recognized collaborative revenue of $0.7 million for the year ended December 31, 2021, which was related to the
milestone payment we earned in January 2021 from Maruishi’s first initiation of a Phase 3 trial for uremic pruritus in Japan
that was allocated to the R&D services performance obligation under the Maruishi Agreement (see Notes 13 and 14 of
Notes to Consolidated Financial Statements, Collaboration and Licensing Agreements and Revenue Recognition,
respectively, in this Annual Report on Form 10-K).
Commercial Supply Revenue
We recognized commercial supply revenue of $5.8 million, $10.2 million, and $0.7 million for the years ended
December 31, 2023, 2022 and 2021, respectively. These changes in commercial supply revenue were related to sales of
KORSUVA injection to CSL Vifor, as we and CSL Vifor began commercializing KORSUVA injection in the United States
in December 2021 and commercial launch began in April 2022.
License and milestone fee revenue
We recognized license and milestone fees revenue of $0.9 million for the year ended December 31, 2023, in
conjunction with the regulatory approval of KORSUVA injection in Japan for a milestone payment we earned in September
2023 from Maruishi that was allocated to the license and milestone fee performance obligation under the
76
Table of Contents
Maruishi Agreement (see Notes 13 and 14 of Notes to Consolidated Financial Statements, Collaboration and Licensing
Agreements and Revenue Recognition, respectively, in this Annual Report on Form 10-K).
We recognized license and milestone fees revenue of $15.0 million for the year ended December 31, 2022, in
conjunction with the regulatory milestone payment earned from CSL Vifor for the approval of Kapruvia by the European
Commission in April 2022 (see Notes 13 and 14 of Notes to Consolidated Financial Statements, Collaboration and
Licensing Agreements and Revenue Recognition, respectively, in this Annual Report on Form 10-K).
We recognized license and milestone fees revenue of $21.2 million for the year ended December 31, 2021, in
conjunction with the milestone payment of $15.0 million we earned upon the regulatory approval of KORSUVA injection
in August 2021, a $5.0 million premium on the common stock purchased by Vifor International as part of the KORSUVA
injection approval milestone, and a milestone payment of $1.2 million that we earned in January 2021 from Maruishi’s first
initiation of a Phase 3 trial for uremic pruritus in Japan that was allocated to the license fee performance obligation under
the Maruishi Agreement (see Notes 13 and 14 of Notes to Consolidated Financial Statements, Collaboration and Licensing
Agreements and Revenue Recognition, respectively, in this Annual Report on Form 10-K).
Royalty revenue
We recognized royalty revenue of approximately $415,000 and $72,000 for the years ended December 31, 2023 and
2022, respectively, which were related to our royalties on the net sales of Kapruvia in Europe prior to October 1, 2023.
Beginning on October 1, 2023, royalty revenue will no longer be recognized until we have fulfilled our obligations under
the HCR Agreement (see “Royalty Purchase and Sale Agreement” above). There was no royalty revenue for the year ended
December 31, 2021.
Clinical compound revenue
We recognized clinical compound revenue of approximately $165,000 and $398,000 for the years ended December
31, 2023 and 2021, respectively, which were related to sales of clinical compound to Maruishi. There was no clinical
compound revenue for the year ended December 31, 2022 (see Note 14 of Notes to Consolidated Financial Statements,
Revenue Recognition, in this Annual Report on Form 10-K).
Other revenue
We recognized non-cash revenue of approximately $699,000 for the year ended December 31, 2023, which represent
royalties and milestone payments earned in conjunction with ex U.S. sales of KORSUVA/Kapruvia under our agreements
with CSL Vifor and Maruishi during the fourth quarter of 2023, which were sold to HCR under the HCR Agreement. There
was no non-cash revenue recognized during the years ended December 31, 2022 or 2021.
Cost of Goods Sold (COGS)
Year Ended December 31,
2023
2022
2021
Dollar amounts in thousands
% change
% change
Cost of Goods Sold
$
6,174
(15)% $
7,266
N/A $ —
During the years ended December 31, 2023 and 2022, we recorded COGS of $6.2 million and $7.3 million,
respectively, which was related to our commercial supply revenue for KORSUVA injection sales to CSL Vifor. During the
year ended December 31, 2023, COGS also included inventory write-downs of approximately $0.5 million.
As commercialization of KORSUVA began in April 2022, no associated COGS was recorded for commercial supply
revenue of $2.3 million in January 2022 as all inventory costs were incurred prior to receipt of regulatory approval of
KORSUVA injection, and accordingly, were expensed as incurred (see Note 2 of Notes to Consolidated
77
Table of Contents
Financial Statements, Summary of Significant Accounting Policies – Inventories and Cost of Goods Sold (COGS), in this
Annual Report on Form 10-K).
Research and Development (R&D) Expense
Direct clinical trial costs
Consultant services in support of clinical trials
Stock-based compensation
Depreciation and amortization
Other R&D operating expenses
Total R&D expense
2023
Year Ended December 31,
2022
Dollar amounts in thousands
% change
% change
2021
$ 67,434
5,055
6,449
129
29,443
$ 108,510
39 % $ 48,668
5,467
(8)%
7,987
(19)%
8 %
120
(1)% 29,637
18 % $ 91,879
56 % $ 31,261
4,708
16 %
8,327
(4)%
123
(3)%
(23)% 38,282
11 % $ 82,701
For the year ended December 31, 2023 compared to the year ended December 31, 2022, the $18.8 million increase in
direct clinical trial costs was primarily due to the increases in clinical trial spend related to our three late-stage oral
difelikefalin programs in 2023. These increases were partially offset by decreases related to the Phase 2 efficacy trial for
chronic pruritus associated with NP, costs associated with supportive Phase 1 oral studies, and other general costs
associated with our oral programs. In December 2023, we announced that we discontinued the atopic dermatitis program
due to clinical trial results and in January 2024, we announced the discontinuation of the advanced chronic kidney disease
program to focus on NP only. The decrease in stock compensation expense is primarily related to lower grant date fair
values for new option grants during the year ended December 31, 2023, and lower stock compensation expense related to
time-based restricted stock units that vested in February 2023. Other R&D operating expenses for the year ended
December 31, 2023 included $1.7 million related to the agreement with Patheon for forecasted manufacturing
commitments that are no longer needed due to the reduced demand expectations of KORSUVA in the United States, as
well as increased payroll-related costs as compared to the prior period. Other R&D operating expenses for the year ended
December 31, 2022 included the recognition of the $5.0 million milestone payment due to Enteris.
For the year ended December 31, 2022 compared to the year ended December 31, 2021, the $17.4 million increase in
direct clinical trial costs was primarily due to the increases in clinical trial spend related to our former oral difelikefalin
Phase 3 programs in advanced chronic kidney disease and atopic dermatitis, and other general costs associated with our
oral programs. These increases were partially offset by decreases of $5.0 million, mainly from the Phase 2 efficacy trials
for pruritus associated with atopic dermatitis and NP. Other R&D operating expenses for the years ended December 31,
2022 and 2021 included milestones of $5.0 million and $15.0 million, respectively, earned by Enteris, which were
primarily offset by increases in payroll and related costs and travel costs.
The following table summarizes our R&D expenses by product candidate for the years ended December 31, 2023,
2022 and 2021:
2023
Year Ended December 31,
2022
Dollar amounts in thousands
% change
% change
2021
External research and development expenses:
KORSUVA (difelikefalin) injection - Pruritus
Oral difelikefalin - Pruritus
Other
Internal research and development expenses/milestone
payments1
Total research and development expenses
$
—
72,475
—
36,035
$ 108,510
(100)% $ 6,692
47,814
—
52 %
N/A
(31)% $
86 %
(100)%
9,736
25,761
18
(4)%
37,373
18 % $ 91,879
(21)%
47,186
11 % $ 82,701
_______________________________
1 Includes milestone payments of $5.0 million and $15.0 million to Enteris for the years ended December 31, 2022 and
2021, respectively.
78
Table of Contents
General and Administrative (G&A) Expense
Professional fees and public/investor relations
Stock-based compensation
Depreciation and amortization
Other G&A operating expenses
Total G&A expense
2023
Year Ended December 31,
2022
Dollar amounts in thousands
2021
% change
% change
$ 6,228
7,281
130
14,140
$ 27,779
6,322
(1)% $
9,747
(25)%
128
2 %
1 %
14,060
(8)% $ 30,257
36 % $
4,642
(22)%
12,459
3 %
125
15 %
12,184
3 % $ 29,410
For the year ended December 31, 2023 compared to the year ended December 31, 2022, the decrease in stock-based
compensation expense was primarily related to higher expenses recorded during the year ended December 31, 2022 for the
modification of our former CEO’s equity awards, and certain performance-based restricted stock units that vested during
the year ended December 31, 2022.
For the year ended December 31, 2022 compared to the year ended December 31, 2021, the increase in professional
fees and public/investor relations expenses was primarily the result of an increase in consultants’ costs, and accounting and
auditing fees for the period. The decrease in stock-based compensation expense was primarily related to the higher expense
relating to the modification of our former CEO’s equity awards in November 2021 versus amounts recorded for the
modification in the 2022 period. The increase in other G&A operating expenses was primarily the result of increases in
payroll related costs.
Other Income, Net
Other income, net
2023
Year Ended December 31,
2022
Dollar amounts in thousands
% change
% change
2021
$ 3,586
74 % $
2,061
221 % $
642
For the year ended December 31, 2023 compared to the year ended December 31, 2022, the increase in other income,
net was primarily due to an increase in interest income resulting from a higher yield on our portfolio of investments during
the year ended December 31, 2023 and an increase in accretion income from our available-for-sale marketable securities.
For the year ended December 31, 2022 compared to the year ended December 31, 2021, the increase in other income,
net was primarily due to an increase in interest income resulting from a higher yield on our portfolio of investments during
the year ended December 31, 2022 and a decrease in net amortization expense of available-for-sale marketable securities.
We reviewed our available-for-sale debt securities as of December 31, 2023, 2022 and 2021 and determined that no
credit loss expense was necessary as a result of unrealized losses on various securities not being considered material
individually or in aggregate, and we expect that the cost basis of these available-for-sale securities is recoverable. We do
not expect that unrealized losses on our available-for-sale debt securities will impact our liquidity in the short-term or long-
term since our investments all mature at various dates through November 2024 based on capital requirements, and it is not
more likely than not that we will be required to sell these investments before recovery of their amortized cost bases.
79
Table of Contents
Non-cash Interest Expense on Liability Related to the Sales of Future Royalties and Milestones
2023
Year Ended December 31,
2022
Dollar amounts in thousands
2021
% change
% change
Non-cash interest expense on liability related to sales of future
royalties and milestones
$ (604)
N/A $
—
N/A $
—
We recognized $0.6 million of non-cash interest expense on the liability related to sales of future royalties and
milestones for the year ended December 31, 2023, which represented imputed interest on the carrying value of the liability
to HCR in the fourth quarter of 2023 and the amortization of the related issuance costs associated with the HCR
Agreement. There was no non-cash interest expense on liability recognized during the years ended December 31, 2022 and
2021 as the HCR Agreement was entered into in November 2023 (see “Royalty Purchase and Sale Agreement” above).
Benefit from Income Taxes
We opted not to exchange our R&D tax credit for the year ended December 31, 2023, and were not eligible to
exchange our R&D tax credit for cash during the years ended December 31, 2022 and 2021, therefore there was no benefit
from income taxes for each of the years ended December 31, 2023, 2022 and 2021. As of December 31, 2023 and 2022, we
recorded $0.7 million within income tax receivable which related to the 2020 R&D credit.
We recognized a full valuation allowance against deferred tax assets at December 31, 2023, 2022 and 2021. The tax
benefit related to the exercise of stock options is recognized as a deferred tax asset that is offset by a corresponding
valuation allowance. As such, our effective tax rate is zero for years ended December 31, 2023, 2022 and 2021.
Cash Requirements, Liquidity, and Capital Resources
Short-Term and Long-Term Cash Requirements
Our primary uses of capital have been, and we expect will continue to be, third-party clinical R&D services, clinical
costs related to the oral difelikefalin program, and compensation and related expenses.
As of December 31, 2023, we have no commitments for capital expenditures in either the short-term or long-term.
The following discussion summarizes our current and long-term material cash requirements as of December 31, 2023,
which we expect to fund primarily with current unrestricted cash and cash equivalents and available-for-sale marketable
securities:
Operating lease obligation(1)
Manufacturing purchase
obligations(2)
Other obligations(3)
Total
Total
$ 14,371
$
Material Cash Requirements (amounts in thousands)
2026
$ 1,330
2027
$ 1,363
2025
$ 1,298
2028
$ 1,398
2024
108
Thereafter
$ 8,874
1,325
1,908
$ 17,604
1,325
408
$ 1,841
—
—
$ 1,298
—
—
$ 1,330
—
—
$ 1,363
—
—
$ 1,398
—
1,500
$ 10,374
(1) Operating lease obligations in 2024 and beyond relate to our new Stamford operating lease entered into in May
2023 for our new principal office, for which rent payments are expected to begin in late 2024. See Note 19 of
Notes to Consolidated Financial Statements, Commitments and Contingencies, in this Annual Report on Form 10-
K for details about our operating lease obligation.
(2) Based on our MSA with Patheon that we entered into in July 2019, we have a purchase capacity reservation
through December 31, 2024. In December 2023, we entered into an agreement with Patheon to reimburse Patheon
approximately $1.7 million for forecasted manufacturing commitments that were no longer needed due
80
Table of Contents
to the reduced demand expectations of KORSUVA in the United States and was recorded within accounts payable
and accrued expenses on our Consolidated Balance Sheet as of December 31, 2023. In the event the purchase
capacity reservation is not met in 2024, it will rollover into 2025. We expect a portion of this capacity reservation
will be reimbursed in accordance with the supply agreement with CSL Vifor. See Note 19 of Notes to
Consolidated Financial Statements, Commitments and Contingencies, in this Annual Report on Form 10-K for
details about our MSA with Patheon. We have no other material non-cancelable purchase commitments with any
other contract manufacturers or service providers, as we have generally contracted on a cancelable purchase order
basis.
(3) We are required to maintain a stand-by letter of credit as a security deposit for our previous lease and a new lease
in May 2023 for our new principal office. The letter of credit for the previous lease for $408 became unrestricted
in January 2024. See Note 8 of Notes to Consolidated Financial Statements, Restricted Cash, in this Annual
Report on Form 10-K for details about our letters of credit associated with our previous lease and new lease for
our principal office in Stamford, Connecticut.
Based on the Enteris License Agreement that we entered into in August 2019, we are obligated to pay (1) milestone
payments upon the achievement of certain development, regulatory and commercial milestones and (2) low-single digit
royalty percentages on net sales of licensed products, subject to reductions in specified circumstances. As these milestone
payments may or may not be achieved, and royalties may or may not be owed depending on our future commercial
success, there were no future potential payments that were considered cash requirements in the table above as of December
31, 2023. We did not make any milestone payments to Enteris during the year ended December 31, 2023. During the years
ended December 31, 2022 and 2021, we made milestone payments of $5.0 million and $15.0 million, respectively, to
Enteris. See Note 19 of Notes to Consolidated Financial Statements, Commitments and Contingencies, in this Annual
Report on Form 10-K for details about our Enteris License Agreement.
During the fourth quarter of 2023, we, through our wholly-owned subsidiary Cara Royalty Sub, entered into the HCR
Agreement with HCR pursuant to which Cara Royalty Sub sold to HCR certain of its rights to the Royalties, due and
payable to Cara Royalty Sub (as our assignee) under our agreements with CSL Vifor and Maruishi, in exchange for up to
$40.0 million. We have retained all of our right, title and interest in, to and under the Covered License Agreements that
relate to any non-intravenous formulation of difelikefalin. These future payments to HCR were not included in the table
above since the amounts and timing of royalty and milestone payments received under the agreements with CSL Vifor and
Maruishi could change in the future as they are subject to CSL Vifor’s and Maruishi’s commercialization efforts (see
“Royalty Purchase and Sale Agreement” above).
We do not have any other requirements or off-balance sheet arrangements that have or are reasonably likely to have a
material current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of
operations, liquidity, cash requirements or capital resources.
Since inception, we have incurred significant operating and net losses. We incurred net losses of $118.5 million,
$85.5 million and $88.4 million for the years ended December 31, 2023, 2022 and 2021, respectively. As of December 31,
2023, we had an accumulated deficit of $684.7 million. We expect to continue to incur significant expenses and operating
and net losses in the foreseeable future, as we develop and seek marketing approval for oral difelikefalin in NP. Our
financial results may fluctuate significantly from quarter to quarter and year to year, depending on the timing of our clinical
trials and the future sales of KORSUVA.
We anticipate that our expenses will be focused on:
●
●
●
the continued development of oral difelikefalin for chronic pruritus associated with NP;
the potential regulatory approvals for any product candidates that successfully complete clinical trials;
potentially establishing a sales, marketing and distribution infrastructure and scale up external manufacturing
capabilities to commercialize any other products for which we may obtain regulatory approval; and
81
Table of Contents
●
maintaining, expanding, and protecting our global intellectual property portfolio.
The successful development of our product candidate is highly uncertain. As such, at this time, we cannot reasonably
estimate or know the nature, timing and costs of the efforts that will be necessary to complete the development of oral
difelikefalin in NP. We are also unable to predict when, if ever, we will generate any further material net cash inflows from
difelikefalin. This is due to the numerous risks and uncertainties associated with developing medicines, including the
uncertainty of:
●
●
●
●
●
●
●
successful enrollment in, and completion of clinical trials;
receipt of marketing approvals from applicable regulatory authorities;
establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;
obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product
candidate;
launching commercial sales of the products, if and when approved, whether alone or in collaboration with
others;
achieving meaningful penetration in the markets which we seek to serve; and
obtaining adequate coverage or reimbursement by third parties, such as commercial payers and government
healthcare programs, including Medicare and Medicaid.
A change in the outcome of any of these variables with respect to the development of oral difelikefalin or any of our
future product candidates would significantly change the costs and timing associated with the development of that product
candidate. Further, the timing of any of the above may be impacted by public pandemics or future global health crises,
introducing additional uncertainty.
Our product candidate is still in clinical development and since the outcome of these efforts is uncertain, we cannot
estimate the actual amounts necessary to successfully complete the development and commercialization of our product
candidate or whether, or when, we may achieve profitability. Until such time, if ever, as we can generate substantial
product revenues, we expect to finance our cash needs through a combination of equity or debt financings and
collaboration arrangements, including our existing licensing and collaboration agreements with CSL Vifor, Maruishi and
CKDP.
We will require additional capital beyond our current balances of cash and cash equivalents and available-for-sale
marketable securities and anticipated amounts as described above, and this additional capital may not be available when
needed, on reasonable terms, or at all. Our ability to raise additional capital may be adversely impacted by potential
worsening global economic conditions and continuing disruptions to and volatility in the credit and equity markets in the
United States and worldwide, including impacts from public pandemics or future global health crises, geopolitical tensions,
such as the ongoing conflicts between Russia and Ukraine, conflicts in the Middle East, and increasing tensions between
China and Taiwan, and government actions implemented as a result of either of the foregoing, high rates of inflation, rising
interest rates, uncertainty and liquidity concerns in the broader financial services industry, such as those caused by certain
recent banking failures, and a potential recession in the United States. If we are not able to do so, we could be required to
postpone, scale back or eliminate some, or all, of these objectives. To the extent that we raise additional capital through the
future sale of equity or convertible debt, the ownership interest of our stockholders will be diluted, and the terms of these
securities may include liquidation or other preferences that adversely affect the rights of our existing common stockholders.
If we raise additional funds through the issuance of debt securities, these securities could contain covenants that would
restrict our operations. If we raise additional funds through collaboration arrangements in the future, we may have to
relinquish valuable rights to our technologies, future revenue streams or product candidates or grant licenses on terms that
may not be favorable to us. If we are unable to raise additional funds
82
Table of Contents
through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our drug
development or future commercialization efforts or grant rights to develop and market product candidates that we would
otherwise prefer to develop and market ourselves.
Sources of Liquidity
Since our inception to date, we have raised an aggregate of $942.3 million to fund our operations, including (1) net
proceeds of $447.4 million from the sale of shares of our common stock in five public offerings, including our initial public
offering and shares issued under our open market sales agreement in 2023; (2) proceeds of $73.3 million from the sale of
shares of our convertible preferred stock and from debt financings prior to our initial public offering; (3) payments of
$258.1 million under our license and supply agreements (including commercial supply sales and royalty payments),
primarily with CSL Vifor, Maruishi, CKDP, and an earlier product candidate for which development efforts ceased in 2007;
(4) our share of the profit generated by KORSUVA injection sales of $29.0 million; (5) net proceeds of $98.0 million from
the purchase of our common stock in relation to the license agreements with CSL Vifor; and (6) net proceeds of $36.5
million from the sale of future ex U.S. royalties and milestones to HCR under our agreements with CSL Vifor and Maruishi
(see Note 13 of Notes to Consolidated Financial Statements, Collaboration and Licensing Agreements, in this Annual
Report on Form 10-K).
During the fourth quarter of 2023, we, through our wholly-owned subsidiary Cara Royalty Sub, entered into the HCR
Agreement with HCR pursuant to which Cara Royalty Sub sold to HCR certain of its rights to receive the Royalties, due
and payable to Cara Royalty Sub (as our assignee) under the Covered License Agreements, in exchange for up to $40.0
million. We have retained all of our right, title and interest in, to and under the Covered License Agreements that relate to
any non-intravenous formulation of difelikefalin.
Under the terms of the HCR Agreement, Cara Royalty Sub received an initial payment of $17.5 million less certain
transaction costs in November 2023. In December 2023, we received an additional $20.0 million, less certain advisory fees,
upon satisfying the milestone event for pricing for Kapruvia® (difelikefalin) in Germany being approved above a certain
threshold amount per dose. The terms of the HCR Agreement also provide for an additional $2.5 million milestone
payment to Cara Royalty Sub upon achievement of a 2024 sales milestone of KORSUVA in Japan.
In order to fund our future operations, including our planned clinical trials, on March 1, 2022, we filed a universal
shelf registration statement, or the Shelf Registration Statement, which provides for aggregate offerings of up to $300.0
million of common stock, preferred stock, debt securities, warrants or any combination thereof. The Shelf Registration
Statement was declared effective by the Securities and Exchange Commission on May 11, 2022. The securities registered
under the Shelf Registration Statement include $154.5 million of unsold securities that had been registered under our
previous Registration Statement on Form S-3 (File No. 333-230333) that was declared effective on April 4, 2019. We
believe that our Shelf Registration Statement will provide us with the flexibility to raise additional capital to finance our
operations as needed.
On March 1, 2022, we entered into an open market sales agreement, or the Sales Agreement, with Jefferies LLC, as
sales agent, pursuant to which we may, from time to time, issue and sell common stock with an aggregate value of up to
$80.0 million in an at-the-market offering pursuant to the Shelf Registration statement. Jefferies is acting as sole sales
agent for any sales made under the Sales Agreement for a 3% commission on gross proceeds. The common stock will be
sold at prevailing market prices at the time of the sale, and, as a result, prices may vary. Unless otherwise terminated
earlier, the Sales Agreement continues until all shares available under the Sales Agreement have been sold. During the year
ended December 31, 2023, 386,881 shares were sold under the Sales Agreement and the Company received net proceeds of
$1.1 million. During the year ended December 31, 2022, no shares were sold under the Sales Agreement.
We may offer additional securities under our Shelf Registration Statement from time to time in response to market
conditions or other circumstances if we believe such a plan of financing is in the best interests of our stockholders.
Under our agreement with CSL Vifor for the commercialization of KORSUVA injection, we are eligible to receive
commercial milestone payments in the aggregate of up to $240.0 million from CSL Vifor upon the achievement of certain
sales-based milestones. In October 2021, we received a $50.0 million milestone payment from CSL Vifor in
83
Table of Contents
exchange for the issuance of 3,282,391 shares of our common stock to CSL Vifor as a result of the regulatory approval of
KORSUVA injection in August 2021. To date, we have received $50.0 million of regulatory milestones from CSL Vifor
under this agreement.
Under a separate agreement with CSL Vifor, we are eligible to receive commercial milestone payments in the
aggregate of up to $440.0 million, all of which are sales related. We are also eligible to receive tiered double-digit royalty
payments based on annual net sales of difelikefalin injection in the licensed territories. In June 2022, we received a $15.0
million milestone payment from CSL Vifor as a result of the regulatory approval of Kapruvia by the European Commission
in April 2022. In October 2021, we received a $15.0 million milestone payment from CSL Vifor as a result of the
regulatory approval of KORSUVA injection in August 2021. To date, we have received $30.0 million of regulatory
milestones from CSL Vifor. During the fourth quarter of 2023, we entered into the HCR Agreement where we sold our
future royalties and milestone payments under this agreement to HCR (see “Royalty Purchase and Sale Agreement”
above).
Under the Maruishi Agreement, we are also potentially eligible to earn up to an aggregate of $6.0 million in clinical
development milestones and $4.5 million in regulatory milestones, before any foreign exchange adjustment, as well as
tiered royalties, with percentages ranging from the low double digits to the low twenties, based on net sales of products
containing difelikefalin in Japan, if any, and share in any sub-license fees. In May 2021, we received a $2.0 million
milestone payment ($1.9 million after contractual foreign currency exchange adjustments) for Maruishi’s first initiation of
a Phase 3 trial for uremic pruritus in Japan in January 2021. In September 2023, Maruishi received manufacturing and
marketing approval from Japan’s Ministry of Health, Labour and Welfare for KORSUVA IV Injection Syringe for the
treatment of pruritus in hemodialysis patients. In conjunction with the approval, we earned a $2.0 million milestone
payment ($1.4 million after contractual foreign currency exchange adjustments) per the terms of the licensing agreement.
To date, we have received $6.5 million (before contractual foreign currency exchange adjustments) of clinical development
and regulatory milestone from Maruishi. During the fourth quarter of 2023, we entered into the HCR Agreement where we
sold our future royalties and milestone payments to HCR (see “Royalty Purchase and Sale Agreement” above).
Under the CKDP Agreement, we are potentially eligible to earn up to an aggregate of $2.3 million in clinical
development milestones and $1.5 million in regulatory milestones, before South Korean withholding tax, as well as tiered
royalties with percentages ranging from the high single digits to the high teens, based on net sales of products containing
difelikefalin in South Korea, if any, and share in any sub-license fees. To date, $2.3 million (before South Korean
withholding tax) of development and regulatory milestones have been received under the CKDP Agreement.
In December 2021, CMS granted TDAPA designation to KORSUVA injection in the anti-pruritic functional
category. TDAPA went into effect on April 1, 2022, for a minimum of two years. On October 27, 2023, CMS published the
final CY 2024 rule, which finalized the post-TDAPA add-on as proposed in the draft CY 2024 rule. Under the final rule,
TDAPA drugs in existing functional categories will receive a post-TDAPA add-on payment set at 65 percent of the total
trailing 12-months expenditure levels for the given renal dialysis drug or biological product. The post-TDAPA add-on
payment adjustment will be applied to all ESRD PPS payments and paid for 3 years, adjusted annually. The add-on
payments for KORSUVA injection will commence on April 1, 2024. The anticipated unfavorable CMS reimbursement
codified in the final CY2024 rule resulted in a lack of sequential revenues growth for KORSUVA injection since its launch.
As a result, we expect no meaningful revenue contribution from KORSUVA injection post its TDAPA expiration.
Our ability to earn these payments and their timing is dependent upon the outcome of oral difelikefalin development
activities and successful commercialization of KORSUVA injection/Kapruvia. However, our receipt of any further such
amounts is uncertain at this time and we may never receive any more of these amounts.
Outlook
After taking into account our strategic prioritization and reduction in workforce, we expect that our current
unrestricted cash and cash equivalents and available-for-sale marketable securities will be sufficient to fund our currently
anticipated operating plan into 2026. Our anticipated operating expenses include contractually committed costs as well
84
Table of Contents
as non-contractually committed clinical trial costs for trials that may be delayed or not initiated and other non-committed
controllable costs. Because the process of testing product candidates in clinical trials is costly and the timing of progress in
these trials is uncertain, it is possible that the assumptions upon which we have based this estimate may prove to be wrong,
and we could use our capital resources sooner than we presently expect.
Cash Flows
The following is a summary of the net cash flows provided by (used in) our operating, investing and financing
activities for the years ended December 31, 2023, 2022 and 2021:
Net cash used in operating activities
Net cash provided by (used in) investing activities
Net cash provided by financing activities
Net (decrease) increase in cash, cash equivalents and
restricted cash
Net cash used in operating activities
2023
Year Ended December 31,
2022
Dollar amounts in thousands
$ (92,078) $ (78,730) $ (60,087)
(4,751)
128,707
46,608
311
43,461
38,151
2021
$ (10,466) $ 50,288
$ (18,230)
Net cash used in operating activities for the year ended December 31, 2023 consisted primarily of a net loss of
$118.5 million, partially offset by a $16.3 million cash inflow from net non-cash charges and a $10.2 million cash inflow
from net changes in operating assets and liabilities. Net non-cash charges primarily consisted of stock-based compensation
expense of $13.7 million, and the noncash lease expense of $2.1 million relating to our current and former Stamford
operating leases. The change in operating assets and liabilities primarily consisted of cash inflows from a decrease in
prepaid expenses of $8.1 million, primarily related to prepaid clinical costs, an increase in accounts payable and accrued
expenses of $3.3 million due to increased expenses in the period, and an $0.8 million reimbursement of a lease incentive
under our new lease agreement that we entered into in May 2023, partially offset by a cash outflow of $1.9 million relating
to operating lease liabilities associated with former lease agreements for our former operating facility in Stamford,
Connecticut.
Net cash used in operating activities for the year ended December 31, 2022 consisted primarily of a net loss of $85.5
million and a $12.9 million cash outflow from net changes in operating assets and liabilities, partially offset by a $19.7
million cash inflow from net non-cash charges. The change in operating assets and liabilities primarily consisted of an
increase in prepaid expenses of $13.7 million, primarily related to an increase in prepaid clinical costs, an increase of $3.3
million in accounts receivable, net – related party primarily relating to amounts due from CSL Vifor from our share of the
profit generated by KORSUVA injection sales and for commercial supply of KORSUVA injection to CSL Vifor, and a cash
outflow of $1.8 million relating to operating lease liabilities associated with our lease agreements for our operating facility
in Stamford, Connecticut, partially offset by cash inflows of $5.7 million from an increase in accounts payable and accrued
expenses. Net non-cash charges primarily consisted of stock-based compensation expense of $17.7 million, and the
amortization expense component of lease expense of $1.4 million relating to our Stamford operating leases.
Net cash used in operating activities for the year ended December 31, 2021 consisted primarily of a net loss of $88.4
million, partially offset by a $23.1 million cash inflow from net non-cash charges and a $5.3 million cash inflow from net
changes in operating assets and liabilities. Net non-cash charges primarily consisted of stock-based compensation expense
of $20.8 million, which includes incremental expense related to the modification of our former CEO’s equity awards in
2021 of $5.1 million, the amortization expense component of lease expense of $1.3 million relating to our Stamford
operating leases, and the amortization of available-for-sale marketable securities, net of $0.9 million. The change in
operating assets and liabilities primarily consisted of an decrease in prepaid expenses of $9.6 million, primarily related to
an decrease in prepaid clinical costs, partially offset by a $2.6 million increase in inventory, net as a result of FDA approval
of KORSUVA injection in August 2021, a cash outflow of $1.6 million relating to
85
Table of Contents
operating lease liabilities associated with our lease agreements for our operating facility in Stamford, Connecticut, and a
cash outflow of $1.0 million from a decrease in accounts payable and accrued expenses.
Net cash provided by (used in) investing activities
Net cash provided by investing activities was $43.5 million for the year ended December 31, 2023, which primarily
included cash inflows of $159.4 million from maturities and redemptions of available-for-sale marketable securities,
partially offset by cash outflows of $113.6 million for the purchases of available-for-sale marketable securities and $2.4
million for the purchases of property and equipment.
Net cash provided by investing activities was $128.7 million for the year ended December 31, 2022, which primarily
included cash inflows of $224.4 million from maturities and redemptions of available-for-sale marketable securities,
partially offset by cash outflows of $95.7 million for the purchases of available-for-sale marketable securities.
Net cash used in investing activities was $4.8 million for the year ended December 31, 2021, which primarily
included cash outflows of $208.8 million for the purchases of available-for-sale marketable securities, partially offset by
cash inflows of $194.0 million from maturities and redemptions of available-for-sale marketable securities and proceeds of
$10.0 million from the sales of available-for-sale marketable securities.
Net cash provided by financing activities
Net cash provided by financing activities for the year ended December 31, 2023 consisted of net proceeds of $36.5
million from the HCR Agreement, net proceeds of $1.1 million from the sales of common stock under our open market
sales agreement, and proceeds of $0.6 million received from the exercise of stock options.
Net cash provided by financing activities for the year ended December 31, 2022 consisted of $0.3 million received
from the exercise of stock options.
Net cash provided by financing activities for the year ended December 31, 2021 consisted of proceeds of $45.0
million from the sale of our common stock relating to Vifor International upon the achievement of a milestone, and $1.6
million received from the exercise of stock options.
Critical Accounting Estimates
The preparation of our consolidated financial statements and related disclosures in conformity with U.S. GAAP and
our discussion and analysis of financial condition and results of operations require us to make estimates, judgments and
assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at
the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. We
base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the
circumstances at the time such estimates are made. Actual results and outcomes may differ materially from our estimates,
judgments, and assumptions. We periodically review our estimates in light of changes in circumstances, facts, and
experience. The effects of material revisions in estimates are reflected in the financial statements prospectively from the
date of the change in estimate. Note 2 of Notes to Consolidated Financial Statements, Summary of Significant Accounting
Policies, in this Annual Report on Form 10-K describes the significant accounting policies and methods used in the
preparation of our financial statements.
We define our critical accounting estimates as those subjective estimates and judgments about matters that are
uncertain and are likely to have a material impact on our financial condition and results of operations as well as the specific
manner in which we apply U.S. GAAP.
Liabilities Related to the Sales of Royalties/Milestones and Non-Cash Interest Expense
We recognized a liability related to the sales of future ex U.S. royalties and milestones under our agreements with
Maruishi and CSL Vifor under ASC 470-10: Debt and ASC 835-30: Interest – Imputation of Interest. The initial funds
86
Table of Contents
received by us in November 2023 and the first milestone received by us in December 2023 pursuant to the terms of the
HCR Agreement were recorded as a liability and will be accreted under the effective interest method up to the estimated
amount of future royalties and milestone payments to be made under the HCR Agreement. The issuance costs were
recorded as a direct deduction to the carrying amount of the liability and will be amortized under the effective interest
method over the estimated period the liability will be repaid, solely using future royalty and milestone payments from CSL
Vifor and Maruishi.
We estimated the total amount of future royalty revenue and milestone payments to be generated over the life of the
HCR Agreement based on estimates and projections from CSL Vifor and Maruishi. We considered this to be a critical
accounting estimate because these future royalties and milestone payments are subject to estimation and uncertainty as we
are dependent on CSL Vifor and Maruishi for timely and accurate information regarding future projections. A significant
increase or decrease in these estimates could materially impact the liability balance and the related non-cash interest
expense. If the timing of the receipt of royalty payments or milestones is materially different from the original estimates,
we will prospectively adjust the effective interest and the related amortization of the liability and related issuance costs.
Accounting Pronouncements Recently Adopted; Recent Accounting Pronouncements Not Yet Adopted
We do not expect that any recently issued accounting pronouncements will have a material effect on our financial
statements. Refer to Note 2 of Notes to Consolidated Financial Statements, Summary of Significant Accounting Policies, in
this Annual Report on Form 10-K, for a full description of accounting pronouncements recently adopted, and issued but not
yet adopted, if applicable.
Item 7A. Quantitative and Qualitative Disclosures About Market Risk.
Interest Rate Risk
Historically, we have invested substantially all of our cash reserves in a variety of available-for-sale marketable
securities, including investment-grade debt instruments, principally corporate bonds, commercial paper, municipal bonds
and direct obligations of the U.S. government and U.S. government-sponsored entities, and in cash equivalents. See Note 3
of Notes to Consolidated Financial Statements, Available-for-Sale Marketable Securities, in this Annual Report on
Form 10-K for details about our available-for-sale marketable securities.
As of December 31, 2023, we had invested $49.0 million of our cash reserves in such marketable securities. Those
marketable securities included $49.0 million of investment grade debt instruments with a yield of approximately 4.41% and
maturities through November 2024. As of December 31, 2022, we had invested $93.0 million of our cash reserves in such
marketable securities. Those marketable securities included $93.0 million of investment grade debt instruments with a
yield of approximately 2.01% and maturities through November 2024.
We maintain an investment portfolio in accordance with our investment policy, which includes guidelines on
acceptable investment securities, minimum credit quality, maturity parameters, and concentration and diversification. The
primary objectives of our investment policy are to preserve principal, maintain proper liquidity and to meet operating
needs. Our investments are subject to interest rate risk and will decrease in value if market interest rates increase. However,
due to the conservative nature of our investments and relatively short duration, we do not believe we are materially
exposed to changes in interest rates related to our investments. As a result, we do not currently use interest rate derivative
instruments to manage exposure to interest rate changes.
Duration is a sensitivity measure that can be used to approximate the change in the fair value of a security that will
result from a change in interest rates. Applying the duration model, a hypothetical 100 basis point, or 1%, increase in
interest rates as of December 31, 2023 and 2022, would have resulted in immaterial decreases in the fair values of our
portfolio of marketable securities at those dates.
87
Table of Contents
Credit Quality Risk
Although our investments are subject to credit risk, our investment policy specifies credit quality standards for our
investments and limits the amount of credit exposure from any single issue, issuer or type of investment. Nonetheless,
deterioration of the credit quality of an investment security subsequent to purchase may subject us to the risk of not being
able to recover the full principal value of the security. As of December 31, 2023 and 2022, the aggregate unrealized losses
on our available-for-sale marketable securities were $0.3 million and $1.7 million, respectively. For the years end
December 31, 2023, 2022 and 2021, we did not record any charges to credit loss expense for our available-for-sale
securities. Refer to Notes 2 of Notes to Consolidated Financial Statements, Summary of Significant Accounting Policies –
Concentration of Credit Risk and Marketable Securities, and Note 3 of Notes to Consolidated Financial Statements,
Available-for-Sale Marketable Securities, in this Annual Report on Form 10-K for further discussion and applicable tabular
presentations.
As of December 31, 2023 and 2022, we had accounts receivable, net – related party from CSL Vifor of $2.8 million
and $3.3 million, respectively, primarily for our share of the profit generated by KORSUVA injection sales and commercial
supply revenues, and payments for ex U.S. royalties from CSL Vifor. We also had a receivable for $0.4 million for Japan
royalties/milestones owed to us from Maruishi which was included within other receivables as of December 31, 2023. We
believe that credit risks associated with CSL Vifor and Maruishi are not significant. We review the need for an allowance
for credit losses for any receivable based on various factors including payment history and historical bad debt experience.
We had an insignificant allowance for credit losses as of December 31, 2023 and 2022. Refer to Note 2 of Notes to
Consolidated Financial Statements, Summary of Significant Accounting Policies – Concentration of Credit Risk and
Accounts Receivable, Net – Related Party.
88
Table of Contents
Item 8. Financial Statements and Supplementary Data.
Cara Therapeutics, Inc.
INDEX TO FINANCIAL STATEMENTS
Reports of Independent Registered Public Accounting Firm (PCAOB ID: 42)
Financial Statements:
Consolidated Balance Sheets
Consolidated Statements of Comprehensive Loss
Consolidated Statements of Stockholders’ Equity
Consolidated Statements of Cash Flows
Notes to Consolidated Financial Statements
89
PAGE
90
93
94
95
96
97
Table of Contents
Report of Independent Registered Public Accounting Firm
To the Shareholders and the Board of Directors of Cara Therapeutics, Inc.
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of Cara Therapeutics, Inc. (the Company) as of December 31, 2023 and
2022, the related consolidated statements of comprehensive loss, stockholders’ equity and cash flows for each of the three years in the
period ended December 31, 2023, and the related notes (collectively referred to as the “consolidated financial statements”). In our
opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December
31, 2023 and 2022, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2023,
in conformity with U.S. generally accepted accounting principles.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB),
the Company's internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control-
Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our
report dated March 6, 2024 expressed an unqualified opinion thereon.
Basis for Opinion
These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the
Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be
independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of
the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to
obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or
fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and
significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our
audits provide a reasonable basis for our opinion.
Critical Audit Matter
The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was
communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to
the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical
audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by
communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the account or disclosure to
which it relates.
Royalty Financing Obligation
Description of the Matter
As discussed in Note 10 to the financial statements, on November 1, 2023, the
Company entered into a Royalty Purchase and Sale Agreement (“royalty financing
obligation”) with a third party, pursuant to which the Company sold certain of its
rights to receive royalty and milestone payments in exchange for up to $40.0
million. The Company received initial upfront proceeds of $17.5 million, less
certain expenses, followed by a $20.0 million milestone payment prior to
December 31, 2023, based on conditions met per the agreement. The Company
will repay the lender at a multiple of the initial proceeds received, which may vary
based on timing and amount of cash flows received from its licensing partners.
The Company determined that the royalty financing should be treated as a
financing arrangement under ASC 470 classified as a liability.
Auditing the Company’s accounting for the royalty financing obligation was
complex due to the judgment that was required in determining the balance sheet
classification of the royalty financing obligation.
90
Table of Contents
How We Addressed the
Matter in Our Audit
We obtained an understanding, evaluated the design, and tested the operating
effectiveness of controls that address the risk of material misstatement, including
controls over management’s review of the terms and conditions of the royalty
financing obligation agreement and the related accounting treatment.
To audit the Company’s accounting related to the royalty financing, we evaluated
the terms of the royalty financing obligation and the interpretation of the related
accounting guidance to determine sale vs. financing and other underlying
accounting conclusions. To test the initial classification of the royalty financing
obligation, we performed audit procedures that included, among others, inspecting
the agreements in order to evaluate the completeness and accuracy of contract
terms included in the Company’s technical accounting analysis and testing
management’s application of relevant accounting guidance, including balance
sheet classification and disclosures.
/s/ Ernst & Young LLP
We have served as the Company’s auditor since 2006.
Stamford, Connecticut
March 6, 2024
91
Table of Contents
Report of Independent Registered Public Accounting Firm
To the Shareholders and the Board of Directors of Cara Therapeutics, Inc.
Opinion on Internal Control Over Financial Reporting
We have audited Cara Therapeutics, Inc.’s internal control over financial reporting as of December 31, 2023, based on criteria
established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway
Commission (2013 framework) (the COSO criteria). In our opinion, Cara Therapeutics, Inc. (the Company) maintained, in all material
respects, effective internal control over financial reporting as of December 31, 2023, based on the COSO criteria.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB),
the consolidated balance sheets of the Company as of December 31, 2023 and 2022, the related consolidated statements of
comprehensive loss, stockholders’ equity and cash flows for each of the three years in the period ended December 31, 2023, and the
related notes and our report dated March 6, 2024 expressed an unqualified opinion thereon.
Basis for Opinion
The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of
the effectiveness of internal control over financial reporting included in the accompanying Management’s Report on Internal Control
over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on
our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company
in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission
and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to
obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.
Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness
exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such
other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
Definition and Limitations of Internal Control Over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting
principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the
maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the
company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in
accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in
accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention
or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the
financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of
any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in
conditions, or that the degree of compliance with the policies or procedures may deteriorate.
/s/ Ernst & Young LLP
Stamford, Connecticut
March 6, 2024
92
Table of Contents
CARA THERAPEUTICS, INC.
CONSOLIDATED BALANCE SHEETS
(amounts in thousands, except share and per share data)
Assets
Current assets:
Cash and cash equivalents
Marketable securities
Accounts receivable, net - related party
Inventory, net
Income tax receivable
Other receivables
Prepaid expenses
Restricted cash
Total current assets
Operating lease right-of-use assets
Marketable securities, non-current
Property and equipment, net
Restricted cash, non-current
Total assets
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable and accrued expenses
Operating lease liabilities, current
Total current liabilities
Liability related to sales of future royalties and milestones, net
Operating lease liabilities, non-current
Total liabilities
Commitments and contingencies (Note 19)
Stockholders’ equity:
Preferred stock; $0.001 par value; 5,000,000 shares authorized at
December 31, 2023 and December 31, 2022, zero shares issued and outstanding
at December 31, 2023 and December 31, 2022
Common stock; $0.001 par value; 100,000,000 shares authorized at
December 31, 2023 and December 31, 2022, 54,480,704 shares and 53,797,341
shares issued and outstanding at December 31, 2023 and December 31, 2022,
respectively
Additional paid-in capital
Accumulated deficit
Accumulated other comprehensive loss
Total stockholders’ equity
Total liabilities and stockholders’ equity
December 31, 2023 December 31, 2022
$
$
$
$
$
51,775
48,983
2,765
2,821
697
555
8,154
408
116,158
4,864
—
3,322
1,500
125,844
$
25,592
$
—
25,592
37,079
6,088
68,759
—
63,741
81,658
3,260
2,383
697
496
16,267
408
168,910
1,551
11,350
426
—
182,237
21,540
1,918
23,458
—
—
23,458
—
—
—
54
742,036
(684,745)
(260)
57,085
125,844
$
53
726,630
(566,232)
(1,672)
158,779
182,237
See Notes to Consolidated Financial Statements.
93
Table of Contents
CARA THERAPEUTICS, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(amounts in thousands, except share and per share data)
Revenue:
Collaborative revenue
Commercial supply revenue
License and milestone fees
Royalty revenue
Clinical compound revenue
Other revenue
Total revenue
Operating expenses:
Cost of goods sold
Research and development
General and administrative
Total operating expenses
Operating loss
Other income, net
Non-cash interest expense on liability related to
sales of future royalties and milestones
Net loss
Net loss per share:
Basic and Diluted
Weighted average shares:
Basic and Diluted
Other comprehensive income (loss), net of tax of $0:
Change in unrealized gains (losses) on available-for-sale marketable
securities
Total comprehensive loss
2023
Year Ended December 31,
2022
2021
$
12,936
5,843
910
415
165
699
20,968
$
16,572
10,223
15,000
72
—
—
41,867
6,174
108,510
27,779
142,463
(121,495)
3,586
7,266
91,879
30,257
129,402
(87,535)
2,061
706
701
21,223
—
398
—
23,028
—
82,701
29,410
112,111
(89,083)
642
(604)
(118,513) $
—
(85,474) $
—
(88,441)
(2.19) $
(1.59) $
(1.74)
$
$
$
54,149,059
53,653,564
50,718,765
1,412
(117,101) $
$
(1,314)
(86,788) $
(431)
(88,872)
See Notes to Consolidated Financial Statements.
94
Table of Contents
CARA THERAPEUTICS, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(amounts in thousands, except share and per share data)
Common Stock
Paid-In
Accumulated Comprehensive
Stockholders’
Additional
Other
Total
Accumulated
Amount
Capital
$
641,195
$
Deficit
(392,317)
$
Income (Loss)
Equity
$
249,001
$
50
3
—
—
Balance at December 31, 2020
Sale of common stock under license agreement
with Vifor International ($15.23 per share)
Stock-based compensation expense
Shares issued upon exercise of stock options
Shares issued upon vesting of restricted stock
units
Net loss
Other comprehensive loss
Balance at December 31, 2021
Stock-based compensation expense
Shares issued upon exercise of stock options
Shares issued upon vesting of restricted stock
units
Net loss
Other comprehensive loss
Balance at December 31, 2022
Net proceeds from sales of common stock under
open market sales agreement
Stock-based compensation expense
Shares issued upon exercise of stock options
Shares issued upon vesting of restricted stock
units
Net loss
Other comprehensive income
Balance at December 31, 2023
Shares
49,872,213
3,282,391
—
136,787
189,421
53,480,812
—
—
$
—
48,307
268,222
—
—
$
53,797,341
386,881
—
93,218
203,264
—
—
54,480,704
$
44,966
17,850
1,639
2,935
—
—
$
708,585
14,345
311
—
—
—
—
(88,441)
(480,758)
—
$
—
—
3,389
—
—
$
726,630
—
(85,474)
—
$
(566,232)
—
—
—
$
53
—
—
—
—
—
$
53
—
—
—
—
—
1
—
—
—
54
1,117
12,710
559
1,020
—
—
742,036
$
73
—
—
—
—
—
(431)
(358)
$
—
—
—
—
(1,314)
(1,672)
$
—
—
—
44,969
17,850
1,639
2,935
(88,441)
(431)
227,522
14,345
311
3,389
(85,474)
(1,314)
158,779
1,117
12,710
560
—
(118,513)
—
(684,745)
$
$
—
—
1,412
(260)
$
1,020
(118,513)
1,412
57,085
See Notes to Consolidated Financial Statements.
95
Table of Contents
CARA THERAPEUTICS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
Operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense
Non-cash interest expense on liability related to sales of future royalties
and milestones, net of issuance costs accretion
Depreciation and amortization
Noncash lease expense
(Accretion)/amortization of available-for-sale marketable securities, net
Realized gain on sale of available-for-sale marketable securities
Realized gain on sale of property and equipment
Changes in operating assets and liabilities:
Accounts receivable, net - related party
Inventory, net
Income tax receivable
Other receivables
Prepaid expenses
Accounts payable and accrued expenses
Operating lease liabilities
Reimbursement of lease incentive
Other
Net cash used in operating activities
Investing activities
Proceeds from maturities of available-for-sale marketable securities
Proceeds from redemptions of available-for-sale marketable securities, at
par
Proceeds from sale of available-for-sale marketable securities
Purchases of available-for-sale marketable securities
Purchases of property and equipment
Proceeds from sale of property and equipment
Net cash provided by (used in) investing activities
Financing activities
Proceeds from royalty purchase and sale agreement, net of $1.0 million of
issuance costs
Net proceeds from sales of common stock under open market sales
agreement
Proceeds from the exercise of stock options
Proceeds from the sale of common stock under license agreement with
Vifor International
Net cash provided by financing activities
Net (decrease) increase in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of period
Cash, cash equivalents and restricted cash at end of period
Noncash investing and financing activities
Accrual for leasehold improvements
Year Ended December 31,
2023
2022
2021
$
(118,513)
$
(85,474)
$ (88,441)
13,730
17,734
20,785
604
259
2,075
(400)
—
—
—
248
1,422
264
—
—
495
(438)
—
(59)
8,113
3,275
(1,918)
807
(108)
(92,078)
(3,260)
201
—
(41)
(13,748)
5,679
(1,755)
—
—
(78,730)
—
248
1,306
861
(39)
(70)
—
(2,584)
810
102
9,557
(1,020)
(1,602)
—
—
(60,087)
155,441
220,435
173,484
4,000
—
(113,605)
(2,375)
—
43,461
4,000
—
(95,685)
(43)
—
128,707
20,500
10,029
(208,795)
(39)
70
(4,751)
36,474
1,117
560
—
38,151
(10,466)
64,149
53,683
778
$
$
—
—
311
—
—
1,639
—
311
50,288
13,861
64,149
44,969
46,608
(18,230)
32,091
13,861
$
— $
—
$
$
See Notes to Consolidated Financial Statements.
96
Table of Contents
1. Business
CARA THERAPEUTICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(amounts in thousands, except share and per share data)
Cara Therapeutics, Inc., or the Company, is a development-stage biopharmaceutical corporation formed on July 2,
2004. The Company is leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The
Company’s primary activities to date have been organizing and staffing the Company, developing its lead product and
product candidates, including conducting preclinical studies and clinical trials of difelikefalin-based product candidates,
and raising capital.
In August 2021, the Company received U.S. Food and Drug Administration, or FDA, approval for KORSUVA®
(difelikefalin) injection, or KORSUVA injection, for the treatment of moderate-to-severe pruritus associated with chronic
kidney disease in adults undergoing hemodialysis. Commercial launch of KORSUVA injection began in the United States
in April 2022 and the Company began recording the associated profit-sharing revenues in the second quarter of 2022.
In April 2022, the European Commission granted marketing authorization to difelikefalin injection under the brand
name Kapruvia® (difelikefalin), or Kapruvia, for the treatment of moderate-to-severe pruritus associated with chronic
kidney disease in adult hemodialysis patients. The marketing authorization approved Kapruvia for use in all member states
of the European Union, or EU, as well as Iceland, Liechtenstein, and Norway. Kapruvia was also approved in the United
Kingdom in April 2022. Commercial launches in Austria, Germany, Sweden, France, the Netherlands, and Finland have
commenced. In August 2022, as part of the Access Consortium, difelikefalin injection was approved in Switzerland under
the brand name Kapruvia, as well as Singapore and Canada under the brand name KORSUVA. In November 2022,
difelikefalin injection was approved in the last Access Consortium country, Australia, under the brand name KORSUVA.
Difelikefalin injection was also approved in the United Arab Emirates, Kuwait, Israel, and Japan under the brand name
KORSUVA in January 2023, May 2023, June 2023, and September 2023, respectively. The Company expects additional
approvals and commercial launches over the next 12-18 months. On November 1, 2023, the Company entered into a
Purchase and Sale Agreement, or the HCR Agreement, with HCRX Investments Holdco, L.P. and Healthcare Royalty
Partners IV, L.P., or collectively HCR, where HCR will receive future royalty and milestone payments for Kapruvia and
KORSUVA (ex U.S. only) up to certain capped amounts in exchange for certain payments to the Company (see Note 10,
Royalty Purchase and Sale Agreement).
In 2018, the Company entered into a licensing and collaboration agreement with a joint venture between Vifor
Pharma Group and Fresenius Medical Care Renal Pharmaceutical Ltd., or Vifor Fresenius Medical Care Renal Pharma
Ltd., that provides full commercialization rights of Kapruvia, and where applicable KORSUVA, to Vifor Fresenius Medical
Care Renal Pharma Ltd. worldwide (excluding the United States, Japan, and South Korea). In 2020, the Company entered
into a second licensing and collaboration agreement, along with stock purchase agreements, with Vifor (International) Ltd.,
or Vifor International, that provides full commercialization rights of KORSUVA injection to Vifor International in dialysis
clinics in the United States under a profit-sharing arrangement (see Note 13, Collaboration and Licensing Agreements).
In May 2022, Vifor International assigned its rights and obligations under the license agreement and a supply
agreement, as permitted under the agreements, to Vifor Fresenius Medical Care Renal Pharma Ltd. The Company’s rights
and obligations under these agreements were unaffected by this assignment, and the assignment did not affect the
Company’s economic rights under the agreements with Vifor International.
In August 2022, Vifor Pharma Group (which includes Vifor International) was acquired by CSL Limited and
subsequently renamed CSL Vifor as part of the acquisition. The acquisition of Vifor Pharma Group did not affect any of the
Company’s rights and obligations pursuant to these agreements.
97
Table of Contents
CARA THERAPEUTICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(amounts in thousands, except share and per share data)
The Company also has a license agreement with Maruishi Pharmaceutical Co. Ltd., or Maruishi, under which the
Company granted Maruishi an exclusive license to develop, manufacture, and commercialize drug products containing
difelikefalin for acute pain and/or uremic pruritus in Japan. In September 2023, Maruishi received manufacturing and
marketing approval from Japan’s Ministry of Health, Labour and Welfare for KORSUVA IV Injection Syringe for the
treatment of pruritus in hemodialysis patients. In conjunction with the approval, the Company earned a $1,449 milestone
payment per the terms of the licensing agreement (see Note 13, Collaboration and Licensing Agreements and Note 14,
Revenue Recognition). On November 1, 2023, the Company entered into the HCR Agreement where HCR will receive
future royalty and milestone payments for KORSUVA (Japan) up to certain capped amounts in exchange for certain
payments to the Company (see Note 10, Royalty Purchase and Sale Agreement).
As of December 31, 2023, the Company has raised aggregate net proceeds of approximately $520,700 from several
rounds of equity financing, including its initial public offering, or IPO, which closed in February 2014 and four follow-on
public offerings of common stock, which closed in July 2019, July 2018, April 2017 and August 2015, respectively, the
issuance of common stock pursuant to its open market sales agreement with Jefferies LLC as sales agent, or the Sales
Agreement, in 2023 and the issuance of convertible preferred stock and debt prior to the IPO. Including profit share
revenue and royalties, the Company has also earned approximately $287,000 under its license and supply agreements for
difelikefalin, primarily with CSL Vifor, Maruishi, and Chong Kun Dang Pharmaceutical Corp., or CKDP, and an earlier
product candidate for which development efforts ceased in 2007. Under the terms of the HCR Agreement, the Company
received net proceeds of $36,474 for the sale of future ex U.S. royalties and milestones under Vifor Agreement No. 2 and
the Maruishi Agreement in November and December 2023. In October 2021, the Company received net proceeds of
$44,969 from the issuance and sale of 3,282,391 shares of the Company’s common stock to Vifor International in
connection with U.S. regulatory approval for KORSUVA injection in August 2021. Additionally, in October 2020, the
Company received net proceeds of $38,449 from the issuance and sale of 2,939,552 shares of the Company’s common
stock to Vifor International in connection with the Company’s license agreement with Vifor International. Furthermore, in
May 2018, the Company received net proceeds of $14,556 from the issuance and sale of 1,174,827 shares of the
Company’s common stock to Vifor International in connection with the Company’s license agreement with CSL Vifor (see
Notes 11, Stockholders’ Equity and 13, Collaboration and Licensing Agreements).
As of December 31, 2023, the Company had unrestricted cash and cash equivalents and marketable securities of
$100,758 and an accumulated deficit of $684,745. The Company has incurred substantial net losses and negative cash
flows from operating activities in nearly every fiscal period since inception and expects this trend to continue for the
foreseeable future. The Company recognized net losses of $118,513, $85,474, and $88,441 for the years ended December
31, 2023, 2022 and 2021, respectively. The Company had net cash used in operating activities of $92,078, $78,730, and
$60,087 for the years ended December 31, 2023, 2022 and 2021, respectively.
The Company is subject to risks common to other life science companies including, but not limited to, uncertainty of
product development and commercialization, lack of marketing and sales history, development by its competitors of new
technological innovations, dependence on key personnel, market acceptance of products, product liability, protection of
proprietary technology, ability to raise additional financing, and compliance with FDA and other government regulations.
If the Company does not successfully develop and commercialize its other product candidate, it will be unable to generate
additional recurring product revenue or achieve profitability.
2. Summary of Significant Accounting Policies
Basis of Presentation and Principles of Consolidation
The Company’s consolidated financial statements include the results of the financial operations of Cara Therapeutics,
Inc. and its wholly-owned subsidiary, Cara Royalty Sub, LLC, or Cara Royalty Sub, a Delaware limited liability company
which was formed in November 2023 for the purpose of the transactions contemplated by the HCR
98
Table of Contents
CARA THERAPEUTICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(amounts in thousands, except share and per share data)
Agreement described in Note 10, Royalty Purchase and Sale Agreement. All intercompany balances and transactions have
been eliminated.
The Company’s consolidated financial statements have been prepared in conformity with accounting principles
generally accepted in the United States, or GAAP.
Use of Estimates
The preparation of consolidated financial statements in conformity with GAAP requires the Company to make
estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and
liabilities, as of the date of the consolidated financial statements as well as the reported amounts of revenues and expenses
during the reporting period. The more significant estimates include the fair value of marketable securities that are classified
as level 2 of the fair value hierarchy, the amount and periods over which certain revenues will be recognized, including
licensing and collaborative revenue recognized from non-refundable up-front and milestone payments and future ex U.S.
royalties and milestones projected in relation to the HCR Agreement, related party accounts receivable reserve, as
applicable, inventory valuation and related reserves, research and development, or R&D, clinical costs and accrued
research projects included in prepaid expenses and accounts payable and accrued expenses, the amount of non-cash
compensation costs related to share-based payments to employees and non-employees, the incremental borrowing rate used
in lease calculations and the likelihood of realization of deferred tax assets.
The impact from global economic conditions and potential and continuing disruptions to and volatility in the credit
and equity markets in the United States and worldwide are highly uncertain and cannot be predicted, including impacts
from public pandemics or future global health crises, geopolitical tensions, such as the ongoing conflicts between Russia
and Ukraine, conflicts in the Middle East, and increasing tensions between China and Taiwan, and government actions
implemented as a result of either of the foregoing, high rates of inflation, rising interest rates, uncertainty and liquidity
concerns in the broader financial services industry, such as those caused by certain recent banking failures, and a potential
recession in the United States. Estimates and assumptions about future events and their effects cannot be determined with
certainty and therefore require the exercise of judgment. As of the date of issuance of these consolidated financial
statements, the Company is not aware of any specific event or circumstance that would require the Company to update its
estimates, assumptions and judgments or revise the reported amounts of assets and liabilities or the disclosure of contingent
assets and liabilities. These estimates, however, may change as new events occur and additional information is obtained,
and are recognized in the consolidated financial statements as soon as they become known.
Actual results could differ materially from the Company’s estimates and assumptions.
Concentration of Credit Risk
The Company’s financial instruments, which potentially subject the Company to significant concentrations of credit
risk consist primarily of cash and cash equivalents, marketable securities, and related party accounts receivable. The
Company invests its cash reserves in money market funds or high-quality marketable securities in accordance with its
investment policy. The stated objectives of its investment policy are to preserve capital, provide liquidity consistent with
forecasted cash flow requirements, maintain appropriate diversification and generate returns relative to these investment
objectives and prevailing market conditions. The Company’s investment policy includes guidelines on acceptable
investment securities, limits interest-bearing security investments to certain types of debt and money market instruments
issued by the U.S. government and institutions with investment grade credit ratings and places restrictions on maturities
and concentration by asset class and issuer. The Company’s cash and cash equivalents and marketable securities are held
by three major financial institutions. In accordance with the Company’s policies, the Company monitors exposure with its
counterparties. The Company also maintains deposits in federally insured financial institutions in excess of federally
insured limits. The Company has not experienced any losses in such accounts and
99
Table of Contents
CARA THERAPEUTICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(amounts in thousands, except share and per share data)
management believes that the Company is not exposed to significant credit risk due to the financial position of the
depository institutions in which those deposits are held.
The percentages of revenue recognized from license agreement partners of the Company in the years ended
December 31, 2023, 2022 and 2021 are included in the following table:
Revenue
Year Ended December 31,
2022
2021
2023
License Agreement Partner:
CSL Vifor*
______________
92 %
100 %
92 %
* Includes amounts earned from Vifor Fresenius Medical Care Renal Pharma Ltd. and Vifor International prior to
Vifor International’s assignment of its rights and obligations to Vifor Fresenius Medical Care Renal Pharma Ltd.
in May 2022.
For the years ended December 31, 2023, 2022 and 2021, no additional license agreement partners or customers
accounted for more than 10% of the Company’s revenue.
Concentration of Suppliers
The Company relies on three suppliers to manufacture KORSUVA injection active pharmaceutical ingredient, or
API, finished drug product, and finished goods. If any of the Company’s suppliers were to limit or terminate production or
otherwise fail to meet the quality or delivery requirements to satisfy the supply commitments, the process of locating and
qualifying alternate sources would require up to two years, during which time production could be delayed. Such delays
could have a material adverse effect on the Company’s business, financial position, and results of operations.
Cash and Cash Equivalents
Cash and cash equivalents include cash on hand, demand deposits, deposits with banks and highly liquid money
market funds with holdings of cash and other investments with original maturities of three months or less.
Marketable Securities
The Company deems certain of its investments to be marketable securities if the investment, or in the case of money
market funds, the securities underlying the money market fund, meet the definition of a debt security. The Company’s
investments in marketable securities, historically including U.S. Treasury securities, U.S. government agency obligations,
corporate bonds, commercial paper, and municipal bonds are highly rated by Moody’s and S&P and have maturities of less
than one year as of December 31, 2023. Accordingly, credit risk associated with the Company’s available-for-sale debt
security portfolio is mitigated.
The Company reviews each of its available-for-sale marketable securities for unrealized losses (declines in fair value
below its amortized cost basis) at each balance sheet date presented in its consolidated financial statements and whenever
events or changes in circumstances indicate that the amortized cost basis of an asset may not be recoverable. The Company
determines whether any portion of the unrealized loss for any available-for-sale debt security is due to a credit loss, and if
so, measures the amount of the credit loss.
The Company relies on both qualitative and quantitative factors to determine whether the unrealized loss for each
available-for-sale debt security at any balance sheet date is due to a credit loss.
100
Table of Contents
CARA THERAPEUTICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(amounts in thousands, except share and per share data)
Qualitative factors may include a credit downgrade, severity of the decline in fair value below amortized cost and
other adverse conditions related specifically to the security, as well as the intent to sell the security, or whether the
Company will “more likely than not” be required to sell the security before recovery of its amortized cost basis. The
Company’s assessment of whether a security is impaired could change in the future due to new developments or changes in
assumptions related to any particular security. If material qualitative factors indicate that a credit loss has occurred, the
Company will determine the magnitude of that credit loss using a discounted cash flow model or other quantitative method.
If the Company intends to sell the security or it is “more likely than not” that the Company will be forced to sell the
security before recovery of the amortized cost of the security, the entire unrealized loss is deemed to be a credit loss, which
is recognized in net loss. Otherwise, the portion of the unrealized loss that is due to a credit loss will be recorded as an
allowance for credit loss, which will offset the balance of marketable securities and as credit loss expense within other
income, net. The portion of the unrealized loss that is not due to a credit loss as well as all unrealized gains will be recorded
in Accumulated Other Comprehensive (Loss) Income (see Note 3, Available-for-Sale Marketable Securities, and Note 12,
Fair Value Measurements).
Accrued interest receivables are excluded from the Company’s amortized cost bases for its available-for-sale
marketable securities and are included within other receivables. The Company’s policy is to not measure an allowance for
credit losses on accrued interest receivable balances at each reporting period since it elects to write off uncollectible
accrued interest receivable balances as credit loss expense in a timely manner, which is by maturity date for all categories
of its debt securities.
Fair Value of Financial Instruments
The Company applies fair value accounting for all financial assets and liabilities that are recognized or disclosed at
fair value in the consolidated financial statements on a recurring basis. The Company defines fair value as the price that
would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants
at the measurement date. When determining the fair value measurements for assets and liabilities which are required to be
recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and the
market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as
risks inherent in valuation techniques, transfer restrictions and credit risks.
The Company’s financial instruments consist of cash, cash equivalents, available-for-sale marketable securities,
accounts receivable, net – related party, prepaid expenses, restricted cash, accounts payable and accrued liabilities, and
liability related to the sales of future royalties and milestones. The fair values of cash, cash equivalents, accounts
receivable, net – related party, prepaid expenses, restricted cash, accounts payable and accrued liabilities approximate their
carrying values due to the short-term nature of these financial instruments. The fair value of the liability related to the sales
of future royalties and milestones approximates the carrying value due to the short period of time that has elapsed from the
origination date. Available-for-sale marketable securities are reported at their fair values, based upon pricing of securities
with the same or similar investment characteristics as provided by third-party pricing services, as described below.
The valuation techniques used by the Company are based on observable and unobservable inputs. Observable inputs
reflect readily obtainable data from independent sources, while unobservable inputs reflect the Company’s assumptions
about the inputs that market participants would use in pricing the asset or liability and are developed based on the best
information available in the circumstances.
101
Table of Contents
CARA THERAPEUTICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(amounts in thousands, except share and per share data)
The Company classifies its investments in a fair value hierarchy that is intended to increase consistency and
comparability in fair value measurements and related disclosures. The fair value hierarchy is divided into three levels based
on the source of inputs as follows:
●
●
●
Level 1 – Observable inputs – quoted prices in active markets for identical assets and liabilities.
Level 2 – Observable inputs other than the quoted prices in active markets for identical assets and liabilities –
such as quoted prices for similar instruments, quoted prices for identical or similar instruments in inactive
markets, or other inputs that are observable or can be corroborated by observable market data.
Level 3 – Unobservable inputs – includes amounts derived from valuation models where one or more
significant inputs are unobservable and require the Company to develop relevant assumptions.
The Company records transfers between levels in the hierarchy by assuming that the transfer occurred at the end of
the quarter or year-to-date period.
Valuation Techniques - Level 2 Inputs
The Company estimates the fair values of its financial instruments categorized as level 2 in the fair value hierarchy,
historically including U.S. Treasury securities, U.S. government agency obligations, corporate bonds, commercial paper
and municipal bonds, by taking into consideration valuations obtained from third-party pricing services. The pricing
services use industry standard valuation models, including both income- and market-based approaches, for which all
significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of
and broker/dealer quotes on the same or similar securities, benchmark yields, issuer credit spreads, benchmark securities,
and other observable inputs. The Company obtains a single price for each financial instrument and does not adjust the
prices obtained from the pricing service.
The Company validates the prices provided by its third-party pricing services by reviewing their pricing methods,
obtaining market values from other pricing sources and comparing them to the share prices presented by the third-party
pricing services. After completing its validation procedures, the Company did not adjust or override any fair value
measurements provided by its pricing services as of December 31, 2023 or December 31, 2022.
Accounts Receivable, Net – Related Party
Accounts receivable, net – related party primarily consists of amounts due from sales of KORSUVA injection under
the Company’s supply agreements with CSL Vifor, as well as revenues earned from its share of the profit generated from
KORSUVA injection sales in the United States under the licensing agreements with CSL Vifor and royalty payments to the
Company under Vifor Agreement No. 2. The Company does not obtain collateral for its accounts receivable.
The Company makes judgments as to its ability to collect outstanding receivables and provides an allowance for
credit losses when collection becomes doubtful. Provisions are made based upon a specific review of all significant
outstanding invoices and the overall quality and age of those invoices not specifically reviewed. The Company believes
that credit risk associated with its licensing partners, CSL Vifor and Maruishi, is not significant. The Company reviews the
need for an allowance for credit losses for any receivable based on various factors including payment history and historical
bad debt experience. The Company had an insignificant allowance for credit losses as of December 31, 2023.
102
Table of Contents
Inventory, net
CARA THERAPEUTICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(amounts in thousands, except share and per share data)
Inventories are stated at the lower of cost or net realizable value. The Company determines the cost of inventory
using first-in, first-out, or FIFO, method.
The Company capitalizes inventory costs associated with the Company’s products prior to regulatory approval,
when, based on management’s judgment, future commercialization is considered probable and the future economic benefit
is expected to be realized; otherwise, such costs are expensed. The determination to capitalize inventory costs is based on
various factors, including status and expectations of the regulatory approval process, any known safety or efficacy
concerns, potential labeling restrictions, and any other impediments to obtaining regulatory approval. As KORSUVA
injection is the Company’s first commercial product and probability could not be established prior to regulatory approval
on August 23, 2021, all inventory costs prior to regulatory approval were expensed as incurred.
The Company periodically analyzes its inventory levels to identify inventory that may expire prior to expected sale
or has a cost basis in excess of its estimated realizable value and writes down such inventories as appropriate. In addition,
the Company’s products are subject to strict quality control and monitoring which the Company performs throughout the
manufacturing process. If certain batches or units of product no longer meet quality specifications or become obsolete due
to expiration, the Company records a charge to write down such unmarketable inventory to its estimated realizable value.
Property and Equipment, net
Property and equipment (consisting of computer and office equipment, furniture and fixtures and leasehold
improvements) are stated at cost, net of accumulated depreciation and amortization of leasehold improvements.
Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the respective
assets. Leasehold improvements are amortized over the lesser of their useful lives or the life of the lease. Leasehold
improvements also include leasehold improvements in process which relate to leasehold improvements not yet completed
for our new principal office. Amortization of leasehold improvements in process begins when the improvements are
completed and transferred to leasehold improvements.
Asset Category
Computer and office equipment
Furniture and fixtures
Leasehold improvements
Useful Lives
5 years
7 years
lesser of useful life of asset or life of lease
(Stamford - 11 years)
The Company reviews the recorded values of property and equipment for impairment whenever events or changes in
business circumstances indicate that the carrying amount of an asset or group of assets may not be fully recoverable.
Leases
The Company has one lease, a new lease agreement in May 2023 for new principal office space in Stamford,
Connecticut, or the New Lease, which is included in operating lease-right of use assets, or ROU assets, operating lease
liabilities – current and operating lease liabilities – non-current as of December 31, 2023. The Company had two leases, a
lease agreement for previous office space, or the Stamford Lease, and an amendment to the Stamford Lease to add
additional office space, or the Lease Amendment, which was included in ROU assets and operating lease liabilities –
103
Table of Contents
CARA THERAPEUTICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(amounts in thousands, except share and per share data)
current as of December 31, 2022. Both the Stamford Lease and Lease Amendment were not renewed and, as a result,
terminated in December 2023 (see Note 19, Commitments and Contingencies: Leases).
In general, the Company determines if a contract, at its inception, is a lease or contains a lease based on whether the
contract conveys the right to control the use of identified property, plant, or equipment (an identified asset) for a period of
time in exchange for consideration. To determine whether a contract conveys the right to control the use of an identified
asset for a period of time, the Company assesses whether, throughout the period of use, it has both the right to obtain
substantially all of the economic benefits from use of the identified asset, and the right to direct the use of the identified
asset. Both of these criteria were met by the Stamford Lease, the Lease Amendment, and the New Lease.
The Company accounted for the terms and conditions of the Lease Amendment as a lease modification because it
granted an additional right-of-use to an underlying asset (the new additional space). A lease modification can result in
either a new lease that is accounted for separately from the original lease or as a single modified lease. The Lease
Amendment was accounted for separately from the original Stamford Lease because the Lease Amendment granted the
right-of-use to additional space and the price of the additional right-of-use was commensurate with its standalone price as
no discounts were provided to the Company. Furthermore, there were no material changes to the original Stamford Lease.
The Stamford Lease, the Lease Amendment and the New Lease contained both a lease and non-lease component
which were accounted for separately. The Company allocated the consideration to the lease and the non-lease component
on a relative standalone price basis.
Since the Stamford Lease and Lease Amendment did not provide an implicit interest rate, the Company used an
annual incremental borrowing rate of 7% for each, which is based on the rate that the Company could obtain in the market
for a fully collateralized loan equal to the term of the Stamford Lease and the Lease Amendment. Similarly, since the New
Lease also did not provide an implicit interest rate, the Company used an incremental borrowing rate equal to the 3-month
Secured Overnight Financing Rate, or SOFR, plus 7.75% per annum subject to a 3-month SOFR floor of 2.75%, which was
based on the rate that the Company could obtain in the market for a fully collateralized loan equal to the term of the New
Lease, or 12.83%.
The Company determines the amount of the operating lease liability for its leases based on the present value of the
future minimum lease payments over the term of the lease. The amount of the operating lease ROU asset is equal to the
amount of the lease liability, less accrued rent and lease incentives received from the landlord. There were no lease
incentives identified in the Stamford Lease and the Lease Amendment, but lease incentives were identified in the New
Lease which reduced the initial ROU asset for the New Lease. Initial direct costs were deemed to be immaterial for all of
the Company’s leases. During the term of the lease, interest expense is calculated using the effective interest method and
the ROU asset is amortized on a straight-line basis over the lease term, and both are recorded as lease expense.
Liability Related to the Sales of Future Royalties and Milestones, Net
The Company recognizes a liability related to the sales of future royalties and milestones under ASC 470-10: Debt
and ASC 835-30: Interest – Imputation of Interest. The initial funds received by the Company pursuant to the terms of the
HCR Agreement were recorded as a liability and will be accreted under the effective interest method up to the estimated
amount of future royalties and milestone payments to be made under the HCR Agreement. The issuance costs were
recorded as a direct deduction to the carrying amount of the liability and will be amortized under the effective interest
method over the estimated period the liability will be repaid. The Company estimated the total amount of future royalty
revenue and milestone payments to be generated over the life of the HCR Agreement based on estimates and projections
from CSL Vifor and Maruishi, and a significant increase or decrease in these estimates could materially impact the liability
balance and the related interest expense. If the timing of the receipt of royalty and milestone
104
Table of Contents
CARA THERAPEUTICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(amounts in thousands, except share and per share data)
payments is materially different from the original estimates, the Company will prospectively adjust the effective interest
and the related amortization of the liability and related issuance costs.
Revenue Recognition
The Company recognizes revenue in an amount that reflects the consideration to which it expects to be entitled in
exchange for the transfer of promised goods or services to customers. To determine revenue recognition for contracts with
customers, the Company performs the following steps: (1) identifies the contract with the customer, (2) identifies the
performance obligations in the contract, (3) determines the transaction price, (4) allocates the transaction price to the
performance obligations in the contract, and (5) recognizes revenue when (or as) the entity satisfies a performance
obligation.
The Company has entered into agreements to license its intellectual property, or IP, related to difelikefalin to develop,
manufacture and/or commercialize drug products. These agreements typically contain multiple performance obligations,
including licenses of IP and R&D services. Payments to the Company under these agreements may include nonrefundable
license fees, payments for research activities, payments based upon the achievement of certain milestones and royalties on
any resulting net product sales. The Company receives its share of the net profits from the sale of KORSUVA injection in
the United States through its license agreement with CSL Vifor. The Company has adopted a policy to recognize revenue
net of tax withholdings, as applicable.
The Company identifies agreements as contracts that create enforceable rights and obligations when the agreement is
approved by the parties, identifies the rights of the parties and the payment terms, has commercial substance and it is
probable that the Company will collect the consideration to which it will be entitled in exchange for the goods and services
that will be transferred to the customer. The counterparty is considered to be a customer when it has contracted with the
Company to obtain goods and services that are the output of the Company’s ordinary activities (i.e., development of
pharmaceutical products) in exchange for consideration.
A performance obligation is a promise to transfer distinct goods or services to a customer. Performance obligations
that are both capable of being distinct and distinct within the context of the contract are considered to be separate
performance obligations. Performance obligations are capable of being distinct if the counterparty is able to benefit from
the good or service on its own or together with other resources that are readily available to it. Performance obligations are
distinct within the context of the contract when each performance obligation is separately identifiable from each other; i.e.,
the Company is not using the goods or services as inputs to produce or deliver the combined output or outputs specified by
the customer; one or more of the goods or services does not significantly modify or customize one of the other goods or
services in the contract; and goods or services are not highly interdependent or not highly interrelated. Performance
obligations that are not distinct are accounted for as a single performance obligation over the period that goods or services
are transferred to the customer. The determination of whether performance obligations in a contract are distinct may require
significant judgment.
The transaction price is the amount of consideration that the Company expects to be entitled to in exchange for
transferring promised goods or services to the customer based on the contract terms at inception of a contract. There is a
constraint on inclusion of variable consideration related to licenses of IP, such as milestone payments or sales-based royalty
payments, in the transaction price if there is uncertainty at inception of the contract as to whether such consideration will
be recognized in the future because it is probable that there will be a significant reversal of revenue in the future when the
uncertainty is resolved. The determination of whether or not it is probable that a significant reversal of revenue will occur
in the future depends on the likelihood and magnitude of the reversal. Factors that could increase the likelihood or
magnitude of a reversal of revenue include (a) the susceptibility of the amount of consideration to factors outside the
entity’s influence, such as the outcome of clinical trials, the timing of initiation of clinical trials by the counterparty and the
approval of drug product candidates by regulatory agencies, (b) situations in which the uncertainty
105
Table of Contents
CARA THERAPEUTICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(amounts in thousands, except share and per share data)
is not expected to be resolved for a long period of time, and (c) level of the Company’s experience in the field. When it
becomes probable that events will occur, for which variable consideration was constrained at inception of the contract, the
Company allocates the related consideration to the separate performance obligations in the same manner as described
below.
At inception of a contract, the Company allocates the transaction price to the distinct performance obligations based
upon their relative standalone selling prices. Standalone selling price is the price at which an entity would sell a promised
good or service separately to a customer. The best evidence of standalone selling price is an observable price of a good or
service when sold separately by an entity in similar circumstances to similar customers. Since the Company typically does
not have such evidence, it estimates standalone selling price so that the amount that is allocated to each performance
obligation equals the amount that the Company expects to receive for transferring goods or services. The methods that the
Company uses to make such estimates include (1) the adjusted market assessment approach, under which the Company
forecasts and analyzes difelikefalin in the appropriate market, the phase of clinical development as well as considering
recent similar license arrangements within the same phase of clinical development, therapeutic area, type of agreement, etc.
and (2) the expected cost of satisfying the performance obligations plus a margin, or the expected cost plus a margin
approach.
The Company recognizes revenue when, or as, it satisfies a performance obligation by transferring a promised good
or service to a customer and the customer obtains control of the good or service. Revenue related to the grant of a license
that is a distinct performance obligation and that is deemed to be functional IP is recognized at the point in time that the
Company has the right to payment for the license, the customer has legal title to the license and can direct the use of the
license (for example, to grant sublicenses), the customer has the significant risks and rewards of ownership of the license
and the customer has accepted the asset (license) by signing the license agreement.
Recognition of revenue related to R&D services that are a distinct performance obligation or that are combined with
granting of a license as a single performance obligation is deferred at inception of a contract and is recognized as those
services are performed based on the costs incurred as a percentage of the estimated total costs to be incurred to complete
the performance obligation.
The Company’s license agreements include the right to grant sub-licenses. The amount of any potential sub-license
fees to be received by the Company, which is based on a formula if applicable to that respective agreement, is considered to
be variable consideration and is constrained from inclusion in the transaction price at inception of the contract since at that
time it was probable that there would be a reversal of such revenue in the future because the Company did not know if a
sublicense would be granted in the future.
Milestone payments are considered to be variable consideration and are not included in the transaction price at
inception of the contract if it is uncertain that the milestone will be achieved. Rather, when it becomes probable that the
milestone will be achieved and, therefore, there will not be a significant reversal of revenue in future periods, the respective
amount to be earned is included in the transaction price, allocated to the distinct performance obligations based on their
relative standalone selling price and recognized as revenue, as described above. Sales milestones and sales-based royalty
payments related to a license of IP are recognized as revenue when the respective sales occur.
Collaborative Revenue
Collaborative revenue includes the Company’s share of the profits generated by CSL Vifor’s sale of KORSUVA
injection to third parties in the United States under its existing license agreements. The Company has adopted a policy to
recognize revenue net of tax withholdings, as applicable.
106
Table of Contents
CARA THERAPEUTICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(amounts in thousands, except share and per share data)
The Company determined that CSL Vifor is a customer in relation to its profit share arrangement with CSL Vifor.
The Company sells commercial product to CSL Vifor, who ultimately sells the commercial product to third parties. The
Company’s profit share arrangement revenues generated from sales of KORSUVA injection in the United States are
considered akin to sales-based royalties. In accordance with the sales-based royalty exception, the Company recognizes its
share of the pre-tax commercial net profit generated from the sales of KORSUVA injection in the United States in the
period the product sales are earned, as reported by CSL Vifor. The related COGS for CSL Vifor associated with the net
profit share arrangement as well as the marketing and distribution fee for the applicable period reduces the Company’s
profit share revenue for the period. The net sales amounts are determined based on amounts provided by CSL Vifor and
involve the use of estimates and judgments, such as product sales allowances and accruals related to prompt payment
discounts, and chargebacks, which could be adjusted based on actual results in the future. The Company is dependent on
CSL Vifor for timely and accurate information regarding the net revenues from sales of KORSUVA injection in the United
States to accurately report its results of operations. If the Company does not receive timely and accurate information or
incorrectly estimates activity levels associated with the profit share arrangement at a given point in time, the Company
could be required to record adjustments in future periods.
The Company records revenue transactions as net product revenue if it is deemed the principal in the transaction,
which includes being the primary obligor, retaining inventory risk, and control over pricing. Given that the Company is not
the primary obligor and does not have the inventory risks in the license agreement with CSL Vifor, it records its share of
the net profits from the sales of KORSUVA injection in the United States on a net basis and presents the settlement
payments from CSL Vifor as collaborative revenue. The Company and CSL Vifor settle the profit sharing quarterly (see
Note 13, Collaboration and Licensing Agreements).
Collaborative revenue also includes milestone payments associated with the Company’s license agreement with
Maruishi. Upfront and milestone payments associated with the license agreement with Maruishi are allocated between
license and milestone fees and collaborative revenue based on the relative standalone selling prices determined at contract
inception that were allocated to the R&D services performance obligation (see Note 14, Revenue Recognition).
Commercial Supply Revenue
Commercial supply revenue includes sales of KORSUVA injection commercial product to CSL Vifor, which
ultimately acts as the principal in the net profit-sharing arrangement between the two parties since commercial launch in
April 2022, which then sells to third parties in the United States. Commercial supply revenue is recognized when CSL
Vifor obtains control of the Company’s commercial product, which occurs at a point in time, typically upon receipt of
KORSUVA injection by CSL Vifor, and generally occurs after the commercial product has passed all quality testing
required for acceptance by CSL Vifor. The Company calculates its commercial supply revenue based on its COGS plus an
agreed upon margin.
License and Milestone Fees
License and milestone fees include upfront and milestone payments associated with the Company’s license
agreements with CSL Vifor, Maruishi and CKDP. All upfront and milestone payments associated with the license
agreements with CSL Vifor and CKDP are recognized as license and milestone fees since they contain only one
performance obligation. Upfront and milestone payments associated with the license agreement with Maruishi are allocated
between license and milestone fees and collaborative revenue based on the relative standalone selling prices determined at
contract inception (see Note 14, Revenue Recognition).
107
Table of Contents
Royalty Revenue
CARA THERAPEUTICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(amounts in thousands, except share and per share data)
Royalty revenue includes amounts related to the Company’s royalties earned from CSL Vifor on the net sales of
Kapruvia in Europe, based on the amount of net sales in a licensed territory during a calendar year. Sales-based royalty
payments related to a license of IP are recognized as revenue when the respective sales occur, and the net sales tier is
achieved. Beginning on October 1, 2023, royalty revenue will no longer be recognized until the Company has fulfilled its
obligations under the HCR Agreement (see Note 10, Royalty Purchase and Sale Agreement).
Clinical Compound Revenue
Clinical compound revenue includes sales of clinical compound to CSL Vifor (prior to FDA approval), and Maruishi.
The Company recognizes revenue on clinical compound sales when control has transferred to CSL Vifor and Maruishi,
which occurs at a point in time, typically upon receipt of the clinical compound, and generally occurs after the clinical
compound has passed all quality testing required for acceptance. The sales of clinical compound are reimbursed at COGS
plus an agreed upon margin.
Other Revenue
Other revenue includes the royalty and milestone payments earned under Vifor Agreement No. 2 and the Maruishi
Agreement in conjunction with ex-U.S. sales of KORSUVA/Kapruvia in the fourth quarter of 2023. This non-cash revenue
will continue to be recorded until the Company has fulfilled its obligations under HCR Agreement.
Cost of Goods Sold (COGS)
COGS includes costs related to sales of the Company’s commercial product, KORSUVA injection, to CSL Vifor.
Costs related to the sales of KORSUVA injection are generally recognized upon receipt of shipment by CSL Vifor. The
Company’s COGS for KORSUVA injection includes the cost of producing commercial product that correspond with
commercial supply revenue, such as third-party supply and overhead costs, as well as certain period costs related to freight,
packaging, stability, and quality testing. No COGS was recognized prior to January 1, 2022, as regulatory approval of
KORSUVA injection occurred in August 2021 and all inventory costs prior to regulatory approval were expensed as
incurred.
Research and Development (R&D) Expenses
R&D costs are charged to expense as incurred. Costs incurred under agreements with third parties are charged to
expense as incurred in accordance with the specific contractual performance terms of such agreements. R&D expenses
include, among other costs, compensation and other personnel-related costs, including consultant costs, and costs to
conduct clinical trials using clinical research organizations, or CROs, which include upfront, milestone and monthly
expenses as well as reimbursement for pass through costs. The amount of clinical trial expense recognized in any period
varies depending on the duration and progress of each clinical trial, including the required level of patient enrollment, the
rate at which patients actually enroll in and drop-out of the clinical trial, and the number of sites involved in the trial as
well as the activities to be performed by the sites each period. R&D costs also include costs to manufacture product
candidates and clinical supplies, laboratory supplies costs, facility-related costs and stock-based compensation for R&D
personnel. Non-refundable R&D advance payments are deferred and capitalized as prepaid R&D expense. The capitalized
amounts are expensed as the related goods are delivered or services are performed. As of December 31, 2023 and 2022, the
Company recorded $7,245 and $15,188 as prepaid R&D expense, respectively.
108
Table of Contents
CARA THERAPEUTICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(amounts in thousands, except share and per share data)
General and Administrative (G&A) Expenses
G&A costs are charged to expense as incurred. G&A expenses consist primarily of salaries and other related costs,
including stock-based compensation, for personnel in executive, finance, accounting, legal, business development,
information technology, human resources, project management, alliance management, and procurement functions. Other
costs include facility costs not otherwise included in R&D expenses, legal fees, insurance costs, investor relations costs,
patent costs and fees for accounting and consulting services.
As noted in Note 13, Collaboration and Licensing Agreements, the Company’s license agreement with CSL Vifor
provides full commercialization rights of KORSUVA injection to CSL Vifor under a profit-sharing arrangement. Under this
profit-sharing arrangement, in consideration of CSL Vifor’s conduct of the marketing, promotion, selling and distribution
of KORSUVA injection in the United States, the Company will pay a marketing and distribution fee to CSL Vifor based on
the level of annual net sales. This fee will be deducted from product sales in calculating the net profits that are subject to
the profit-sharing arrangement.
Stock-Based Compensation
The Company grants stock options to employees, non-employee members of the Company’s Board of Directors and
non-employee consultants as compensation for services performed. All share-based payments, including grants of stock
options, are recognized based on their grant date fair values. The grant date fair value of stock options is estimated using
the Black-Scholes option valuation model.
Using this model, fair value is calculated based on assumptions with respect to (i) the fair value or market price of
the Company’s common stock on the grant date; (ii) expected volatility of the Company’s common stock price, (iii) the
periods of time over which employees and members of the Company’s Board of Directors or non-employee consultants are
expected to hold their options prior to exercise (expected term), (iv) expected dividend yield on the Company’s common
stock, and (v) risk-free interest rates.
The Company’s common stock has been traded on a public exchange only since January 31, 2014. Since that time,
exercises of stock options have been limited due to various factors, including fluctuations in the Company’s stock price to
below the exercise prices of awards and blackout periods during which exercises are not allowed, among others. Therefore,
the Company believes that as of December 31, 2023, it does not have sufficient company-specific information available to
determine the expected term based on its historical data. As a result, the expected term of stock options granted is
determined using the average of the vesting period and term (6.25 years), an accepted method for the Company’s option
grants under the SEC’s Staff Accounting Bulletin No. 110, Share-Based Payment.
The Company calculates the expected volatility using company-specific trading activity of its common stock over the
option’s expected term. The expected dividend yield is zero as the Company has never paid dividends and does not
currently anticipate paying any in the foreseeable future. Risk-free interest rates are based on quoted U.S. Treasury rates for
securities with maturities approximating the option’s expected term.
The Company’s policy is to account for forfeitures of share-based payments as they occur. Compensation cost for all
share-based payments granted with service-based graded vesting schedules is recognized using the straight-line method
over the requisite service period.
Other Income, Net
Other income, net consists of interest and dividend income earned on the Company’s cash, cash equivalents, and
marketable securities, realized gains and losses on the sale of marketable securities and property and equipment, as well
109
Table of Contents
CARA THERAPEUTICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(amounts in thousands, except share and per share data)
as accretion of discounts/amortization of premiums on purchases of marketable securities. In the event the Company
records a credit loss expense on its available-for-sale debt securities, those expenses would be offset against other income.
Non-Cash Interest Expense on Liability Related to Sales of Future Royalties and Milestones
Non-cash interest expense on liability related to sales of future royalties and milestones consists of imputed interest
on the carrying value of the liability and the amortization of the related issuance costs.
Income Taxes
The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets
and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and
are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.
Deferred income tax assets are reduced, as necessary, by a valuation allowance when management determines it is more
likely than not that some or all of the tax benefits will not be realized.
There were no material uncertain tax positions taken as of December 31, 2023 and 2022. The Company does not
have any interest or penalties accrued related to tax positions as it does not have any unrecognized tax benefits. In the event
the Company determines that accrual of interest or penalties are necessary in the future, the amount will be presented as a
component of interest expense.
Loss Per Share
The Company computes basic net loss per share by dividing net loss by the weighted average number of shares of
common stock outstanding. Diluted net loss per share includes the potential dilutive effect of common stock equivalents as
if such securities were converted or exercised during the period, when the effect is dilutive. Common stock equivalents
may include outstanding stock options and restricted stock units, which are included under the treasury stock method when
dilutive. For each of the years ended December 31, 2023, 2022 and 2021, the Company excluded the effects of potentially
dilutive shares that were outstanding during those respective periods from the denominator as their inclusion would have
been anti-dilutive due to the Company’s net losses for those periods.
Segment Reporting
Operating segments are identified as components of an enterprise about which separate discrete financial information
is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and
assessing performance. The Company views its operations and manages its business as one operating segment, which
includes all activities related to the discovery, development, and commercialization of novel therapeutics to treat serious
medical conditions, including pruritus.
Litigation Reserves
From time to time, the Company may become subject to arbitration, litigation or claims arising in the ordinary course
of its business. Accruals are recorded when it is probable that a liability has been incurred and the amount of the liability
can be reasonably estimated. The Company reviews these reserves at least quarterly and adjusts these reserves to reflect
current law, progress of each case, opinions and views of legal counsel and other advisers, the Company’s experience in
similar matters and intended response to the litigation. The Company expenses amounts for administering or litigating
claims as incurred. Accruals for legal proceedings, if any, are included in accounts payable and accrued expenses.
110
Table of Contents
CARA THERAPEUTICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(amounts in thousands, except share and per share data)
Accounting Pronouncements Recently Issued
In December 2023, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or
ASU, 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, or ASU 2023-09, which applies to all
entities subject to income taxes. ASU 2023-09 requires disaggregated information about a reporting entity’s effective tax
rate reconciliation as well as information on income taxes paid. ASU 2023-09 is intended to provide more detailed income
tax disclosures. For public business entities (PBEs), the new requirements will be effective for annual periods beginning
after December 15, 2024. ASU 2023-09 will be applied on a prospective basis with the option to apply the standard
retrospectively. The Company expects to adopt ASU 2023-09 on January 1, 2025, and it does not expect the adoption to
have a material effect on its results of operations, financial position, and cash flows.
In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable
Segment Disclosures, or ASU 2023-07, which expands the disclosures for reportable segments made by public entities.
These amendments within ASU 2023-07 retain the existing disclosure requirements in ASC 280 and expand upon them to
require public entities to disclose significant expenses for reportable segments in both interim and annual reporting periods,
as well as items that were previously disclosed only annually on an interim basis, including disclosures related to a
reportable segment’s profit or loss and assets. In addition, entities with a single reportable segment must provide all
segment disclosures required in ASC 280, including the new disclosures for reportable segments under the amendments in
ASU 2023-07. The amendments do not change the existing guidance on how a public entity identifies and determines its
reportable segments. A public entity should apply the amendments in ASU 2023-07 retrospectively to all prior periods
presented in the financial statements. Upon transition, the segment expense categories and amounts disclosed in the prior
periods should be based on the significant segment expense categories identified and disclosed in the period of adoption.
The amendments in ASU 2023-07 are effective for annual periods for all public entities in fiscal years beginning after
December 15, 2023, and in interim periods within fiscal years beginning after December 15, 2024. Early adoption is
permitted. The Company will adopt ASU 2023-07 on January 1, 2024, and it does not expect the adoption to have a
material effect on its results of operations, financial position, and cash flows.
3. Available-for-Sale Marketable Securities
As of December 31, 2023 and 2022, the Company’s available-for-sale marketable securities consisted of debt
securities issued by the U.S. Treasury, U.S. government-sponsored entities and investment grade institutions (corporate
bonds). As of December 31, 2022, the Company’s available-for-sale marketable securities also consisted of debt securities
issued by investment grade institutions (commercial paper) and municipal bonds.
The following tables summarize the Company’s available-for-sale marketable securities by major type of security as
of December 31, 2023 and 2022:
As of December 31, 2023
Type of Security
Amortized Cost
Gains
Losses
Gross Unrealized
Estimated Fair
Value
U.S. Treasury securities
U.S. government agency obligations
Corporate bonds
Total available-for-sale marketable securities
$
$
37,243
7,500
4,500
49,243
$
$
111
3
$
—
—
$
3
— $
(262)
(1)
(263)
$
37,246
7,238
4,499
48,983
Table of Contents
CARA THERAPEUTICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(amounts in thousands, except share and per share data)
As of December 31, 2022
Type of Security
Amortized Cost
Gains
Losses
Gross Unrealized
Estimated Fair
Value
U.S. government agency obligations
Corporate bonds
Commercial paper
Municipal bonds
Total available-for-sale marketable securities
$
$
9,500
35,828
26,879
22,473
94,680
$
$
— $
—
2
—
2
$
(623)
(643)
(6)
(402)
(1,674)
$
$
8,877
35,185
26,875
22,071
93,008
The following tables summarize the fair value and gross unrealized losses of the Company’s available-for-sale
marketable securities by investment category and disaggregated by the length of time that individual debt securities have
been in a continuous unrealized loss position as of December 31, 2023 and 2022:
As of December 31, 2023
U.S. government agency obligations
Corporate bonds
Total
As of December 31, 2022
U.S. government agency obligations
Corporate bonds
Commercial paper
Municipal bonds
Total
$
$
$
$
Less than 12 Months
Gross
Unrealized
Losses
Fair
Value
12 Months or Greater
Gross
Unrealized
Losses
Fair
Value
Total
Gross
Unrealized
Losses
Fair
Value
— $
—
— $
— $
—
— $
7,238
2,000
9,238
$
$
(262) $
(1)
(263) $
7,238
2,000
9,238
$
$
(262)
(1)
(263)
Less than 12 Months
Gross
Unrealized
Losses
Fair
Value
12 Months or Greater
Gross
Unrealized
Losses
Fair
Value
— $
1,470
15,906
982
18,358
$
— $
(26)
(6)
(16)
(48) $
8,877
33,715
$
—
19,589
62,181
$
(623) $
(617)
—
(386)
(1,626) $
Total
Fair
Value
8,877
35,185
15,906
20,571
80,539
Gross
Unrealized
Losses
$
$
(623)
(643)
(6)
(402)
(1,674)
As of December 31, 2023 and 2022, respectively, no allowance for credit losses were recognized on the Company’s
available-for-sale debt securities as no portion of the unrealized losses associated with those securities were due to credit
losses. The information that the Company considered in reaching the conclusion that an allowance for credit losses was not
necessary for the following categories of securities is as follows:
As of December 31, 2023 and 2022, the Company held a total of 3 out of 9 positions and 35 out of 39 positions,
respectively, that were in an unrealized loss position, all of which had been in an unrealized loss position for 12 months or
greater as of December 31, 2023. Unrealized losses individually and in aggregate, including any in an unrealized loss
position for 12 months or greater, were not considered to be material for each respective period. Based on the Company’s
review of these securities, the Company believes that the cost basis of its available-for-sale marketable securities is
recoverable.
U.S. Treasury securities and U.S. government agency obligations. The unrealized losses on the Company’s
investments in direct obligations of U.S. Treasury securities and U.S. government agencies were due to changes in
112
Table of Contents
CARA THERAPEUTICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(amounts in thousands, except share and per share data)
interest rates and non-credit related factors. The credit ratings of these investments in the Company’s portfolio have not
been downgraded below investment grade status. The contractual terms of these investments do not permit the issuer to
repay principal at a price less than the amortized cost bases of the investments, which is equivalent to the par value on the
maturity date. The Company expects to recover the entire amortized cost bases of these securities on the maturity date. The
Company does not intend to sell these investments, and it is not “more likely than not” that the Company will be required
to sell these investments before recovery of their amortized cost bases. The Company held 0 out of 5 positions for its U.S.
Treasury securities and 2 out of 2 positions for its U.S. government agency obligations, that were in unrealized loss
positions as of December 31, 2023.
Corporate bonds. The unrealized losses on the Company’s investments in corporate bonds were due to changes in
interest rates and non-credit related factors. The credit ratings of these investments in the Company’s portfolio have not
been downgraded below investment grade status. The contractual terms of these investments do not permit the issuer to
repay principal at a price less than the amortized cost bases of the investments, which is equivalent to the par value on the
maturity date. The Company expects to recover the entire amortized cost bases of these securities on the maturity date. The
Company does not intend to sell these investments, and it is not “more likely than not” that the Company will be required
to sell these investments, before recovery of their amortized cost bases. The Company held 1 out of 2 positions for its
corporate bonds, that were in unrealized loss positions as of December 31, 2023.
The Company classifies its marketable debt securities based on their contractual maturity dates. As of December 31,
2023, the Company’s marketable debt securities mature at various dates through November 2024. The amortized cost and
fair values of marketable debt securities by contractual maturity were as follows:
Contractual maturity
As of December 31, 2023
As of December 31, 2022
Amortized Cost
Fair Value
Amortized Cost
Fair Value
Less than one year
One year to two years
Total
$
$
49,243
$
—
$
49,243
48,983
$
—
$
48,983
82,678
12,002
94,680
$
$
81,658
11,350
93,008
All available-for-sale marketable securities are classified as marketable securities, current or marketable securities,
non-current depending on the contractual maturity date of the individual available-for-sale security. Other income, net
includes interest and dividends, accretion/amortization of discounts/premiums, realized gains and losses on sales of
securities and credit loss expense due to declines in the fair value of securities, if any. The cost of securities sold is based
on the specific identification method.
There were no sales of available-for-sale marketable securities during the years ended December 31, 2023 and 2022.
During the year ended December 31, 2021, the Company sold certain of its available-for-sale debt securities with a total
fair value of $10,029, which resulted in realized gains of $39.
As of December 31, 2023 and 2022, accrued interest receivables on our available-for-sale debt securities were $139
and $489, respectively.
113
Table of Contents
CARA THERAPEUTICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(amounts in thousands, except share and per share data)
4. Accumulated Other Comprehensive (Loss) Income
The following table summarizes the changes in accumulated other comprehensive (loss) income, net of tax, from
unrealized gains (losses) on available-for-sale marketable securities, the Company’s only component of accumulated other
comprehensive (loss) income, for the years ended December 31, 2023, 2022 and 2021.
Balance, December 31, 2020
Other comprehensive loss before reclassifications
Amount reclassified from accumulated other comprehensive income
Net current period other comprehensive loss
Balance, December 31, 2021
Other comprehensive loss before reclassifications
Amount reclassified from accumulated other comprehensive loss
Net current period other comprehensive loss
Balance, December 31, 2022
Other comprehensive income before reclassifications
Amount reclassified from accumulated other comprehensive loss
Net current period other comprehensive income
Balance, December 31, 2023
Total Accumulated
Other Comprehensive
Income (Loss)
73
(392)
(39)
(431)
(358)
(1,314)
—
(1,314)
(1,672)
1,412
—
1,412
(260)
$
$
$
Amounts reclassified out of accumulated other comprehensive (loss) income into net loss are determined by specific
identification. The reclassifications out of accumulated other comprehensive (loss) income and into net loss were as
follows:
Component of Accumulated Other
Comprehensive Income (Loss)
Unrealized gains on available-for-sale marketable
securities:
Realized gains on sales of securities
Income tax effect
Realized gains on sales of securities, net of tax
5. Inventory, net
Inventories consist of the following:
Raw materials
Work-in-process
Less Inventory Reserve for Obsolescence
Total
Year Ended December 31,
2022
2021
2023
Affected Line Item in the
Consolidated Statements of
Comprehensive Loss
$
$
— $
—
— $
— $
—
— $
39 Other income, net
— Benefit from income taxes
39
$
$
December 31, 2023 December 31, 2022
1,918
499
2,417
(34)
2,383
2,639
708
3,347
(526)
2,821
$
$
As of December 31, 2023 and December 31, 2022, inventory balances include inventory costs subsequent to
regulatory approval of KORSUVA injection on August 23, 2021. During the years ended December 31, 2023 and 2022,
114
Table of Contents
CARA THERAPEUTICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(amounts in thousands, except share and per share data)
the Company wrote down $526 and $34, respectively, of commercial supply inventory due to obsolescence. There were no
write-downs of commercial supply inventory during the year ended December 31, 2021.
6. Prepaid Expenses
As of December 31, 2023, the amount of prepaid expenses was $8,154, consisting of $7,245 of prepaid R&D clinical
costs, $492 of prepaid insurance and $417 of other costs. As of December 31, 2022, the amount of prepaid expenses was
$16,267, consisting of $15,188 of prepaid R&D clinical costs, $543 of prepaid insurance and $536 of other costs.
7. Property and Equipment, net
Property and equipment, net consists of the following:
Computer and office equipment
Furniture and fixtures
Leasehold improvements
Less accumulated depreciation and amortization
Property and equipment, net
December 31,
2023
2022
$
$
$
239
596
4,154
4,989
(1,667)
3,322
$
$
$
239
330
1,266
1,835
(1,409)
426
Leasehold improvements include $2,533 relating to the New Lease entered into in May 2023 that are still in process
as of December 31, 2023 and will begin amortization once the improvements are complete. In October and November
2023, the Company determined that $1,755 of these costs qualified for reimbursement as lease incentives, of which $808
had been reimbursed to the Company as of December 31, 2023 (see Note 19, Commitments and Contingencies - Lease
(New Corporate Headquarters in May 2023).
Depreciation and amortization expense included in R&D expense and G&A expense was $259, $248 and $248 for
the years ended December 31, 2023, 2022 and 2021, respectively.
There were no gains or losses on sales of property and equipment during the years ended December 31, 2023 and
2022. During the year ended December 31, 2021, the Company sold laboratory equipment that was fully depreciated,
which resulted in gains on sales of property and equipment of $70.
8. Restricted Cash
In May 2023, the Company entered into the New Lease with 400 Atlantic Joint Venture LLC and SLJ Atlantic
Stamford LLC (tenants-in-common), or the Landlord, for the lease of 26,374 square feet of office space located at 400
Atlantic Street, Stamford, Connecticut 06901 for its new principal offices. The Company is required to maintain a stand-by
letter of credit as a security deposit under the New Lease for its office space in Stamford, Connecticut (refer to Note 19,
Commitments and Contingencies: Leases). The fair value of the letter of credit approximates its contract value. The
Company’s bank requires the Company to maintain a restricted cash balance to serve as collateral for the letters of credit
issued to the landlord by the bank for the New Lease and the previous Stamford Lease. As of December 31, 2023, the
restricted cash balance for the New Lease and the Stamford Lease was invested in a commercial money market account.
115
Table of Contents
CARA THERAPEUTICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(amounts in thousands, except share and per share data)
As of December 31, 2023, the Company had $408 of restricted cash related to the Stamford Lease (which was
terminated in December 2023 but not yet released) that became unrestricted in January 2024 and $1,500 of restricted cash
related to the New Lease in long-term assets. After the first and second anniversaries of the rent commencement date, the
face amount of the letter of credit relating to the New Lease can be reduced by $500 each period if the Company is not in
default of its lease obligations. As of December 31, 2022, the Company had $408 of restricted cash related to the Stamford
Lease in current assets.
The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the
Consolidated Balance Sheets that sum to the total of the same such amounts shown in the Consolidated Statements of Cash
Flows.
Cash and cash equivalents
Restricted cash, current assets
Restricted cash, long-term assets
$
December 31, 2023 December 31, 2022
63,741
408
—
51,775
408
1,500
$
Total cash, cash equivalents, and restricted cash shown in the Consolidated
Statements of Cash Flows
$
53,683
$
64,149
9. Accounts Payable and Accrued Expenses
Accounts payable and accrued expenses consist of the following:
Accounts payable
Accrued research projects
Accrued compensation and benefits
Accrued professional fees and other
Total
10. Royalty Purchase and Sale Agreement
$
$
December 31, 2023 December 31, 2022
9,604
5,200
5,219
1,517
21,540
11,583
4,343
6,519
3,147
25,592
$
$
During the fourth quarter of 2023, the Company, through its wholly-owned subsidiary Cara Royalty Sub, LLC, a
Delaware limited liability company, or Cara Royalty Sub, entered into the HCR Agreement with HCR, pursuant to which
Cara Royalty Sub sold, or agreed to sell, to HCR certain of its rights to receive royalty payments, or the Royalties, due and
payable to Cara Royalty Sub (as assignee of the Company) under the Maruishi Agreement and Vifor Agreement No. 2.,
collectively the Covered License Agreements, in exchange for up to $40,000. The Company has retained all of its right,
title and interest in, to and under the Covered License Agreements that relate to any non-intravenous formulation of
difelikefalin.
Under the terms of the HCR Agreement, Cara Royalty Sub received an upfront payment of $16,915 in November
2023, representing the $17,500 to which the Company was initially entitled, net of advisory fees and certain of HCR’s
transaction-related expenses which the Company agreed to reimburse. In December 2023, Cara Royalty Sub received an
additional payment of $19,770, representing the $20,000 milestone it achieved for Kapruvia (difelikefalin) pricing in
Germany being approved above a certain threshold amount per dose, net of advisory fees. There were additional issuance
costs of $211 related to the HCR Agreement resulting in aggregate net proceeds of $36,474. An additional $2,500
milestone payment is due to Cara Royalty Sub upon achievement of a 2024 sales milestone of KORSUVA in Japan.
116
Table of Contents
CARA THERAPEUTICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(amounts in thousands, except share and per share data)
The HCR Agreement will automatically expire, and the payment of Royalties to HCR will cease, when HCR has
received payments of Royalties equal to two times the aggregate amount of payments made by HCR under the HCR
Agreement if achieved on or prior to December 31, 2029, or 2.8 times the aggregate amount of payments made by HCR
under the HCR Agreement, if not achieved on or prior to December 31, 2029. After the HCR Agreement expires, all rights
to receive the Royalties return to Cara Royalty Sub.
Issuance costs pursuant to the HCR Agreement consisting primarily of advisory and legal fees totaled $1,025
including the amount of HCR’s transaction-related expenses that the Company reimbursed. The effective interest rate
includes cash flow projections for future royalty and milestone payments, which are sensitive to certain assumptions,
including market size, market penetration and sales price, that are forward looking and could be affected by future market
conditions.
The following table summarizes the activity of the HCR Agreement (in thousands):
HCR Agreement (including milestone payment received in December 2023)
Issuance costs
Non-cash interest expense
Balance at December 31, 2023
Effective interest rate
11. Stockholders’ Equity
$
$
37,500
(1,025)
604
37,079
22.6 %
The Company’s Board of Directors has authorized 100,000,000 shares of the Company’s common stock, par value
$0.001 per share, and 5,000,000 shares of undesignated preferred stock, par value $0.001 per share, that may be issued
from time to time by the Board of Directors of the Company in one or more series. As of December 31, 2023, there were
54,480,704 shares of common stock and no shares of preferred stock issued and outstanding.
Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s
stockholders. Common stockholders are entitled to dividends when and if declared by the Board of Directors, subject to the
preferential rights of the holders of preferred stock, if any.
In October 2023, as a result of completion of the quarterly vesting period for restricted stock units granted in October
2021, an aggregate of 8,875 time-based restricted stock units vested and were settled in shares of the Company’s common
stock (see Note 15, Stock-Based Compensation).
In August 2023, as a result of completion of the vesting period for restricted stock units granted in October 2022, an
aggregate of 7,267 time-based restricted stock units vested and were settled in shares of the Company’s common stock (see
Note 15, Stock-Based Compensation).
In July 2023, as a result of completion of the quarterly vesting period for restricted stock units granted in October
2021, an aggregate of 8,875 time-based restricted stock units vested and were settled in shares of the Company’s common
stock (see Note 15, Stock-Based Compensation).
In June 2023, as a result of completion of the final vesting period for restricted stock units granted in December
2021, an aggregate of 26,199 time-based restricted stock units vested and were settled in shares of the Company’s common
stock (see Note 15, Stock-Based Compensation).
117
Table of Contents
CARA THERAPEUTICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(amounts in thousands, except share and per share data)
In June 2023, as a result of the completion of the one-year vesting period, an aggregate of 59,380 restricted stock
units of members of the Board of Directors vested and were settled in shares of the Company’s common stock (see Note
15, Stock-Based Compensation).
In April 2023, as a result of completion of the quarterly vesting period for restricted stock units granted in October
2021, an aggregate of 8,875 time-based restricted stock units vested and were settled in shares of the Company’s common
stock (see Note 15, Stock-Based Compensation).
In March 2023, as a result of the completion of the second year of the three-year vesting period for restricted stock
units granted in March 2021, an aggregate of 15,999 time-based restricted stock units vested and were settled in shares of
the Company’s common stock (see Note 15, Stock-Based Compensation).
In February 2023, as a result of the completion of the first year of the three-year vesting period for restricted stock
units granted in February 2022, an aggregate of 42,920 time-based restricted stock units vested and were settled in shares
of the Company’s common stock (see Note 15, Stock-Based Compensation).
Also in February 2023, as a result of the completion of the third year of the three-year vesting period for restricted
stock units granted in February 2020, an aggregate of 15,999 time-based restricted stock units vested and were settled in
shares of the Company’s common stock (see Note 15, Stock-Based Compensation).
In January 2023, as a result of completion of the quarterly vesting period for restricted stock units granted in October
2021, an aggregate 8,875 time-based restricted stock units vested and were settled in shares of the Company’s common
stock (see Note 15, Stock-Based Compensation).
In December 2022, as a result of the achievement of certain performance targets, an aggregate of 26,204
performance-based restricted stock units of certain employees vested and were settled in shares of the Company’s common
stock (see Note 15, Stock-Based Compensation).
In October 2022, as a result of the completion of the first year of vesting associated with awards granted to the
Company’s new Chief Executive Officer, or CEO, an aggregate of 35,500 restricted stock units vested and were settled in
shares of the Company’s common stock (see Note 15, Stock-Based Compensation).
In September 2022, as a result of the appointment of the Company’s new Chief Financial Officer, or CFO, 7,500
time-based restricted stock units held by the Company’s interim principal financial and accounting officer vested and were
settled in shares of the Company’s common stock (see Note 15, Stock-Based Compensation).
In June 2022, as a result of the accelerated vesting of restricted stock units previously granted to the Company’s
former CEO, an aggregate of 33,999 restricted stock units vested and were settled in shares of the Company’s common
stock (see Note 15, Stock-Based Compensation).
In June 2022, as a result of the completion of the one-year vesting period, an aggregate of 43,200 restricted stock
units of members of the Board of Directors vested and were settled in shares of the Company’s common stock. Also in
June 2022, the Company granted 11,876 fully vested restricted stock units, which were immediately settled in shares of
common stock, to the Company’s chairman in consideration of his effort in connection with the Company’s CEO transition
in 2021 (see Note 15, Stock-Based Compensation).
In March 2022, as a result of the achievement of certain performance targets, an aggregate of 37,999 performance-
based restricted stock units of certain employees vested and were settled in shares of the Company’s common stock (see
Note 15, Stock-Based Compensation).
118
Table of Contents
CARA THERAPEUTICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(amounts in thousands, except share and per share data)
In March 2022, as a result of the completion of the first year of the three-year vesting period for restricted stock units
granted in March 2021 and the full vesting of the second tranche of restricted stock units granted to the new CEO in
October 2021, an aggregate of 39,278 time-based restricted stock units vested and were settled in shares of the Company’s
common stock (see Note 15, Stock-Based Compensation).
In March 2022, the Company filed a universal shelf registration statement, or the Shelf Registration Statement,
which provides for aggregate offerings of up to $300,000 of common stock, preferred stock, debt securities, warrants or
any combination thereof. The Shelf Registration Statement was declared effective on May 11, 2022. The securities
registered under the Shelf Registration Statement include $154,525 of unsold securities that had been registered under the
Company’s previous Registration Statement on Form S-3 (File No. 333-230333) that was declared effective on April 4,
2019.
Also in March 2022, the Company entered into the Sales Agreement, pursuant to which it may, from time to time,
issue and sell common stock with an aggregate value of up to $80,000 in an at-the-market offering pursuant to the Shelf
Registration Statement. Jefferies is acting as sole sales agent for any sales made under the Sales Agreement for a 3%
commission on gross proceeds. The common stock will be sold at prevailing market prices at the time of the sale, and, as a
result, prices may vary. Unless otherwise terminated earlier, the Sales Agreement continues until all shares available under
the Sales Agreement have been sold. During the year ended December 31, 2023, 386,881 shares were sold under the Sales
Agreement and the Company received net proceeds of $1,117.
The Company may offer additional securities under its Shelf Registration Statement from time to time in response to
market conditions or other circumstances if it believes such a plan of financing is in the best interests of its stockholders.
In February 2022, as a result of the completion of the second year of the three-year vesting period for restricted stock
units granted in February 2020, an aggregate of 32,666 time-based restricted stock units vested and were settled in shares
of the Company’s common stock (see Note 15, Stock-Based Compensation).
In October 2021, the Company issued 3,282,391 shares of its common stock to Vifor International in connection with
the milestone earned for the U.S. regulatory approval of KORSUVA injection in August 2021 (see Note 13, Collaboration
and Licensing Agreements).
In August 2021, as a result of the achievement of certain performance targets, an aggregate of 44,002 performance-
based restricted stock units of various executive officers vested and were settled in shares of the Company’s common stock
(see Note 15, Stock-Based Compensation).
In June 2021, as a result of the completion of the one-year vesting period, an aggregate of 36,000 restricted stock
units of members of the Board of Directors vested and were settled in shares of the Company’s common stock (see Note
15, Stock-Based Compensation).
In February and March 2021, as a result of the achievement of certain performance targets, an aggregate of 76,750
performance-based restricted stock units of various executive officers vested and were settled in shares of the Company’s
common stock (see Note 15, Stock-Based Compensation).
In February 2021, as a result of the completion of the first year of the three-year vesting period, an aggregate of
32,669 time-based restricted stock units of various executive officers vested and were settled in shares of the Company’s
common stock (see Note 15, Stock-Based Compensation).
119
Table of Contents
CARA THERAPEUTICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(amounts in thousands, except share and per share data)
12. Fair Value Measurements
The following tables summarize the Company’s financial assets measured at fair value on a recurring basis as of
December 31, 2023 and 2022, and by level within the fair value hierarchy:
Fair value measurement as of December 31, 2023:
Financial assets
Type of Instrument
Total
Quoted prices in
active markets for
identical assets
(Level 1)
Significant other
observable
inputs
(Level 2)
Significant
unobservable
inputs
(Level 3)
Cash and cash equivalents:
Money market funds and checking accounts
Available-for-sale marketable securities:
U.S. Treasury securities
U.S. government agency obligations
Corporate bonds
Restricted cash:
Commercial money market account
Total financial assets
Fair value measurement as of December 31, 2022:
$ 51,775
$
51,775
$
— $
37,246
7,238
4,499
—
—
—
37,246
7,238
4,499
1,908
$ 102,666
$
1,908
53,683
$
—
$
48,983
—
—
—
—
—
—
Financial assets
Type of Instrument
Total
Quoted prices in
active markets for
identical assets
(Level 1)
Significant other
observable
inputs
(Level 2)
Significant
unobservable
inputs
(Level 3)
Cash and cash equivalents:
Money market funds and checking accounts
Available-for-sale marketable securities:
U.S. government agency obligations
Corporate bonds
Commercial paper
Municipal bonds
Restricted cash:
Commercial money market account
Total financial assets
$ 63,741
$
63,741
$
— $
8,877
35,185
26,875
22,071
—
—
—
—
8,877
35,185
26,875
22,071
408
$ 157,157
$
408
64,149
$
—
$
93,008
—
—
—
—
—
—
—
There were no purchases, sales or maturities of Level 3 financial assets and no unrealized gains or losses related to
Level 3 available-for-sale marketable securities for the years ended December 31, 2023, 2022 and 2021. There were no
transfers of financial assets between Levels 1, 2, or 3 classifications during the years ended December 31, 2023 and 2022.
13. Collaboration and Licensing Agreements
Vifor (International) Ltd. (Vifor International)
In October 2020, the Company entered into a license agreement with Vifor International, or Vifor Agreement No. 1,
under which the Company granted Vifor International an exclusive license solely in the United States to use, distribute,
offer for sale, promote, sell and otherwise commercialize difelikefalin injection for all therapeutic uses
120
Table of Contents
CARA THERAPEUTICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(amounts in thousands, except share and per share data)
relating to the inhibition, prevention or treatment of itch associated with pruritus in hemodialysis and peritoneal dialysis
patients in the United States. Under Vifor Agreement No. 1, the Company retains all rights with respect to the clinical
development of, and activities to gain regulatory approvals of, difelikefalin injection in the United States. The Joint
Commercialization Committee, or JCC, have the responsibility for overall coordination and oversight of Vifor International
(and any affiliates or sublicensees). The Company’s membership on the JCC is at its sole discretion and is not its
obligation.
After the assignment of rights of Vifor Agreement No. 1 from Vifor International to Vifor Fresenius Medical Care
Renal Pharma Ltd. in May 2022, Vifor Agreement No. 1 provides full commercialization rights in dialysis clinics to CSL
Vifor in the United States under a profit-sharing arrangement. Pursuant to the profit-sharing arrangement, the Company is
generally entitled to 60% of the net profits (as defined in Vifor Agreement No. 1) from sales of difelikefalin injection in the
United States and CSL Vifor is entitled to 40% of such net profits (excluding sales to Fresenius Medical Center dialysis
clinics, compensation for which is governed by Vifor Agreement No. 2, as defined below), subject to potential temporary
adjustment in future years based on certain conditions. Under Vifor Agreement No. 1, in consideration of CSL Vifor’s
conduct of the marketing, promotion, selling and distribution of difelikefalin injection in the United States, the Company
pays a marketing and distribution fee to CSL Vifor based on the level of annual net sales. This fee as well as CSL Vifor’s
COGS are deducted from net sales in calculating the net profits that are subject to the profit-sharing arrangement under
Vifor Agreement No. 1.
After U.S. regulatory approval of KORSUVA injection in August 2021, the Company received $50,000 in October
2021 for the purchase of an aggregate of 3,282,391 shares of the Company’s common stock at a price of $15.23 per share,
which represented a 20% premium to the 30-day trailing average price of the Company’s common stock as of the date of
the achievement of the milestone. The purchase of the Company’s common stock was governed by a separate stock
purchase agreement, or the Vifor Stock Purchase Agreement. The excess of the stock purchase price over the cost of the
purchased shares at the closing price of the Company’s common stock on the date of the achievement of the milestone of
$5,031 was included as license and milestone fees revenue for accounting purposes (see Note 14, Revenue Recognition –
License and Milestone Fees).
In addition, pursuant to Vifor Agreement No. 1, the Company is eligible to receive payments of up to $240,000 from
CSL Vifor upon the achievement of certain sales-based milestones.
The license also requires CSL Vifor to promote and take orders for difelikefalin injection, or Licensed Product,
throughout the United States, including coordinating with CSL Vifor promotional activities to FMC U.S. Dialysis Clinics
which are subject to the Company’s rights under Vifor Agreement No. 2. The license also allows CSL Vifor to grant sub-
licenses, which, in certain cases, requires the Company’s prior written consent. The Company retains the rights to import,
distribute, promote, sell and otherwise commercialize the Licensed Product on an exclusive basis outside of the Field either
in or outside of the United States.
The Company retains the rights to make and have made the Licensed Product, on a non-exclusive basis, in the United
States for commercial sale of the Licensed Product for use for all therapeutic uses to prevent, inhibit or treat itch associated
with pruritus in hemodialysis and peritoneal-dialysis patients, or the Field, anywhere in the world and for supply of
Licensed Product to CSL Vifor under the terms of a supply agreement, or the Vifor International Supply Agreement, which
was executed in September 2021. The supply price is the Company’s COGS, as calculated under GAAP, plus an agreed
upon margin. The Vifor International Supply Agreement will co-terminate with Vifor Agreement No. 1.
The Vifor International Supply Agreement is accounted for as a customer option that is not a material right because
the selling price of the Licensed Product under the Vifor International Supply Agreement is the Company’s COGS plus an
agreed upon margin, which is commensurate with the “COGS plus” model that the Company would
121
Table of Contents
CARA THERAPEUTICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(amounts in thousands, except share and per share data)
charge other parties under similar agreements (the standalone selling price) and not at a discount. Therefore, the sale of
commercial supply to CSL Vifor is not a performance obligation under Vifor Agreement No. 1 but rather the Vifor
International Supply Agreement is a separate agreement from Vifor Agreement No. 1. The only performance obligation
under the Vifor International Supply Agreement is the delivery of the Licensed Product to CSL Vifor for
commercialization.
Vifor Agreement No. 1 will continue in effect until its expiration upon the cessation of commercial sale of
difelikefalin injection in the United States by CSL Vifor and its affiliates and sublicensees, or until the earlier termination
of Vifor Agreement No. 1.
Vifor Agreement No. 1 may be terminated earlier by either party for material breach that is not cured within 60 days,
bankruptcy by either party and by both parties upon mutual written consent. The Company may terminate Vifor Agreement
No. 1 if CSL Vifor challenges the validity of any licensed patent rights, except if such patent challenge results from the
Company’s action against CSL Vifor for infringement of any licensed patent in the United States. In addition, upon the
earlier of (1) the acceptance for filing of an NDA covering Licensed Product filed with the FDA (after completion of the
Phase 3 program) or (2) the third anniversary of the Effective Date, Vifor Agreement No. 1 may be terminated by CSL
Vifor in its entirety upon written notice to the Company. Such termination will be effective twelve months following the
date of such notice.
Vifor Fresenius Medical Care Renal Pharma Ltd.
In May 2018, the Company entered into a license agreement with Vifor Fresenius Medical Care Renal Pharma Ltd.,
or Vifor Agreement No. 2, under which the Company granted Vifor Fresenius Medical Care Renal Pharma Ltd. an
exclusive, royalty-bearing license, or the Vifor License, to seek regulatory approval to commercialize, import, export, use,
distribute, offer for sale, promote, sell and otherwise commercialize the Licensed Product in the Field worldwide
(excluding the United States, Japan and South Korea), or the Territory. Vifor Fresenius Medical Care Renal Pharma Ltd.
cannot perform development activities on their own unless specifically allocated to Vifor Fresenius Medical Care Renal
Pharma Ltd. by the Joint Development Committee, or JDC, and Joint Steering Committee, or JSC. The Company’s
membership on the JSC or JDC is at its sole discretion and is not its obligation.
The Company was responsible, at its own cost, to undertake clinical and non-clinical development, or the R&D
services. The Company was also responsible to provide all content and subject matter expertise required for registration
with the European Medicines Agency, or EMA, in the EU that will be needed by Vifor Fresenius Medical Care Renal
Pharma Ltd. for such registration, including participation in regulatory meetings, as needed. CSL Vifor contributed, at its
own cost, its clinical development expertise as reasonably useful for such development activities, such as preparing the
clinical results that the Company presents to it in a format acceptable to the EMA to obtain marketing approval in the EU.
As a result of the European Commission’s regulatory approval of Kapruvia in April 2022, the Company received a
$15,000 regulatory milestone payment from Vifor Fresenius Medical Care Renal Pharma Ltd. under Vifor Agreement No.
2 during the year ended December 31, 2022. In addition, after U.S. regulatory approval of KORSUVA injection in August
2021, the Company earned a $15,000 regulatory milestone payment from Vifor Fresenius Medical Care Renal Pharma Ltd.
under Vifor Agreement No. 2 during the year ended December 31, 2021.
The Company is eligible to receive from Vifor Fresenius Medical Care Renal Pharma Ltd. additional commercial
milestone payments in the aggregate of up to $440,000, all of which are sales related. The Company is also eligible to
receive tiered double-digit royalty payments based on annual net sales, as defined in Vifor Agreement No. 2, of
difelikefalin injection in the licensed territories. The Company retains full commercialization rights for difelikefalin
injection for the treatment of CKD-aP in the United States except in the dialysis clinics of FMCNA, where Vifor
122
Table of Contents
CARA THERAPEUTICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(amounts in thousands, except share and per share data)
Fresenius Medical Care Renal Pharma Ltd. promotes difelikefalin injection under a profit-sharing arrangement (as defined
in Vifor Agreement No. 2) based on net FMCNA clinic sales (as defined in Vifor Agreement No. 2) and Vifor Fresenius
Medical Care Renal Pharma Ltd. is entitled to 50% of such net profits, subject to potential adjustments in a calendar year
based on certain conditions.
The license also requires Vifor Fresenius Medical Care Renal Pharma Ltd. to promote and take orders in the United
States for sale by the Company to FMC U.S. Dialysis Clinics and allows Vifor Fresenius Medical Care Renal Pharma Ltd.
to grant sub-licenses, which, in certain cases, requires the Company’s prior written consent. The Company retains the rights
to import, distribute, promote, sell and otherwise commercialize the Licensed Product outside of the Field and outside of
the Territory.
The Company retains the rights to make and have made the Licensed Product in the Territory for commercial sale by
Vifor Fresenius Medical Care Renal Pharma Ltd. in the Field in or outside the Territory and for supply of Licensed Product
to Vifor Fresenius Medical Care Renal Pharma Ltd. under the terms of a supply agreement, or the Vifor Supply Agreement,
which was executed in May 2020. The supply price is the Company’s COGS, as calculated under U.S. GAAP, plus an
agreed upon margin. The Vifor Supply Agreement will co-terminate with the Vifor Agreement No. 2.
The Vifor Supply Agreement is accounted for as a customer option that is not a material right because the selling
price of the Licensed Product under the Vifor Supply Agreement is the Company’s COGS plus an agreed upon margin,
which is commensurate with the “COGS plus” model that the Company would charge other parties under similar
agreements (the standalone selling price) and not at a discount. Therefore, the sale of clinical compound to Vifor Fresenius
Medical Care Renal Pharma Ltd. is not a performance obligation under Vifor Agreement No. 2 but rather the Vifor Supply
Agreement is a separate agreement from Vifor Agreement No. 2. The only performance obligation under the Vifor Supply
Agreement is the delivery of the Licensed Product to Vifor Fresenius Medical Care Renal Pharma Ltd. for
commercialization.
Vifor Agreement No. 2 terminates upon the expiration of all royalty terms with respect to the Licensed Products,
which expire on a Product-by-Product and country-by-country basis, at the latest of (a) the expiration of all patent rights
licensed to Vifor Fresenius Medical Care Renal Pharma Ltd. covering such Licensed Product; (b) the expiration of all
regulatory and data exclusivity applicable to such Licensed Product in such country and (c) the tenth anniversary of the
first commercial sale of such Product in such country.
Vifor Agreement No. 2 may be terminated earlier by either party for material breach that is not cured within 60 days,
bankruptcy by either party and by both parties upon mutual written consent. The Company may terminate Vifor Agreement
No. 2 if Vifor Fresenius Medical Care Renal Pharma Ltd. challenges the validity of any licensed patent rights, except if
such patent challenge results from the Company’s action against Vifor Fresenius Medical Care Renal Pharma Ltd. for
infringement of any licensed patent in the Territory. In addition, upon the earlier of (1) the acceptance for filing of an NDA
covering Licensed Product filed with the FDA (after completion of the Phase 3 program) or (2) the third anniversary of the
Effective Date, Vifor Agreement No. 2 may be terminated by Vifor Fresenius Medical Care Renal Pharma Ltd. in its
entirety or with respect to any countries within the Territory upon written notice to the Company. Such termination will be
effective twelve months following the date of such notice.
If Vifor Agreement No. 2 terminates early for any reason stated above, Vifor Fresenius Medical Care Renal Pharma
Ltd.’s licenses will terminate, Vifor Fresenius Medical Care Renal Pharma Ltd.’s rights to use the Company’s confidential
information and the Company’s know-how will revert to the Company and Vifor Fresenius Medical Care Renal Pharma
Ltd. will assign and transfer to the Company all right, title and interest in all regulatory applications (IND’s and NDA’s),
regulatory approval applications and regulatory approvals in the Territory covering Licensed Product.
123
Table of Contents
CARA THERAPEUTICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(amounts in thousands, except share and per share data)
Maruishi Pharmaceutical Co., Ltd. (Maruishi)
In April 2013, the Company entered into a license agreement with Maruishi, or the Maruishi Agreement, under
which the Company granted Maruishi an exclusive license to develop, manufacture, and commercialize drug products
containing difelikefalin for acute pain and/or uremic pruritus in Japan. Maruishi has the right to grant sub-licenses in Japan,
which entitles the Company to receive sub-license fees, net of prior payments made by Maruishi to the Company. Under
the Maruishi Agreement, the Company and Maruishi are required to use commercially reasonable efforts, at their own
expense, to develop, obtain regulatory approval for and commercialize difelikefalin in the United States and Japan,
respectively. In addition, the Company provided Maruishi specific clinical development services for difelikefalin used in
Maruishi’s field of use.
Under the terms of the Maruishi Agreement, the Company is eligible to receive milestone payments upon the
achievement of defined clinical and regulatory events as well as tiered, low double-digit royalties with respect to any sales
of the licensed product sold in Japan by Maruishi, if any, and share in any sub-license fees.
The Maruishi Agreement continues until terminated. Either the Company or Maruishi may terminate the Maruishi
Agreement for the other party’s breach of the agreement or bankruptcy. Maruishi may terminate the agreement at any time
at will. The Company may terminate the agreement as a whole if Maruishi challenges the licensed patent rights, and it may
terminate the agreement with respect to any indication if Maruishi discontinues its development activities.
In September 2022, Maruishi submitted a New Drug Application in Japan for approval of difelikefalin injection for
the treatment of pruritus in hemodialysis patients. In September 2023, Maruishi received manufacturing and marketing
approval from Japan’s Ministry of Health, Labour and Welfare for KORSUVA IV Injection Syringe for the treatment of
pruritus in hemodialysis patients. In conjunction with the approval, the Company earned a $1,449 milestone payment per
the terms of the licensing agreement (see Note 14, Revenue Recognition). In November 2023, the Company entered into an
API supply agreement with Maruishi for difelikefalin.
Chong Kun Dang Pharmaceutical Corporation (CKDP)
In April 2012, the Company entered into a license agreement with CKDP, or the CKDP Agreement, in South Korea,
under which the Company granted CKDP an exclusive license to develop, manufacture and commercialize drug products
containing difelikefalin in South Korea. The Company and CKDP are each required to use commercially reasonable
efforts, at their respective expense, to develop, obtain regulatory approval for and commercialize difelikefalin in the United
States and South Korea, respectively.
Under the terms of the CKDP Agreement, the Company is eligible to receive milestone payments upon the
achievement of defined clinical and regulatory events as well as tiered royalties, with percentages ranging from the high
single digits to the high teens, based on net sales of products containing difelikefalin in South Korea, if any, and share in
any sub-license fees.
The CKDP Agreement continues until CKDP no longer has any obligation to pay the Company royalties on any
product. Either the Company or CKDP may terminate the CKDP Agreement for the other party’s breach of the CKDP
Agreement or bankruptcy. CKDP may terminate the CKDP Agreement if any of the licensed patent rights is invalid,
unenforceable, is narrowed in scope or is deemed unpatentable, except as a result of a challenge by CKDP, or a third party
commercializes a product containing a compound identical to difelikefalin without infringing any of the licensed patent
rights in South Korea. The Company may terminate the CKDP Agreement if CKDP challenges the licensed patent rights or
if a third party in South Korea owns an issued patent that claims difelikefalin and CKDP’s sale of products would infringe
that patent.
124
Table of Contents
14. Revenue Recognition
CARA THERAPEUTICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(amounts in thousands, except share and per share data)
The Company has primarily recognized revenue under its license and collaboration agreements from (1) its share of
the profit generated by KORSUVA injection sales in the United States; (2) upfront license fees and milestone payments,
including development and regulatory milestones; (3) commercial supply revenue from CSL Vifor; (4) royalty revenue
from net sales of Kapruvia; and (5) clinical compound sales from certain license agreements. As of December 31, 2023, the
Company has not earned any sales-based milestones under its collaboration agreements.
As of December 31, 2023, the Company had license and collaboration agreements with CSL Vifor, Maruishi and
CKDP. The following table provides amounts included in the Company’s Consolidated Statements of Comprehensive Loss
as revenue for the years ended December 31, 2023, 2022 and 2021:
Collaborative revenue
CSL Vifor (KORSUVA injection profit sharing)
Maruishi
Total collaborative revenue
Commercial supply revenue
CSL Vifor* (KORSUVA injection)
Total commercial supply revenue
License and milestone fees
CSL Vifor*
Maruishi
Total license and milestone fees
Royalty revenue
CSL Vifor (Kapruvia ex U.S.)
Total royalty revenue
Clinical compound revenue
CSL Vifor* (difelikefalin injection)
Maruishi
Total clinical compound revenue
Other revenue (non-cash)
CSL Vifor (Kapruvia ex U.S.)
Maruishi
$
$
$
$
$
$
$
$
$
$
$
2023
Year Ended December 31,
2022
2021
12,397
539
12,936
5,843
5,843
$
$
$
$
— $
910
910
$
415
415
$
$
— $
165
165
$
16,572
—
16,572
10,223
10,223
15,000
—
15,000
72
72
$
$
$
$
$
$
$
$
— $
—
— $
—
706
706
701
701
20,031
1,192
21,223
—
—
361
37
398
284
415
699
$
$
— $
—
— $
—
—
—
Total other revenue
_____________________________
* Includes amounts earned from Vifor Fresenius Medical Care Renal Pharma Ltd. and Vifor International prior to Vifor
International’s assignment of its rights and obligations to Vifor Fresenius Medical Care Renal Pharma Ltd. in May 2022.
$
Collaborative revenue
Beginning in April 2022, the Company began recording its share of the profit generated by KORSUVA injection
sales by CSL Vifor to third parties in the United States. Under the license agreements with CSL Vifor, KORSUVA
injection net sales are calculated by CSL Vifor which are net of discounts, rebates, and allowances. These amounts include
the use of estimates and judgments, which could be adjusted based on actual results in the future. The Company records its
share of the net profits from the sales of KORSUVA injection in the United States on a net basis (since the Company is not
the primary obligor and does not retain inventory risk) and presents the revenue earned each period as
125
Table of Contents
CARA THERAPEUTICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(amounts in thousands, except share and per share data)
collaborative revenue. During the years ended December 31, 2023 and 2022, the Company recorded $12,397 and $16,572,
respectively, as collaborative revenue for its profit-share from the sales of KORSUVA injection in the United States. There
was no profit share revenue recorded during the year ended December 31, 2021.
The Company’s distinct performance obligations under the Maruishi Agreement included transfer of the license to
the Company’s IP, which allowed Maruishi to develop and commercialize difelikefalin, for acute pain and uremic pruritus
indications in Japan, which occurred at inception of the contract in 2013 (considered license and milestone fees revenue),
and performance of R&D services, which occurred from 2013 to 2015 (considered collaborative revenue), as those services
were rendered. The Company agreed to conduct limited work on an oral tablet formulation of difelikefalin and to conduct
Phase 1 and proof-of-concept Phase 2 clinical trials of an intravenous formulation of difelikefalin to be used to treat
patients with uremic pruritus. The Company agreed to transfer the data and information from such development to
Maruishi for its efforts to obtain regulatory approval in Japan. These activities are referred to as R&D services and were
included as collaborative revenue.
In addition, the Company’s promise in the Maruishi Agreement to transfer the license is separately identifiable from
the promise to provide defined R&D services (i.e., distinct within the context of the contract) because the Company was
not using the goods or services as inputs to produce or deliver the combined output or outputs specified by the customer.
The combined output specified by Maruishi is its right to conduct development activities related to difelikefalin in Japan,
which could result in regulatory approval in Japan. That right is derived from the Company’s grant of the license. Maruishi
is conducting clinical trials on its own and does not require the R&D services provided by the Company. Furthermore, the
R&D services do not significantly modify or customize the license and vice versa. Finally, the license and R&D services
were not highly interdependent or highly interrelated because the Company was able to fulfill its promise to transfer the
initial license independently from its promise to subsequently provide the R&D services, which Maruishi can obtain on its
own. There were no remaining performance obligations under the Maruishi Agreement as of December 31, 2023.
During the year ended December 31, 2023, the criteria for revenue recognition for a regulatory milestone event set
forth in the Maruishi Agreement was achieved, and the Company earned $1,449, of which $539 was recorded as
collaborative revenue based on the relative standalone selling prices described at contract inception. This regulatory
milestone payment was considered variable consideration due to the uncertainty of occurrence of this event as specified at
inception of the agreement. Therefore, this potential regulatory milestone payment was not included in the transaction price
at the inception of the agreement. There was no collaborative revenue recognized under the Maruishi Agreement during the
year ended December 31, 2022. During the year ended December 31, 2021, the criteria for revenue recognition for a
milestone event set forth in the Maruishi Agreement was achieved, and the Company recorded $706 as collaborative
revenue based on the relative standalone selling prices described above at contract inception (see Note 2, Summary of
Significant Accounting Policies – Revenue Recognition).
Commercial supply revenue
Under the Vifor International Supply Agreement, the Company’s only performance obligation is the delivery of
KORSUVA injection to CSL Vifor in accordance with the receipt of purchase orders. Revenue from the sale of commercial
supply product to CSL Vifor is recognized as delivery of the Licensed Product occurs. The Company had commercial
supply revenue of $5,843 with associated COGS of $6,174 since these inventory costs were capitalized as inventory
subsequent to regulatory approval. The Company had commercial supply revenue of $10,223 for the year ended December
31, 2022, of which $2,295 was recognized in January 2022 with no associated COGS since these inventory costs were
incurred prior to regulatory approval on August 23, 2021, and $7,928 was recognized throughout the remainder of 2022
with associated COGS of $7,266 since these inventory costs were capitalized as inventory subsequent to regulatory
approval.
126
Table of Contents
CARA THERAPEUTICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(amounts in thousands, except share and per share data)
The Company had $701 of commercial supply revenue for the year ended December 31, 2021 with no associated
COGS since these inventory costs were incurred prior to regulatory approval on August 23, 2021.
License and milestone fees revenue
Under Vifor Agreement No. 2, the Company identified two performance obligations at contract inception in 2018:
(1) granting of the license to CSL Vifor, and (2) the R&D services. The Company determined that these two performance
obligations were not capable of being distinct (i.e., did not have standalone value for CSL Vifor) because CSL Vifor could
not benefit (derive potential cash flows) from either one on its own or together with other resources that are readily
available to it since CSL Vifor was relying on the Company’s expertise in investigating chronic kidney disease-associated
pruritus, or CKD-aP, and its know-how obtained from multiple years of pre-clinical and clinical development, and years of
interactions with the FDA which other companies or CROs would not have. The license to CSL Vifor did not provide
benefit to CSL Vifor until and unless the Company conducted the pivotal clinical trials and other supportive trials in CKD-
aP to gather sufficient clinical data for CSL Vifor to obtain marketing approval in the Territory. Furthermore, CSL Vifor
did not have the right to perform development activities on its own unless specifically allocated by the JDC or JSC.
The two identified performance obligations were also not distinct within the context of the contract, (i.e., were not
separately identifiable from each other) because of the nature of the promise within the context of the contract. The nature
of the promise was to transfer a combined deliverable to CSL Vifor based on the agreement (to support the ability of CSL
Vifor to commercialize the Licensed Product) and the Company determined that the license granted to CSL Vifor and the
R&D services are inputs rather than a transfer of each of these goods and services individually. In addition, the two
identified performance obligations were highly interrelated and interdependent because satisfaction of both performance
obligations was required for CSL Vifor to derive benefit from Vifor Agreement No. 2 for commercialization of the
Licensed Product in the Territory. Therefore, the two performance obligations were not distinct from each other and were
accounted for as a single performance obligation.
After U.S. regulatory approval of KORSUVA injection in August 2021, the Company achieved a $15,000 regulatory
milestone payment and was recorded as license and milestone fees revenue for the year ended December 31, 2021, since
this regulatory milestone payment was considered variable consideration at contract inception, was not included in the
transaction price at the inception of the agreement and was allocated to the one performance obligation identified at
contract inception (see Note 2, Summary of Significant Accounting Policies – Revenue Recognition).
In addition, after U.S. regulatory approval of KORSUVA injection in August 2021, the Company received an
additional $50,000 in October 2021 for the purchase of an aggregate of 3,282,391 shares of the Company’s common stock
at a price of $15.23 per share, which represented a 20% premium to the 30-day trailing average price of the Company’s
common stock as of the date of the achievement of the milestone. The excess of the stock purchase price over the cost of
the purchased shares at the closing price of the Company’s common stock on the date of the achievement of the milestone
of $5,031 was allocated to the one performance obligation identified at contract inception and included as license and
milestone fees revenue for the year ended December 31, 2021 (see Note 2, Summary of Significant Accounting Policies –
Revenue Recognition).
As a result of the European Commission’s regulatory approval of Kapruvia in April 2022, the Company received a
$15,000 regulatory milestone payment from CSL Vifor under Vifor Agreement No. 2, which was recorded as license and
milestone fees revenue for the year ended December 31, 2022, since this regulatory milestone payment was considered
variable consideration at contract inception, was not included in the transaction price at the inception of the agreement and
was allocated to the one combined performance obligation identified at contract inception (see Note 2, Summary of
Significant Accounting Policies – Revenue Recognition).
127
Table of Contents
CARA THERAPEUTICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(amounts in thousands, except share and per share data)
During the year ended December 31, 2023, the criteria for revenue recognition for a regulatory milestone event set
forth in the Maruishi Agreement was achieved and the Company earned $1,449, of which $910 was recorded as license and
milestone fees revenue based on the relative standalone selling prices described at contract inception. This regulatory
milestone payment was considered variable consideration due to the uncertainty of occurrence of this event as specified at
inception of the agreement. Therefore, this potential regulatory milestone payment was not included in the transaction price
at the inception of the agreement. There were no license and milestone fees revenue recognized under the Maruishi
Agreement during the year ended December 31, 2022. During the year ended December 31, 2021, the criteria for revenue
recognition for a milestone event set forth in the Maruishi Agreement was achieved, and the Company recorded $1,192 as
license and milestone fees revenue based on the relative standalone selling prices described above at contract inception (see
Note 2, Summary of Significant Accounting Policies – Revenue Recognition).
Royalty revenue
Royalty revenue includes amounts related to the Company’s royalties earned from CSL Vifor on the net sales of
Kapruvia in Europe, based on the amount of net sales in a licensed territory during a calendar year. Sales-based royalty
payments related to a license of IP are recognized as revenue when the respective sales occur, and the net sales tier is
achieved. The Company recognized royalty revenue of approximately $415 and $72 for the years ended December 31,
2023 and 2022, respectively, which were related to the Company’s royalties on the net sales of Kapruvia in Europe prior to
October 1, 2023. There was no royalty revenue for the year ended December 31, 2021.
Beginning on October 1, 2023, royalty revenue will no longer be recognized until the Company has fulfilled its
obligations under the HCR Agreement (see Note 10, Royalty Purchase and Sale Agreement).
Clinical compound revenue
The Company’s only performance obligation under the supply agreement with Maruishi is to deliver clinical
compound to Maruishi in accordance with the receipt of purchase orders. During the years ended December 31, 2023 and
2021, the Company recognized clinical compound revenue of $165 and $37, respectively, from the sale of clinical
compound to Maruishi. There were no sales of clinical compound to Maruishi during the year ended December 31, 2022.
The Company’s only performance obligation under the Vifor Supply Agreement is to deliver compound to CSL Vifor
in accordance with the receipt of purchase orders. There were no sales of clinical compound under the Vifor Supply
Agreement during the years ended December 31, 2023 and 2022. During the year ended December 31, 2021, the Company
recognized clinical compound revenue of $361 from the sale of clinical compound to CSL Vifor.
Other revenue
The Company recorded other non-cash revenue of $699 which represents the royalty and milestone payments earned
by the Company under Vifor Agreement No. 2 and the Maruishi Agreement during the fourth quarter of 2023 in
conjunction with ex-U.S. sales of KORSUVA/Kapruvia, which will be remitted to HCR under the terms of the HCR
Agreement. This non-cash revenue will continue to be recorded until the Company has fulfilled its obligations under the
HCR Agreement (see Note 10, Royalty Purchase and Sale Agreement).
Contract balances
As of December 31, 2023 and 2022, the Company recorded accounts receivable, net – related party of $2,765 and
$3,260 which primarily related to its profit-sharing revenue from sales of KORSUVA injection in the United States by CSL
Vifor, its commercial supply of KORSUVA injection to CSL Vifor, and royalty payments from CSL Vifor. The Company
also recorded other receivables of $415 which related to royalty payments from Maruishi. There were no other
128
Table of Contents
CARA THERAPEUTICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(amounts in thousands, except share and per share data)
contract assets or contract liabilities related to the CSL Vifor, Maruishi and CKDP agreements as of December 31, 2023
and December 31, 2022.
The Company routinely assesses the creditworthiness of its license and collaboration partners. The Company has not
experienced any losses related to receivables from its license and collaboration partners as of December 31, 2023 and
December 31, 2022.
15. Stock-Based Compensation
2019 Inducement Plan
In October 2019, the Company’s Board of Directors adopted the 2019 Inducement Plan, or the 2019 Plan, which is a
non-stockholder approved stock plan adopted pursuant to the “inducement exception” provided under Nasdaq Listing Rule
5635(c)(4), or Rule 5635, for the purpose of awarding (i) non-statutory stock options, (ii) restricted stock awards, (iii)
restricted stock unit awards, (iv) other stock awards (collectively, the Inducement Awards) to new employees of the
Company, as inducement material to such new employees entering into employment with the Company. In November
2019, the Company filed a Registration Statement on Form S-8 with the SEC covering the offering of up to 300,000 shares
of its common stock, par value $0.001, pursuant to the Company’s 2019 Plan. No stock options were granted under the
2019 Plan during the years ended December 31, 2023, 2022 and 2021. Initial grants of Inducement Awards made to
employees vest as to 25% on the first anniversary of the date of grant and the balance ratably over the next 36 months and
subsequent grants vest monthly over a period of four years from the grant date. As of December 31, 2023, 300,000 shares
remained available for grant pursuant to the Plan.
2014 Equity Incentive Plan
The Company’s 2014 Equity Incentive Plan, or the 2014 Plan, is administered by the Company’s Board of Directors
or a duly authorized committee thereof, referred to as the Plan administrator. The 2014 Plan provides for the grant of
incentive stock options, non-statutory stock options, restricted stock awards, restricted stock unit awards, stock
appreciation rights, performance stock awards and other forms of equity compensation, collectively referred to as Stock
Awards. Additionally, the 2014 Plan provides for the grant of performance cash awards. Incentive stock options may be
granted only to employees. All other awards may be granted to employees, including officers, non-employee directors, and
consultants. No incentive stock options may be granted under the 2014 Plan after the tenth anniversary of the effective date
of the 2014 Plan. Stock Awards granted under the 2014 Plan vest at the rate specified by the Plan administrator. Initial
grants of Stock Awards made to employees and non-employee consultants generally vest as to 25% on the first anniversary
of the date of grant and the balance ratably over the next 36 months and subsequent grants vest monthly over a period of
four years from the grant date. Stock options initially granted to members of the Company’s Board of Directors vest over a
period of three years in equal quarterly installments from the date of the grant, subject to the option holder’s continued
service as a Director through such date. Subsequent grants to Directors that are made automatically at Annual Meetings of
Stockholders vest fully on the earlier of the first anniversary of the date of grant and the next Annual Meeting of
Stockholders. The Plan administrator determines the term of Stock Awards granted under the 2014 Plan up to a maximum
of ten years.
129
Table of Contents
CARA THERAPEUTICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(amounts in thousands, except share and per share data)
The aggregate number of shares of the Company’s common stock reserved for issuance under the 2014 Plan has
automatically increased on January 1 of each year, beginning on January 1, 2015 and will continue to increase on January 1
of each year through and including January 1, 2024, by 3% of the total number of shares of the Company’s capital stock
outstanding on December 31 of the preceding calendar year, or a lesser number of shares determined by the Company’s
Board of Directors. On January 1, 2024, the aggregate number of shares of common stock that may be issued pursuant to
Stock Awards under the 2014 Plan automatically increased from 12,203,023 to 13,837,444. The maximum number of
shares that may be issued pursuant to the exercise of incentive stock options under the 2014 Plan is 30,000,000 shares.
Restricted Stock Units
Pursuant to the Company’s non-employee director compensation policy, an aggregate of 194,172 restricted stock
units were granted to non-employee directors on June 1, 2023, the date of the Company’s 2023 Annual Meeting of
Stockholders, under the 2014 Plan with a grant date fair value of $3.09 per share. The restricted stock units will vest on the
earlier of (i) June 1, 2024 and (ii) immediately prior to the Company’s next Annual Meeting of Stockholders following the
grant date, subject to the recipient’s continued service through such date. As a result, the Company recognizes
compensation expense associated with these restricted stock units ratably over the one-year vesting period following the
grant date. For the year ended December 31, 2023, stock compensation expense associated with these awards of $292 was
recognized in general and administrative expense, or G&A expense. In November 2023, 32,362 of these restricted stock
units were forfeited as a result of the retirement of a member of the Company’s Board of Directors. As of December 31,
2023, 161,810 restricted stock units were outstanding and available to vest and settle in shares of the Company’s common
stock.
On March 1, 2023, the Compensation Committee of the Company’s Board of Directors, or the Compensation
Committee, approved and granted a total of 407,000 restricted stock units to certain employees under the 2014 Plan with a
grant date fair value of $10.06 per share. Vesting of the restricted stock units is contingent on the achievement of certain
performance targets, subject to the recipient’s continuous service through each performance target. Recognition of
compensation expense associated with these awards begins when, and to the extent, the performance criteria are probable
of achievement and the employee has met the service conditions. For the year ended December 31, 2023, no stock
compensation expense relating to these restricted stock units was recognized. In December 2023, 168,150 of these
restricted stock units were forfeited as the performance targets associated with them were not achieved. As of December
31, 2023, 238,850 restricted stock units were outstanding and available to vest and settle in shares of the Company’s
common stock.
On October 12, 2022, the Compensation Committee of the Company’s Board of Directors, or the Compensation
Committee, approved and granted a total of 7,267 time-based restricted stock units under the 2014 Plan, with a grant date
fair value of $9.42 per share, to an executive officer of the Company. The restricted stock unit grant fully vests on August
31, 2023, subject to the recipient’s continued service through such date. For the years ended December 31, 2023 and 2022,
the Company recognized $51 and $17, respectively, of stock compensation expense associated with these awards, all of
which was recorded within G&A expense. As of December 31, 2023, none of these restricted stock units were outstanding
as these restricted stock units vested fully in August 2023.
On June 15, 2022, the Compensation Committee approved and granted a total of 7,500 time-based restricted stock
units to the Company’s interim principal financial officer and principal accounting officer, as a result of his assuming the
responsibilities of the Company’s former Chief Financial Officer, or CFO, on an interim basis, under the 2014 Plan with a
grant date fair value of $7.94 per share. The Company accelerated the recognition of compensation expense and the
restricted stock units vested fully on September 12, 2022, when the appointment of the Company’s new CFO occurred. For
the year ended December 31, 2022, the Company recognized $60 of stock compensation expense associated with these
awards, all of which was recorded within G&A expense. As of December 31, 2023, none of these restricted stock units
were outstanding as these restricted stock units vested fully in September 2022.
130
Table of Contents
CARA THERAPEUTICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(amounts in thousands, except share and per share data)
Pursuant to the Company’s non-employee director compensation policy, an aggregate of 59,380 restricted stock units
were granted to non-employee directors on June 2, 2022, the date of the Company’s 2022 Annual Meeting of Stockholders,
under the 2014 Plan with a grant date fair value of $8.42 per share. These restricted stock unit grants fully vested on June 2,
2023. As a result, the Company recognizes compensation expense associated with these restricted stock units ratably over
the one-year vesting period following the grant date. For the years ended December 31, 2023 and 2022, stock
compensation expense of $209 and $290, respectively, was recognized in G&A expense. As of December 31, 2023, none
of these restricted stock units were outstanding as these restricted stock units vested fully on June 2, 2023. Also in June
2022, the Company granted 11,876 fully vested restricted stock units, which were immediately settled in shares of common
stock, to the Company’s chairman in consideration of his effort in connection with the Company’s CEO transition in 2021.
For the year ended December 31, 2022, stock compensation expense of $100 was recognized in G&A expense associated
with this award.
On February 25, 2022, the Compensation Committee also approved and granted a total of 243,000 restricted stock
units to certain employees under the 2014 Plan with a grant date fair value of $10.46 per share. Vesting of the restricted
stock units was contingent on the achievement of certain performance targets related to commercial milestones, subject to
the recipient’s continuous service through each performance target. Recognition of compensation expense associated with
these awards began when, and to the extent, the performance criteria are probable of achievement and the employee has
met the service conditions. For the year ended December 31, 2022, no stock compensation expense relating to these
restricted stock units was recognized. In June 2022, 29,000 of these restricted stock units were forfeited as a result of the
resignation of the Company’s former CFO. In December 2022, 214,000 of these restricted stock units were forfeited as the
performance targets associated with them were not achieved. As of December 31, 2023, none of these restricted stock units
were outstanding as they were forfeited in 2022.
Additionally on February 25, 2022, the Compensation Committee also approved and granted a total of 145,170 time-
based restricted stock units to certain employees under the 2014 Plan with a grant date fair value of $10.46 per share. The
restricted stock units vest in three equal installments annually from the date of the grant. As a result, the Company
recognizes compensation expense associated with these restricted stock units ratably over the three-year vesting period
following the grant date. In April 2023, 3,585 of these restricted stock units were forfeited. In February 2023, 42,920 of
these restricted stock units vested and were settled in shares of the Company’s common stock in satisfaction of the first
year of vesting. In June 2022, 20,000 of these restricted stock units were forfeited as a result of the resignation of the
Company’s former CFO. For the years ended December 31, 2023 and 2022, the Company recognized $406 and $390,
respectively, of stock compensation expense associated with these awards, with $135 recorded in R&D expense and $271
recorded in G&A expense for the 2023 period, and $161 recorded in R&D expense and $229 in G&A expense for the 2022
period. As of December 31, 2023, 78,665 restricted stock units were outstanding and available to vest and settle in shares
of the Company’s common stock.
On December 17, 2021, the Compensation Committee approved and granted a total of 63,573 time-based restricted
stock units to certain executive officers under the 2014 Plan with a grant date fair value of $12.45 per share. The restricted
stock units vested in two equal installments on December 15, 2022 and June 15, 2023. As a result, the Company
recognized compensation expense associated with these restricted stock units ratably over the 18-month vesting period
following the grant date. On June 15, 2023, 26,199 of these restricted stock units fully vested and were settled in shares of
the Company’s common stock. In December 2022, an aggregate of 26,204 of these restricted stock units vested and were
settled in shares of the Company’s common stock. In June 2022, 11,170 of these restricted stock units were forfeited as a
result of the resignation of the Company’s former CFO. For the years ended December 31, 2023, 2022 and 2021, the
Company recognized $199, $433 and $20, respectively, of stock compensation expense, with $96 recorded in R&D
expense and $103 recorded in G&A expense for the 2023 period, $210 recorded in R&D expense and $223 recorded in
G&A expense for the 2022 period, and $8 recorded in R&D expense and $12 in G&A expense for the 2021 period. As of
December 31, 2023, none of these restricted stock units were outstanding as these restricted stock units fully vested in June
2023.
131
Table of Contents
CARA THERAPEUTICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(amounts in thousands, except share and per share data)
On October 29, 2021, the Compensation Committee also approved and granted 147,942 time-based restricted stock
units in connection with the appointment of the Company’s new Chief Executive Officer, or CEO, under the 2014 Plan
with a grant date fair value of $16.83 per share. The first tranche of 142,000 restricted stock units vested 25% on the first
anniversary of the date of grant and the balance vests quarterly over the next 36 months. The Company recognizes
compensation expense associated with these two restricted stock unit tranches ratably over their respective vesting periods
following the grant date. During the year ended December 31, 2023, 35,500 of these restricted stock units vested and were
settled in shares of the Company’s common stock in satisfaction of the quarterly periods of vesting. In addition, 35,500 of
these restricted stock units vested and were settled in shares of the Company’s common stock in October 2022. The second
tranche of 5,942 restricted stock units fully vested on March 31, 2022. For the years ended December 31, 2023, 2022 and
2021, stock compensation expense of $598, $657 and $144 respectively, was recognized in G&A expense. As of December
31, 2023, 71,000 restricted stock units were outstanding and available to vest and settle in shares of the Company’s
common stock.
Pursuant to the Company’s non-employee director compensation policy, an aggregate of 43,200 restricted stock units
were granted to non-employee directors on June 3, 2021, the date of the Company’s 2021 Annual Meeting of Stockholders,
under the 2014 Plan with a grant date fair value of $13.06 per share. The restricted stock units vested on June 3, 2022. As a
result, the Company recognized compensation expense associated with these restricted stock units ratably over the one-year
vesting period following the grant date. For the years ended December 31, 2022 and 2021, stock compensation expense of
$238 and $326 respectively, was recognized in G&A expense. As of December 31, 2023, none of these restricted stock
units were outstanding as these were fully vested in June 2022.
On March 30, 2021, the Compensation Committee approved and granted a total of 176,000 restricted stock units to
certain employees under the 2014 Plan with a grant date fair value of $20.59 per share. Vesting of the restricted stock units
was contingent on the achievement of certain performance targets related to clinical and regulatory milestones, subject to
the recipient’s continuous service through each performance target. Recognition of compensation expense associated with
these awards begins when, and to the extent, the performance criteria was probable of achievement and the employee had
met the service conditions. In March 2022, 93,999 restricted stock units were forfeited as a result of not achieving certain
defined performance targets of the awards. In February 2022 and August 2021, performance targets relating to 37,999 and
44,002 restricted stock units, respectively, had been achieved and thus restricted stock units vested and the awards were
settled in shares of common stock. For the year ended December 31, 2022, the Company recognized $729 of stock
compensation expense associated with these awards in G&A expense. G&A amounts recorded for the year ended
December 31, 2022 included $303 of stock compensation expense relating to the modification of certain of these restricted
stock units on November 1, 2021 (see Stock Award Modifications below). For the year ended December 31, 2021, the
Company recognized $906 of stock compensation expense, with $329 recorded in R&D expense and $577 recorded in
G&A expense. As of December 31, 2023, none of these restricted stock units were outstanding as these restricted stock
units were either fully vested or forfeited in prior periods.
Additionally on March 30, 2021, the Compensation Committee also approved and granted a total of 100,000 time-
based restricted stock units to certain executive officers under the 2014 Plan with a grant date fair value of $20.59 per
share. The restricted stock units vest in three equal installments annually from the date of the grant. As a result, the
Company recognizes compensation expense associated with these restricted stock units ratably over the three-year vesting
period following the grant date. In March 2023, 15,999 of these restricted stock units vested and were settled in shares of
the Company’s common stock in satisfaction of the second year of vesting. In June 2022, 17,333 of these restricted stock
units vested and were settled in shares of the Company’s common stock in accordance with the acceleration of vesting
provisions relating to the modification of certain of these restricted stock units on November 1, 2021. Also in June 2022,
17,333 restricted stock units were forfeited as a result of the completion of the consulting agreement in relation to the
modification of certain of these restricted stock units on November 1, 2021 (see Stock Award Modifications below). In
March 2022, 33,336 of these restricted stock units vested and were settled in shares of the Company’s common stock in
satisfaction of the first year of vesting. For the years ended December 31, 2023, 2022 and
132
Table of Contents
CARA THERAPEUTICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(amounts in thousands, except share and per share data)
2021, the Company recognized $329, $646 and $592, respectively, of stock compensation expense associated with these
awards, with $219 recorded in R&D expense and $110 in G&A expense for the 2023 period, $219 recorded in R&D
expense and $427 in G&A expense for the 2022 period, and $166 recorded in R&D expense and $426 in G&A expense for
the 2021 period. G&A amounts recorded for the years ended December 31, 2022 and 2021 included $317 and $75,
respectively, of stock compensation expense relating to the modification of certain of these restricted stock units on
November 1, 2021 (see Stock Award Modifications below). As of December 31, 2023, 15,999 restricted stock units were
outstanding and available to vest and settle in shares of the Company’s common stock.
Pursuant to the Company’s non-employee director compensation policy, an aggregate of 36,000 restricted stock units
were granted to non-employee directors on June 4, 2020, the date of the Company’s 2020 Annual Meeting of Stockholders,
under the 2014 Plan with a grant date fair value of $15.62 per share. The restricted stock units fully vested on June 3, 2021.
As a result, the Company recognized compensation expense associated with these restricted stock units ratably over the
one-year vesting period following the grant date. For the year ended December 31, 2021, $239 of stock compensation
expense relating to these restricted stock units was recognized in G&A expense. As of December 31, 2023, none of these
restricted stock units were outstanding as these restricted stock units were fully vested in June 2021.
In February 2020, the Compensation Committee approved and granted a total of 138,000 restricted stock units to
certain employees under the 2014 Plan with a grant date fair value of $16.36 per share. Vesting of the restricted stock units
was contingent on the achievement of certain performance targets related to clinical and regulatory milestones, subject to
the recipient’s continuous service through each performance target. Recognition of compensation expense associated with
these awards begins when, and to the extent, the performance criteria is probable of achievement and the employee has met
the service conditions. During the year ended December 31, 2022, 24,500 of these restricted stock units were forfeited as a
result of not achieving certain defined performance targets of the awards. In February and March 2021, performance targets
relating to 36,750 and 40,000 restricted stock units, respectively, had been achieved and thus restricted stock units vested
and the awards were settled in shares of common stock. For the year ended December 31, 2021, the Company recognized
$1,256 of stock compensation expense relating to the vesting of these restricted stock units, with $524 recorded in R&D
expense and $732 in G&A expense. As of December 31, 2023, none of these restricted stock units were outstanding as
these restricted stock units were either fully vested or forfeited in prior periods.
Additionally in February 2020, the Compensation Committee also approved and granted a total of 98,000 time-based
restricted stock units to certain employees under the 2014 Plan with a grant date fair value of $16.36 per share. The
restricted stock units vested in three equal installments annually from the date of the grant. As a result, the Company
recognized compensation expense associated with these restricted stock units ratably over the three-year vesting period
following the grant date. In February 2023, 15,999 of these restricted stock units vested and were settled in shares of the
Company’s common stock in satisfaction of the third year of vesting. In June 2022, 16,666 of these restricted stock units
vested and were settled in shares of the Company’s common stock in accordance with the acceleration of vesting
provisions relating to the modification of certain of these restricted stock units on November 1, 2021 (see Stock Award
Modifications below). In February 2022, 32,666 of these restricted stock units vested and were settled in shares of the
Company’s common stock in satisfaction of the second year of vesting. In February 2021, 32,669 of these restricted stock
units vested and were settled in shares of the Company’s common stock in satisfaction of the first year of vesting. For the
years ended December 31, 2023, 2022 and 2021, the Company recognized $39, $526 and $607 of stock compensation
expense associated with these awards, with $26 recorded in R&D expense and $13 in G&A expense for the 2023 period,
$175 recorded in R&D expense and $351 in G&A expense for the 2022 period, and $174 recorded in R&D expense and
$433 recorded in G&A expense for the 2021 period. G&A amounts recorded for the years ended December 31, 2022 and
2021 included $264 and $73, respectively, of stock compensation expense relating to the modification of certain of these
restricted stock units on November 1, 2021 (see Stock Award Modifications below). As of December 31, 2023, none of
these restricted stock units were outstanding as these restricted stock units were fully vested in February 2023.
133
Table of Contents
CARA THERAPEUTICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(amounts in thousands, except share and per share data)
A summary of restricted stock unit activity related to employees and non-employee members of the Company’s
Board of Directors as of and for the year ended December 31, 2023 is as follows:
Outstanding, December 31, 2022
Awarded
Vested and released
Forfeited
Outstanding, December 31, 2023
Restricted stock units exercisable (vested and deferred), December 31, 2023
Stock Options
$
Weighted
Average Grant
Date Fair Value
13.20
7.81
12.46
8.96
9.27
$
Number of
Units
372,513
601,172
(203,264)
(204,097)
566,324
—
A summary of the Company’s stock option activity related to employees, non-employee members of the Board of
Directors and non-employee consultants for the 2019 Plan and the 2014 Plan as of and for the year ended December 31,
2023 is as follows:
Outstanding, December 31, 2022
Granted
Exercised
Forfeited
Expired
Outstanding, December 31, 2023
Weighted average remaining contractual life as of December 31, 2023 (in
years)
Options exercisable, December 31, 2023
Weighted average remaining contractual life as of December 31, 2023 (in
years)
Options vested and expected to vest as of December 31, 2023
Weighted average remaining contractual life as of December 31, 2023 (in
years)
Weighted
Average Exercise
Price
Aggregate
Intrinsic
Value
$
$
$
$
14.35
8.15
6.00
9.25
14.74
12.99
$
14.69
$
12.99
$
—
—
—
Number of
Shares
7,689,449
2,004,668
(93,218)
(286,035)
(1,417,217)
7,897,647
6.71
4,840,045
5.46
7,897,647
6.71
The total fair value of options vested during the years ended December 31, 2023, 2022 and 2021 was $12,810,
$14,156, and $12,844, respectively. The intrinsic value of options exercised during the years ended December 31, 2023,
2022 and 2021 was $476, $118, and $965, respectively.
During the years ended December 31, 2023, 2022 and 2021, the Company granted 2,004,668, 1,899,919 and
1,422,750 stock options, respectively, to employees and non-employee members of the Board of Directors. There were no
options granted to nonemployee consultants during the years ended December 31, 2023, 2022 and 2021. The fair values of
the stock options granted to those groups were estimated using the Black-Scholes option valuation model with
134
Table of Contents
CARA THERAPEUTICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(amounts in thousands, except share and per share data)
the following ranges of assumptions (see Note 2, Summary of Significant Accounting Policies – Stock-Based
Compensation):
Risk-free interest rate
Expected volatility
Expected dividend yield
Expected life of employee and Board options (in years)
2023
Year Ended December 31,
2022
3.38% - 4.65 % 1.70% - 4.21 % 0.66% - 1.41 %
76.3% - 81.3 % 77.7% - 81.9 % 71.6% - 83.5 %
0
%
6.25
0
6.25
0
6.25
%
%
2021
The weighted average grant date fair value of options granted to employees and non-employee members of the Board
of Directors for their Board service during the years ended December 31, 2023, 2022 and 2021 was $5.75, $7.25, and
$12.00, respectively.
During the years ended December 31, 2023, 2022 and 2021, the Company recognized compensation expense relating
to stock options as follows:
Research and development
General and administrative
Total stock option expense
$
2023
5,973
5,634
$ 11,607
Year Ended December 31,
2022
7,222
6,426
$ 13,648
2021
7,126
9,569
$ 16,695
$
$
The following were excluded from the table above as they are not related to stock options: compensation expense for
i) the vesting of certain employees’ restricted stock units for $476, $765 and $1,201 in R&D expense for the years ended
December 31, 2023, 2022 and 2021, respectively, and $1,146, $2,693 and $2,324 in G&A expense for the years ended
December 31, 2023, 2022 and 2021, respectively; and ii) compensation expense relating to the Board of Directors’
restricted stock units for $501, $628 and $565 in G&A expense for the years ended December 31, 2023, 2022 and 2021,
respectively.
As of December 31, 2023, the total compensation expense relating to unvested options granted to employees and
non-employee members of the Board of Directors that had not yet been recognized was $20,263, which is expected to be
realized over a weighted average period of 2.33 years. The Company will issue shares upon exercise of options from
common stock reserved.
The Company does not expect to realize any tax benefits from its stock option activity or the recognition of stock-
based compensation expense because the Company currently has net operating losses and has a full valuation allowance
against its deferred tax assets. Accordingly, no amounts related to excess tax benefits have been reported in cash flows
from operations for the years ended December 31, 2023, 2022 and 2021.
Stock Award Modifications
In November 2021, the Company and the former President and CEO mutually agreed to a transition from CEO to a
consulting role through June 30, 2022, if not terminated earlier per the terms of the consulting agreement. As a result, the
Company modified the terms of its former CEO’s outstanding Stock Awards to (1) automatically vest any unvested stock
options or time-based restricted stock units that would have vested in the twelve month period following the end of the
consulting period if continuous service is achieved with the Company during such twelve-month period; (2) extend the
period during which the vested stock options may be exercised through the earlier of (i) eighteen months following
135
Table of Contents
CARA THERAPEUTICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(amounts in thousands, except share and per share data)
the separation date (November 8, 2021); or (ii) the original expiration date applicable to each of the stock options, unless
terminated earlier in accordance with the 2014 Plan, if continuous service is achieved with the Company; and (3) extend
the period in which performance-based vesting milestones for restricted stock units may be achieved through March 31,
2022, if continuous service is achieved with the Company. The consulting agreement ended on June 30, 2022.
The Company determined that vested Stock Awards which had modifications due to the extension of the exercise
period were Type 1 modifications pursuant to ASC 718 because those Stock Awards would have vested before and after the
modification. Acceleration of vesting for the Stock Awards that would have vested in the twelve-month period following
the consulting term was determined to be a Type 3 modification requiring stock compensation expense pursuant to ASC
718 because absent the modification terms, those Stock Awards would have been forfeited as of the last day that the former
CEO provided continuous service as a consultant. In addition, Type 4 performance-based restricted stock units were not
considered probable of achieving performance targets on the modification date, but the vesting targets were achieved with
respect to 17,333 performance-based restricted stock units in February 2022, which resulted in additional stock
compensation expense being recorded through June 30, 2022.
During the year ended December 31, 2022, total incremental stock compensation expense relating to modifications
of stock options, time-based and performance-based restricted stock units of the former CEO was $2,563, which was
included in G&A expense. Of this total amount, $1,679 was included in G&A expense in the stock option expense table
above for the year ended December 31, 2022. During the year ended December 31, 2021, total incremental stock
compensation expense relating to modifications of stock options and time-based restricted stock units of the former CEO
was $5,056, which was included in G&A expense. Of that total amount, $4,908 is included in G&A expense in the stock
option compensation expense table above for the year ended December 31, 2021.
16. Income Taxes
The Company’s benefit from income taxes is as follows:
Current:
Federal
State
Deferred:
Federal
State
Benefit from income taxes
2023
December 31,
2022
2021
$
$
— $
—
—
—
—
—
— $
— $
—
—
—
—
—
— $
—
—
—
—
—
—
—
136
Table of Contents
CARA THERAPEUTICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(amounts in thousands, except share and per share data)
Historically, the Company’s benefit from income taxes related to state R&D tax credits exchanged for cash. The
State of Connecticut provides companies with the opportunity to exchange certain R&D credit carryforwards for cash in
exchange for foregoing the carryforward of the R&D credit. The program provides for such exchange of the R&D credits
at a rate of 65% of the annual R&D credit, as defined. The Company opted not to exchange its R&D tax credit for the year
ended December 31, 2023, and the Company was not eligible to exchange its R&D tax credit for cash during the years
ended December 31, 2022 and 2021, therefore there was no benefit from income taxes for the years ended December 31,
2023, 2022 and 2021. As of December 31, 2023, the Company recorded $697 within income tax receivable which related
to the 2020 R&D credit.
A reconciliation of income taxes computed using the U.S. federal statutory rate to that reflected in operations is as
follows:
Income taxes using U.S. federal statutory rate
State income taxes, net of federal benefit
Impact of R&D tax credit on effective tax rate
Stock option shortfalls and cancellations
Permanent items and other
Change in valuation allowance
Provision to return
December 31,
2022
2021
5.30 %
3.68 %
(1.22)%
(0.89)%
2023
21.00 % 21.00 % 21.00 %
7.84 %
(1.00)%
2.87 %
4.91 %
(4.74)%
(3.33)%
(1.29)%
(1.86)%
(27.34)% (19.88)% (25.69)%
0.01 %
0.00 %
(0.53)%
0.00 %
0.16 %
0.00 %
Significant components of the Company’s deferred tax assets and liabilities are as follows:
Valuation allowance
Net operating loss carryforwards
Federal and state tax credits
Stock-based compensation expense
Intangible asset amortization
Other
Deferred tax assets
Other
Deferred tax liabilities:
Net deferred tax asset:
December 31,
2023
2022
$ (192,791) $ (160,814)
123,739
31,245
3,855
33,162
2,101
194,102
(1,311)
(1,311)
113,058
26,358
3,434
17,265
1,167
161,282
(468)
(468)
$
— $
—
A 100% valuation allowance has been recorded on the deferred tax asset as of December 31, 2023 and 2022 because
management believes it is more likely than not that the asset will not be realized. The change in the valuation allowance
during 2023 and 2022 was an increase of $31,977 and $17,426, respectively.
137
Table of Contents
CARA THERAPEUTICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(amounts in thousands, except share and per share data)
The consolidated financial statements reflect expected future tax consequences of such positions presuming the
taxing authorities possess full knowledge of the position and all relevant facts. As of December 31, 2023 and 2022, the
Company had no unrecognized tax benefits or related interest and penalties accrued. In the event the Company determines
that accrual of interest or penalties are necessary in the future, the amount will be presented as a component of income tax
expense.
At December 31, 2023, the Company had federal and state net operating loss, or NOL, carryforwards of $467,005
and $473,265, respectively. The federal and state tax loss carryforwards will begin to expire in 2026 and 2027, respectively,
unless previously utilized. The federal NOLs arising in 2018 and forward have an unlimited carryforward period and losses
from 2018-2020 may be carried back five years due to the Coronavirus Aid, Relief, and Economic Security Act of 2020, or
the CARES Act. The Company conducted a 382 analysis in the first quarter of 2021. This analysis showed a limited
change of ownership had occurred, and thus the full amount of the Company’s NOL carryforwards and R&D tax credits
could be utilized annually in the future to offset taxable income or tax, respectively. The Company also had federal and
state R&D tax credit carryforwards of $27,488 and $4,495, respectively. The federal credits will begin expiring in 2025
unless previously utilized. The Connecticut credit carryforwards have no expiration period. Because of the NOL and
research credit carryforwards, tax years 2006 through 2023 remain open to U.S. federal and state tax examinations.
Further, beginning in the Company’s tax year ending December 31, 2022, as a result of the Tax Cuts and Jobs Act of
2017, current R&D expenditures incurred in the United States must be capitalized for tax purposes, and amortized over a
period of five years (fifteen years in the case of R&D performed outside the United States).
In March 2020, former President Trump signed into law the CARES Act (H.R. 748), which was further expanded
with the signing of the Consolidation Appropriations Act of 2021 (H.R. 133) on December 27, 2020. The CARES Act (and
December expansion) includes a variety of economic and tax relief measures intended to stimulate the economy, including
loans for small businesses, payroll tax credits/deferrals, and corporate income tax relief. Due to the Company’s history of
tax loss carryforwards and full valuation allowance, the CARES Act did not have a significant effect on the income tax
provision, as the corporate income tax relief was directed towards cash taxpayers.
17. Net Loss per Share
The denominators used in the net loss per share computations are as follows:
Basic:
Weighted average common shares outstanding
Diluted:
Weighted average common shares outstanding - Basic
Common stock equivalents*
Denominator for diluted net loss per share
Year Ended December 31,
2022
2021
2023
54,149,059 53,653,564 50,718,765
54,149,059 53,653,564 50,718,765
—
54,149,059 53,653,564 50,718,765
—
—
*
For the years ended December 31, 2023, 2022 and 2021, no amounts were considered common stock equivalents as
their effects would have been anti-dilutive due to net losses for those periods.
138
Table of Contents
CARA THERAPEUTICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(amounts in thousands, except share and per share data)
Basic and diluted net loss per share is computed as follows:
Net loss - basic and diluted
Weighted-average common shares outstanding:
Basic and diluted
Net loss per share, basic and diluted:
2023
(118,513) $
Year Ended December 31,
2022
(85,474) $
$
2021
(88,441)
54,149,059
$
(2.19) $
53,653,564
50,718,765
(1.74)
(1.59) $
As of December 31, 2023, 7,897,647 stock options and 566,324 restricted stock units were outstanding, which could
potentially dilute basic earnings per share in the future, but were not included in the computation of diluted net loss per
share because to do so would have been anti-dilutive as a result of the net loss for the period.
As of December 31, 2022, 7,689,449 stock options and 372,513 restricted stock units were outstanding, which could
potentially dilute basic earnings per share in the future, but were not included in the computation of diluted net loss per
share because to do so would have been anti-dilutive as a result of the net loss for the period.
As of December 31, 2021, 6,512,280 stock options and 576,544 restricted stock units were outstanding, which could
potentially dilute basic earnings per share in the future, but were not included in the computation of diluted net loss per
share because to do so would have been anti-dilutive as a result of the net loss for the period.
18. Employee Benefit Plan
The Company’s defined contribution retirement plan complies with Section 401(k) of the Internal Revenue Code. All
employees over the age of 21 are eligible to participate in the plan on the first day of the month after completing three
consecutive months of service. Employees are able to defer a portion of their pay into the plan on the first day of the month
on or after the day all age and service requirements have been met. All eligible employees receive an employer
contribution equal to 3% of their salary up to the annual IRS limit. During the years ended December 31, 2023, 2022 and
2021, employer contributions to the plan were $643, $505, and $460, respectively.
19. Commitments and Contingencies
License Agreement with Enteris Biopharma, Inc.
In August 2019, the Company entered into a non-exclusive license agreement, or the Enteris License Agreement,
with Enteris Biopharma, Inc., or Enteris, pursuant to which Enteris granted to the Company a non-exclusive, royalty-
bearing license, including the right to grant sublicenses, under certain proprietary technology and patent rights related to or
covering formulations for oral delivery of peptide active pharmaceutical ingredients with functional excipients to enhance
permeability and/or solubility, known as Enteris’s Peptelligence® technology, to develop, manufacture and commercialize
products using such technology worldwide, excluding Japan and South Korea.
As consideration for the licensed rights under the Enteris License Agreement, the Company paid an upfront fee equal
to $8,000, consisting of $4,000 in cash and $4,000 in shares of the Company’s common stock pursuant to the Purchase
Agreement with Enteris.
The Company is also obligated, pursuant to the Enteris License Agreement, to pay Enteris (1) milestone payments
upon the achievement of certain development, regulatory and commercial milestones and (2) low-single digit royalty
percentages on net sales of licensed products, subject to reductions in specified circumstances. During the year ended
139
Table of Contents
CARA THERAPEUTICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(amounts in thousands, except share and per share data)
December 31, 2023, no milestone payments or royalties were paid to Enteris by the Company in relation to the Enteris
License Agreement. During the years ended December 31, 2022 and 2021, the Company paid $5,000 and $15,000,
respectively, to Enteris for milestones earned in relation to the Enteris License Agreement and as a result, the Company
recognized $5,000 and $15,000 of R&D expense related to the Enteris License Agreement during these respective years.
The Enteris License Agreement will expire on a country-by-country, licensed product-by-licensed product basis upon
the later of (1) the expiration (or invalidation) of all valid claims in licensed patent rights that cover such product in such
country, (2) the end of the calendar quarter in which generic competition (as defined in the Enteris License Agreement)
occurs for such product in such country and (3) ten years from the first commercial sale of such product.
Either party may terminate the Enteris License Agreement upon written notice if the other party has failed to remedy
a material breach within 60 days (or 30 days in the case of a material breach of a payment obligation). Enteris may
terminate the Enteris License Agreement upon 30 days’ written notice to the Company if the Company or any of its
affiliates formally challenge the validity of any licensed patent rights or assists a third party in doing so. The Company may
terminate the Enteris License Agreement for any reason or no reason (a) prior to receipt of first regulatory approval for a
licensed product in the United States for any indication upon 30 days’ prior written notice to Enteris or (b) on or after
receipt of first regulatory approval for a licensed product in the United States for any indication upon 60 days’ prior written
notice to Enteris.
Manufacturing Agreements
In July 2021, the Company entered into an API Commercial Supply Agreement with Polypeptide Laboratories S.A.,
or PPL, that defines each party’s responsibilities with respect to PPL’s manufacture and supply of the API difelikefalin, for
the difelikefalin injection product candidate. Under the API Commercial Supply Agreement, PPL shall manufacture API at
its facility for sale and supply to the Company, in the amounts as set forth in purchase orders to be provided by the
Company. The Company will be required to purchase its requirements of API for each year of the term of the agreement,
based on internal forecasts.
The API Commercial Supply Agreement will continue until the fifth anniversary of the approval by the FDA of the
new drug application for KORSUVA injection, unless the API Commercial Supply Agreement is earlier terminated, and
will automatically be extended for successive five-year periods unless either party gives notice to the other party of its
intention to terminate.
In July 2019, the Company entered into a Master Manufacturing Services Agreement, or MSA, with Patheon UK
Limited, or Patheon. The MSA governs the general terms under which Patheon, or one of its affiliates, will provide non-
exclusive manufacturing services to the Company for the drug products specified by the Company from time to time.
Pursuant to the MSA, the Company has agreed to order from Patheon at least a certain percentage of its commercial
requirements for a product under a related Product Agreement. Each Product Agreement that the Company may enter into
from time to time will be governed by the terms of the MSA, unless expressly modified in such Product Agreement.
The MSA has an initial term ending December 31, 2024, and will automatically renew after the initial term for
successive terms of two years each if there is a Product Agreement in effect, unless either party gives notice of its intention
to terminate the MSA at least 18 months prior to the end of the then current term.
Either party may terminate the MSA or a Product Agreement upon written notice if the other party (1) has failed to
remedy a material breach within a specified time or (2) is declared insolvent or bankrupt, voluntarily files a petition of
bankruptcy or assigns such agreement for the benefit of creditors. The Company may terminate a Product Agreement
(a) upon 90 days’ prior written notice if any governmental agency takes any action that prevents the Company from selling
the relevant product in the relevant territory, (b) upon six months’ prior written notice if it does not intend to
140
Table of Contents
CARA THERAPEUTICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(amounts in thousands, except share and per share data)
order manufacturing services due to a product’s discontinuance in the market, or (c) upon 90 days’ prior written notice if it
determines that the manufacture or supply of a product likely infringes third-party rights. Patheon may terminate the MSA
or a Product Agreement (i) upon six months’ prior written notice if the Company assigns such agreement to an assignee
that is unacceptable to Patheon for certain reasons, or (ii) upon 30 days’ prior written notice if, after the first year of
commercial sales, the Company forecasts zero volume for 12 months.
The MSA contains, among other provisions, customary representations and warranties by the parties, a grant to
Patheon of certain limited license rights to the Company’s intellectual property in connection with Patheon’s performance
of the services under the MSA, certain indemnification rights in favor of both parties, limitations of liability and customary
confidentiality provisions.
Also in July 2019, the Company entered into two related Product Agreements under the MSA, one with each of
Patheon and Patheon Manufacturing Services LLC, or Patheon Greenville, to govern the terms and conditions of the
manufacture of commercial supplies of difelikefalin injection, the Company’s lead product candidate. Pursuant to the
Product Agreements, Patheon and Patheon Greenville will manufacture commercial supplies of difelikefalin injection at
the Monza, Italy and Greenville, North Carolina manufacturing sites, respectively, from API supplied by the Company.
Patheon and Patheon Greenville will be responsible for supplying the other required raw materials and packaging
components, and will also provide supportive manufacturing services such as quality control testing for raw materials,
packaging components, and finished product.
In December 2023, the Company entered into an agreement with Patheon to reimburse Patheon approximately
$1,700 for forecasted manufacturing commitments that are no longer needed due to the reduced demand expectations of
KORSUVA in the United States and was recorded within accounts payable and accrued expenses on its Consolidated
Balance Sheet. In connection with the agreement with Patheon, the Company agreed to schedule additional manufacturing
commitments in 2024.
Lease (New Corporate Headquarters in May 2023)
On May 11, 2023, the Company entered into the New Lease for the Company’s new principal executive offices. The
initial term of the New Lease commences on the earlier to occur of (a) the date the Company first occupies the premises for
the regular conduct of its business therein, and (b) the date the Landlord delivers the premises to the Company in the
condition required under the terms of the New Lease, provided that such date shall be no sooner than November 1, 2023, or
the Commencement Date, and will expire on the last day of the calendar month in which occurs the tenth anniversary of the
Rent Commencement Date, as defined below, or the Term.
In connection with the signing of the New Lease, the Company entered into a standby letter of credit agreement for
$1,500 which serves as a security deposit for the leased office space. This standby letter of credit is secured with restricted
cash in a money market account and is included within long-term assets as of December 31, 2023 (refer to Note 8,
Restricted Cash).
The annual fixed rent rate under the New Lease will initially be $1,300 (considered by the Company to be at market
rate as of the signing of the New Lease), commencing on the date which is the later to occur of (a) the date which is 12
months after the Commencement Date and (b) November 1, 2024, or the Rent Commencement Date, and will increase
2.5% annually thereafter. The Company expects to begin paying rent in November 2024.
The Company is also responsible for the payment of Additional Rent, as defined in the New Lease, including its
share of the operating and tax expenses for the building. As a result, the New Lease contains both a lease (the right to use
the asset) and a non-lease component (common area maintenance services) which are accounted for separately. The
Company allocates the consideration to the lease and non-lease component on a relative standalone price basis.
141
Table of Contents
CARA THERAPEUTICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(amounts in thousands, except share and per share data)
The Company will have the option to extend the Term under the New Lease for an additional five years on the same
terms and conditions (other than with respect to the annual fixed rent at the annual fair market rental rate, as defined in the
New Lease) as set forth in the New Lease. This renewable term is not included as part of the lease term as defined in ASC
842 since it is not reasonably certain that the Company will exercise that option on the Commencement Date.
On July 28, 2023, the Company recorded a lease liability and a ROU asset for the New Lease since it obtained
control of the premises to begin work on its leasehold improvements prior to the Commencement Date. The initial lease
liability of $6,672 was recorded as the sum of the present value of the future minimum lease payments over the term of the
lease. Lease incentives of $2,900 were not included within lease payments since the timing of these costs being incurred
and reimbursed to the Company was uncertain, and they are neither paid nor payable as of July 28, 2023. These lease
incentives will reduce the lease liability and ROU asset by the costs incurred once the Company actually incurs the costs
and the amounts qualify for reimbursement. The reduction to the lease liability will be reversed once the Company is
reimbursed for the qualified costs. The reduction to the ROU asset will be recognized prospectively over the remainder of
the lease term. The ROU asset of $6,779 was initially recorded as the amount of the lease liability plus prepaid rent paid in
May 2023. In October and November 2023, the Company incurred $1,755 of costs that qualified for reimbursement as
lease incentives, of which $808 had been reimbursed to the Company as of December 31, 2023.
Beginning on July 28, 2023 and during the entire term of the New Lease, interest expense is calculated using the
effective interest method and the ROU asset (including prepaid rent) will be amortized on a straight-line basis over the
lease term, and both will be recorded as lease expense. As a result, lease expense of $524 for the New Lease was recorded
for the year ended December 31, 2023, consisting of $367 relating to R&D lease expense and $157 relating to G&A lease
expense.
Leases (Original Corporate Headquarters in 2015 & Amendment for Additional Space in 2020)
The Company’s original Stamford Lease and Lease Amendment for prior office space both terminated in December
2023. Lease expense for the Stamford Lease and Lease Amendment was recognized on a straight-line basis over the lease
term of the Company’s prior lease agreements in Stamford, Connecticut. As a result, $1,624 of operating lease cost, or
lease expense, was recognized for each of the years ended December 31, 2023, 2022 and 2021, respectively, consisting of
$1,137 relating to R&D lease expense and $487 relating to G&A lease expense in each respective period.
Other information related to the leases (both new in May 2023 and terminated in December 2023) was as follows:
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash outflows relating to operating leases
ROU assets obtained in exchange for new operating lease liabilities
Remaining lease term - operating leases (years)
Discount rate - operating leases
Year Ended December 31,
2022
2023
$
$
$
$
1,992
6,779
10.8
12.8 %
1,957
—
1.0
7.0 %
142
Table of Contents
CARA THERAPEUTICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(amounts in thousands, except share and per share data)
Future minimum lease payments under the non-cancellable operating lease for the New Lease, as well as a
reconciliation of these undiscounted cash flows to the operating lease liability as of December 31, 2023, were as follows:
Year Ending December 31,
2024
2025
2026
2027
2028
Thereafter
Total future minimum lease payments, undiscounted
Less imputed interest
Less lease incentive to be reimbursed
Total
Operating lease liability reported as of December 31, 2023:
Operating lease liability - current
Operating lease liability - non-current
Total
20. Legal Matters
$
$
$
$
108
1,298
1,330
1,363
1,398
8,874
14,371
(7,336)
(947)
6,088
—
6,088
6,088
From time to time, the Company may become subject to arbitration, litigation or claims arising in the ordinary course
of its business. The Company is not currently a party to any arbitration or legal proceeding that, if determined adversely to
the Company, would have a material adverse effect on its business, operating results or financial condition. The results of
any future claims or proceedings cannot be predicted with certainty, and regardless of the outcome, litigation can have an
adverse impact on the Company because of defense and settlement costs, diversion of management resources and other
factors.
143
Table of Contents
CARA THERAPEUTICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(amounts in thousands, except share and per share data)
21. Related Party Transactions
As of December 31, 2023, Vifor International owned 7,396,770, or 13.6%, of the Company’s common stock. CSL
Vifor and its affiliates are considered related parties as of December 31, 2023, 2022 and 2021 (see Note 13, Collaboration
and Licensing Agreements).
As of December 31, 2023 and 2022, amounts due from CSL Vifor of $2,765 and $3,260, respectively, primarily
relating to the Company’s share of the profit generated by sales of KORSUVA injection in the United States by CSL Vifor,
its commercial supply of KORSUVA injection to CSL Vifor, and royalty payments from CSL Vifor were included within
accounts receivable, net – related party.
The Company’s collaborative revenue of $12,397 and $16,572 from its share of the profit generated by sales of
KORSUVA injection in the United States by CSL Vifor was included within collaborative revenue for the years ended
December 31, 2023 and 2022, respectively.
Sales of KORSUVA injection to CSL Vifor of $5,843, $10,223 and $701 were included within commercial supply
revenue for the years ended December 31, 2023, 2022 and 2021, respectively. The associated COGS for the Company’s
commercial supply revenue from CSL Vifor was $6,174, $7,266, and $0 for the years ended December 31, 2023, 2022 and
2021, respectively.
The Company recorded $15,000 as license and milestone fees revenue from Vifor Fresenius Medical Care Renal
Pharma Ltd. for the year ended December 31, 2022, as a result of the European Commission’s regulatory approval of
KORSUVA in April 2022. During the year ended December 31, 2021, the Company recorded as license and milestone fees
revenue: i) $15,000 as license and milestone fees revenue from Vifor Fresenius Medical Care Renal Pharma Ltd. for the
approval of KORSUVA injection in August 2021, and ii) $5,031 of premium from Vifor International’s purchase of the
Company’s common stock.
The Company recorded $415 and $72 as royalty revenue based on net sales of Kapruvia outside of the United States
during the years ended December 31, 2023 and 2022, respectively.
Sales of clinical compound to CSL Vifor for $361 were included within clinical compound revenue for the year
ended December 31, 2021.
The Company recorded $284 as other revenue from its royalty payments from CSL Vifor for the year ended
December 31, 2023.
22. Subsequent Event
On January 22, 2024, the Company announced a planned workforce reduction of up to 50% of its employees in order
to reduce its operating expenses and focus its efforts on development of oral difelikefalin in chronic pruritus associated
with notalgia paresthetica. The Company expects to record a pre-tax severance expense of approximately $2,700 during the
first quarter of 2024. As a result of these workforce reductions, approximately 703,000 stock options and 46,000 restricted
stock units, as of December 31, 2023, are expected to be forfeited (see Note 15, Stock-Based Compensation).
144
Table of Contents
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.
None.
Item 9A. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated
the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under
the Exchange Act) as of December 31, 2023. Based on such evaluation, our Chief Executive Officer (principal executive
officer) and Chief Financial Officer (principal financial officer) have concluded that, as of December 31, 2023, our
disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed
by us in the reports that we file or submit under the Exchange Act is (1) recorded, processed, summarized, and reported
within the time periods specified in the rules and forms of the SEC, and (2) accumulated and communicated to our
management, including our principal executive officer and principal financial officer, as appropriate to allow timely
decisions regarding required disclosures.
Management’s Report on Internal Control over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting as
defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Our internal control over financial reporting is a process
designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted accounting principles. Because of its inherent
limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any
evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes
in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Our management utilized the criteria established in the Internal Control – Integrated Framework (2013) issued by the
Committee of Sponsoring Organizations of the Treadway Commission (COSO) to conduct an assessment of the
effectiveness of our internal control over financial reporting as of December 31, 2023. Based on the assessment,
management has concluded that, as of December 31, 2023, our internal control over financial reporting was effective.
Ernst & Young LLP, an independent registered public accounting firm, has audited the effectiveness of our internal
control over financial reporting as of December 31, 2023, as stated in their attestation report, which is included in Part II
Item 8 of this Annual Report.
Changes in Internal Control Over Financial Reporting
There were no changes in our internal control over financial reporting that occurred during the quarter ended
December 31, 2023 that have materially affected, or is reasonably likely to materially affect, our internal control over
financial reporting.
Limitations on Controls and Procedures
Management, including our Chief Executive Officer and Chief Financial Officer, recognizes that any controls and
procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives
and management necessarily applies its judgment in evaluating the cost benefit relationship of possible controls and
procedures. Because of the inherent limitations in all control systems, no evaluation of controls and procedures can provide
absolute assurance that all control issues and instances of fraud, if any, within Cara have been detected.
145
Table of Contents
Item 9B. Other Information.
None.
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.
Not applicable.
Item 10. Directors, Executive Officers and Corporate Governance.
PART III
The information required by this item will be set forth under the captions “Executive Officers”, “Election of
Directors” and “Board of Directors and Corporate Governance” in our Definitive Proxy Statement with respect to our 2024
Annual Meeting of Stockholders and is incorporated herein by reference.
We have adopted the Cara Therapeutics, Inc. Code of Business Conduct and Ethics that applies to all officers,
directors, and employees. The Code of Business Conduct and Ethics is available on our website at
https://www.caratherapeutics.com. If we make any substantive amendments to the Code of Business Conduct and Ethics or
grant any waiver from a provision of the Code to any executive officer or director, we will promptly disclose the nature of
the amendment or waiver on our website.
Item 11. Executive Compensation.
The information required by this item will be set forth under the captions “Executive Compensation” and “Board of
Directors and Corporate Governance” in our Definitive Proxy Statement with respect to our 2024 Annual Meeting of
Stockholders and is incorporated herein by reference.
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.
The information required by this item will be set forth under the captions “Security Ownership of Certain Beneficial
Owners and Management” and “Securities Authorized for Issuance under Equity Compensation Plans” in our Definitive
Proxy Statement with respect to our 2024 Annual Meeting of Stockholders and is incorporated by reference.
Item 13. Certain Relationships and Related Transactions and Director Independence.
The information required by this item will be set forth under the captions “Transactions with Related Persons” and
“Board of Directors and Corporate Governance” in our Definitive Proxy Statement with respect to our 2024 Annual
Meeting of Stockholders and is incorporated herein by reference.
Item 14. Principal Accountant Fees and Services.
The information required by this item will be set forth under the caption “Independent Registered Public Accounting
Firm’s Fees” in our Definitive Proxy Statement with respect to our 2024 Annual Meeting of Stockholders and is
incorporated herein by reference.
146
Table of Contents
PART IV
Item 15. Exhibits, Financial Statement Schedules.
(a) We have filed the following documents as part of this Annual Report on Form 10-K:
(1) Consolidated Financial Statements of Cara Therapeutics, Inc.
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
Reports of Independent Registered Public Accounting Firm
Financial Statements:
Consolidated Balance Sheets
Consolidated Statements of Comprehensive Loss
Consolidated Statements of Stockholders’ Equity
Consolidated Statements of Cash Flows
Notes to Consolidated Financial Statements
(2) Financial Statement Schedules
PAGE
90
93
94
95
96
97
All schedules for which provision is made in the applicable accounting regulations of the SEC which are not
included with this additional financial data have been omitted because they are not applicable or the required information is
shown in the Consolidated Financial Statements or Notes included in Item 8. Financial Statements and Supplementary
Data.
(3) List of Exhibits
Exhibit
No.
3.1
3.2
4.1
4.2
4.3#
10.1+
10.2+
10.2.1
10.2.2
Description of Exhibit
Amended and Restated Certificate
of Incorporation.
Amended and Restated Bylaws.
Form of Common Stock
Certificate.
Description of Securities.
Securities Purchase Agreement,
dated October 15, 2020, by and
between the Registrant and Vifor
(International) Ltd.
Form of Indemnity Agreement.
2014 Equity Incentive Plan.
Form of Stock Option Agreement
under 2014 Equity Incentive Plan.
Form of Restricted Stock Unit
Award under 2014 Equity
Incentive Plan.
Form
File No.
Incorporated by Reference
Date Filed
Exhibit No.
8-K
8-K
001-36279
001-36279
S-1/A
333-192230
10-K
10-K
001-36279
001-36279
3.1
3.2
4.1
4.3
4.4
February 7, 2014
February 7, 2014
January 17, 2014
February 27, 2020
February 25, 2021
S-1/A
S-1/A
S-1/A
333-192230
333-192230
10.1
10.3
January 17, 2014
January 17, 2014
333-192230
10.3.1
January 17, 2014
S-1/A
333-192230
10.3.2
January 17, 2014
147
Table of Contents
10.3*
10.4*
10.5
10.6#
License Agreement dated April 4,
2013 by and between the
Registrant and Maruishi
Pharmaceutical Co., Ltd.
License and API Supply
Agreement effective as of April
16, 2012 by and between the
Registrant and Chong Kun Dang
Pharmaceutical Corp.
Amendment to License and API
Supply Agreement effective as of
May 1, 2012 by and between the
Registrant and Chong Kun Dang
Pharmaceutical Corp.
API Commercial Supply
Agreement between Cara
Therapeutics, Inc. and Polypeptide
Laboratories S.A.
10.7+
Employment Agreement with
Christopher Posner
10.8+
Offer Letter with Ryan Maynard
10.9+
Employment Agreement with
Frédérique Menzaghi.
10.10+
Employment Agreement with
Joana Goncalves.
10.11+
Form of Retention Agreement
10.12+
10.13+
10.14
10.15
10.16#
Cara Therapeutics, Inc. Severance
Plan and Form of Participation
Agreement
Amended and Restated Non-
Employee Director Compensation
Policy.
Lease Agreement dated December
21, 2015 between the Registrant
and Four Stamford Plaza Owner
L.L.C.
Amendment to Lease Agreement
between the Registrant and Four
Stamford Plaza Owner L.L.C.
Stamford Lease, dated June 23,
2020.
License Agreement by and
between Cara Therapeutics, Inc.
and Vifor Fresenius Medical Care
Renal Pharma Ltd.
S-1
333-192230
10.7
November 8, 2013
S-1
333-192230
10.8
November 8, 2013
S-1
333-192230
10.9
November 8, 2013
10-Q
001-36279
10.1
November 8, 2021
8-K
8-K
8-K
001-36279
10.1
November 3, 2021
001-36279
001-36279
10.1
10.2
September 12, 2022
February 7, 2014
10-K
001-36279
10.11
March 12, 2019
10-K
10-K
001-36279
001-36279
10.13
10.14
March 1, 2022
March 1, 2022
10-Q
001-36279
10.2
August 7, 2023
8-K
001-36279
10.1
December 23, 2015
10-Q
001-36279
10.2
August 10, 2020
10-Q
001-36279
10.2
August 8, 2022
148
Table of Contents
10.17#
10.18#
Master Manufacturing Services
Agreement between the Registrant
and Patheon UK Limited and
related Product Agreements
Non-Exclusive License
Agreement, dated August 20,
2019, between the Registrant and
Enteris Biopharma, Inc.
10.19+
2019 Inducement Plan.
10.20
10.21
10.22#
10.23
10.24
10.25#†
21.1†
23.1†
24.1†
31.1†
Form of Stock Option Grant
Notice under 2019 Inducement
Plan
Form of Restricted Stock Unit
Notice under 2019 Inducement
Plan
License Agreement, dated October
15, 2020, by and between Cara
Therapeutics, Inc. and Vifor
(International) Ltd.
Open Market Sale Agreement,
dated March 1, 2022, between the
Registrant and Jefferies LLC
Agreement of Lease dated May 11,
2023 by and between 400 Atlantic
Joint Venture LLC and SLJ
Atlantic Stamford LLC (tenants-
in-common) and Cara
Therapeutics, Inc.
Purchase and Sale Agreement
dated November 1, 2023 by and
between Cara Royalty Sub, LLC
and HCRX Investments Holdco,
L.P. and Healthcare Royalty
Partners IV, L.P.
Subsidiaries of Cara Therapeutics,
Inc.
Consent of Ernst & Young, LLP,
independent registered public
accounting firm.
Power of Attorney (included on
signature page).
Certification of Chief Executive
Officer of Cara Therapeutics, Inc.
pursuant to Rule 13a-14(a)/15d-
14(a) of the Securities Exchange
Act of 1934.
10-Q
001-36279
10.2
August 7, 2019
10-Q
001-36279
10.1
November 5, 2019
8-K
8-K
001-36279
001-36279
10.1
10.2
November 20, 2019
November 20, 2019
8-K
001-36279
10.3
November 20, 2019
10-K
001-36279
10.21
February 25, 2021
S-3
333-263165
1.2
March 1, 2022
10-Q
001-36279
10.1
August 7, 2023
149
Table of Contents
31.2†
32.1†**
Certification of Chief Financial
Officer of Cara Therapeutics, Inc.
pursuant to Rule 13a-14(a)/15d-
14(a) of the Securities Exchange
Act of 1934.
Certifications of Chief Executive
Officer and Chief Financial Officer
of Cara Therapeutics, Inc. pursuant
to 18 U.S.C. Section 1350, as
adopted pursuant to Section 906 of
the Sarbanes-Oxley Act of 2002.
97†
Incentive Compensation
Recoupment Policy
101.CAL†
Inline XBRL Taxonomy Extension
Calculation Linkbase.
101.INS†
Inline XBRL Instance Document.
101.LAB†
Inline XBRL Taxonomy Extension
Label Linkbase.
101.PRE†
Inline XBRL Taxonomy Extension
Presentation Linkbase.
101.SCH†
Inline XBRL Taxonomy Extension
Schema Linkbase.
101.DEF†
Inline XBRL Taxonomy Extension
Definition Linkbase Document.
104†
Cover page interactive data file
(formatted as Inline XBRL and
contained in Exhibit 101).
+
indicates management contract or compensatory plan.
* Confidential treatment has been granted with respect to certain portions of this exhibit. Omitted portions have been
filed separately with the Securities and Exchange Commission.
#
†
Portions of this exhibit (indicated by asterisks) have been omitted because the Registrant has determined they are not
material and are the type that the Registrant treats as private and confidential.
Filed herewith.
** This certification is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended,
or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing
under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.
Item 16. Form 10-K Summary.
None.
150
Table of Contents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 6th day of March 2024.
CARA THERAPEUTICS, INC.
/s/ CHRISTOPHER POSNER
By:
Name: Christopher Posner
Title:
President and Chief Executive Officer
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes
and appoints Christopher Posner and Scott Terrillion, and each of them, as his true and lawful attorneys-in-fact and agents,
with full power of substitution for him, and in his name in any and all capacities, to sign any and all amendments to this
Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with
the U.S. Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full
power and authority to do and perform each and every act and thing requisite and necessary to be done therewith, as fully
to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact
and agents, and either of them, his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the
following persons on behalf of the registrant and in the capacities and on the dates indicated.
Signature
Title
/s/ CHRISTOPHER POSNER
Christopher Posner
President, Chief Executive Officer
(Principal Executive Officer)
/s/ RYAN MAYNARD
Ryan Maynard
Chief Financial Officer
(Principal Financial and Accounting Officer)
/s/ MARTIN VOGELBAUM
Martin Vogelbaum
/s/ JEFFREY IVES
Jeffrey Ives, Ph.D.
/s/ LISA VON MOLTKE
Lisa von Moltke, M.D.
/s/ SUSAN SHIFF
Susan Shiff, Ph.D.
/s/ HELEN BOUDREAU
Helen Boudreau
Director
Director
Director
Director
Director
151
Date
March 6, 2024
March 6, 2024
March 6, 2024
March 6, 2024
March 6, 2024
March 6, 2024
March 6, 2024
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
[***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR
CONFIDENTIAL.
PURCHASE AND SALE AGREEMENT
EXHIBIT 10.25
dated as of November 1, 2023
by and between
CARA ROYALTY SUB, LLC
and
HCRX INVESTMENTS HOLDCO, L.P.
and
HEALTHCARE ROYALTY PARTNERS IV, L.P.
TABLE OF CONTENTS
ARTICLE I DEFINED TERMS AND RULES OF CONSTRUCTION
Section 1.1
Defined Terms
Section 1.2
Rules of Construction
ARTICLE II PURCHASE AND SALE OF THE PURCHASED ROYALTIES
Section 2.1
Purchase and Sale.
Section 2.2
Payment of the Investment Amount
Section 2.3
Change of Control
Section 2.4
Prepayment
Section 2.5
No Assumed Obligations
Section 2.6
Excluded Assets
ARTICLE III REPRESENTATIONS AND WARRANTIES OF THE SELLER
Section 3.1
Organization
Section 3.2
No Conflicts.
Section 3.3
Authorization
Section 3.4
Ownership
Section 3.5
Governmental and Third-Party Authorizations
Section 3.6
No Litigation
Section 3.7
Solvency
Section 3.8
Tax Matters
Section 3.9
No Brokers’ Fees
Section 3.10
Compliance with Laws
Section 3.11
Intellectual Property Matters
Section 3.12
Regulatory Approval and Marketing.
Section 3.13
Counterparty Agreements.
Section 3.14
UCC Matters
Section 3.15
Set-off and Other Sources of Royalty Reduction
Section 3.16 Margin Stock
Section 3.17
Representations and Warranties as to the Company
ARTICLE IV REPRESENTATIONS AND WARRANTIES OF THE PURCHASER
Section 4.1
Organization
Section 4.2
No Conflicts
Section 4.3
Authorization
Section 4.4
Governmental and Third Party Authorizations
Section 4.5
No Litigation
i
1
1
11
12
12
13
14
14
14
14
15
15
15
16
16
16
16
17
17
17
17
18
19
20
21
21
21
21
26
26
26
27
27
27
Section 4.6
Access to Information..
Section 4.7
Funds Available.
ARTICLE V COVENANTS
Section 5.1
Books and Records; Notices.
Section 5.2
Public Announcement
Section 5.3
Further Assurances.
Section 5.4
Payments on Account of the Purchased Royalties.
Section 5.5
Covered License Agreements.
Section 5.6
Termination of the Covered License Agreements.
Section 5.7
Audits
Section 5.8
Tax Matters.
Section 5.9
Existence
Section 5.10
Payment Direction Letters
Section 5.11
Additional Covenants of the Seller
Section 5.12
Amendment to Disclosure Schedule.
ARTICLE VI THE CLOSING
Section 6.1
Closing
Section 6.2
Closing Deliverables of the Seller and the Company
Section 6.3
Closing Deliverables of the Purchaser
Section 6.4
Lockbox Account; Account Control Agreement.
Section 6.5
First Milestone Closing Conditions
Section 6.6
Second Milestone Closing Conditions.
ARTICLE VII INDEMNIFICATION
Section 7.1
Indemnification by the Seller
Section 7.2
Indemnification by the Purchaser
Section 7.3
Procedures for Third Party Claims
Section 7.4
Other Claims
Section 7.5
Survival
Section 7.6
Remedies
Section 7.7
Limitations
Section 7.8
Tax Treatment of Indemnification Payments
ARTICLE VIII CONFIDENTIALITY
Section 8.1
Confidentiality
Section 8.2
Termination of Confidentiality Agreement
Section 8.3
Permitted Disclosure
ii
27
27
27
28
29
29
30
31
34
35
36
36
37
37
38
38
38
38
39
39
40
40
40
40
41
41
42
42
42
42
43
43
43
43
43
Section 8.4
Other Relevant Obligations
ARTICLE IX TERMINATION
Section 9.1
Termination of Agreement
Section 9.2
Effect of Termination
ARTICLE X MISCELLANEOUS
Section 10.1
Specific Performance
Section 10.2
Notices
Section 10.3
Successors and Assigns
Section 10.4
Independent Nature of Relationship
Section 10.5
Entire Agreement
Section 10.6
Governing Law.
Section 10.7 Waiver of Jury Trial
Section 10.8
Severability
Section 10.9
Counterparts
Section 10.10 Amendments; No Waivers
Section 10.11 No Third Party Rights
Section 10.12
Table of Contents and Headings
iii
44
45
44
44
44
45
45
46
46
46
47
47
47
48
48
48
48
Exhibits
Exhibit A-1:
Exhibit A-2:
Exhibit A-3:
Exhibit A-4:
Exhibit B:
Exhibit C:
Exhibit D:
Exhibit E:
Exhibit F:
Exhibit G-1:
Exhibit G-2:
Exhibit H:
Schedules
Form of Closing Date Bill of Sale – Purchaser
Form of Closing Date Bill of Sale – Seller
Form of First Milestone Closing Date Bill of Sale – Purchaser
Form of First Milestone Closing Date Bill of Sale – Seller
Form of Contribution Agreement
Disclosure Schedule
Form of Equity Pledge Agreement
Form of License Agreement
Form of Payment Direction Letter
Maruishi License Agreement
Vifor License Agreement
Seller Account
Schedule 1.1(a)
Schedule 1.1(b)
Definition of “Competitor”
Definition of “Knowledge”
iv
PURCHASE AND SALE AGREEMENT
This PURCHASE AND SALE AGREEMENT (this “Purchase and Sale Agreement”), dated as of November 1,
2023, is by and between CARA ROYALTY SUB, LLC, a Delaware limited liability company (the “Seller”), HCRX
INVESTMENTS HOLDCO, L.P., a Delaware limited partnership (“HCRX”) and HEALTHCARE ROYALTY PARTNERS
IV, L.P. a Delaware limited partnership (“HCR IV”, and collectively with HCRX, the “Purchaser”).
WHEREAS, the Seller holds certain assets and rights relating to the Licensed Products; and
W I T N E S S E T H :
WHEREAS, the Seller desires to sell, contribute, assign, transfer, convey and grant to the Purchaser, and the
Purchaser desires to purchase, acquire and accept from the Seller, the Purchased Royalties described herein, upon and
subject to the terms and conditions set forth in this Purchase and Sale Agreement.
NOW, THEREFORE, in consideration of the premises and the mutual agreements, representations and warranties
set forth herein and of other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged,
the Parties covenant and agree as follows:
ARTICLE I
DEFINED TERMS AND RULES OF CONSTRUCTION
Section 1.1
Defined Terms. The following terms, as used herein, shall have the following respective meanings:
“Account Bank” means Wells Fargo Bank, N.A., or such other bank or financial institution approved by each of the
Purchaser and the Seller.
“Account Control Agreement” means any agreement entered into by the Account Bank, the Seller and the Purchaser
in form and substance reasonably satisfactory to the Purchaser, pursuant to which, among other things, the Purchaser shall
have control over the Lockbox Account within the meaning of Section 9-104 of the UCC.
“Affiliate” means, with respect to any designated Person, any other Person that, directly or indirectly, controls, is
controlled by or is under common control with such designated Person. For purposes of this definition, “control” of a
Person means the possession, directly or indirectly, of the power to direct or cause the direction of the management and
policies of such Person, whether through the ownership of Equity Interests, by contract or otherwise, and the terms
“controlled” and “controlling” have meanings correlative to the foregoing.
“Applicable Law” means, with respect to any Person, all laws, rules, regulations and orders of Governmental
Authorities applicable to such Person or any of its properties or assets.
“Bankruptcy Event” means the occurrence of any of the following in respect of any Person: (a) an admission in
writing by such Person of its inability to pay its debts as they become due or a general assignment by such Person for the
benefit of creditors; (b) the filing of any petition or answer by such Person seeking to adjudicate itself as bankrupt or
insolvent, or seeking for itself any liquidation, winding-up, reorganization, arrangement, adjustment, protection, relief or
composition of such Person or its debts under any law relating to bankruptcy, insolvency, receivership, winding-up,
liquidation, reorganization,
examination, relief of debtors or other similar law now or hereafter in effect, or seeking, consenting to or acquiescing in the
entry of an order for relief in any case under any such law, or the appointment of or taking possession by a receiver, trustee,
custodian, liquidator, examiner, assignee, sequestrator or other similar official for such Person or for any substantial part of
its property; (c) corporate or other entity action taken by such Person to authorize any of the actions set forth in clause (a) or
(b) of this definition; or (d) without the consent or acquiescence of such Person, the entering of an order for relief or
approving a petition for relief or reorganization or any other petition seeking any reorganization, arrangement, composition,
readjustment, liquidation, dissolution or other similar relief under any present or future bankruptcy, insolvency or similar
statute, law or regulation, or the filing of any such petition against such Person, or, without the consent or acquiescence of
such Person, the entering of an order appointing a trustee, custodian, receiver or liquidator of such Person or of all or any
substantial part of the property of such Person, in each case where such petition or order shall remain unstayed or shall not
have been stayed or dismissed within ninety (90) days from entry thereof.
“Business Day” means any day that is not a Saturday, Sunday or other day on which commercial banks in New York
City are authorized or required by Applicable Law to remain closed.
“Change of Control” means (a) any reorganization, recapitalization, consolidation or merger (or similar transaction
or series of related transactions) of the Company or issuance, sale or exchange of Equity Interests (or similar transaction or
series of related transactions but excluding any issuance of Equity Interests by the Company the net proceeds of which are
received by the Company solely for bona fide general operating purposes) of the Company in which the beneficial owners
(as defined in Rules 13d-3 and 13d-5 under the Securities Exchange Act of 1934, as amended) of the Company’s outstanding
Equity Interests immediately before consummation of such transaction or series of related transactions do not, immediately
after consummation of such transaction or series of related transactions, continue to beneficially own, directly or indirectly,
Equity Interests representing more than 50.0% of the voting power of the surviving entity of such transaction or series of
related transactions, in each case without regard to whether the Company is the surviving entity, (b) the sale of all or
substantially all of the assets of the Company, (c) the Company no longer being the beneficial owner directly or indirectly of
100% of the outstanding Equity Interests of the Seller, (d) the Seller no longer directly owning the Transferred Assets,
including 100% of the royalties and milestone payments under the Covered License Agreements, other than the portion
payable to the Purchaser hereunder as Purchased Royalties or (e) any other transaction or series of transactions whereby the
Company’s economic interests in the Seller are sold, assigned, transferred or conveyed in whole or in part.
“Change of Control Payment” has the meaning set forth in Section 2.3.
“Closing” has the meaning set forth in Section 6.1.
“Closing Date” has the meaning set forth in Section 6.1.
“Closing Date Bill of Sale - Purchaser” means that certain bill of sale, dated as of the Closing Date, executed by the
Seller and the Purchaser, substantially in the form of Exhibit A-1.
“Closing Date Bill of Sale - Seller” means that certain bill of sale, dated as of the Closing Date, executed by the
Company and the Seller pursuant to the Contribution Agreement with respect to the Transferred Assets, substantially in the
form of Exhibit A-2.
“Closing Date Bills of Sale” means, collectively, the Closing Date Bill of Sale – Purchaser and the Closing Date Bill
of Sale – Seller.
2
“Closing Payment” has the meaning set forth in Section 2.2(a).
“Code” means the U.S. Internal Revenue Code of 1986, as amended, and the regulations thereunder.
“Commercially Reasonable Efforts” or “Commercially Reasonable Actions” means, with respect to any Intellectual
Property Rights in any country, efforts or actions that would be commercially reasonable for an owner and licensor of such
Intellectual Property Rights in such country, which owner and licensor is entitled to the full economic benefit of such
Intellectual Property Rights without regard to the transactions contemplated by this Purchase and Sale Agreement or any
other business of, or assets owned by, such owner and licensor.
“Company” means Cara Therapeutics, Inc., a Delaware corporation.
“Competitor” has the meaning set forth on Schedule 1.1(a).
“Confidential Information” has the meaning set forth in Section 8.1.
“Contribution” means the sale, transfer, assignment, contribution and conveyance by the Company of the
Transferred Assets to the Seller pursuant to the Contribution Agreement.
“Contribution Agreement” means the Contribution and Servicing Agreement, dated as of the Closing Date, between
the Company and the Seller, in the form of Exhibit B attached hereto.
“Counterparty” means, as the context requires, Maruishi or Vifor. For the avoidance of doubt, Vifor shall only be
deemed a Counterparty from and after, and subject to the occurrence of, the First Milestone Closing Date.
“Covered License Agreement Royalties” means (i) as of the Closing Date, the Maruishi Royalties and, from and
after, and subject to the occurrence of, the First Milestone Closing Date, the Maruishi Royalties and the Vifor Royalties,
collectively.
“Covered License Agreements” means (i) as of the Closing Date, the Maruishi License Agreement and (ii) from and
after, and subject to the occurrence of, the First Milestone Closing Date, the Maruishi License Agreement and the Vifor
License Agreement, collectively.
“Defaulting Party” has the meaning set forth in Section 5.5(d).
“Difelikefalin” means the kappa opioid receptor agonist compound known as difelikefalin or CR-845, which has the
chemical structure set forth in Exhibit A of the Maruishi License Agreement and Exhibit 1.18 of the Vifor License
Agreement, and any improvements and enhancements thereof made by or on behalf of the Company and its Affiliates.
“Disclosing Party” has the meaning set forth in Section 8.1.
“Disclosure Schedule” means, (i) initially, the Disclosure Schedule, dated as of the date hereof and attached hereto
as Exhibit C and (ii) from and after the First Milestone Closing Date, Exhibit C hereto as supplemented in accordance with
Section 5.12.
“Disputes” has the meaning set forth in Section 3.11(i).
“Dollar” or the sign “$” means United States dollars.
3
“Equity Interests” means, with respect to any Person, all of the (i) shares of capital stock of (or other ownership or
profit interests in) such Person, (ii) warrants, options or other rights for the purchase or acquisition from such Person of
shares of capital stock of (or other ownership or profit interests in) such Person, (iii) securities convertible into or
exchangeable for shares of capital stock of (or other ownership or profit interests in) such Person or warrants, rights or
options for the purchase or acquisition from such Person of such shares (or such other interests), and (iv) other ownership or
profit interests in such Person (including partnership, member, membership or trust interests therein), whether voting or
nonvoting, and whether or not such shares, warrants, options, rights or other interests are outstanding on any date of
determination.
“Equity Pledge Agreement” means the Equity Pledge Agreement, substantially in the form of Exhibit D attached
hereto.
“Excluded Liabilities and Obligations” has the meaning set forth in Section 2.5.
“Excluded Maruishi Development Milestone Payments” means the development milestone payments included in
Section 6.2(a) of the Maruishi License Agreement under the heading “Japan Development.”
“Existing Confidentiality Agreement” means that certain letter agreement, dated March 17, 2023, by and between
the Company and HealthCare Royalty Management, LLC, an Affiliate of the Purchaser, as amended.
“Exploit” and “Exploitation” shall mean, with respect to a product such as a Licensed Product, the manufacture, use,
sale, offer for sale (including marketing and promotion), importation, distribution or other commercialization of such
product.
“FDA” means the U.S. Food and Drug Administration and any successor agency thereto.
“First Milestone Closing Date” has the meaning set forth in Section 2.2(b).
“First Milestone Closing Date Bill of Sale - Purchaser” means that certain bill of sale, dated as of the Closing Date,
executed by the Seller and the Purchaser, substantially in the form of Exhibit A-3.
“First Milestone Closing Date Bill of Sale - Seller” means that certain bill of sale, dated as of the Closing Date,
executed by the Company and the Seller pursuant to the Contribution Agreement with respect to the Transferred Assets,
substantially in the form of Exhibit A-4.
“First Milestone Closing Date Bills of Sale” means, collectively, the First Milestone Closing Date Bill of Sale –
Purchaser and the First Milestone Closing Date Bill of Sale – Seller.
“First Milestone Closing Date Representations” means the representations of the Seller contained in Sections 3.1,
3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.10, 3.13, 3.17(a), (b), (c), (d), (e), (f), (g), (j) and (k).
“First Milestone Event” means Reimbursement Approval has been obtained, prior to December 31, 2023, for the
Vifor Licensed Products from the Gemeinsamer Bundesausschuss in Germany reflecting a list price of at least €29 per dose.
“First Milestone Payment” has the meaning set forth in Section 2.2(b).
4
“GAAP” means generally accepted accounting principles in effect in the United States from time to time.
“Governmental Authority” means the government of the United States, any other nation or any political subdivision
thereof, whether state or local, and any agency, authority (including supranational authority), commission, instrumentality,
regulatory body, court, central bank or other Person exercising executive, legislative, judicial, taxing, regulatory or
administrative powers or functions of or pertaining to government, including each Patent Office, the FDA and any other
government authority in any country.
“Hard Cap Amount” means the amount set forth in the chart below, which amount shall vary depending on the
applicable period in the chart below:
Applicable Period
Hard Cap Amount
Closing through and including
December 31, 2029
On and following January 1, 2030
200% of the Investment Amount
280% of the Investment Amount (the
“Maximum Hard Cap Amount”)
“HCR IV” has the meaning set forth in the preamble.
“HCRX” has the meaning set forth in the preamble.
“Intellectual Property Rights” means all the Patents, trademarks, trademark applications and know-how, used in,
relating to or necessary for the sale, manufacture, use, importation or marketing of the Licensed Products in the Territory that
is owned or controlled by the Seller or the Company, and including, for the avoidance of doubt, (i) all intellectual property
licensed to the applicable Counterparty under the Covered License Agreements to the extent used in, relating to or necessary
for the sale, manufacture, use, importation or marketing of the Licensed Products in the Territory, and (ii) all Know-How.
“Investment Amount” means, as of any time, the sum of (a) $17,500,000, (b) the First Milestone Payment (if any),
and (c) the Second Milestone Payment (if any), in each case to the extent actually received by the Seller.
“Knowledge” means [***].
“Know-How” means, collectively, the meaning given to the terms (i) “Licensed Know-How” in Section 1.28 of the
Maruishi License Agreement and (ii) “Licensed Know-How” in Section 1.49 of the Vifor License Agreement, in each case
of (i) and (ii) solely to the extent used in, relating to or necessary for the sale, manufacture, use, importation or marketing of
the Licensed Products in the Territory. For the avoidance of doubt, Know-How shall only include “Licensed Know-How” as
defined in Section 1.49 of the Vifor License Agreement from and after, and subject to the occurrence of, the First Milestone
Closing Date.
“License Agreement” means the Intercompany License Agreement, by and between the Company and the Seller,
substantially in the form of Exhibit E attached hereto.
5
“Licensed Products” means any intravenous (I.V.) pharmaceutical drug product that contains Difelikefalin as its
active ingredient.
“Lien” means any security interest, mortgage, pledge, hypothecation, assignment, deposit arrangement,
encumbrance, lien (statutory or otherwise), charge against or interest in property or other priority or preferential arrangement
of any kind or nature whatsoever, including any conditional sale or any sale with recourse, or any other restriction on
transfer.
“Lockbox Account” means a segregated deposit account established and maintained at the Account Bank pursuant
to an Account Control Agreement.
“Loss” means any loss, liability, cost, expense (including reasonable costs of investigation and defense and
reasonable attorneys’ fees and expenses), charge, fine, penalty, obligation, judgment, award, assessment, claim or cause of
action.
“Maruishi” means Maruishi Pharmaceutical Co., Ltd.
“Maruishi License Agreement” means that certain License Agreement, dated as of April 4, 2013, by and between
the Company and Maruishi, as amended from time to time (but subject to the terms of this Purchase and Sale Agreement
with respect to the amendment thereof).
“Maruishi Licensed Products” has the meaning given to the term “Licensed Product” in Section 1.30 of the Maruishi
License Agreement.
“Maruishi Reimbursement Terms” has the meaning set forth in Section 3.12(c).
“Maruishi Royalties” means all of the Seller’s (as assignee of the Company pursuant to the Contribution Agreement)
right, title and interest in and to (a) all amounts due, payable or paid to the Seller under Section 6.2(b) of the Maruishi
License Agreement; (b) all amounts due, payable or paid to the Seller under Section 6.3 of the Maruishi License Agreement,
as such amount may be adjusted pursuant to Section 6.4 of the Maruishi License Agreement; (c) all amounts due, payable or
paid to the Seller under Section 6.5 of the Maruishi License Agreement; (d) all amounts recovered by the Seller and not paid
to Maruishi, or by Maruishi and paid to the Seller, in excess of litigation costs and representing damages for lost sales of
Licensed Product in the Maruishi Territory or royalties on such lost sales, under Section 8.3 of the Maruishi License
Agreement; (e) all amounts due, payable or paid to the Seller in respect of any provisions concerning underpayment of or in
lieu of the amounts set forth in (a)-(d) above; (f) all interest that becomes payable in respect of the late payment of any of the
amounts referred to in the foregoing clauses (a) through (e) pursuant to Section 6.8 of the Maruishi License Agreement; (g)
all accounts (as defined under the UCC) evidencing the rights to the payments and amounts described in this definition and
(h) all proceeds (as defined under the UCC) of any of the foregoing; in each case with respect to clauses (a) through (h)
above, to the extent attributed to the Licensed Products from and after October 1, 2023 and due, payable and paid to the
Seller on or after the Closing Date. For the avoidance of doubt, Maruishi Royalties shall (x) include all amounts due,
payable or paid to the Seller or any of its Affiliates by one or more licensees or sublicensees under any New Arrangement to
the extent attributed to the Licensed Product, (y) be computed without reduction for withholding of any Taxes by any
licensee, sublicensee or the Seller, other than withholding in respect of any Purchaser Connection Taxes to the extent
properly withheld and remitted to the applicable taxing authority and (z) shall not include Excluded Maruishi Development
Milestone Payments or any amounts attributed to any non-intravenous formulation of Difelikefalin or any amounts due and
payable prior to the Closing Date that is paid on or after the Closing Date.
6
For clarity, (a) the amount of sales milestone payment under Section 6.2(b) of the Maruishi License Agreement that
is attributed to the Licensed Product shall equal to the amount of such milestone payment multiplied by a fraction A/B,
where A is the total aggregate (from first commercial sale) Net Sales (as defined in the Maruishi License Agreement) of the
Licensed Product in the Maruishi Territory when the Net Sales threshold set forth therein is reached, and B is the total
aggregate (from first commercial sale) Net Sales of all Maruishi Licensed Products in the Maruishi Territory when the Net
Sales threshold set forth therein is reached; and (b) the amount of royalty payment under Section 6.3 of the Maruishi License
Agreement that is attributed to the Licensed Product shall equal to the Net Sales of the Licensed Product multiplied by the
average royalty rate applicable to all Maruishi Licensed Products in the relevant reporting period.
“Maruishi Royalty Reports” means the royalty reports delivered to the Seller by Maruishi pursuant to Section 6.6 of
the Maruishi License Agreement.
“Maruishi Territory” means “Territory” as defined in Section 1.53 of the Maruishi License Agreement.
“Material Adverse Effect” means a material adverse effect on (a) the legality, validity or enforceability of any of the
Transaction Documents or the Covered License Agreements, (b) the ability of the Seller or the Company to perform its
obligations under any of the Transaction Documents or the Covered License Agreements, (c) the rights or remedies of the
Purchaser under any of the Transaction Documents or the Covered License Agreements, (d) the right of the Purchaser to
receive the Purchased Royalties, the timing, amount or duration of the Purchased Royalties, or the right to receive royalty
reports and other information (including audit information) on the terms set forth in the Covered License Agreements and
this Purchase and Sale Agreement, or (e) the business of the Seller and its Subsidiaries, taken as a whole.
“New Arrangement” has the meaning set forth in Section 5.6(a).
“Party” shall mean the Seller or the Purchaser, as the context requires, and “Parties” shall mean, together, the Seller
and the Purchaser.
“Patent Office” means the applicable patent office, including the United States Patent and Trademark Office and any
comparable foreign patent office, for any Intellectual Property Rights that are Patents.
“Patents” means any and all issued patents and pending patent applications, including without limitation, all
provisional applications, substitutions, continuations, continuations-in part, divisions, and renewals, all letters patent granted
thereon, and all patents-of-addition, reissues, reexaminations and extensions or restorations by existing or future extension or
restoration mechanisms (including regulatory extensions), and all supplementary protection certificates, together with any
foreign counterparts thereof anywhere, claiming or covering the Licensed Products, or composition of matter, formulation,
or methods of manufacture or use thereof, that are issued or filed on or after the date of this Purchase and Sale Agreement, in
each such case, which are owned or controlled by, issued or licensed to, licensed by, or hereafter acquired or licensed by, the
Company, the Seller or any Subsidiary of the Company or the Seller, and including, for the avoidance of doubt, the Patents
listed on Section 3.11(a) of the Disclosure Schedule.
“Payment Direction Letter” means, with respect to each Counterparty, a payment direction letter substantially in the
form of Exhibit F attached hereto.
7
“Payment Direction Letters” means, collectively, the Payment Direction Letters required to be delivered pursuant to
this Purchase and Sale Agreement.
“Permitted Tax Withholding” means (a) in the case of the Maruishi License Agreement, any Tax withholding
expressly permitted under Section 6.9 of the Maruishi License Agreement and (b) in the case of the Vifor License
Agreement, any Tax withholding expressly permitted under Section 6.9(a) of the Vifor License Agreement.
“Person” means any natural person, firm, corporation, limited liability company, partnership, joint venture,
association, joint-stock company, trust, unincorporated organization, Governmental Authority or any other legal entity,
including public bodies, whether acting in an individual, fiduciary or other capacity.
“Purchase and Sale Agreement” has the meaning set forth in the preamble.
“Purchased Royalties” means, on any date prior to the Royalty Termination Date, (i) with respect to HCRX, 50% of
the Covered License Agreement Royalties and (ii) with respect to HCR IV, 50% of the Covered License Agreement
Royalties.
“Purchaser” has the meaning set forth in the preamble.
“Purchaser Account” has the meaning set forth in Section 5.4(b).
“Purchaser Connection Tax” means any Tax to the extent that it would not be imposed but for (i) any connection of
the Purchaser with the jurisdiction of the applicable taxing authority (other than a connection arising from this Purchase and
Sale Agreement and/or any transactions contemplated hereby) or (ii) any failure of the Purchaser to provide any applicable
documentation that is reasonably requested by the applicable withholding agent and that the Purchaser is legally eligible to
provide.
“Purchaser Expenses” means all documented third-party expenses incurred by the Purchaser in connection with the
transactions contemplated by this Purchase and Sale Agreement on or prior to the Closing; provided, however, that
Purchaser Expenses shall not exceed $500,000.
“Purchaser Indemnified Party” has the meaning set forth in Section 7.1.
“Purchaser Indemnified Tax” means any withholding Tax (other than a Purchaser Connection Tax) withheld by any
licensee, sublicensee, the Seller, or any other applicable withholding agent in respect of any payment made to the Purchaser
pursuant to this Purchase and Sale Agreement.
“Qualified Buyer” means either (i) a publicly traded biopharmaceutical company with a market capitalization in
excess of $250,000,000, calculated on a combined basis with the Company as of the close of business on the trading day
immediately preceding the date of the public announcement of a Change of Control, or (ii) any other biopharmaceutical
company with total assets of not less than $500,000,000, calculated on a combined basis with the Company as of the most
recent respective dates for which the Company or the applicable Third Party (on a consolidated basis with its parent) in such
Change of Control have unaudited balance sheets available.
“Receiving Party” has the meaning set forth in Section 8.1.
“Regulatory Agency” means a Governmental Authority with responsibility for the approval of the marketing and
sale of pharmaceuticals or other regulation of pharmaceuticals in any country.
8
“Regulatory Approval” means, collectively, all regulatory approvals, registrations, certificates, authorizations,
permits and supplements thereto, as well as associated materials (including the product dossier) pursuant to which the
Licensed Products may be marketed, sold and distributed by Maruishi or Vifor, as the case may be, in a jurisdiction, issued
by the appropriate Regulatory Agency.
“Reimbursement Approval” means an approval, agreement, determination or other decision by the applicable
Governmental Authority and/or Regulatory Agency that establishes prices charged to end-users for biopharmaceutical
products that a Licensed Product will be reimbursed by the Governmental Authorities and/or Regulatory Agency in the
applicable jurisdiction.
“Royalty Reduction” has the meaning set forth in Section 3.13(f).
“Royalty Reports” means the Maruishi Royalty Reports and the Vifor Royalty Reports. For the avoidance of doubt,
Royalty Reports shall only include the Vifor Royalty Reports from and after, and subject to the occurrence of, the First
Milestone Closing Date.
“Royalty Termination Date” means the earlier of (a) the date on which the Total Net Amount equals the Hard Cap
Amount or (b) the date of the last royalty or milestone payment under the Covered License Agreements.
“SEC” means the U.S. Securities and Exchange Commission.
“Second Milestone Closing Date” has the meaning set forth in Section 2.2(c).
“Second Milestone Event” has the meaning set forth in Section 2.2(c).
“Second Milestone Payment” has the meaning set forth in Section 2.2(c).
“Seller” has the meaning set forth in the preamble.
“Seller Account” has the meaning set forth in Section 5.4(d).
“Seller Indemnified Party” has the meaning set forth in Section 7.2.
“Set-off” means any set-off or off-set.
“Subsidiary” means, with respect to any Person, any other Person of which more than 50% of the outstanding Equity
Interests of such other Person (irrespective of whether at the time Equity Interests of any other class or classes of such other
Person shall or might have voting power upon the occurrence of any contingency) is at the time directly or indirectly owned
or controlled by such Person, by such Person and one or more other Subsidiaries of such Person or by one or more other
Subsidiaries of such Person.
“Tax” or “Taxes” means any U.S. federal, state, local or non-U.S. income, gross receipts, license, payroll,
employment, excise, severance, occupation, premium, windfall profits, environmental, customs duties, capital stock,
franchise, profits, withholding, social security, unemployment, disability, real property, personal property, escheat or
unclaimed property, sales, use, value added, alternative or add-on minimum, estimated or other tax of any kind whatsoever,
including, in each case, (a) any interest, penalty or addition thereto and (b) whether disputed or not.
9
“Territory” means, collectively, Maruishi Territory and Vifor Territory. For the avoidance of doubt, Territory shall
only include the Vifor Territory from and after, and subject to the occurrence of, the First Milestone Closing Date.
“Third Party” means any Person that is not a Party.
“Third Party Claim” means any claim, action, suit or proceeding by a Third Party, including any investigation by
any Governmental Authority.
“Total Net Amount” means, as of any time, the aggregate payments remitted to or otherwise received by the
Purchaser on or prior to such time pursuant to the Transaction Documents which shall be computed, for the avoidance of
doubt, by (a) including any additional amounts payable to the Purchaser pursuant to Section 5.8(a) in respect of any
Purchaser Indemnified Taxes and (b) excluding any amounts withheld in respect of any Purchaser Indemnified Taxes
(including in respect of any additional amounts payable pursuant to Section 5.8(a) to the extent such amounts are properly
withheld and remitted to the applicable taxing authority).
“Transaction Documents” means this Purchase and Sale Agreement, the Account Control Agreement, the Closing
Date Bills of Sale, the First Milestone Closing Date Bills of Sale, the Contribution Agreement, the Equity Pledge
Agreement, the License Agreement, and the Payment Direction Letters.
“Transferred Assets” has the meaning set forth in the Contribution Agreement.
“UCC” means the Uniform Commercial Code as in effect from time to time in the State of Delaware; provided, that
if, with respect to any financing statement or by reason of any provisions of law, the perfection or the effect of perfection or
non-perfection of the back-up security interest or any portion thereof granted pursuant to Section 2.1(d) is governed by the
Uniform Commercial Code as in effect in a jurisdiction of the United States other than the State of Delaware, then “UCC”
means the Uniform Commercial Code as in effect from time to time in such other jurisdiction for purposes of the provisions
of this Purchase and Sale Agreement and any financing statement relating to such perfection or effect of perfection or non-
perfection.
“U.S.” or “United States” means the United States of America, its 50 states, each territory thereof and the District of
Columbia.
“Vifor” means Vifor Fresenius Medical Care Renal Pharma Ltd., a corporation organized and existing under the
laws of Switzerland.
“Vifor License Agreement” means that certain License Agreement, dated as of May 17, 2018, by and between the
Company and Vifor, as amended from time to time (but subject to the terms of this Purchase and Sale Agreement with
respect to the amendment thereof).
“Vifor Licensed Products” has the meaning given to the term “Licensed Product” in Section 1.51 of the Vifor
License Agreement.
“Vifor Royalties” means all of the Seller’s (as assignee of the Company pursuant to the Contribution Agreement)
right, title and interest in and to (a) all amounts due, payable or paid to the Seller under Sections 6.3 and 6.4 of the Vifor
License Agreement; (b) all amounts recovered by the Seller and not paid to Vifor, or by Vifor and paid to the Seller, in
excess of litigation costs and representing damages for lost sales of Licensed Product in the Vifor Territory or royalties on
such lost sales, under Section 7.7 or Section 7.8 of the Vifor License Agreement; (c) all interest that becomes payable in
respect of the late
10
payment of any of the amounts referred to in the foregoing clauses (a) through (b) pursuant to Section 6.12 of the Vifor
License Agreement; (d) all accounts (as defined under the UCC) evidencing the rights to the payments and amounts
described in this definition and (e) all proceeds (as defined under the UCC) of any of the foregoing; in each case with respect
to clauses (a) through (e) above, to the extent attributed to the Licensed Product from and after October 1, 2023 and due,
payable and paid to the Seller on or after Closing Date. For the avoidance of doubt, Vifor Royalties shall (x) include all
amounts due, payable or paid to the Seller or any of its Affiliates by one or more licensees or sublicensees under any New
Arrangement and to the extent attributed to the Licensed Product, (y) be computed without reduction for withholding of any
Taxes by any licensee, sublicensee or the Seller, other than withholding in respect of any Purchaser Connection Taxes to the
extent properly withheld and remitted to the applicable taxing authority and (z) shall not include any amounts attributed to
any non-intravenous formulation of Difelikefalin or any amounts due and payable prior to the Closing Date that is paid on or
after the Closing Date.
“Vifor Royalty Reports” means all royalty reports delivered to the Seller by Vifor pursuant to Section 6.7 of the
Vifor License Agreement.
“Vifor Territory” means “Licensed Territory” as defined in Section 1.52 of the Vifor License Agreement.
Section 1.2
Rules of Construction.
(a)
Unless the context otherwise requires, in this Purchase and Sale Agreement:
(i)
a term has the meaning assigned to it and an accounting term not otherwise defined has the meaning
assigned to it in accordance with GAAP;
(ii)
unless otherwise defined, all terms that are defined in the UCC shall have the meanings stated in the
UCC;
(iii)
words of the masculine, feminine or neuter gender shall mean and include the correlative words of
other genders;
(iv)
“without limitation”;
the terms “include,” “including” and similar terms shall be construed as if followed by the phrase
(v)
unless otherwise specified, references to a contract or agreement include references to such contract
or agreement as from time to time amended, restated, reformed, supplemented or otherwise modified in accordance
with its terms (subject to any restrictions on such amendments, restatements, reformations, supplements or
modifications set forth herein), and include any annexes, exhibits and schedules hereto or thereto, as the case may
be;
(vi)
any reference to any Person shall be construed to include such Person’s successors and assigns
(subject to any restrictions on assignment, transfer or delegation set forth herein or in any of the other Transaction
Document) and any reference to a Person in a particular capacity excludes such Person in other capacities;
(vii)
references to any Applicable Law shall include such Applicable Law as from time to time in effect,
including any amendment, modification, codification, replacement, or reenactment thereof or any substitution
therefor;
11
(viii)
the word “will” shall be construed to have the same meaning and effect as the word “shall”;
(ix)
the words “hereof,” “herein,” “hereunder” and similar terms shall refer to this Purchase and Sale
Agreement as a whole and not to any particular provision hereof, and Article, Section and Exhibit references herein
are references to Articles and Sections of, and Exhibits to, this Purchase and Sale Agreement unless otherwise
specified;
(x)
the definitions of terms shall apply equally to the singular and plural forms of the terms defined;
(xi)
in the computation of a period of time from a specified date to a later specified date, the word
“from” means “from and including” and each of the words “to” and “until” means “to but excluding”; and
(xii)
where any payment is to be made, any funds are to be applied or any calculation is to be made under
this Purchase and Sale Agreement on a day that is not a Business Day, unless this Purchase and Sale Agreement
otherwise provides, such payment shall be made, such funds shall be applied and such calculation shall be made on
the succeeding Business Day, and payments shall be adjusted accordingly
(b)
The provisions of this Purchase and Sale Agreement shall be construed according to their fair meaning and
neither for nor against any Party irrespective of which Party caused such provisions to be drafted. Each Party acknowledges
that it has been represented by an attorney in connection with the preparation and execution of this Purchase and Sale
Agreement and the other Transaction Documents.
ARTICLE II
PURCHASE AND SALE OF THE PURCHASED ROYALTIES
Section 2.1
Purchase and Sale.
(a)
Subject to the terms and conditions of this Purchase and Sale Agreement, (i) on the Closing Date, the Seller
hereby sells, contributes, assigns, transfers, conveys and grants to the Purchaser, and the Purchaser hereby purchases,
acquires and accepts from the Seller, all of the Seller’s rights, title and interest in and to the Maruishi Royalties, free and
clear of any and all Liens, other than those Liens created under the Transaction Documents and (ii) on the First Milestone
Closing Date, the Seller shall sell, contribute, assign, transfer, convey and grant to the Purchaser, and the Purchaser shall
purchase, acquire and accept from the Seller, all of the Seller’s rights, title and interest in and to the Vifor Royalties, free and
clear of any and all Liens, other than those Liens created under the Transaction Documents. For the avoidance of doubt, in
the event that the First Milestone Event is not achieved by December 31, 2023, the Vifor Royalties shall not be sold or
otherwise assigned to the Purchaser without the mutual agreement of the Purchaser and the Seller.
(b)
The Seller and the Purchaser intend and agree that the sale, contribution, assignment, transfer, conveyance
and granting of the Purchased Royalties under this Purchase and Sale Agreement shall be, and are, a true, complete, absolute
and irrevocable assignment and sale by the Seller to the Purchaser of the Purchased Royalties (including for U.S. federal
income tax purposes) and that such assignment and sale shall provide the Purchaser with the full benefits of ownership of the
Purchased Royalties. Neither the Seller nor the Purchaser intends the transactions contemplated hereby to be, or for any
purpose (including U.S. federal income tax purposes) characterized as, a loan from the Purchaser to the Seller or a pledge or
assignment or a security agreement. The Seller waives any right to contest or otherwise assert that this
12
Purchase and Sale Agreement does not constitute a true, complete, absolute and irrevocable sale and assignment by the
Seller to the Purchaser of the Purchased Royalties under Applicable Law, which waiver shall be enforceable against the
Seller or the Company, as applicable, in any Bankruptcy Event in respect of the Seller, or the Company, as applicable. The
sale, contribution, assignment, transfer, conveyance and granting of the Purchased Royalties shall be reflected on the
Company’s financial statements and other records as a sale of assets to the Purchaser (except to the extent GAAP or the rules
of the SEC require otherwise with respect to the Seller’s consolidated financial statements).
(c)
The Seller hereby authorizes the Purchaser and its agents and representatives to execute, record and file, and
consents to the Purchaser and its agents and representatives executing, recording and filing, at the Purchaser’s sole cost and
expense, financing statements in the appropriate filing offices under the UCC (and continuation statements with respect to
such financing statements when applicable), and amendments thereto, in such manner and in such jurisdictions as are
necessary or appropriate to evidence or perfect the sale, contribution, assignment, transfer, conveyance and grant by the
Seller to the Purchaser, and the purchase, acquisition and acceptance by the Purchaser from the Seller, of the Purchased
Royalties and to perfect the security interest in the Purchased Royalties granted by the Seller to the Purchaser pursuant to
Section 2.1(d)-(e).
(d)
Notwithstanding that the Seller and the Purchaser expressly intend for the sale, contribution, assignment,
transfer, conveyance and granting of the Maruishi Royalties to be a true, complete, absolute and irrevocable sale and
assignment, the Seller hereby assigns, conveys, grants and pledges to the Purchaser, as security for its obligations created
hereunder in the event that the transfer of the Maruishi Royalties contemplated by this Purchase and Sale Agreement is held
not to be a sale, a first priority security interest in and to all of the Seller’s right, title and interest in, to and under the
Maruishi Royalties and, in such event, this Purchase and Sale Agreement shall constitute a security agreement.
(e)
Notwithstanding that the Seller and the Purchaser expressly intend for the sale, contribution, assignment,
transfer, conveyance and granting of the Vifor Royalties to be a true, complete, absolute and irrevocable sale and
assignment, the Seller shall, on the First Milestone Closing Date, assign, convey, grant and pledge to the Purchaser, as
security for its obligations created hereunder in the event that the transfer of the Vifor Royalties contemplated by this
Purchase and Sale Agreement is held not to be a sale, a first priority security interest in and to all of the Seller’s right, title
and interest in, to and under the Vifor Royalties and, in such event, this Purchase and Sale Agreement shall constitute a
security agreement.
(f)
Upon the occurrence of the Royalty Termination Date, the Purchaser authorizes the Seller (or its designee)
to execute, record and file, and consents to the Seller (or its designee) executing, recording and filing, at the Seller’s sole
cost and expense, financing termination statements in the appropriate filing offices under the UCC for all UCC financing
statements (and continuation statements with respect to such financing statements when applicable), and amendments
thereto, in such manner and in such jurisdictions as are necessary or appropriate to evidence or effectuate the release and
discharge of all such security interests and liens created pursuant to the Transaction Documents.
Section 2.2
Payment of the Investment Amount. In full consideration for the sale, transfer, conveyance and
granting of the Purchased Royalties, and subject to the terms and conditions set forth herein, the Purchaser shall make the
following payments:
(a)
Closing Payments: (i) At the Closing, an amount equal to EIGHT MILLION SEVEN HUNDRED AND
FIFTY THOUSAND DOLLARS ($8,750,000) minus the Purchaser Expenses, in immediately available funds by wire
transfer to the Seller Account which may be transferred by the Seller to the Company (the “Initial Closing Payment”) and
(ii) on or prior to November 10, 2023, an additional EIGHT MILLION SEVEN HUNDRED AND FIFTY THOUSAND
DOLLARS ($8,750,000), in immediately
13
available funds by wire transfer to the Seller Account which may be transferred by the Seller to the Company (together with
the Initial Closing Payment, the “Closing Payment”).
(b)
First Milestone Payment: Within fifteen (15) Business Days after receipt by the Purchaser of a written notice
from the Seller of the First Milestone Event, subject to the satisfaction of the conditions set forth in Section 6.5(a), an
amount equal to TWENTY MILLION DOLLARS ($20,000,000) (the “First Milestone Payment”), in immediately available
funds by wire transfer to the Seller Account which may be transferred by the Seller to the Company (the date of such
payment, the “First Milestone Closing Date”). For the avoidance of doubt, if the First Milestone Event is not achieved by
December 31, 2023, the Purchaser shall have no obligation to make the First Milestone Payment.
(c)
Second Milestone Payment: If sales of Maruishi Licensed Products in calendar year 2024 result in Maruishi
Royalties of at least $[***] (the “Second Milestone Event”), an amount equal to TWO MILLION FIVE HUNDRED
THOUSAND DOLLARS ($2,500,000) (the “Second Milestone Payment”) shall be funded by the Purchaser, at the
Purchaser’s option, either (x) by wire transfer of immediately available funds to the Seller Account on the first Business Day
of the calendar quarter following the calendar quarter in which the Second Milestone Event is achieved or (y) by the
Purchaser delivering a written instruction to the Account Bank within ten Business Days of the occurrence of the Second
Milestone Event directing that all payments received in the Lockbox Account be released to Seller until such time as the
amount of such payments equals the amount of the Second Milestone Payment (the first to occur of the wire transfer
pursuant to clause (x) or the delivery of the written instruction pursuant to clause (y), the “Second Milestone Closing Date”).
Section 2.3
Change of Control. Upon the occurrence of a Change of Control, the Seller shall promptly pay to
the Purchaser an amount equal to (i) the Maximum Hard Cap Amount less (ii) the Total Net Amount as of the effective date
of such Change of Control (the “Change of Control Payment”). Notwithstanding anything to the contrary set forth in this
Section 2.3, if the applicable acquiror (on a consolidated basis with its parent entity, if any) in such Change of Control is a
Qualified Buyer, the Seller shall not be obligated to pay the Change of Control Payment to the Purchaser upon the
occurrence of such Change of Control, provided, however, that in the case of Change of Control constituting a sale of all or
substantially all of the assets of the Company or the Seller, the applicable acquiror shall execute and deliver to the Purchaser
documentation, in form and substance reasonably satisfactory to the Purchaser, evidencing that such applicable acquiror has
assumed the obligations of the Company or the Seller, as applicable, under the Transaction Documents.
Section 2.4
Prepayment. At any time, the Seller shall have the right, but not the obligation, to pay to the
Purchaser the Maximum Hard Cap Amount less the Total Net Amount as of such date, by wire transfer of immediately
available funds to an account designated in writing by the Purchaser, and upon such payment, no further payments of the
Purchased Royalties are due to the Purchaser hereunder and the Royalty Termination Date shall be deemed to have occurred.
Section 2.5
No Assumed Obligations. Notwithstanding any provision in this Purchase and Sale Agreement or
any other writing to the contrary, the Purchaser is purchasing, acquiring and accepting only the Purchased Royalties and is
not assuming any liability or obligation of the Seller or any of the Seller’s Affiliates of whatever nature, whether presently in
existence or arising or asserted hereafter, including any liability or obligation of the Seller under the Covered License
Agreements. All such liabilities and obligations shall be retained by, and remain liabilities and obligations of, the Seller or
the Seller’s Affiliates, as the case may be (the “Excluded Liabilities and Obligations”).
Section 2.6
Excluded Assets. The Purchaser does not, by purchase, acquisition or acceptance of the right, title
or interest granted hereunder or otherwise pursuant to any of the Transaction Documents,
14
purchase, acquire or accept any assets or contract rights of the Seller under any of the Covered License Agreements, other
than the Purchased Royalties, or any other assets of the Seller.
ARTICLE III
REPRESENTATIONS AND WARRANTIES OF THE SELLER
Except as set forth on the Disclosure Schedule, the Seller hereby makes each of the following representations and
warranties to the Purchaser, (i) as of the date hereof, and in each case after giving effect to the Contribution (except as
otherwise set forth below) and (ii) as of the First Milestone Closing Date after giving effect to the Contribution to occur on
the First Milestone Closing Date:
Section 3.1
Organization. The Seller is a limited liability company duly organized, validly existing and in good
standing under the laws of the State of Delaware and has all limited liability company power and authority, and all licenses,
permits, franchises, authorizations, consents and approvals of all Governmental Authorities, required to own its property and
conduct its business, as now conducted, and to exercise its rights and to perform its obligations under the Covered License
Agreements. The Seller is duly qualified to transact business and is in good standing in every jurisdiction in which such
qualification or good standing is required by Applicable Law (except where the failure to be so qualified or in good standing
would not have a Material Adverse Effect).
Section 3.2
No Conflicts.
(a)
The execution and delivery by the Seller of any of the Transaction Documents, the performance by the
Seller of its obligations hereunder or thereunder or the consummation by the Seller of the transactions contemplated hereby
or thereby will not (i) contravene, conflict with or violate any term or provision of any of the organizational documents of
the Seller or any of its Subsidiaries, (ii) contravene, conflict with or violate, or give any Governmental Authority or other
Person the right to exercise any remedy or obtain any relief under, any Applicable Law or any judgment, order, writ, decree,
permit or license of any Governmental Authority to which the Seller or any of its Subsidiaries or any of their respective
assets or properties may be subject or bound, except as would not have a Material Adverse Effect, (iii) result in a breach or
violation of, constitute a default (with or without notice or lapse of time, or both) under, or give any Person the right to
exercise any remedy or obtain any additional rights under, or accelerate the maturity or performance of, or payment under, or
cancel or terminate, (A) except as would not be reasonably expected to result in a Material Adverse Effect, to any contract,
agreement, indenture, lease, license, deed, commitment, obligation or instrument to which the Seller or any of its
Subsidiaries is a party or by which the Seller or any of its Subsidiaries or any of their respective assets or properties is bound
or committed (other than any Covered License Agreement) or (B) any Covered License Agreement, or (iv) except as
provided in any of the Transaction Documents, result in or require the creation or imposition of any Lien on the Intellectual
Property Rights in the Territory, the Licensed Products in the Territory, the Covered License Agreements or the Purchased
Royalties.
(b)
The Seller has not granted, nor does there exist, any Lien on or relating to the Covered License Agreements,
the Intellectual Property Rights in the Territory, or the Licensed Products in the Territory. Except for Liens created under the
Transaction Documents, neither the Seller nor the Company has granted, nor does there exist, any Lien on or relating to the
Purchased Royalties. Except for the license granted by the Seller to each Counterparty under the Covered License
Agreements (and the sublicenses granted thereunder and set forth on Section 3.13(k) of the Disclosure Schedule), there are
no licenses, sublicenses or other rights under the Intellectual Property Rights that have been granted by the Seller to any
Third Party with respect to the Exploitation of the Licensed Products in the Territory.
15
Section 3.3
Authorization. The Seller has all necessary limited liability company power and authority to
execute and deliver the Transaction Documents, to perform its obligations hereunder and thereunder and to consummate the
transactions contemplated hereby and thereby. The execution and delivery of each of the Transaction Documents and the
performance by the Seller of its obligations hereunder and thereunder have been duly authorized by all necessary limited
liability company action on the part of the Seller. Each of the Transaction Documents has been duly executed and delivered
by an authorized officer of the Seller. Each of the Transaction Documents constitutes the legal, valid and binding obligation
of the Seller, enforceable against the Seller in accordance with its terms, subject to applicable bankruptcy, insolvency,
reorganization, moratorium or similar laws affecting creditors’ rights generally, general equitable principles and principles of
public policy.
Section 3.4
Ownership. The Seller and the Company are collectively the exclusive owner, or exclusive licensee,
of the entire right, title (legal and equitable) and interest in, to and under the Purchased Royalties and the Intellectual
Property Rights (with respect to the Exploitation of the Licensed Product in the Territory). The Company has duly and
legally filed or applied for registration for its ownership interest in the Patents included in the Intellectual Property Rights in
the Territory, including the Patents listed on Section 3.4 of the Disclosure Schedule, in the appropriate agencies and in the
jurisdictions listed on Section 3.4 of the Disclosure Schedule. The Purchased Royalties sold, contributed, assigned,
transferred, conveyed and granted to the Purchaser on the Closing Date or the First Milestone Closing Date, as applicable,
have not been pledged, sold, contributed, assigned, transferred, conveyed or granted by the Seller to any other Person. The
Seller has full right to sell, contribute, assign, transfer, convey and grant the Purchased Royalties to the Purchaser. Upon the
sale, contribution, assignment, transfer, conveyance and granting by the Seller of the Purchased Royalties to the Purchaser,
the Purchaser shall acquire good and marketable title to the Purchased Royalties free and clear of all Liens, other than those
Liens created under the Transaction Documents, and shall be the exclusive owner of the Purchased Royalties. The Purchaser
shall have the same rights as the Seller would have with respect to the Purchased Royalties (if the Seller were still the owner
of such Purchased Royalties) against any other Person.
Section 3.5
Governmental and Third-Party Authorizations. The execution and delivery by the Seller of the
Transaction Documents, the performance by the Seller of its obligations hereunder and thereunder and the consummation by
the Seller of the transactions contemplated hereby and thereby do not require any consent, approval, license, order,
authorization or declaration from, notice to, action or registration by, or filing with, any Governmental Authority or any
other Person, except for (i) the filing of a Current Report on Form 8-K with the SEC, (ii) the filing of UCC financing
statements, and (iii) the delivery of the Payment Direction Letters to Maruishi and Vifor.
Section 3.6
No Litigation.
(a)
There is no action, suit, arbitration proceeding, claim, demand, citation, summons, subpoena or other
proceeding (whether civil, criminal, administrative, regulatory or informal) (i) pending or, to the Knowledge of the Seller,
threatened by or against the Seller, the Company or any of their Subsidiaries or (ii) to the Knowledge of the Seller, pending
or threatened by or against Maruishi or Vifor, their Affiliates, or any of their sublicensees, in each case, in respect of the
Covered License Agreements, the Intellectual Property Rights, the Licensed Products or the Purchased Royalties, at law or
in equity, that (i) would reasonably be expected to result in a liability to the Seller in excess of $1,000,000 or (ii) challenges
or seeks to prevent or delay the consummation of any of the transactions contemplated by any of the Transaction Documents
to which the Seller is party.
(b)
There is no inquiry or investigation (whether civil, criminal, administrative, regulatory, investigative or
informal) by or before a Governmental Authority (i) pending or, to the Knowledge of the Seller, threatened against the Seller
or any of its Subsidiaries or (ii) to the Knowledge of the Seller, pending
16
or threatened by or against Maruishi or Vifor, in each case in respect of the Covered License Agreements, the Intellectual
Property Rights, the Licensed Products or the Purchased Royalties that (i) would reasonably be expected to result in a
liability to the Seller in excess of $1,000,000 or (ii) challenges or seeks to prevent or delay the consummation of any of the
transactions contemplated by any of the Transaction Documents to which the Seller is party.
(c)
To the Knowledge of the Seller, no event has occurred or circumstance exists that may give rise to or serve
as a basis for the commencement of any such action, suit, arbitration proceeding, claim, investigation, proceeding, inquiry or
investigation referred to in Section 3.6(a) or 3.6(b).
Section 3.7
Solvency. Immediately after giving effect to the consummation of the transactions contemplated by
the Transaction Documents and the application of the proceeds therefrom, (a) the fair value of the Seller’s assets will be
greater than the sum of its debts, liabilities and other obligations, including contingent liabilities, (b) the present fair saleable
value of the Seller’s assets will be greater than the amount that would be required to pay its probable liabilities on its existing
debts, liabilities and other obligations, including contingent liabilities, as they become absolute and matured in the normal
course of business, (c) the Seller will be able to realize upon its assets and pay its debts, liabilities and other obligations,
including contingent obligations, as they mature, (d) the Seller will not have unreasonably small capital with which to
engage in its business, as now conducted and as proposed to be conducted following the Closing Date, (e) the Seller does not
have any present plans or intentions to incur debts or other obligations or liabilities beyond its ability to pay such debts or
other obligations or liabilities as they become absolute and matured, (f) the Seller will not have become subject to any
Bankruptcy Event and (g) the Seller will not have been rendered insolvent within the meaning of Section 101(32) of Title 11
of the United States Code. For purposes of this Section 3.7, the amount of all contingent obligations at any time shall be
computed as the amount that, in light of all facts and circumstances existing at such time, can reasonably be expected to
become an actual or matured liability.
Section 3.8
Tax Matters.
(a)
No deduction or withholding for or on account of any Tax has been made from any payment to the Seller or
any of its Affiliates under any Covered License Agreement. No applicable withholding agent under any Covered License
Agreement or any taxing authority has ever notified the Seller that any such withholding was required or would have been
required absent the Seller’s qualification for benefits under an applicable income Tax treaty.
(b)
(c)
There are no existing Liens for Taxes on the Purchased Royalties (or any portion thereof).
As of the Closing Date, the Seller will be treated as an entity that is disregarded from the Company, a
Delaware corporation, for U.S. federal income tax purposes.
Section 3.9
No Brokers’ Fees. The Seller has not taken any action that would entitle any person or entity other
than Armentum Partners, whose fees will be paid by the Company, to any commission or broker’s fee in connection with the
transactions contemplated by this Purchase and Sale Agreement.
Section 3.10
Compliance with Laws. None of the Seller or any of its Subsidiaries (a) has violated or is in
violation of, has been given notice of any violation of, or, to the Knowledge of the Seller, is under investigation with respect
to or has been threatened to be charged with, any violation of, any Applicable Law or any judgment, order, writ, decree,
injunction, stipulation, consent order, permit or license granted, issued or entered by any Governmental Authority or (b) is
subject to any judgment, order, writ, decree, injunction, stipulation or consent order issued or entered by any Governmental
Authority.
17
Section 3.11
Intellectual Property Matters.
(a)
Section 3.11(a) of the Disclosure Schedule sets forth an accurate and complete list of all issued Patents and
pending Patent applications. For each Patent listed on Section 3.11(a) of the Disclosure Schedule the Seller has indicated (i)
the countries in which such Patent is pending, allowed, granted or issued, (ii) including a notation of any term extensions,
the patent number and/or patent application serial number, (iii) the scheduled expiration date of each such issued Patent,
(iv) the expected scheduled expiration date of each Patent issuing from such pending Patent application once issued and (v)
the registered owner thereof.
(b)
The Company is the sole and exclusive owner of each of the Patents listed on Section 3.11(a) of the
Disclosure Schedule and each of the inventions claimed in such Patents.
(c)
To the Knowledge of the Seller, in each Patent listed on Section 3.11(a) of the Disclosure Schedule, there is
at least one valid claim (treating pending claim as if issued) that would be infringed by the Exploitation of the Maruishi
Licensed Products or Vifor Licensed Products, as applicable.
(d)
There are no unpaid maintenance or renewal fees payable by the Seller to any Third Party that currently are
overdue for any of the Patents. No Patents listed on Section 3.11(a) of the Disclosure Schedule have lapsed or been
abandoned, cancelled or expired.
(e)
To the Knowledge of the Seller, each Person who has or has had any rights in or to the Patents, including
each inventor named on the Patents, has executed a contract assigning his, her or its entire right, title and interest in and to
such Patents and the inventions embodied, described and or claimed therein, to the owner thereof, and each such contract has
been duly recorded in each Patent Office wherein it would be necessary or advisable, as determined by the Seller in its
commercially reasonable judgement, to document such assignment.
(f)
To the Knowledge of the Seller, each individual associated with the filing and prosecution of the Patents,
including the named inventors of the Patents, has complied in all material respects with all applicable duties of candor and
good faith in dealing with any Patent Office, including any duty to disclose to any Patent Office all information known by
such inventors to be material to the patentability of the Patents (including any relevant prior art), in each case, in those
jurisdictions where such duties exist.
(g)
Subsequent to the issuance of each Patent, neither the Seller nor, to the Knowledge of the Seller, any
Counterparty, has filed any disclaimer or made or permitted any other voluntary reduction in the scope of such Patent.
(h)
There is no pending or, to the Knowledge of the Seller, threatened opposition, interference, reexamination,
injunction, claim, suit, action, citation, summon, subpoena, hearing, inquiry, investigation (by the International Trade
Commission or otherwise), complaint, arbitration, mediation, demand, decree or other dispute, disagreement, proceeding or
claim (collectively, “Disputes”) challenging the legality, validity, scope, enforceability or ownership of any of the Intellectual
Property Rights or that would give rise to any Royalty Reduction against the payments due to the Seller under the Covered
License Agreements. To the Knowledge of the Seller, there are no pending or threatened Disputes by any Counterparty, or
their Affiliates or sublicensees, challenging the legality, validity, scope, enforceability or ownership of any of the Intellectual
Property Rights or that would give rise to any Royalty Reduction against the payments due to the Seller under the Covered
License Agreements. There are no Disputes by or with any Third Party against the Seller or, to the Knowledge of the Seller,
any Counterparty or any of its sublicensees involving any of the Licensed Products. The Intellectual Property Rights are not
subject to any outstanding injunction, judgment, order, decree, ruling, change, settlement or other disposition of a Dispute.
There are no
18
proceedings, other than proceedings in the ordinary course of patent prosecution with respect to the Patents listed on Section
3.11(a) of the Disclosure Schedule.
(i)
There is no pending action, suit, proceeding, investigation or claim and, to the Knowledge of the Seller,
there is no threatened action, suit, proceeding, investigation or claim, and, to the Knowledge of the Seller, no event has
occurred or circumstance exists that (with or without notice or lapse of time, or both) would reasonably be expected to give
rise to or serve as a basis for any action, suit, proceeding, investigation or claim by any Person that claims that the
manufacture, use, marketing, sale, offer for sale, importation or distribution of any Licensed Product does or could infringe
on any patent or other intellectual property rights of any Third Party or constitute misappropriation of any other Person’s
trade secrets or other intellectual property rights.
(j)
To the Knowledge of the Seller, there are no patents issued, and no pending patent applications with claims
reasonably likely to issue, owned by any Third Party, that Maruishi or Vifor, as applicable, do not have a right to use (i) that
would be infringed by Maruishi’s or Vifor’s Exploitation of a Licensed Product in the Territory, as applicable, but for
Maruishi’s and Vifor’s rights in such patents and patent applications, or (ii) that would give rise to any Royalty Reduction
against the payments due to the Seller under the Covered License Agreements.
(k)
KORSUVATM and KAPRUVIATM are each Licensed Products.
(l)
To the Knowledge of the Seller, there is no Person infringing any of the Intellectual Property Rights, and
neither the Seller nor the Company has received any notice under any of the Covered License Agreements or put any Person
on notice, of actual or alleged infringement of any of the Intellectual Property Rights.
(m)
Each of the Seller and the Company and, to the Knowledge of the Seller, each of Maruishi and Vifor has
taken all reasonable precautions to protect the secrecy, confidentiality and/or value of the applicable Know-How.
(n)
The Intellectual Property Rights constitute all of the intellectual property owned or licensed by the Seller or
the Company or any of their Affiliates that is, to the Seller’s Knowledge, necessary or useful for the manufacture, use or sale
of the Licensed Products in the Territory.
(o)
No legal opinion concerning or with respect to any Third Party intellectual property rights relating to the
Licensed Products, including any freedom-to-operate, product clearance, patentability, validity or right-to-use opinion, has
been delivered to the Seller.
(p)
To the Knowledge of the Seller, there is no Person who is or claims to be an inventor under any Patent who
is not a named inventor thereof and the list of inventors named in each issued and unexpired Patent listed on Section 3.11(a)
of the Disclosure Schedule is current and complete.
Section 3.12
Regulatory Approval and Marketing.
(a)
To the Knowledge of the Seller, each Counterparty is in compliance with its material obligations to seek,
obtain and maintain Regulatory Approval for the Licensed Products in the Territory to the extent required by the applicable
Covered License Agreement.
(b)
To the Knowledge of the Seller, each of the Licensed Products has received Regulatory Approval for
marketing and distribution for the indications and in the countries listed on Section 3.12(b) of the Disclosure Schedule.
19
(c)
Section 3.12(c) of the Disclosure Schedule sets forth the terms of the Reimbursement Approval for the
Maruishi Licensed Product in Japan (the “Maruishi Reimbursement Terms”). The Seller has not received any notice or
communication from Maruishi or any Regulatory Agency in Japan of any change to the Maruishi Reimbursement Terms,
and to the knowledge of the Seller, no event has occurred or circumstance exists that may give rise to or serve as the basis
for any change to the Maruishi Reimbursement Terms.
Section 3.13
Counterparty Agreements.
(a)
Except as set forth on the Disclosure Schedule, other than the Transaction Documents and the Covered
License Agreements, there is no contract, agreement or other arrangement (whether written or oral) to which the Seller or the
Company or any of their Subsidiaries is a party or by which any of their respective assets or properties is bound or
committed that affects or otherwise relates to the Purchased Royalties, the Covered License Agreements or the Intellectual
Property Rights with respect to the Exploitation of the Licensed Products in the Territory and that are material to the interest
of the Purchaser.
(b)
Attached as Exhibits G-1 and G-2 are true, correct and complete copies of the Covered License Agreements.
The Seller has provided to the Purchaser true, correct and complete copies of (i) all Maruishi Royalty Reports and Vifor
Royalty Reports and (ii) all material notices and correspondence delivered to the Seller by the Counterparties or by the Seller
to the Counterparties pursuant to, or relating to, the Covered License Agreements.
(c)
Each of the Covered License Agreements is in full force and effect and is the legal, valid and binding
obligation of the Seller and, to the Knowledge of the Seller, each Counterparty, enforceable against the Seller and, to the
Knowledge of the Seller, each Counterparty in accordance with its terms, subject, as to enforceability, to bankruptcy,
insolvency, reorganization, moratorium or similar laws now or hereafter in effect relating to or affecting creditors’ rights
generally, general equitable principles and principles of public policy. The Seller is not in breach or violation of or in default
under any of the Covered License Agreements. There is no event or circumstance that, upon notice or the passage of time,
or both, would constitute or give rise to any breach or default in the performance of any of the Covered License Agreements
by the Seller or, to the Knowledge of the Seller, any Counterparty.
(d)
The Seller has not waived any rights or defaults under the Covered License Agreements or released any
Counterparty, in whole or in part, from any of its obligations under any of the Covered License Agreements. There are no
oral waivers or modifications (or pending requests therefor) in respect of any of the Covered License Agreements. Neither
the Seller nor any Counterparty has agreed to amend or waive any provision of the Covered License Agreements, and the
Seller has not received or submitted any proposal to do so.
(e)
No event has occurred that would give the Seller or, to the Knowledge of the Seller, any Counterparty, the
right to terminate any of the Covered License Agreements or cease paying Purchased Royalties under any of the Covered
License Agreements. The Seller has not received any notice of an intention by any Counterparty to terminate or breach any
of the Covered License Agreements, in whole or in part, or challenging the validity or enforceability of any of the Covered
License Agreements or the obligation to pay the Purchased Royalties under any of the Covered License Agreements, or
alleging that the Seller or any Counterparty is currently in default of its obligations under any of the Covered License
Agreements. To the Knowledge of the Seller, there is and has been no default, violation or breach of any Counterparty under
any of the Covered License Agreements. The Seller has no intention of terminating any of the Covered License Agreements
and has not given any Counterparty any notice of termination of any of the Covered License Agreements, in whole or in
part.
20
(f)
Except as provided in the Covered License Agreements, the Seller is not a party to any agreement providing
for any sharing of, or providing for or permitting any right of counterclaim, credit, reduction or deduction by contract or
otherwise (a “Royalty Reduction”) or permitting any Set-off against, the Purchased Royalties.
(g)
The Seller has not consented to an assignment by any Counterparty of any of such Counterparty’s rights or
obligations under any Covered License Agreement, and the Seller does not have Knowledge of any such assignment by any
Counterparty. Except as contemplated by Section 2.1(a) and Section 2.1(d), neither the Seller nor the Company has
assigned, in whole or in part, nor has granted, incurred or suffered to exist any Lien on, the Covered License Agreements or
any of the Seller’s or the Company’s rights, title or interest in or to the Intellectual Property Rights or the Licensed Products
in the Territory.
(h)
Neither the Seller nor the Company nor any Counterparty has made any claim of indemnification under any
of the Covered License Agreements.
(i)
(j)
Agreements.
The Seller has not exercised its rights to conduct an audit under any of the Covered License Agreements.
To the Knowledge of the Seller, it has received all amounts owed to it under the Covered License
(k)
To the Knowledge of the Seller, except as set forth in Section 3.13(k) of the Disclosure Schedule, no
Counterparty to any Covered License Agreement has granted (and the Seller has not received any written notice that any
such Counterparty has granted) a sublicense to any other Person.
Section 3.14
UCC Matters. The Seller’s exact legal name is, and since formation has been, “Cara Royalty Sub,
LLC”. The Seller’s principal place of business is, and since formation has been, located in the State of Connecticut. The
Seller’s jurisdiction of formation is, and since formation has been, the State of Delaware.
Section 3.15
Set-off and Other Sources of Royalty Reduction. No Counterparty has exercised, and, to the
Knowledge of the Seller, no Counterparty has had the right to exercise, and no event or condition exists that, upon notice or
passage of time, or both, would permit any Counterparty to exercise, any Royalty Reduction or Set-off against the Purchased
Royalties or any other amounts payable to the Seller under any of the Covered License Agreements. To the Knowledge of
the Seller, there are no Third Party patents that would provide a basis for a Royalty Reduction. There are no compulsory
licenses granted or, to the Knowledge of the Seller, threatened to be granted with respect to the Intellectual Property Rights
with respect to the Exploitation of the Licensed Products in the Territory.
Section 3.16 Margin Stock. The Seller is not engaged in the business of extending credit for the purpose of
buying or carrying margin stock, and no portion of the Investment Amount shall be used by the Seller for a purpose that
violates Regulation T, U or X promulgated by the Board of Governors of the Federal Reserve System from time to time.
Section 3.17
Representations and Warranties as to the Company. Except as set forth on the Disclosure Schedule,
the Seller hereby makes each of the following representations and warranties as to the Company to the Purchaser, as of the
date hereof, and in each case after giving effect to the Contribution (except as otherwise set forth below), as follows:
21
(a)
Organization. The Company is a corporation duly incorporated, validly existing and in good standing under
the laws of the State of Delaware and has all corporate power and authority, and all licenses, permits, franchises,
authorizations, consents and approvals of all Governmental Authorities, required to own its property and conduct its
business, as now conducted, and to exercise its rights and to perform its obligations under the Covered License Agreements.
The Company is duly qualified to transact business and is in good standing in every jurisdiction in which such qualification
or good standing is required by Applicable Law (except where the failure to be so qualified or in good standing would not
have a Material Adverse Effect).
(b)
No Conflicts.
(i)
The execution and delivery by the Company of any of the Transaction Documents to which it is a
party, the performance by the Company of its obligations thereunder or the consummation by the Company of the
transactions contemplated thereby will not (i) contravene, conflict with or violate any term or provision of any of the
organizational documents of the Company or any of its Subsidiaries, (ii) contravene, conflict with or violate, or give
any Governmental Authority or other Person the right to exercise any remedy or obtain any relief under, any
Applicable Law or any judgment, order, writ, decree, permit or license of any Governmental Authority to which the
Company or any of its Subsidiaries or any of their respective assets or properties may be subject or bound, (iii) result
in a breach or violation of, constitute a default (with or without notice or lapse of time, or both) under, or give any
Person the right to exercise any remedy or obtain any additional rights under, or accelerate the maturity or
performance of, or payment under, or cancel or terminate, (A) except as would not be reasonably expected to result
in a Material Adverse Effect, to any contract, agreement, indenture, lease, license, deed, commitment, obligation or
instrument to which the Company or any of its Subsidiaries is a party or by which the Company or any of its
Subsidiaries or any of their respective assets or properties is bound or committed (other than an Covered License
Agreement) or (B) any Covered License Agreement, or (iv) except as provided in any of the Transaction
Documents, result in or require the creation or imposition of any Lien on the Intellectual Property Rights, the
Licensed Products, the Covered License Agreements or the Purchased Royalties.
(ii)
The Company has not granted, nor does there exist, any Lien on or relating to the Covered License
Agreements, the Intellectual Property Rights or the Licensed Products in the Territory (except for Liens created
under the Transaction Documents). Except for Liens created under the Transaction Documents, the Company has
not granted, nor does there exist, any Lien on or relating to the Purchased Royalties. Except for the license granted
by the Company to each Counterparty under the Covered License Agreements prior to the Contribution and the
license granted by the Company to the Seller pursuant to the License Agreement and the sublicense granted
thereunder and set forth on Section 3.13(k) of the Disclosure Schedule, there are no licenses, sublicenses or other
rights under the Intellectual Property Rights that have been granted by the Company to any Third Party with respect
to the Exploitation of the Licensed Products in the Territory.
(c)
Authorization. The Company has all necessary corporate power and authority to execute and deliver the
Transaction Documents to which it is a party, to perform its obligations thereunder and to consummate the transactions
contemplated thereby. The execution and delivery of each of the Transaction Documents and the performance by the
Company of its obligations hereunder and thereunder have been duly authorized by all necessary corporate action on the part
of the Company. Each of the Transaction Documents to which it is a party has been duly executed and delivered by an
authorized officer of the Company. Each of the Transaction Documents constitutes the legal, valid and binding obligation of
the Company, enforceable against the Company in accordance with its terms, subject to applicable bankruptcy,
22
insolvency, reorganization, moratorium or similar laws affecting creditors’ rights generally, general equitable principles and
principles of public policy.
(d)
Ownership. Prior to the Contribution, the Company was the exclusive owner of the entire right, title (legal
and equitable) and interest in, to and under the Purchased Royalties and the Intellectual Property Rights (with respect the
Exploitation of the Licensed Product in the Territory). Prior to the Contribution, the Company duly and legally filed or
applied for registration for its ownership interest in the Patents included in the Intellectual Property Rights in the Territory,
including the Patents listed on Section 3.17(d) of the Disclosure Schedule, in the appropriate agencies and in the
jurisdictions listed on Section 3.17(d) of the Disclosure Schedule. The Purchased Royalties sold, contributed, assigned,
transferred, conveyed and granted to the Purchaser on the Closing Date of the First Milestone Closing Date, as applicable,
have not been pledged, sold, contributed, assigned, transferred, conveyed or granted by the Company to any other Person
prior to the Contribution.
(e)
Governmental and Third Party Authorizations. The execution and delivery by the Company of the
Transaction Documents to which it is a party, the performance by the Company of its obligations hereunder and thereunder
and the consummation by the Company of the transactions contemplated hereby and thereby do not require any consent,
approval, license, order, authorization or declaration from, notice to, action or registration by, or filing with, any
Governmental Authority or any other Person, except for (i) the filing of a Current Report on Form 8-K with the SEC, (ii) the
filing of UCC financing statements, and (iii) the delivery of the Payment Direction Letters to Maruishi and Vifor.
(f)
No Litigation.
(i)
There is no action, suit, arbitration proceeding, claim, demand, citation, summons, subpoena or
other proceeding (whether civil, criminal, administrative, regulatory or informal) (i) pending or, to the Knowledge of
the Seller, threatened by or against the Company or any of its Subsidiaries or (ii) pending against the Company or, to
the Knowledge of the Seller, pending or threatened by or against Maruishi or Vifor, their Affiliates, or any of their
sublicensees, at law or in equity, that (i) would reasonably be expected to result in a liability to the Company or any
of its Subsidiaries in excess of $1,000,000 or (ii) challenges or seeks to prevent or delay the consummation of any of
the transactions contemplated by any of the Transaction Documents to which the Company is party.
(ii)
There is no inquiry or investigation (whether civil, criminal, administrative, regulatory, investigative
or informal) by or before a Governmental Authority (i) pending or, to the Knowledge of the Seller, threatened
against the Company or any of its Subsidiaries or (ii) pending against the Company or, to the Knowledge of the
Seller, pending or threatened by or against Maruishi or Vifor, in each case in respect of the Covered License
Agreements, the Intellectual Property Rights, the Licensed Products or the Purchased Royalties, that (i) would
reasonably be expected to result in a liability to the Company or any of its Subsidiaries in excess of $1,000,000 or
(ii) challenges or seeks to prevent or delay the consummation of any of the transactions contemplated by any of the
Transaction Documents to which the Company is party.
(iii)
To the Knowledge of the Seller, no event has occurred or circumstance exists that may give rise to
or serve as a basis for the commencement of any such action, suit, arbitration proceeding, claim, investigation,
proceeding, inquiry or investigation referred to in Section 3.17(f)(i) or 3.17(f)(ii).
(g)
Solvency. Immediately after giving effect to the Contribution and the application of the proceeds therefrom,
(a) the fair value of the Company’s assets will be greater than the sum of its debts,
23
liabilities and other obligations, including contingent liabilities, (b) the present fair saleable value of the Company’s assets
will be greater than the amount that would be required to pay its probable liabilities on its existing debts, liabilities and other
obligations, including contingent liabilities, as they become absolute and matured in the normal course of business, (c) the
Company will be able to realize upon its assets and pay its debts, liabilities and other obligations, including contingent
obligations, as they mature, (d) the Company will not have unreasonably small capital with which to engage in its business,
as now conducted and as proposed to be conducted following the Closing Date, (e) the Company does not have any present
plans or intentions to incur debts or other obligations or liabilities beyond its ability to pay such debts or other obligations or
liabilities as they become absolute and matured, (f) the Company will not have become subject to any Bankruptcy Event and
(g) the Company will not have been rendered insolvent within the meaning of Section 101(32) of Title 11 of the United
States Code. For purposes of this Section 3.17(g), the amount of all contingent obligations at any time shall be computed as
the amount that, in light of all facts and circumstances existing at such time, can reasonably be expected to become an actual
or matured liability.
(h)
Tax Matters.
(i)
No deduction or withholding for or on account of any Tax has been made from any payment to the
Company under any Covered License Agreement prior to the Contribution. No payor under any Covered License
Agreement or any taxing authority has ever notified the Company that any such withholding was required or would
have been required absent the Company’s qualification for benefits under an applicable income Tax treaty.
(ii)
There are no existing Liens for Taxes on the Purchased Royalties (or any portion thereof).
(i)
No Brokers’ Fees. The Company has not taken any action that would entitle any person or entity other than
Armentum Partners, whose fees will be paid by the Company, to any commission or broker’s fee in connection with the
transactions contemplated by this Purchase and Sale Agreement.
(j)
Compliance with Laws. None of the Company or any of its Subsidiaries (a) has violated or is in violation
of, has been given notice of any violation of, or, to the Knowledge of the Seller, is under investigation with respect to or has
been threatened to be charged with, any violation of, any Applicable Law or any judgment, order, writ, decree, injunction,
stipulation, consent order, permit or license granted, issued or entered by any Governmental Authority or (b) is subject to
any judgment, order, writ, decree, injunction, stipulation or consent order issued or entered by any Governmental Authority.
(k)
Counterparty Agreements.
(i)
Except as set forth on the Disclosure Schedule, other than the Transaction Documents and the
Covered License Agreements, there is no contract, agreement or other arrangement (whether written or oral) to
which, prior to the Contribution, the Company or any of its Subsidiaries is a party or by which any of their
respective assets or properties is bound or committed that affects or otherwise relates to the Purchased Royalties, the
Covered License Agreements or the Intellectual Property Rights with respect to the Exploitation of the Licensed
Product in the Territory.
(ii)
Each of the Covered License Agreements is in full force and effect and, prior to the Contribution,
was the legal, valid and binding obligation of the Company and, to the Knowledge of the Seller, each Counterparty,
enforceable against the Company and, to the Knowledge of the Seller, each Counterparty in accordance with its
terms, subject, as to enforceability, to bankruptcy, insolvency, reorganization, moratorium or similar laws now or
hereafter in effect relating to or
24
affecting creditors’ rights generally, general equitable principles and principles of public policy. Prior to the
Contribution, the Company was not in breach or violation of or in default under any of the Covered License
Agreements. There is no event or circumstance that, upon notice or the passage of time, or both, would constitute or
give rise to any breach or default in the performance of any of the Covered License Agreements by the Company or,
to the Knowledge of the Seller, any Counterparty.
(iii)
Prior to the Contribution, the Company had not waived any rights or defaults under the Covered
License Agreements or released any Counterparty, in whole or in part, from any of its obligations under any of the
Covered License Agreements. There are no oral waivers or modifications (or pending requests therefor) in respect
of any of the Covered License Agreements. Neither the Company nor any Counterparty has agreed to amend or
waive any provision of the Covered License Agreements, and the Company has not received or submitted any
proposal to do so.
(iv)
No event has occurred that, prior to the Contribution, would give the Company or, to the Knowledge
of the Seller, any Counterparty the right to terminate any of the Covered License Agreements or cease paying
Purchased Royalties under any of the Covered License Agreements. The Company has not received any notice of
an intention by any Counterparty to terminate or breach any of the Covered License Agreements, in whole or in part,
or challenging the validity or enforceability of any of the Covered License Agreements or the obligation to pay the
Purchased Royalties under any of the Covered License Agreements, or alleging that the Company or any
Counterparty is currently in default of its obligations under any of the Covered License Agreements. To the
Knowledge of the Seller, there is and has been no default, violation or breach of any Counterparty under any of the
Covered License Agreements. The Company has no intention of terminating any of the Covered License
Agreements and has not given any Counterparty any notice of termination of any of the Covered License
Agreements, in whole or in part.
(v)
Except as provided in the Covered License Agreements, the Company is not a party to any
agreement providing for any Royalty Reduction or permitting any Set-off against, the Purchased Royalties.
(vi)
The Company has not consented to an assignment by any Counterparty of any of such
Counterparty’s rights or obligations under any Covered License Agreement, and the Seller does not have Knowledge
of any such assignment by any Counterparty. Except as contemplated in the Contribution Agreement, the License
Agreement and the Equity Pledge Agreement, the Company has not assigned, in whole or in part, and has not
granted, incurred or suffered to exist any Lien on, the Covered License Agreements or any of the Company’s rights,
title or interest in or to the Intellectual Property Rights or the Licensed Products in the Territory.
(vii)
Neither the Company nor any Counterparty has made any claim of indemnification under any of the
Covered License Agreements.
(viii)
Agreements.
The Company has not exercised its rights to conduct an audit under any of the Covered License
(ix)
To the Knowledge of the Seller, the Company has received all amounts owed to it under the
Covered License Agreements.
(x)
To the Knowledge of the Seller, except as set forth on Section 3.17(k)(xi) of the Disclosure
Schedule, no Counterparty to any Covered License Agreement has granted (and the
25
Seller has not received any written notice that any such Counterparty has granted) a sublicense to any other Person.
(xi)
The Company has not consented to any assignment by any Counterparty of, and, to the Knowledge
of the Seller, no Counterparty has assigned, the applicable Covered License Agreement or any part thereof. Except
as contemplated by the Transaction Documents, the Company has not assigned, in whole or in part, and has not
granted any liens upon or security interests with respect to, the applicable Covered License Agreement or the
Purchased Royalties.
(l)
UCC Matters. The Company’s exact legal name is, and for the preceding 10 years has been, “Cara
Therapeutics, Inc.” The Company’s principal place of business is, and for the preceding 10 years has been, located in the
State of Connecticut. The Company’s jurisdiction of organization is, and for the preceding 10 years has been, the State of
Delaware. For the preceding 5 years, the Company has not been the subject of any merger or other corporate or other
reorganization in which its identity or status was materially changed, except in each case where it was the surviving or
resulting Person.
(m)
Set-off and Other Sources of Royalty Reduction. No Counterparty has exercised, and, to the Knowledge of
the Seller, no Counterparty has had the right to exercise, and no event or condition exists that, upon notice or passage of
time, or both, would permit any Counterparty to exercise, any Royalty Reduction or Set-off against the Purchased Royalties
or any other amounts payable to the Company under any of the Covered License Agreements. To the Knowledge of the
Seller, there are no Third Party patents that would provide a basis for a Royalty Reduction. There are no compulsory
licenses granted or, to the Knowledge of the Seller, threatened to be granted with respect to the Intellectual Property Rights
with respect to the Exploitation of the Licensed Product in the Territory.
(n)
Margin Stock. The Company is not engaged in the business of extending credit for the purpose of buying or
carrying margin stock, and no portion of the Investment Amount shall be used by the Seller for a purpose that violates
Regulation T, U or X promulgated by the Board of Governors of the Federal Reserve System from time to time.
ARTICLE IV
REPRESENTATIONS AND WARRANTIES OF THE PURCHASER
The Purchaser hereby represents and warrants to the Seller, as of the date hereof, as follows:
Section 4.1
Organization. The Purchaser is a limited partnership duly organized, validly existing and in good
standing under the laws of Delaware.
Section 4.2
No Conflicts. The execution and delivery by the Purchaser of any of the Transaction Documents to
which the Purchaser is a party, the performance by the Purchaser of its obligations hereunder or thereunder or the
consummation by the Purchaser of the transactions contemplated hereby or thereby will not (i) contravene, conflict with or
violate any term or provision of any of the organizational documents of the Purchaser, (ii) contravene, conflict with or
violate, or give any Governmental Authority or other Person the right to exercise any remedy or obtain any relief under, in
any material respect, any Applicable Law or any judgment, order, writ, decree, permit or license of any Governmental
Authority to which the Purchaser or any of its assets or properties may be subject or bound or (iii) result in a breach or
violation of, constitute a default (with or without notice or lapse of time, or both) under, or give any Person any right to
exercise any remedy, or accelerate the maturity or performance of, in any material respect, any contract, agreement,
indenture, lease, license, deed, commitment, obligation or instrument to which the Purchaser is a party or by which the
Purchaser or any of its assets or properties is bound or committed.
26
Section 4.3
Authorization. The Purchaser has all necessary limited partnership power and authority to execute
and deliver the Transaction Documents to which the Purchaser is a party, to perform its obligations hereunder and thereunder
and to consummate the transactions contemplated hereby and thereby. The execution and delivery of each of the Transaction
Documents to which the Purchaser is a party and the performance by the Purchaser of its obligations hereunder and
thereunder have been duly authorized by the Purchaser. Each of the Transaction Documents to which the Purchaser is a
party has been duly executed and delivered by the Purchaser. Each of the Transaction Documents to which the Purchaser is
a party constitutes the legal, valid and binding obligation of the Purchaser, enforceable against the Purchaser in accordance
with its respective terms, subject to applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting
creditors’ rights generally, and general equitable principles.
Section 4.4
Governmental and Third Party Authorizations. The execution and delivery by the Purchaser of the
Transaction Documents to which the Purchaser is a party, the performance by the Purchaser of its obligations hereunder and
thereunder and the consummation of the transactions contemplated hereby and thereby do not require any consent, approval,
license, order, authorization or declaration from, notice to, action or registration by, or filing with, any Governmental
Authority or any other Person, except for the filing of UCC financing statements, and the delivery of the Payment Direction
Letters to Maruishi and Vifor.
Section 4.5
No Litigation. There is no (a) action, suit, arbitration proceeding, claim, demand, citation,
summons, subpoena, investigation or other proceeding (whether civil, criminal, administrative, regulatory, investigative or
informal) pending or, to the knowledge of the Purchaser, threatened by or against the Purchaser, at law or in equity, or (b)
inquiry or investigation (whether civil, criminal, administrative, regulatory, investigative or informal) by or before a
Governmental Authority pending or, to the knowledge of the Purchaser, threatened against the Purchaser, that, in any case
challenges or seeks to prevent or delay the consummation of any of the transactions contemplated by any of the Transaction
Documents.
Section 4.6
Access to Information. The Purchaser acknowledges that it has (a) reviewed such documents and
information relating to the Intellectual Property Rights and the Licensed Products and (b) had the opportunity to ask
questions of, and to receive answers from, representatives of the Seller concerning the Intellectual Property Rights and the
Licensed Products, in each case, as it deemed necessary to make an informed decision to purchase, acquire and accept the
Purchased Royalties in accordance with the terms of this Purchase and Sale Agreement. The Purchaser has knowledge,
sophistication and experience in financial and business matters that it is capable of evaluating the risks and merits of
purchasing, acquiring and accepting the Purchased Royalties in accordance with the terms of this Purchase and Sale
Agreement.
Section 4.7
Funds Available. As of the date hereof, the Purchaser has sufficient funds on hand to satisfy its
obligations to pay the Closing Payment due and payable within the time period specified in Section 2.2(a). The Purchaser
acknowledges and agrees that its obligations under this Purchase and Sale Agreement are not contingent on obtaining
financing.
The Parties covenant and agree as follows:
ARTICLE V
COVENANTS
27
Section 5.1
Books and Records; Notices.
(a)
The Seller shall keep and maintain, or cause to be kept and maintained, at all times, full and accurate books
and records adequate to reflect accurately all financial information received and all amounts paid or received under the
Covered License Agreements in respect of the Purchased Royalties.
(b)
Within three (3) Business Days after receipt by the Seller of (i) (x) notice of the commencement by any
Third Party of, or (y) written notice from any Third Party threatening to commence, in either case any action, suit, arbitration
proceeding, claim, demand, investigation or other proceeding relating to this Purchase and Sale Agreement, any of the other
Transaction Documents, any Covered License Agreement, any transaction contemplated hereby or thereby or the Purchased
Royalties (in any case other than any notice contemplated in Section 5.1(e)), or (ii) any other correspondence relating to the
foregoing, the Seller shall (A) notify the Purchaser in writing of the receipt of such notice or correspondence and (B) provide
the Purchaser with a written summary of all material details thereof or, to the extent not prohibited by obligations of
confidentiality contained in the Covered License Agreements, if such notice is in writing, furnish the Purchaser with a copy
thereof and any materials reasonably related thereto.
(c)
Subject to Sections 5.5 (a) and 5.5(b), following the completion of each calendar quarter during the term of
this Purchase and Sale Agreement, within three (3) Business Days after the Seller receives a Royalty Report for such
calendar quarter, the Seller shall deliver to the Purchaser a true, correct and complete copy of each report in respect of such
completed calendar quarter.
(d)
Subject to Sections 5.5(a) and 5.5(b), within three (3) Business Days after receipt by the Seller of any
material written notice, certificate, offer, proposal, correspondence, report or other communication from the applicable
Counterparty relating to any Covered License Agreement, the Intellectual Property Rights, the Purchased Royalties or any
Licensed Product in the Territory (in any case, other than any notice contemplated by Section 5.1(b) or 5.1(e)), the Seller
shall (i) notify the Purchaser in writing of the receipt thereof and provide the Purchaser with a written summary of all
material details thereof and (ii) to the extent not prohibited by obligations of confidentiality contained in the Covered
License Agreements, furnish the Purchaser with a copy thereof.
(e)
The Seller shall provide the Purchaser with written notice within three (3) Business Days after obtaining
Knowledge of any of the following:
(i)
(ii)
the occurrence of any Bankruptcy Event in respect of the Seller;
any material breach or default by the Seller of or under any material covenant, agreement or other
provision of any Transaction Document;
(iii)
the Seller, any Counterparty or any other Third Party receiving any notice of audit or regulatory
action by Regulatory Agency in the Territory relating to any of the Licensed Products or the Purchased Royalties;
(iv)
any representation or warranty made by the Seller in this Purchase and Sale Agreement or any of the
other Transaction Documents (or in any certificate delivered by the Seller to the Purchaser pursuant to this Purchase
and Sale Agreement) shall prove to be untrue, inaccurate or incomplete in any material respect on the date as of
which made; or
(v)
the occurrence or existence of any change, effect, event, occurrence, state of facts, development or
condition that has had, or would reasonably be expected to have, a Material Adverse Effect.
28
(f)
In addition to the quarterly Royalty Reports to be delivered to the Purchaser pursuant to Section 5.1(c), the
Seller shall, on a quarterly basis, provide a written update to the Purchaser regarding the Purchased Royalties, which shall
include without limitation (i) all material information and reports relating to the Exploitation of the Licensed Products in the
Territory and (ii) the reports and other information received by the Seller pursuant to Section 4.2 of the Maruishi License
Agreement and, subject to the occurrence of the First Milestone Closing Date, Section 5.3 of the Vifor License Agreement.
Upon the delivery of such quarterly update by the Seller to the Purchaser, either the Seller or the Purchaser may reasonably
request to hold one videoconference for the purpose of discussing such quarterly update. In addition to the foregoing, the
Purchaser shall have the right, no more than once per calendar year, to request an in-person meeting at the Company’s office.
Any such videoconference or meeting shall be at a mutually agreeable reasonable date and time and shall include an
executive officer of each of the Company, the Seller and the Purchaser. Each of the Company, the Seller and the Purchaser
shall be solely responsible for their own costs and expenses associated with such videoconferences and meetings, including
all travel and accommodations.
(g)
The Seller shall notify the Purchaser in writing not less than thirty (30) days prior to any change in, or
amendment or alteration of, the Seller’s (i) legal name, (ii) form or type of organizational structure or (iii) jurisdiction of
organization.
(h)
The Seller shall notify the Purchaser in writing not more than thirty (30) days after becoming aware that any
Tax may be required to withheld with respect to any payment under any Covered License Agreement or otherwise to the
Purchaser pursuant to the Purchase and Sale Agreement.
Section 5.2
Public Announcement. No Party shall, and each Party shall cause its Affiliates not to, without the
prior written consent of the other Parties (which consent shall not be unreasonably withheld or delayed), issue any press
release or make any other public disclosure with respect to this Purchase and Sale Agreement or any of the other Transaction
Documents or any of the transactions contemplated hereby or thereby, except if and to the extent that any such release or
disclosure is required by Applicable Law, by the rules and regulations of any securities exchange or market on which any
security of such Party may be listed or traded or by any Governmental Authority of competent jurisdiction, in which case,
the Party proposing to issue such press release or make such public disclosure shall, to the extent reasonably practicable, (a)
provide to the other Parties a copy of such proposed release or disclosure and (b) consider in good faith any comments or
changes that the other Party may propose or suggest; provided that a Party may freely make any public disclosure identical
to a disclosure previously reviewed by the other Party in accordance with the foregoing clauses (a) and (b). Notwithstanding
the foregoing, the Purchaser understands and agrees that the Company intends to file with the SEC a Current Report on
Form 8-K describing the material terms of the transactions contemplated by this Purchase and Sale Agreement and the other
Transaction Documents and some or all of the Transaction Documents as exhibits thereto or to another filing with the SEC,
provided, that the Seller shall (a) provide to the Purchaser a draft of such filings with the SEC and (b) consider in good faith
any comments or changes that the Purchaser may propose or suggest. The Seller and the Purchaser shall jointly prepare a
press release for dissemination promptly following the Closing, such press release to be agreed upon by the Purchaser and
the Seller.
Section 5.3
Further Assurances.
(a)
Subject to the terms and conditions of this Purchase and Sale Agreement, each Party shall use commercially
reasonable efforts to execute and deliver such other documents, certificates, instruments, agreements and other writings, take
such other actions and perform such additional acts under Applicable Law as may be reasonably requested by the other Party
and necessary to implement expeditiously the transactions contemplated by, and to carry out the purposes and intent of the
provisions of, this Purchase and Sale Agreement and the other Transaction Documents, including to (i) perfect the sale,
contribution,
29
assignment, transfer, conveyance and granting of the Purchased Royalties to the Purchaser pursuant to this Purchase and Sale
Agreement, (ii) perfect, protect, more fully evidence, vest and maintain in the Purchaser good, valid and marketable rights
and interests in and to the Purchased Royalties free and clear of all Liens (other than Liens under the Transaction
Documents), (iii) create, evidence and perfect the Purchaser’s back-up security interest granted pursuant to Section 2.1(d),
and (iv) enable the Purchaser to exercise or enforce any of the Purchaser’s rights under any Transaction Document to which
the Purchaser is a party.
(b)
The Seller and the Purchaser shall cooperate and provide assistance as reasonably requested by any other
Party, at the expense of such other Party (except as otherwise set forth herein), in connection with any litigation, arbitration,
investigation or other proceeding (whether threatened, existing, initiated or contemplated prior to, on or after the Closing
Date) to which the other Party, any of its Affiliates or controlling persons or any of their respective officers, directors,
managers, employees or controlling persons is or may become a party or is or may become otherwise directly or indirectly
affected or as to which any such Persons have a direct or indirect interest, in each case relating to any Transaction
Document, the transactions contemplated hereby or thereby or the Purchased Royalties, but in all cases excluding any
litigation brought by the Seller (for itself or on behalf of any Seller Indemnified Party) against the Purchaser or brought by
the Purchaser (in each case, for itself or on behalf of any Purchaser Indemnified Party) against the Seller.
(c)
The Seller shall use its commercially reasonable efforts to comply in all material respects with all
Applicable Laws with respect to the Transaction Documents, the Covered License Agreements and the Purchased Royalties,
except where compliance therewith is being contested by the Seller in good faith by appropriate proceedings.
(d)
The Seller shall not enter into any contract, agreement or other legally binding arrangement (whether written
or oral), or grant any right to any other Person, in any case that would reasonably be expected to conflict with the
Transaction Documents or serve or operate to limit, circumscribe or alter any of the Purchaser’s rights under the Transaction
Documents (or the Purchaser’s ability to exercise any such rights).
(e)
Promptly following the Closing, in accordance with the Contribution Agreement, the Company shall pay all
commissions and broker’s fees owed to Armentum Partners by the Seller in connection with the transactions contemplated
by this Purchase and Sale Agreement.
Section 5.4
Payments on Account of the Purchased Royalties.
(a)
If, notwithstanding the terms of the Payment Direction Letters and the Account Control Agreement, any
Counterparty, any of its Affiliates, any of its sublicensees, or any other Person makes any future payment of the Purchased
Royalties to the Seller or any of its Subsidiaries, then (i) such amount shall be held by the Seller (or such Subsidiary) in trust
for the benefit of the Purchaser, (ii) the Seller (or such Subsidiary) shall have no right, title or interest whatsoever in such
portion of such payment and shall not create or suffer to exist any Lien thereon and (iii) the Seller (or such Subsidiary)
promptly, and in any event no later than five (5) Business Days following the receipt by the Seller (or such Subsidiary) of
such portion of such payment, shall remit such portion of such payment to the Purchaser Account pursuant to Section 5.4(b)
in the exact form received with all necessary endorsements.
(b)
All payments required to be made to the Purchaser pursuant to this Purchase and Sale Agreement shall be
made by wire transfer of immediately available funds, without Set-off or deduction, to the account provided by the Purchaser
in writing (or to such other account as the Purchaser shall notify the Seller in writing from time to time) (the “Purchaser
Account”).
30
(c)
If, notwithstanding the terms of the Payment Direction Letters and the Account Control Agreement, any
Counterparty, any of its Affiliates, any of its sublicensees or any other Person makes any payment to the Purchaser that does
not consist entirely of Purchased Royalties, then (i) the portion of such payment that does not constitute Purchased Royalties
shall be held by the Purchaser in trust for the benefit of the Seller, (ii) the Purchaser shall have no right, title or interest
whatsoever in such payment and shall not create or suffer to exist any Lien thereon and (iii) the Purchaser promptly, and in
any event no later than three (3) Business Days following the receipt by the Purchaser of such payment, shall remit such
payment to the Seller Account pursuant to Section 5.4(d) in the exact form received with all necessary endorsements.
(d)
The Purchaser shall make all payments required to be made by it to the Seller pursuant to this Purchase and
Sale Agreement by wire transfer of immediately available funds, without Set-off or deduction to the account set forth on
Exhibit H (or to such other account as the Seller shall notify the Purchaser in writing from time to time) (the “Seller
Account”).
(e)
If any Counterparty takes any Set-off against the Purchased Royalties (other than for any prior overpayment
of Purchased Royalties actually made to the Purchaser) for any liability, debt or other obligation that the Seller owes or
allegedly owes to such Counterparty then the Seller shall cause the amount of such Set-off to be paid promptly (but in no
event later than three (3) Business Days) following such Set-off to the Purchaser Account. If such Counterparty
subsequently makes a payment to the Purchaser in respect of a Set-off previously taken against the Purchased Royalties and
the Seller previously made a payment to the Purchaser in the amount of such Set-off pursuant to the foregoing sentence, then
the Purchaser shall promptly (but in no event later than three (3) Business Days) after the Purchaser receives such payment
by such Counterparty, pay to the Seller the amount of such payment.
(f)
The Seller shall promptly notify the Purchaser of any reduction or proposed reduction by Maruishi of the
royalty rate applicable to Maruishi Royalties pursuant to Section 6.4(a) or 6.4(c) of the Maruishi License Agreement (a
“Maruishi Rate Reduction”).
(g)
(h)
[***].
[***].
Section 5.5
Covered License Agreements.
(a)
The Seller (i) shall perform and comply with in all material respects its obligations under the Covered
License Agreements, (ii) shall not, except with the Purchaser’s consent, (A) forgive, release or compromise any Purchased
Royalties payable by the applicable Counterparty under any Covered License Agreement, or (B) amend, modify,
supplement, restate, waive, cancel or terminate (or consent to any cancellation or termination of), in whole or in part, any
provision of or right under any Covered License Agreement in a manner that would adversely affect the Purchaser’s right
under this Purchase and Sale Agreement (including the timing, amount or duration of the Purchased Royalties), (iii) shall
not, except with the Purchaser’s consent, enter into any new contract, agreement or legally binding arrangement in respect of
the Purchased Royalties, the Intellectual Property Rights with respect to the Exploitation of the Licensed Products in the
Territory, or the Licensed Products in the Territory, and (iv) shall not agree to do any of the foregoing. The Seller shall
promptly (and in any case within five (5) Business Days after the occurrence of the applicable event) deliver to the Purchaser
(i) copies of all fully-executed or definitive writings related to the matters set forth in clauses (ii), (iii) and (iv) of the
immediately preceding sentence, and (ii) written notice of the occurrence of any of the matters set forth in clauses (iii) and
(iv) above outside of the Territory.
(b)
Except as otherwise expressly set forth in this ARTICLE V and except as otherwise consented to by the
Purchaser, the Seller shall not grant or withhold any consent, exercise or waive any right
31
or option, fail to exercise any right or option or deliver to any Counterparty any notice under any Covered License
Agreement. The Seller shall promptly (and in any case within five (5) Business Days) deliver to the Purchaser copies of all
fully-executed or definitive writings related to the matters set forth in the immediately preceding sentence.
(c)
Promptly (and in any case within five (5) Business Days) after (i) receiving (x) notice from any
Counterparty, including any notice terminating any Covered License Agreement (in whole or in part), alleging any breach of
or default under any Covered License Agreement by the Seller related to the Purchased Royalties, or any other material
breach or default, or asserting the existence of any facts, circumstances or events that, alone or together with other facts,
circumstances or events, would reasonably be expected (with or without the giving of notice or passage of time, or both) to
give rise to a breach of or default under any Covered License Agreement by the Seller related to the Purchased Royalties, or
any other material breach or default, or the right to terminate any Covered License Agreement (in whole or in part) by such
Counterparty, or (y) any other correspondence relating to the foregoing; or (ii) the Seller otherwise has Knowledge of any
fact, circumstance or event that, alone or together with other facts, circumstances or events, would reasonably be expected
(with or without the giving of notice or passage of time, or both) to give rise to a breach of or default under any Covered
License Agreement by the Seller related to the Purchased Royalties, or any other material breach or default, or the right to
terminate any Covered License Agreement (in whole or in part) by any Counterparty, in each case the Seller shall (A) (x)
give written notice thereof to the Purchaser and provide the Purchaser with a written summary of all material details thereof,
(y) to the extent not prohibited by obligations of confidentiality contained in the Covered License Agreements, include a
copy of any written notice received from such Counterparty, and (z) in the case of any such breach or default or alleged
breach or default by the Seller, describe in reasonable detail any corrective action the Seller proposes to take in respect of
such breach or default; and (B) in the case of any such breach or default or alleged breach or default by the Seller, use
commercially reasonable efforts to cure such breach or default and give written notice to the Purchaser upon curing such
breach or default; provided, however, that if the Seller fails to promptly cure any such breach or default, without limiting any
other rights it may have, the Purchaser shall, upon written notice to the Seller and to the extent permitted by the Covered
License Agreements, be entitled to take any and all actions the Purchaser considers reasonably necessary to promptly cure
such breach or default, and the Seller shall cooperate with the Purchaser for such purpose and reimburse the Purchaser,
promptly (but in no event later than three (3) Business Days) following demand, for all out-of-pocket costs and expenses
incurred by the Purchaser in connection therewith.
(d)
Promptly after the Seller obtains Knowledge of any actual or alleged breach of or default that relates to the
Purchased Royalties or any other actual or alleged material breach of or default under any Covered License Agreement by
the applicable Counterparty (each, a “Defaulting Party”) or of the existence of any facts, circumstances or events that, alone
or together with other facts, circumstances or events, would reasonably be expected (with or without the giving of notice or
passage of time, or both) to give rise to any such breach of or default or the right to terminate any Covered License
Agreement (in whole or in part) by the Seller, in each case the Seller shall promptly (but in any event within five (5)
Business Days) give written notice thereof to the Purchaser and provide the Purchaser with a written summary of all material
details thereof and act as mutually agreed to take such permissible actions (including commencing legal action against the
Defaulting Party and the selection of legal counsel reasonably satisfactory to the Purchaser) to enforce compliance by the
Defaulting Party with the relevant provisions of the applicable Covered License Agreement and to exercise any or all of the
Seller’s rights and remedies, whether under such Covered License Agreement or by operation of law, with respect thereto. If
the Seller is required to act as directed by the Purchaser pursuant to this Section 5.5(d), then the Purchaser shall reimburse
the Seller, promptly on demand, for all out-of-pocket costs and expenses (including the reasonable fees and expenses of the
Seller’s counsel) incurred by the Seller in connection with the Seller’s actions and exercise of rights and remedies pursuant
to clause (ii) of the immediately preceding sentence; provided, however, that such
32
out-of-pocket costs and expenses (including the reasonable fees and expenses of the Seller’s counsel) shall be borne by the
Seller if (x) such breach, default or termination event or alleged breach, default or termination event results from a breach of
or default under any Covered License Agreement by the Seller or (y) the Seller acts without or contrary to the Purchaser’s
direction. The Purchaser shall, except to the extent prohibited by the obligations of confidentiality contained in the Covered
License Agreements, have the right, at its sole cost and expense, to attend (or, if the Seller is required to act as directed by
the Purchaser pursuant to this Section 5.5(d), participate in) any meeting, discussion, action, suit or other proceeding relating
to any such breach, default or termination event or alleged breach, default or termination event, including any counterclaim,
settlement discussions or meetings; provided, however, that the Purchaser shall have no such right to attend or participate, as
applicable, if the exercise thereof would adversely affect the maintenance by the Seller of any applicable attorney-client
privilege (and, in such event, the Parties agree to use commercially reasonable efforts to effect such other arrangements to
preserve such privilege, including negotiating to enter into a mutually acceptable joint defense agreement). Notwithstanding
anything to the contrary contained in this ARTICLE V, nothing herein shall prevent, restrict or limit the Purchaser from
directly enforcing, at the Purchaser’s sole cost and expense, a Defaulting Party’s payment obligations in respect of the
Purchased Royalties with counsel selected by the Purchaser in its sole discretion; provided, however, that the Seller shall,
except to the extent prohibited by obligations of confidentiality contained in the Covered License Agreements, make
available its relevant records and personnel to the Purchaser in connection with any such enforcement and provide
reasonable assistance and authority to file and bring any legal action in connection therewith, including, if required, being
joined as a party plaintiff, and the Purchaser shall reimburse the Seller, promptly on demand, for all out-of-pocket costs and
expenses incurred by the Seller in connection therewith, (x) unless the Defaulting Party’s breach, default or termination
event or alleged breach, default or termination event results from a breach of or default under any Covered License
Agreement by the Seller or (y) the Seller acts without or contrary to the Purchaser’s direction in respect of any such breach
or default or alleged breach or default (if the Seller is required to act as directed by the Purchaser pursuant to this Section
5.5(d)).
(e)
Patent Prosecution, Enforcement and Defense.
(i)
To the extent required or permitted by the applicable Covered License Agreements, the Seller
shall (and shall cause the Company to), at the Seller’s expense, take any and all actions, and prepare, execute,
deliver and file any and all agreements, documents and instruments, that are reasonably necessary or desirable to
diligently preserve and maintain the applicable Intellectual Property Rights in the Territory, including payment of
maintenance fees or annuities. In connection with any actions or decisions by the Seller not to act (or to cause the
Company not to act) in respect of matters contemplated by the foregoing sentence, to the extent such action or
decision would reasonably be expected to have a Material Adverse Effect, the Seller shall provide advance written
notice of all such actions or decisions not to act in order to consult with the Purchaser, and the Seller shall, in good
faith, give due consideration to any reasonable suggestions of, the Purchaser.
(ii)
To the extent required or permitted by the applicable Covered License Agreements, the Seller
shall (and shall cause the Company to), at the Seller’s expense, (A) diligently defend and enforce the applicable
Intellectual Property Rights in the Territory against infringement or interference by any other Person, and against
any claims of invalidity or unenforceability, in any jurisdiction (including by bringing any legal action for
infringement or defending any counterclaim of invalidity or action of any other Person for declaratory judgment of
non-infringement or non-interference) and (B) when available in respect of any applicable Licensed Product in the
Territory, obtain patents and any corrections, substitutions, reissues and reexaminations thereof and obtain patent
term extensions and any other forms of patent term restoration in any country in the Territory. In connection with
the Seller’s actions or decisions not to act in respect of matters
33
contemplated by the foregoing sentence, the Seller shall provide advance written notice of all such actions or
decisions not to act in order to consult with the Purchaser, if applicable, and, if applicable, allow the Purchaser
sufficient time to issue instructions. The Seller shall promptly (but in any event within five (5) Business Days)
provide to the Purchaser a copy of any written notice or other documentation received in connection with any such
legal action, suit or other proceeding, regardless of whether such legal action, suit or other proceeding occurs inside
or outside of the Territory.
(iii)
The Seller shall, except to the extent prohibited by obligations of confidentiality contained in the
Covered License Agreements, promptly (but in any event within five (5) Business Days) after receipt thereof,
provide to the Purchaser a copy of all substantive written notices or other documentation relating to the patentability,
enforceability, validity, scope or term of the Patents, and shall provide the Purchaser with a copy of drafts of any
written material proposed to be filed in response thereto.
(iv)
The Seller shall not disclaim or abandon, or fail to take any Commercially Reasonable Action
necessary or desirable to prevent the disclaimer or abandonment of, any Intellectual Property Rights in the Territory
(and the Seller shall provide written notice to the Purchaser if it disclaims or abandons or fails to take any
Commercially Reasonable Action necessary or desirable to prevent the disclaimer or abandonment of any
Intellectual Property Rights outside of the Territory).
(f)
Except in connection with any assignment by the Seller of its rights and a delegation by the Seller of its
obligations under this Purchase and Sale Agreement pursuant to and in accordance with Section 10.4, the Seller shall not
dispose of, assign or otherwise transfer, in whole or in part, any Covered License Agreement, the Purchased Royalties or any
of the Seller’s right, title or interest in or to the applicable Intellectual Property Rights with respect to the Exploitation of the
Licensed Products in the Territory (and the Seller shall provide written notice to the Purchaser if it takes any such action
outside of the Territory). The Seller shall not grant any Lien on the Intellectual Property Rights in the Territory or the
License Agreements (and the Seller shall provide written notice to the Purchaser if it grants any such Lien outside of the
Territory).
(g)
The Parties shall bear their own costs and expenses in connection with the actions pursuant to this Section
5.5.
Section 5.6
Termination of the Covered License Agreements.
(a)
Without limiting the provisions of Section 5.5 or any other rights or remedies the Purchaser may have under
this Purchase and Sale Agreement, if a Counterparty terminates or provides written notice of termination of a Covered
License Agreement or a Covered License Agreement otherwise terminates (whether in whole or in part), in any case during
the term of such Covered License Agreement, then the Seller shall, at the Purchaser’s request and direction, use
Commercially Reasonable Efforts for a period of 180 days following such termination to negotiate a license with a Third
Party with respect to the applicable Intellectual Property Rights for such Third Party to make, have made, use, import, offer
for sale and sell the applicable Licensed Products for any purpose that the terminating Counterparty would have been
permitted to make, have made, use, import, offer for sale and sell the applicable Licensed Products under the applicable
Covered License Agreement, which license shall (i) become effective not earlier than the effective date of such termination,
(ii) expire not later than the last day of the applicable royalty term under such Covered License Agreement (and, if such
termination is only in part in respect of the applicable Licensed Product in a particular country (and not in whole), the
applicable royalty term shall be such term that is applicable under the applicable Covered License Agreement for such
applicable Licensed Product in such country) and (iii) include terms, conditions and limitations that are not materially less
favorable to the
34
Seller, taking into account the sale of the Purchased Royalties pursuant to the Transaction Documents, than those contained
in the Covered License Agreements, including with respect to obligations and costs imposed on the Seller, disclaimers of the
Seller’s liability, intellectual property ownership and control and indemnification of the Seller (any such license, a “New
Arrangement”). The Seller shall consult and reasonably consider any comments from the Purchaser with respect to such
negotiation of a New Arrangement. If the Seller is unable to secure a New Arrangement within 180 days of the termination
of the applicable Covered License Agreement (or such shorter period as the Seller and the Purchaser shall agree), then the
Purchaser shall have the right to negotiate a New Arrangement on behalf of the Seller, and the Seller agrees to use
Commercially Reasonable Efforts to cooperate and assist the Purchaser in connection with the Purchaser’s efforts pursuant
to this sentence.
(b)
Should the Seller or the Purchaser identify any New Arrangement pursuant to Section 5.6(a), the Seller
agrees to exercise commercially reasonable efforts to promptly duly execute and deliver a new license agreement effecting
such New Arrangement that satisfies the foregoing requirements.
(c)
Each of the Seller and the Purchaser shall bear its own costs and expenses in connection with any New
Arrangement.
Section 5.7
Audits.
(a)
The Seller shall not, without first consulting the Purchaser, cause an inspection or audit of any
Counterparty’s books and records to be conducted pursuant to and in accordance with Section 6.10 of the Maruishi License
Agreement and, subject to the occurrence of the First Milestone Closing Date, Section 6.8 of the Vifor License Agreement,
as the case may be. From time to time, but not more frequently than once per calendar year, the Purchaser may request the
Seller to, and the Seller shall, cause an inspection or audit of any Counterparty’s books and records in respect of the
Purchased Royalties to be conducted pursuant to and in accordance with Section 6.10 of the Maruishi License Agreement
and, subject to the occurrence of the First Milestone Closing Date, Section 6.8 of the Vifor License Agreement, as the case
may be. For the purposes of exercising the Purchaser’s rights pursuant to this Section 5.7(a) in respect of the Maruishi
License Agreement or the Vifor License Agreement, if applicable, the Seller shall appoint such public accounting firm of
nationally recognized standing as the Purchaser shall select for such purpose (it being understood and agreed that any such
public accounting firm shall, pursuant to Section 6.10 of the Maruishi License Agreement and Section 6.8 of the Vifor
License Agreement, if applicable, be reasonably acceptable to Maruishi or Vifor, respectively). The Seller and the Purchaser
agree that all of the expenses of, and amounts payable to Maruishi or Vifor, as the case may be, as a result of any inspection
or audit carried out at the request of the Purchaser pursuant to this Section 5.7(a) that would otherwise be borne by the Seller
pursuant to the applicable License Agreement shall instead be borne by the Purchaser and reimbursed to the Seller promptly
on demand, including such reasonable fees and expenses of such public accounting firm as are to be borne by the Seller
pursuant to Section 6.10 of the Maruishi License Agreement and Section 6.8 of the Vifor License Agreement, as the case
may be, together with the Seller’s out-of-pocket costs and expenses incurred in connection with such inspection or audit;
provided that the Purchaser shall be reimbursed by the Seller for any such fees and expenses to the extent the Seller is
entitled to receive reimbursement from Maruishi or Vifor, as the case may be; provided, further, that for the avoidance of
doubt, any audit caused by the Seller pursuant to the first sentence of this Section 5.7(a) shall not be deemed to be carried
out at the request of the Purchaser and the Purchaser shall have no obligation to reimburse the Seller, pursuant to this
sentence, for any fees, costs or expenses incurred by the Seller in connection therewith; provided, further, that for the
avoidance of doubt, this Section 5.7(a) shall apply to the Vifor License Agreement only from and after the First Milestone
Closing Date. The Seller shall, to the extent not prohibited by obligations of confidentiality contained in the License
Agreement pursuant to which an inspection or audit in respect of the Purchased Royalties is conducted, promptly (but in no
event later than five (5)
35
Business Days) furnish to the Purchaser any inspection or audit report prepared in connection with such inspection or audit.
(b)
In the event that any inspection or audit conducted pursuant to Section 5.7(a) uncovers that the amounts
actually paid to the Purchaser for any period in respect of the Purchased Royalties were greater than the amounts that should
have been paid to the Purchaser for such period in respect of the Purchased Royalties, the Purchaser shall cause the amount
of such overpayment to be paid to the applicable Counterparty promptly (but in no event later than three (3) Business Days)
after delivery to the Purchaser, pursuant to Section 5.7(a), of the applicable inspection or audit report or certificate, as the
case may be, showing such overpayment. In the event that any inspection or audit conducted pursuant to Section 5.7(a)
uncovers that the amounts actually paid to the Purchaser for any period in respect of the Purchased Royalties were less than
the amounts that should have been paid to the Purchaser for such period in respect of the Purchased Royalties, the Seller
shall cooperate and provide assistance as reasonably requested by the Purchaser to cause the amount of such underpayment
to be paid to the Purchaser by the applicable Counterparty in accordance with the timeframe set forth in the applicable
License Agreement promptly after delivery to the Purchaser, pursuant to Section 5.7(a), of the applicable inspection or audit
report or certificate, as the case may be, showing such underpayment.
Section 5.8
Tax Matters.
(a)
All payments to the Purchaser under this Purchase and Sale Agreement shall be made without any deduction
or withholding for or on account of any Tax unless required by Applicable Law; provided that if any deduction or
withholding for or on account of any Purchaser Indemnified Tax is required by Applicable Law to be made, and is made, by
any applicable withholding agent in respect of any payment to the Purchaser under this Purchase and Sale Agreement, then
the Seller shall, within five (5) Business Days after such deduction or withholding is made, make a payment to the Purchaser
so that, after all such required deductions and withholdings are made by any applicable withholding agent (including any
deductions and withholdings required with respect to any additional payments under this Section 5.8(a)), the Purchaser
receives an amount equal to the amount that it would have received had no withholding of such Purchaser Indemnified Taxes
been made.
(b)
The Seller shall notify the Purchaser in writing promptly (but in no event later than five (5) Business Days)
following the receipt of any written notification by any Counterparty or by an Affiliate of such Counterparty that such
Counterparty intends to make any Permitted Tax Withholding. The Parties shall cooperate reasonably and in good faith to
reduce or eliminate any such Permitted Tax Withholding, including by providing to the applicable withholding agent
certificates and such other information that is necessary to establish an exemption or reduction from such Permitted Tax
Withholding that the payee is legally eligible to deliver. In addition, the Seller shall, upon the reasonable request of the
Purchaser and at the Purchaser’s expense, reasonably cooperate with the Purchaser and use its commercially reasonable
efforts to make such filings and take such other actions as may be reasonably necessary and specified by the Purchaser in
order to allow an exemption from or reduction of any Permitted Tax Withholding.
(c)
The Parties agree not to take any position that is inconsistent with the provisions of Section 2.1(b) on any
Tax return or in any Tax audit or other administrative or judicial proceeding unless required by Applicable Law or the good
faith resolution of a tax audit or other tax proceeding. If there is an inquiry by any Governmental Authority of the Seller or
the Purchaser related to the treatment described in Section 2.1(b), the Parties shall cooperate with each other in responding to
such inquiry in a commercially reasonable manner that is consistent with Section 2.1(b).
Section 5.9
Existence. The Seller shall (a) preserve and maintain its existence (provided, however, that nothing
in this Section 5.9 shall prohibit the Seller from entering into any merger or consolidation
36
with, or selling or otherwise transferring all or substantially all of its assets to, any other Person if the Seller is the continuing
or surviving entity or if the surviving or continuing or acquiring entity assumes (either expressly or by operation of law) all
of the obligations of the Seller under the Transaction Documents), (b) preserve and maintain its rights, franchises and
privileges unless failure to do any of the foregoing would not reasonably be expected to have a Material Adverse Effect, (c)
qualify and remain qualified in good standing in each jurisdiction where the failure to preserve and maintain such
qualifications would reasonably be expected to have a Material Adverse Effect, including appointing and employing such
agents or attorneys in each jurisdiction where it shall be necessary to take action under this Purchase and Sale Agreement,
and (d) comply with its organizational documents, except, in the case of this clause (d), for any non-compliance that would
not reasonably be expected to have a Material Adverse Effect. The Purchaser acknowledges and agrees (to the maximum
extent permitted under Applicable Law), that it shall not, and shall not cause any other Person to, petition for the bankruptcy
of the Seller.
Section 5.10
Payment Direction Letters. At the Closing, the Seller and the Company shall deliver to Maruishi a
duly executed Payment Direction Letter in accordance with the notice provisions of the Maruishi License Agreement and
also by e-mail (with the Payment Direction Letter attached thereto as a PDF attachment), and such e-mail shall include a
request that Maruishi confirm receipt thereof by e-mail reply. On the First Milestone Closing Date, the Seller and the
Company shall deliver to Vifor a duly executed Payment Direction Letter in accordance with the notice provisions of the
Vifor License Agreement and also by e-mail (with the Payment Direction Letter attached thereto as a PDF attachment), and
such e-mail shall include a request that Vifor confirm receipt thereof by e-mail reply The Seller shall not amend any
Payment Direction Letter or deliver any subsequent payment direction or instruction letter to a Counterparty without the
prior written consent of the Purchaser (not to be unreasonably withheld, conditioned or delayed).
Section 5.11
Additional Covenants of the Seller. The Seller shall:
(a)
only enter into contracts in its own name as a legal entity separate from the owners of its Equity Interests
and from any other Person;
(b)
not commingle its assets with assets of any other Person, except in connection with, and for the limited
purposes of, the Lockbox Account, except to the extent expressly permitted under the Contribution Agreement;
(c)
conduct its business only in its own name and comply with all organizational formalities necessary to
maintain its separate existence, except, in each case, to the extent expressly permitted under the Contribution Agreement;
(d)
maintain separate books and records, showing its assets and liabilities separate and apart from those of any
other person and not have its assets listed on any financial statement of any other person; provided, however, that the Seller’s
assets may be included in consolidated financial statements of the Company in conformity with the applicable provisions of
GAAP (provided that such assets are also listed on the Seller’s own separate balance sheet);
(e)
pay its own liabilities and expenses only out of its own funds; provided that the foregoing shall not prohibit
the payment of liabilities and expenses by the Company on behalf of the Seller so long as such payments are subject to
reimbursement or are otherwise recorded as capital contributions or intercompany loans;
(f)
maintain adequate capital in light of its contemplated business purpose, transactions and liabilities; and
37
(g)
cause the representatives of the Seller to act at all times with respect to the Seller consistently and not in a
manner opposed to the foregoing.
Section 5.12
Amendment to Disclosure Schedule. At least five (5) Business Days prior to the anticipated First
Milestone Closing Date, the Seller shall deliver to the Purchaser amendments to the Disclosure Schedule with respect to any
event or matter which occurs after the Closing Date in respect of a First Milestone Closing Date Representation, if any, or
confirm in writing that the Seller makes no amendments to the Disclosure Schedule in respect of a First Milestone Closing
Date Representation. With respect to any amendment of the Disclosure Schedule (and the underlying events with respect to
such disclosure), if such disclosure and underlying event would constitute or reasonably be expected to result in a Material
Adverse effect, the Purchaser shall have the right to terminate this Agreement with respect to the Vifor Royalties. If the
Purchaser does not exercise its right to terminate this Agreement with respect to the Vifor Royalties within the five (5)
Business Day period preceding the anticipated First Milestone Closing Date, the Purchaser shall be deemed to have waived
such right with respect to such event or matter and the First Milestone Closing Date Representation shall be deemed to have
been qualified as set forth in the amended Disclosure Schedule for purposes of satisfying the conditions to the First
Milestone Closing Date set forth in Section 6.5.
ARTICLE VI
THE CLOSING
Section 6.1
Closing. The closing of the transactions contemplated hereby (the “Closing”) shall take place at
9:00 a.m., Eastern Standard Time, on the date hereof, subject to the conditions set forth in Sections 6.2 and 6.3 being
satisfied (the “Closing Date”) by electronic exchange of signatures, or on such other date, at such other time or at such other
place, in each case as the Parties mutually agree.
Section 6.2
Closing Deliverables of the Seller and the Company. At the Closing, the Seller shall deliver or
cause to be delivered to the Purchaser the following:
(a)
a counterpart signature page to the Closing Date Bills of Sale, each duly executed by the Seller and the
Company, as applicable;
(b)
a counterpart signature page to each of the Maruishi Payment Direction Letter duly executed by each of the
Seller and the Company;
(c)
Purchaser;
an opinion of Cooley LLP, counsel to the Seller, in form and substance reasonably satisfactory to the
(d)
a duly executed certificate of an executive officer of the Seller dated as of the Closing Date and (i) attaching
copies, certified by such officer as true and complete, of (x) the organizational documents of the Seller and (y) resolutions of
the governing body of the Seller authorizing and approving the execution, delivery and performance by the Seller of the
Transaction Documents and the transactions contemplated hereby and thereby, (ii) setting forth the incumbency of the officer
or officers of the Seller who have executed and delivered the Transaction Documents, including therein a signature specimen
of each such officer or officers and (iii) attaching a copy, certified by such officer as true and complete, of a good standing
certificate of the appropriate Governmental Authority of the Seller’s jurisdiction of organization, stating that the Seller is in
good standing under the laws of such jurisdiction;
(e)
Company;
a counterpart signature page to the Contribution Agreement duly executed by each of the Seller and the
38
(f)
Company;
(g)
(h)
a counterpart signature page to the License Agreement duly executed by each of the Seller and the
a counterpart signature page to the Equity Pledge Agreement duly executed by the Company;
UCC-1 financing statements to evidence and perfect the sale, assignment, transfer, conveyance and grant of
the Maruishi Royalties pursuant to Section 2.1 and the back-up security interest granted pursuant to Section 2.1(d); and
(i)
duly executed IRS Form W-9s from each of the Company and the Seller certifying that such Party is a
United States person as defined in Section 7701(a)(30) of the Code and exempt from U.S. federal backup withholding.
Section 6.3
Closing Deliverables of the Purchaser. At the Closing, the Purchaser shall deliver or cause to be
delivered to the Seller the following:
(a)
(b)
(c)
(d)
a counterpart signature page to the Closing Date Bill of Sale – Purchaser, duly executed by the Purchaser;
a counterpart signature page to the Equity Pledge Agreement, duly executed by the Purchaser;
the Initial Closing Payment in accordance with Section 2.2(a);
a duly executed IRS Form W-9 from the Purchaser certifying it is a United States person as defined in
Section 7701(a)(30) of the Code and exempt from U.S. federal backup withholding; and
(e)
a duly executed certificate of an executive officer of the Purchaser dated as of the Closing Date and setting
forth the incumbency of the officer or officers of the Purchaser who have executed and delivered the Transaction Documents
to which the Purchaser is a party, including therein a signature specimen of each such officer or officers.
Section 6.4
Lockbox Account; Account Control Agreement.
(a)
The Seller will establish the Lockbox Account within ten (10) Business Days of the Closing Date for the
purpose of depositing all payments to be made by any Counterparty pursuant to each Covered License Agreement, which
payments shall include all Purchased Royalties payable to the Purchaser pursuant to this Purchase and Sale Agreement.
(b)
[Reserved].
(c)
The Seller shall pay all fees, expenses and charges of the Account Bank pursuant to the terms of the
Account Control Agreement by depositing sufficient funds into the Lockbox Account when such fees, charges and expenses
are due. The Seller agrees that all Purchased Royalties deposited into the Lockbox Account are to be held in trust for the
benefit of the Purchaser, and that the Seller disclaims and waives any claim or interest in such Purchased Royalties, so that
the Purchaser may be assured of receiving the Purchased Royalties owned by the Purchaser.
(d)
Prior to the Royalty Termination Date, the Seller shall have no right to terminate the Lockbox Account
without the Purchaser’s prior written consent.
39
(e)
The Seller hereby grants and pledges to the Purchaser, as security for its obligations created hereunder, a
first priority security interest in and to all of the Seller’s right, title and interest in and the Lockbox Account and all funds
deposited therein.
Section 6.5
First Milestone Closing Conditions. On the First Milestone Closing Date, the Seller shall deliver or
cause to be delivered to the Purchaser the following:
(a)
a counterpart signature page to the First Milestone Closing Date Bills of Sale, each duly executed by the
Seller and the Company, as applicable;
(b)
a counterpart signature page to each of the Vifor Payment Direction Letter duly executed by each of the
Seller and the Company;
(c)
a duly executed certificate of an executive officer of the Seller dated as of the First Milestone Closing Date
and (i) attaching (A) evidence of the First Milestone Event reasonably satisfactory to the Purchaser [***], (ii) certifying that
no Material Adverse Effect shall have occurred and (iii) certifying that the First Milestone Closing Date Representations, as
amended pursuant to Section 5.12, if applicable, are true, correct and complete in all respects;
(d)
UCC-1 financing statements to evidence and perfect the sale, assignment, transfer, conveyance and grant of
the Vifor Royalties pursuant to Section 2.1 and the back-up security interest granted pursuant to Section 2.1(e); and
(e)
Purchaser.
an opinion of Cooley LLP, counsel to the Seller, in form and substance reasonably satisfactory to the
Section 6.6
Second Milestone Closing Conditions. The obligation of the Purchaser to make the Second
Milestone Payment pursuant to Section 2.2(c), shall be subject to the satisfaction of the following conditions, as of the
Second Milestone Closing Date, any of which may be waived by the Purchaser in its sole discretion: (i) the Seller shall have
provided evidence of the Second Milestone Event reasonably satisfactory to the Purchaser; and (ii) no Material Adverse
Effect shall have occurred; and the Seller shall have provided to the Purchaser a certificate dated as of the Second Milestone
Closing Date and executed by an officer of the Seller expressly confirming that this condition has been met.
ARTICLE VII
INDEMNIFICATION
Section 7.1
Indemnification by the Seller. The Seller agrees to indemnify and hold harmless the Purchaser and
its Affiliates and any or all of their respective partners, directors, trustees, officers, managers, employees, members, agents
and controlling persons (each, a “Purchaser Indemnified Party”) harmless from and against, and will pay to each Purchaser
Indemnified Party the amount of, any and all Losses awarded against or incurred or suffered by such Purchaser Indemnified
Party, whether or not involving a Third Party Claim, arising out of (a) any breach of any representation or warranty made by
the Seller or the Company in any of the Transaction Documents or in any certificate delivered by the Seller or the Company
to the Purchaser in writing pursuant to this Purchase and Sale Agreement, (b) any breach of or default under any covenant or
agreement of the Seller or the Company in any of the Transaction Documents or License Agreements, (c) any Excluded
Liabilities and Obligations or (d) any brokerage or finder’s fees or commissions or similar amounts incurred or owed by the
Seller or the Company to any brokers, financial advisors or comparable other Persons retained or employed by it in
connection with the transactions contemplated by this Purchase and Sale Agreement. Any amounts due to any Purchaser
Indemnified Party hereunder shall be payable by the Seller to such Purchaser Indemnified Party upon demand.
40
Section 7.2
Indemnification by the Purchaser. The Purchaser agrees to indemnify and hold each of the Seller
and its Affiliates and any or all of their respective partners, directors, officers, managers, members, employees, agents and
controlling Persons (each, a “Seller Indemnified Party”) harmless from and against, and will pay to each Seller Indemnified
Party the amount of, any and all Losses awarded against or incurred or suffered by such Seller Indemnified Party, whether or
not involving a Third Party Claim, arising out of (a) any breach of any representation or warranty made by the Purchaser in
any of the Transaction Documents or any certificate delivered by the Purchaser to the Seller in writing pursuant to this
Purchase and Sale Agreement, (b) any breach of or default under any covenant or agreement of the Purchaser in any
Transaction Document to which the Purchaser is a party or (c) any brokerage or finder’s fees or commissions or similar
amounts incurred or owed by the Purchaser to any brokers, financial advisors or comparable other Persons retained or
employed by it in connection with the transactions contemplated by this Purchase and Sale Agreement. Any amounts due to
any Seller Indemnified Party hereunder shall be payable by the Purchaser to such Seller Indemnified Party upon demand.
Section 7.3
Procedures for Third Party Claims. If any Third Party Claim shall be brought or alleged against an
indemnified party in respect of which indemnity is to be sought against an indemnifying party pursuant to Section 7.1 or
Section 7.2, the indemnified party shall, promptly after receipt of notice of the commencement of such Third Party Claim,
notify the indemnifying party in writing of the commencement thereof, enclosing a copy of all papers served, if any;
provided that the omission to so notify such indemnifying party will not relieve the indemnifying party from any liability
that it may have to any indemnified party under Section 7.1 or Section 7.2 unless, and only to the extent that, the
indemnifying party is actually prejudiced by such omission. In the event that any Third Party Claim is brought against an
indemnified party and it notifies the indemnifying party of the commencement thereof in accordance with this Section 7.3,
the indemnifying party will be entitled, at the indemnifying party’s sole cost and expense, to participate therein and, to the
extent that it may wish, to assume the defense thereof, with counsel reasonably satisfactory to such indemnified party (who
shall not, except with the consent of the indemnified party, be counsel to the indemnifying party), and, after notice from the
indemnifying party to such indemnified party of its election so to assume the defense thereof, the indemnifying party will
not be liable to such indemnified party under this ARTICLE VII for any legal or other expenses subsequently incurred by
such indemnified party in connection with the defense thereof other than reasonable costs of investigation. In any such
Third Party Claim, an indemnified party shall have the right to retain its own counsel, but the reasonable fees and expenses
of such counsel shall be at the sole cost and expense of such indemnified party unless (a) the indemnifying party and the
indemnified party shall have mutually agreed to the retention of such counsel, (b) the indemnifying party has assumed the
defense of such proceeding and has failed within a reasonable time to retain counsel reasonably satisfactory to such
indemnified party or (c) the named parties to any such Third Party Claim (including any impleaded parties) include both the
indemnifying party and the indemnified party and representation of both parties by the same counsel would be inappropriate
due to actual or potential conflicts of interests between them based on the advice of counsel to the indemnified party. It is
agreed that the indemnifying party shall not, in connection with any Third Party Claim or related proceedings in the same
jurisdiction, be liable for the reasonable fees and expenses of more than one separate law firm (in addition to local counsel
where necessary) for all such indemnified parties. The indemnifying party shall not be liable for any settlement of any Third
Party Claim effected without its written consent, but, if settled with such consent or if there be a final judgment for the
plaintiff, the indemnifying party agrees to indemnify the indemnified party from and against any Loss by reason of such
settlement or judgment. No indemnifying party shall, without the prior written consent of the indemnified party, effect any
settlement, compromise or discharge of any pending or threatened Third Party Claim in respect of which any indemnified
party is or could have been a party and indemnity could be sought hereunder by such indemnified party, unless such
settlement, compromise or discharge, as the case may be, (i) includes an unconditional, full written release of such
indemnified party, in form and substance reasonably satisfactory to the indemnified party, from all liability on claims that are
the subject matter of such claim or proceeding, (ii) does not include any statement as to an admission of fault, culpability or
failure to act
41
by or on behalf of any indemnified party and (iii) does not impose any continuing obligations or restrictions other than
customary and reasonable confidentiality obligations relating to such claim, settlement or compromise.
Section 7.4
Other Claims. A claim by an indemnified party under this ARTICLE VII for any matter not
involving a Third Party Claim and in respect of which such indemnified party would be entitled to indemnification
hereunder may be made by delivering, in good faith, a written notice of demand to the indemnifying party, which notice
shall contain (a) a description and the amount of any Losses incurred or suffered or reasonably expected to be incurred or
suffered by the indemnified party, (b) a statement that the indemnified party is entitled to indemnification under this
ARTICLE VII for such Losses and a reasonable explanation of the basis therefor, and (c) a demand for payment in the
amount of such Losses. For all purposes of this Section 7.4, the Seller shall be entitled to deliver such notice of demand to
the Purchaser on behalf of the Seller Indemnified Parties, and the Purchaser shall be entitled to deliver such notice of
demand to the Seller on behalf of the Purchaser Indemnified Parties.
Section 7.5
Survival. All representations, warranties and covenants made in this Purchase and Sale Agreement,
in any other Transaction Document or in any certificate delivered pursuant to this Purchase and Sale Agreement shall
survive the execution and delivery of this Purchase and Sale Agreement and the Closing. The rights hereunder to
indemnification, payment of Losses or other remedies based on any such representation, warranty or covenant shall not be
affected by any investigation conducted with respect to, or any knowledge acquired (or capable of being acquired) at any
time (whether before or after the execution and delivery of this Purchase and Sale Agreement or the Closing) in respect of
the accuracy or inaccuracy of or compliance with, any such representation, warranty or covenant.
Section 7.6
Remedies. Except in the case of actual fraud, intentional misrepresentation, intentional wrongful
acts, intentional breach, bad faith or willful misconduct and except as set forth in Section 10.2 or in the other Transaction
Documents, (a) the indemnification afforded by this ARTICLE VII shall be the sole and exclusive remedy for any and all
Losses awarded against or incurred or suffered by a Party in connection with any breach of any representation or warranty
made by a Party in any of the Transaction Documents or any certificate delivered by a Party to the other Party in writing
pursuant to this Purchase and Sale Agreement or any breach of or default under any covenant or agreement by a Party
pursuant to any Transaction Document and (b) the Purchaser acknowledges and agrees that the Purchaser, together with its
Affiliates and representatives, has made its own investigation of the Purchased Royalties and the Transferred Assets and the
transactions contemplated by the Transaction Documents and is not relying on, and shall have no remedies in respect of, any
implied warranties or upon any representation or warranty whatsoever as to the future amount or potential amount of the
Purchased Royalties, or as to the creditworthiness of any Counterparty (or any of their respective Affiliates).
Section 7.7
Limitations. Notwithstanding anything in this Purchase and Sale Agreement to the contrary, (a) in
no event shall any Seller Indemnified Party or the Purchaser Indemnified Party have any liability for, or Losses be deemed to
include, any special, punitive or exemplary damages, or any lost profits, whether in contract or tort, regardless of whether the
other Party shall be advised, shall have reason to know, or in fact shall know of the possibility of such damages suffered or
incurred by any such Seller Indemnified Party or the Purchaser Indemnified Party in connection with this Purchase and Sale
Agreement any of the other Transaction Documents or any of the transactions contemplated hereby or thereby, except to the
extent any such damages are actually paid to a Third Party in accordance with Section 7.3 and (b) the Seller’s aggregate
liability under Section 7.1 shall in no event exceed an amount equal to (1) the Hard Cap Amount, minus (2) the Total Net
Amount, minus (3) the aggregate amount collected or received by the Purchaser (and any direct or indirect transferee of the
Purchaser to whom any interest in the Purchased Royalties is transferred) pursuant to the exercise of its rights under Section
7.1 (without duplication of any amounts received pursuant to clause (2)). Notwithstanding the foregoing, the limitations set
forth in this Section 7.7
42
shall not apply to any claim for indemnification hereunder in the case of actual fraud, intentional misrepresentation,
intentional wrongful acts, intentional breach, bad faith or willful misconduct. The Parties acknowledge and agree that (a) the
Purchaser’s Losses, if any, for any indemnifiable events under this Purchase and Sale Agreement will typically include
Losses for Purchased Royalties that the Purchaser was entitled to receive in respect of its ownership of the Purchased
Royalties but did not receive timely or at all due to such indemnifiable event and (b) subject to this Section 7.7, the
Purchaser shall be entitled to make indemnification claims for all such missing or delayed Purchased Royalties that the
Purchaser was entitled to receive in respect of its ownership of the Purchased Royalties as Losses hereunder (which claims
shall be reviewed and assessed by the Parties in accordance with the procedures set forth in this ARTICLE VII), and such
missing or delayed Purchased Royalties shall not be deemed special, punitive or exemplary damages, or lost profits for any
purpose of this Purchase and Sale Agreement.
Section 7.8
Tax Treatment of Indemnification Payments. For all purposes hereunder, any indemnification
payments made pursuant to this ARTICLE VII will be treated as an adjustment to the Investment Amount for all Tax
purposes to the fullest extent permitted by Applicable Law.
ARTICLE VIII
CONFIDENTIALITY
Section 8.1
Confidentiality. Except as provided in this ARTICLE VIII or otherwise agreed in writing by the
Parties, the Parties agree that, during the term of this Purchase and Sale Agreement and until the tenth (10th) anniversary of
the date of termination of this Purchase and Sale Agreement, each Party (the “Receiving Party”) shall keep confidential, and
shall not publish or otherwise disclose and shall not use for any purpose other than as provided for in this Purchase and Sale
Agreement (which includes the exercise of any rights or the performance of any obligations hereunder), any information
(whether written or oral, or in electronic or other form) furnished to it by or on behalf of the other Party (the “Disclosing
Party”) pursuant to the Existing Confidentiality Agreement or this Purchase and Sale Agreement, including the terms of this
Purchase and Sale Agreement (such information, “Confidential Information” of the Disclosing Party), except for that portion
of such information that:
(a)
was already in the Receiving Party’s possession on a non-confidential basis prior to its disclosure to it by the
Disclosing Party, or becomes known to the Receiving Party from a source other than the Disclosing Party and its
representatives without any breach of this Purchase and Sale Agreement, in each case as evidenced by written records
(provided that if such information was disclosed to the Receiving Party on a non-confidential basis by a source that is not the
Disclosing Party, such source to the knowledge of the Receiving Party had the right to disclose such information to the
Receiving Party without any legal, contractual or fiduciary obligation to, any person with respect to such information);
(b)
is or becomes generally available to the public other than as a result of an act or omission by the Receiving
Party or its Affiliates in breach of this Purchase and Sale Agreement; or
(c)
was independently developed by the Receiving Party, as evidenced by written records, without use of or
reference to the Confidential Information or in violation of the terms of this Purchase and Sale Agreement.
Section 8.2
Termination of Confidentiality Agreement. Effective upon the date hereof, the Existing
Confidentiality Agreement shall terminate and be of no further force or effect, and shall be superseded by the provisions of
this Article VIII.
Section 8.3
Permitted Disclosure. In the event that the Receiving Party or its Affiliates or any of its or its
Affiliates’ representatives are requested by a governmental or regulatory authority or required
43
by Applicable Law, regulation or legal process (including the regulations of a stock exchange or governmental or regulatory
authority or the order or ruling of a court, administrative agency or other government or regulatory body of competent
jurisdiction) to disclose any Confidential Information, the Receiving Party shall promptly, to the extent permitted by
Applicable Law, notify the Disclosing Party in writing of such request or requirement so that the Disclosing Party may seek
an appropriate protective order or other appropriate remedy (and if the Disclosing Party seeks such an order or other remedy,
the Receiving Party will provide such cooperation, at the Receiving Party’s sole expense, as the Disclosing Party shall
reasonably request). If no such protective order or other remedy is obtained and the Receiving Party or its Affiliates or its or
its Affiliates’ representatives are, in the view of their respective counsel (which may include their respective internal
counsel), legally required to disclose Confidential Information, the Receiving Party or its Affiliates or its or its Affiliates’
representatives, as the case may be, shall only disclose that portion of the Confidential Information that their respective
counsel advises that the Receiving Party or its Affiliates or its or its Affiliates’ representatives, as the case may be, are
required to disclose and will exercise commercially reasonable efforts, at the Disclosing Party’s sole expense, to obtain
reliable assurance that confidential treatment will be accorded to that portion of the Confidential Information that is being
disclosed. In any event, the Receiving Party will not oppose action by the Disclosing Party to obtain an appropriate
protective order or other reliable assurance that confidential treatment will be accorded the Confidential Information.
Notwithstanding the foregoing, notice to the Disclosing Party shall not be required where disclosure is made (i) in response
to a request by a governmental or regulatory authority having competent jurisdiction over the Receiving Party, its Affiliates
or its or its Affiliates’ representatives, as the case may be, or (ii) in connection with a routine examination by a regulatory
examiner, where in each case such request or examination does not expressly reference the Disclosing Party, its Affiliates,
the Purchased Royalties or this Purchase and Sale Agreement. The Receiving Party may disclose Confidential Information
to its Affiliates, its and their employees, directors, officers, contractors, agents, and representatives, and to potential or actual
acquirers, merger partners, permitted assignees, investment bankers, investors, limited partners, partners, lenders, or other
financing sources (including, in the case of the Seller, any party evaluating the acquisition of any portion of the Purchased
Royalties that are not included in the Purchased Royalties), and their respective directors, employees, contractors and agents;
provided that such person or entity agrees to confidentiality and non-use obligations with respect thereto at least as stringent
as those specified for in this Article VIII. Further, notwithstanding anything contained in this Article VIII to the contrary,
the Seller may disclose Confidential Information to the extent such disclosure is reasonably necessary to comply with the
Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, or with any rule, regulation or legal
process promulgated by the SEC or a stock exchange, subject to the Seller’s obligations set forth in Section 5.2.
Section 8.4 Other Relevant Obligations. In addition to, and without limiting, the Purchaser’s obligations under
this Article VIII, the Purchaser shall fully comply with any confidentiality obligations of the Seller or any of its Affiliates
under the Maruishi License Agreement and the Vifor License Agreement that are applicable to the Confidential Information.
ARTICLE IX
TERMINATION
Section 9.1
Termination of Agreement. This Purchase and Sale Agreement shall terminate on the earlier of (a)
the Royalty Termination Date and (b) mutual written agreement of the Purchaser and the Seller.
Section 9.2
Effect of Termination. Upon the termination of this Purchase and Sale Agreement pursuant to
Section 9.1, this Purchase and Sale Agreement shall become void and of no further force and effect; provided, however, that
(a) the provisions of Section 5.2, ARTICLE VII, ARTICLE VIII, this ARTICLE IX and ARTICLE X shall survive such
termination and shall remain in full force and effect, (b)
44
if, upon the termination of this Purchase and Sale Agreement, any Purchased Royalties or other amounts are payable to the
Purchaser, this Purchase and Sale Agreement shall remain in full force and effect until any and all such payments have been
made in full, and (except as provided in this Section 9.2) solely for that purpose, and (c) nothing contained in this Section
9.2 shall relieve any Party from liability for any breach of this Purchase and Sale Agreement that occurs prior to termination.
ARTICLE X
MISCELLANEOUS
Section 10.1
Specific Performance. Each Party acknowledges and agrees that, if it fails to perform any of its
obligations under any of the Transaction Documents, the other Parties will have no adequate remedy at law. In such event,
each Party agrees that the other Parties shall have the right, in addition to any other rights it may have (whether at law or in
equity), to specific performance of this Purchase and Sale Agreement.
Section 10.2
Notices. All notices, consents, waivers and other communications hereunder shall be in writing and
shall be effective (a) upon receipt when sent by registered or certified mail, return receipt requested, postage prepaid, with
such receipt to be effective the date of delivery indicated on the return receipt, (b) upon receipt when sent by an overnight
courier (costs prepaid and receipt requested), (c) on the date personally delivered to an authorized officer of the Party to
which sent or (d) on the date transmitted by e-mail with a confirmation of receipt, addressed to the recipient as follows:
if to the Seller, to:
CARA ROYALTY SUB, LLC
c/o Cara Therapeutics, Inc.
4 Stamford Plaza
107 Elm Street, 9th Floor
Stamford, CT 06902
Attention: Chief Executive Officer; General Counsel
Email: [***]
with a copy to (which shall not constitute notice):
Cooley LLP
1299 Pennsylvania Avenue, NW, Suite 700
Washington, DC 20004
Attention: Michael Tollini
Email: [***]
if to the Purchaser, to:
300 Atlantic Street, Suite 600
Stamford, CT 06901
Attention: Clarke Futch
Email: clarke.futch@hcroyalty.com
with copy to (which shall not constitute notice):
300 Atlantic Street, Suite 600
Stamford, CT 06901
45
Attention: Timothy Bryant; Anthony Rapsomanikis
Email: tim.bryant@hcrx.com; anthony.rapsomanikis@hcrx.com; royalty-legal@hcrx.com
and
Morgan, Lewis & Bockius LLP
1701 Market Street
Philadelphia, PA 19103
Attention: Conor F. Larkin; Andrew R. Mariniello
Email: conor.larkin@morganlewis.com; andrew.mariniello@morganlewis.com
Each Party may, by notice given in accordance herewith to the other Party, designate any further or different address to
which subsequent notices, consents, waivers and other communications shall be sent.
Section 10.3
Successors and Assigns. The Seller shall not be entitled to assign any of its rights or delegate any of
its obligations under this Purchase and Sale Agreement without the prior written consent of the Purchaser, (i) subject to the
proviso in clause (a) of Section 5.9 and (ii) provided that consent shall not be required for an acquisition of all or
substantially all assets of the Seller as contemplated pursuant to the proviso in the second sentence of Section 2.3. The
Purchaser may, without the consent of the Seller, assign any of its rights and delegate any of its obligations under this
Purchase and Sale Agreement without restriction to any entity or entities other than a Competitor; provided that in
connection with any such assignment the Seller shall be provided with an IRS Form W-9 or applicable IRS Form W-8, as
appropriate, with respect to such assignee. Each Party shall give written notice to the other Parties of any assignment
permitted by this Section 10.3 promptly (but in any event within five (5) Business Days) after the occurrence thereof. The
Seller shall be under no obligation to reaffirm any representations, warranties or covenants made in this Purchase and Sale
Agreement or any of the other Transaction Documents or take any other action in connection with any such assignment by
the Purchaser. Any purported assignment of rights or delegation of obligations in violation of this Section 10.3 will be void.
Subject to the foregoing, this Purchase and Sale Agreement will apply to, be binding upon, and inure to the benefit of, the
successors and permitted assigns of the Parties.
Section 10.4
Independent Nature of Relationship. The relationship between the Seller and the Purchaser is solely
that of seller and purchaser, and neither the Seller nor the Purchaser has any fiduciary or other special relationship with the
other Party or any of its Affiliates. This Purchase and Sale Agreement is not a partnership or similar agreement, and nothing
contained herein or in any other Transaction Document shall be deemed to constitute the Seller and the Purchaser as a
partnership, an association, a joint venture or any other kind of entity or legal form for any purposes, including any Tax
purposes. The Parties agree that they shall not take any inconsistent position with respect to such treatment in a filing with
any Governmental Authority.
Section 10.5
Entire Agreement. This Purchase and Sale Agreement, together with the Exhibits and Schedules
hereto and the other Transaction Documents, constitute a complete and exclusive statement of the terms of agreement
between the Parties, and supersede all prior agreements, understandings and negotiations, both written and oral, between the
Parties, with respect to the subject matter of this Purchase and Sale Agreement. No representation, inducement, promise,
understanding, condition or warranty not set forth herein (or in the Exhibits or Schedules hereto or the other Transaction
Documents) has been made or relied upon by any Party.
46
Section 10.6
Governing Law.
(a)
THIS PURCHASE AND SALE AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN
ACCORDANCE WITH THE INTERNAL SUBSTANTIVE LAWS OF THE STATE OF NEW YORK WITHOUT
REFERENCE TO THE RULES THEREOF RELATING TO CONFLICTS OF LAW OTHER THAN SECTION 5-1401 OF
THE GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK, AND THE OBLIGATIONS, RIGHTS AND
REMEDIES OF THE PARTIES HEREUNDER SHALL BE DETERMINED IN ACCORDANCE WITH SUCH LAWS.
(b)
Each Party irrevocably and unconditionally submits, for itself and its property, to the exclusive jurisdiction
of (i) the United States District Court for the Southern District of New York and (ii) the Supreme Court of the State of New
York, Borough of Manhattan, for purposes of any claim, action, suit or proceeding arising out of this Purchase and Sale
Agreement, any of the other Transaction Documents or any of the transactions contemplated hereby or thereby, and agrees
that all claims in respect thereof shall be heard and determined only in such courts. Each Party agrees to commence any
such claim, action, suit or proceeding only in the United States District Court for the Southern District of New York or, if
such claim, action, suit or proceeding cannot be brought in such court for jurisdictional reasons, in the Supreme Court of the
State of New York, Borough of Manhattan, and agrees not to bring any such claim, action, suit or proceeding in any other
court. Each Party hereby waives, and agrees not to assert in any such claim, action, suit or proceeding, to the fullest extent
permitted by Applicable Law, any claim that (i) such Party is not personally subject to the jurisdiction of such courts, (ii)
such Party and such Party’s property is immune from any legal process issued by such courts or (iii) any claim, action, suit
or proceeding commenced in such courts is brought in an inconvenient forum. Each Party agrees that a final judgment in
any such claim, action, suit or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the
judgment or in any other manner provided by Applicable Law. Each Party acknowledges and agrees that this Section
10.6(b) constitutes a voluntary and bargained-for agreement between the Parties.
(c)
The Parties agree that service of process in any claim, action, suit or proceeding referred to in Section
10.6(b) may be served on any Party anywhere in the world, including by sending or delivering a copy of such process to
such Party in any manner provided for the giving of notices in Section 10.2. Nothing in this Purchase and Sale Agreement
will affect the right of any Party to serve process in any other manner permitted by Applicable Law. Each Party waives
personal service of any summons, complaint or other process, which may be made by any other means permitted by New
York law.
Section 10.7 Waiver of Jury Trial. EACH PARTY HERETO HEREBY WAIVES, TO THE FULLEST EXTENT
PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN ANY LEGAL
PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS PURCHASE AND SALE
AGREEMENT, OR THE TRANSACTIONS CONTEMPLATED HEREBY (WHETHER BASED ON CONTRACT, TORT
OR ANY OTHER THEORY). EACH PARTY HERETO (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR
ATTORNEY OF THE OTHER PARTY HERETO HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT THE
OTHER PARTY HERETO WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING
WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTY HERETO HAVE BEEN INDUCED TO
ENTER INTO THIS PURCHASE AND SALE AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL
WAIVERS AND CERTIFICATIONS IN THIS SECTION 10.7.
Section 10.8
Severability. If one or more provisions of this Purchase and Sale Agreement are held to be invalid
or unenforceable by a court of competent jurisdiction, such provision shall be excluded from this Purchase and Sale
Agreement and the balance of this Purchase and Sale Agreement shall be interpreted as if such provision were so excluded
and shall remain in full force and effect and be enforceable
47
in accordance with its terms. Any provision of this Purchase and Sale Agreement held invalid or unenforceable only in part
or degree by a court of competent jurisdiction shall remain in full force and effect to the extent not held invalid or
unenforceable.
Section 10.9
Counterparts. This Purchase and Sale Agreement may be signed in any number of counterparts,
each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same
instrument. This Purchase and Sale Agreement shall become effective when each Party shall have received a counterpart
hereof signed by the other Party. Any counterpart may be executed by facsimile or other similar means of electronic
transmission, including “PDF”, and such facsimile or other electronic transmission shall be deemed an original.
Section 10.10 Amendments; No Waivers. Neither this Purchase and Sale Agreement nor any term or provision
hereof may be amended, supplemented, restated, waived, changed or modified except with the written consent of the Parties.
No failure or delay by any Party in exercising any right, power or privilege hereunder shall operate as a waiver thereof nor
shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right,
power or privilege. No notice to or demand on any Party in any case shall entitle it to any notice or demand in similar or
other circumstances. No waiver or approval hereunder shall, except as may otherwise be stated in such waiver or approval,
be applicable to subsequent transactions. No waiver or approval hereunder shall require any similar or dissimilar waiver or
approval thereafter to be granted hereunder. The rights and remedies herein provided shall be cumulative and not exclusive
of any rights or remedies provided by Applicable Law.
Section 10.11 No Third Party Rights. Other than the Parties, no Person will have any legal or equitable right,
remedy or claim under or with respect to this Purchase and Sale Agreement or any of the other Transaction Documents.
This Purchase and Sale Agreement may be amended or terminated, and any provision of this Purchase and Sale Agreement
may be waived, without the consent of any Person who is not a Party. The Seller shall enforce any legal or equitable right,
remedy or claim under or with respect to this Purchase and Sale Agreement for the benefit of the Seller Indemnified Parties
and the Purchaser shall enforce any legal or equitable right, remedy or claim under or with respect to this Purchase and Sale
Agreement for the benefit of the Purchaser Indemnified Parties.
Section 10.12 Table of Contents and Headings. The Table of Contents and headings of the Articles and Sections
of this Purchase and Sale Agreement have been inserted for convenience of reference only, are not to be considered a part
hereof and shall in no way modify or restrict any of the terms or provisions hereof.
{SIGNATURE PAGE FOLLOWS}
48
IN WITNESS WHEREOF, the Parties have executed this Purchase and Sale Agreement as of the day and year first
written above.
SELLER:
CARA ROYALTY SUB, LLC, a Delaware limited liability
company
By: /s/ Christopher Posner
Name: Christopher Posner
Title: Chief Executive Officer
[Signature Page to Purchase and Sale Agreement]
PURCHASER:
HCRX INVESTMENTS HOLDCO, L.P.
By: HCRX Master GP, LLC, its general partner
By: /s/ Clarke B. Futch
Name: Clarke B. Futch
Title: Chairman and Chief Executive Officer
HEALTHCARE ROYALTY PARTNERS IV, L.P.
By: HealthCare Royalty GP IV, LLC, its general partner
By: /s/ Clarke B. Futch _
Name: Clarke B. Futch
Title: Managing Partner
Subsidiaries of Cara Therapeutics, Inc.
Exhibit 21.1
Name of Subsidiary
Cara Royalty Sub, LLC
Jurisdiction of Incorporation
Delaware
EXHIBIT 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following Registration Statements:
(1) Registration Statement (Form S-3 No. 333-263165) of Cara Therapeutics, Inc.
(2) Registration Statement (Form S-8 No. 333-270302) of Cara Therapeutics, Inc., pertaining to the 2014 Equity
Incentive Plan of Cara Therapeutics, Inc.
(3) Registration Statement (Form S-8 No. 333-263159) of Cara Therapeutics, Inc., pertaining to the 2014 Equity
Incentive Plan of Cara Therapeutics, Inc.
(4) Registration Statement (Form S-8 No. 333-253714) of Cara Therapeutics, Inc., pertaining to the 2014 Equity
Incentive Plan of Cara Therapeutics, Inc.
(5) Registration Statement (Form S-8 No. 333-236728) of Cara Therapeutics, Inc., pertaining to the 2014 Equity
Incentive Plan of Cara Therapeutics, Inc.
(6) Registration Statement (Form S-8 No. 333-234800) of Cara Therapeutics, Inc., pertaining to the Cara
Therapeutics, Inc. 2019 Inducement Plan
(7) Registration Statement (Form S-8 No. 333-230335) of Cara Therapeutics, Inc., pertaining to the 2014 Equity
Incentive Plan of Cara Therapeutics, Inc.
(8) Registration Statement (Form S-8 No. 333-223726) of Cara Therapeutics, Inc., pertaining to the 2014 Equity
Incentive Plan of Cara Therapeutics, Inc.
(9) Registration Statement (Form S-8 No. 333-216606) of Cara Therapeutics, Inc., pertaining to the 2014 Equity
Incentive Plan of Cara Therapeutics, Inc.
(10) Registration Statement (Form S-8 No. 333-210096) of Cara Therapeutics, Inc., pertaining to the 2014 Equity
Incentive Plan of Cara Therapeutics, Inc.
(11) Registration Statement (Form S-8 No. 333-203057) of Cara Therapeutics, Inc., pertaining to the 2014 Equity
Incentive Plan of Cara Therapeutics, Inc., and
(12) Registration Statement (Form S-8 No. 333-193905) pertaining to the 2004 Stock Incentive Plan, as amended,
and 2014 Equity Incentive Plan;
of our reports dated March 6, 2024, with respect to the financial statements of Cara Therapeutics, Inc. and the
effectiveness of internal control over financial reporting of Cara Therapeutics, Inc. included in this Annual Report
(Form 10-K) of Cara Therapeutics, Inc., for the year ended December 31, 2023.
/s/ Ernst & Young LLP
Stamford, Connecticut
March 6, 2024
EXHIBIT 31.1
Certification of Chief Executive Officer Pursuant to
Rule 13a-14(a) under the Securities Exchange Act
of 1934, as Adopted Pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002
I, Christopher Posner, certify that:
1. I have reviewed this Annual Report on Form 10-K of Cara Therapeutics, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as
defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules
13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known
to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such
evaluation; and
(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the
registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially
affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent
functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information;
and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's
internal control over financial reporting.
Date: March 6, 2024
By:/s/ Christopher Posner
CHRISTOPHER POSNER
CHIEF EXECUTIVE OFFICER
(Principal Executive Officer)
EXHIBIT 31.2
Certification of Chief Financial Officer Pursuant to
Rule 13a-14(a) under the Securities Exchange Act
of 1934, as Adopted Pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002
I, Ryan Maynard, certify that:
1. I have reviewed this Annual Report on Form 10-K of Cara Therapeutics, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as
defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules
13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known
to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such
evaluation; and
(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the
registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially
affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent
functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information;
and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's
internal control over financial reporting.
Date: March 6, 2024
By:
/s/ Ryan Maynard
RYAN MAYNARD
CHIEF FINANCIAL OFFICER
(Principal Financial Officer)
CERTIFICATIONS OF
CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
OF CARA THERAPEUTICS, INC.
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002
EXHIBIT 32.1
In connection with the Annual Report on Form 10-K of Cara Therapeutics, Inc. (the "Company") for the year ended December 31,
2023, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), Christopher Posner, Chief Executive
Officer of the Company, and Ryan Maynard, Chief Financial Officer of the Company, each hereby certifies, pursuant to the requirement
set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and Section 1350 of Chapter 63 of
Title 18 of the United States Code (18 U.S.C. §1350), that, to the best of his knowledge, based upon a review of the Report:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.
/s/ CHRISTOPHER POSNER
Name: Christopher Posner
Title: Chief Executive Officer
(Principal Executive Officer)
Date: March 6, 2024
/s/ RYAN MAYNARD
Name: Ryan Maynard
Title: Chief Financial Officer
(Principal Financial Officer)
Date: March 6, 2024
This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and
is not to be incorporated by reference into any filing of Cara Therapeutics, Inc. under the Securities Act of 1933, as amended, or the
Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general
incorporation language contained in such filing.
CARA THERAPEUTICS, INC.
INCENTIVE COMPENSATION RECOUPMENT POLICY
Exhibit 97
1.
INTRODUCTION
The Board of Directors (the “Board”) of Cara Therapeutics, Inc., a Delaware corporation (the “Company”), has determined that
it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this “Policy”)
providing for the Company’s recoupment of Recoverable Incentive Compensation that is received by Covered Officers of the Company
under certain circumstances. Certain capitalized terms used in this Policy have the meanings given to such terms in Section 3 below.
This Policy is designed to comply with, and shall be interpreted to be consistent with, Section 10D of the Exchange Act, Rule
10D-1 promulgated thereunder (“Rule 10D-1”) and Nasdaq Listing Rule 5608 (the “Listing Standards”).
2.
EFFECTIVE DATE
This Policy shall apply to all Incentive Compensation that is received by a Covered Officer on or after October 2, 2023 (the
“Effective Date”). Incentive Compensation is deemed “received” in the Company’s fiscal period in which the Financial Reporting
Measure specified in the Incentive Compensation award is attained, even if the payment or grant of such Incentive Compensation occurs
after the end of that period.
3.
DEFINITIONS
“Accounting Restatement” means an accounting restatement that the Company is required to prepare due to the material
noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting
restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or
that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period.
“Accounting Restatement Date” means the earlier to occur of (a) the date that the Board, a committee of the Board authorized
to take such action, or the officer or officers of the Company authorized to take such action if Board action is not required, concludes, or
reasonably should have concluded, that the Company is required to prepare an Accounting Restatement, or (b) the date that a court,
regulator or other legally authorized body directs the Company to prepare an Accounting Restatement.
“Administrator” means the Compensation Committee or, in the absence of such committee, the Board.
“Code” means the U.S. Internal Revenue Code of 1986, as amended, and the regulations promulgated thereunder.
“Compensation Committee” means the Compensation Committee of the Board.
“Covered Officer” means each current and former Executive Officer.
“Exchange” means the Nasdaq Stock Market.
“Exchange Act” means the U.S. Securities Exchange Act of 1934, as amended.
“Executive Officer” means the Company’s president, principal financial officer, principal accounting officer (or if there is no
such accounting officer, the controller), any vice-president of the Company in charge of a principal business unit, division, or function
(such as sales, administration, or finance), any other officer who performs a policy-making function, or any other person who performs
similar policy-making functions for the Company. Executive officers of the Company’s parent(s) or subsidiaries are deemed executive
officers of the Company if they perform such policy-making functions for the Company. Policy-making function is not intended to
include policy-making functions that are not significant. Identification of an executive officer for purposes of this Policy would include at
a minimum executive officers identified pursuant to Item 401(b) of Regulation S-K promulgated under the Exchange Act.
“Financial Reporting Measures” means measures that are determined and presented in accordance with the accounting
principles used in preparing the Company’s financial statements, and any measures derived wholly or in part from such measures,
including Company stock price and total stockholder return (“TSR”). A measure need not be presented in the Company’s financial
statements or included in a filing with the SEC in order to be a Financial Reporting Measure.
“Incentive Compensation” means any compensation that is granted, earned or vested based wholly or in part upon the
attainment of a Financial Reporting Measure.
“Lookback Period” means the three completed fiscal years immediately preceding the Accounting Restatement Date, as well as
any transition period (resulting from a change in the Company’s fiscal year) within or immediately following those three completed fiscal
years (except that a transition period of at least nine months shall count as a completed fiscal year). Notwithstanding the foregoing, the
Lookback Period shall not include fiscal years completed prior to the Effective Date.
“Recoverable Incentive Compensation” means Incentive Compensation received by a Covered Officer during the Lookback
Period that exceeds the amount of Incentive Compensation that would have been received had such amount been determined based on
the Accounting Restatement, computed without regard to any taxes paid (i.e., on a gross basis without regard to tax withholdings and
other deductions). For any compensation plans or programs that take into account Incentive Compensation, the amount of Recoverable
Incentive Compensation for purposes of this Policy shall include, without limitation, the amount contributed to any notional account
based on Recoverable Incentive Compensation and any earnings to date on that notional amount. For any Incentive Compensation that is
based on stock price or TSR, where the Recoverable Incentive Compensation is not subject to mathematical recalculation directly from
the information in an Accounting Restatement, the Administrator will determine the amount of Recoverable Incentive Compensation
based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or TSR upon which the Incentive
Compensation was received. The Company shall maintain documentation of the determination of that reasonable estimate and provide
such documentation to the Exchange in accordance with the Listing Standards.
“SEC” means the U.S. Securities and Exchange Commission.
4.
RECOUPMENT
(a)
Applicability of Policy. This Policy applies to Incentive Compensation received by a Covered Officer (i) after
beginning services as an Executive Officer, (ii) who served as an Executive Officer at any time during the performance period for such
Incentive Compensation, (iii) while the Company had a class of securities listed on a national securities exchange or a national securities
association, and (iv) during the Lookback Period.
(b)
Recoupment Generally. Pursuant to the provisions of this Policy, if there is an
2
Accounting Restatement, the Company must reasonably promptly recoup the full amount of the Recoverable Incentive Compensation,
unless the conditions of one or more subsections of Section 4(c) of this Policy are met and the Compensation Committee, or, if such
committee does not consist solely of independent directors,1 a majority of the independent directors serving on the Board, has made a
determination that recoupment would be impracticable. Recoupment is required regardless of whether the Covered Officer engaged in
any misconduct and regardless of fault, and the Company’s obligation to recoup Recoverable Incentive Compensation is not dependent
on whether or when any restated financial statements are filed.
(c)
Impracticability of Recovery. Recoupment may be determined to be impracticable if, and only if:
(i)
the direct expense paid to a third party to assist in enforcing this Policy would exceed the amount of the
applicable Recoverable Incentive Compensation; provided that, before concluding that it would be impracticable to recover any
amount of Recoverable Incentive Compensation based on expense of enforcement, the Company shall make a reasonable
attempt to recover such Recoverable Incentive Compensation, document such reasonable attempt(s) to recover, and provide that
documentation to the Exchange in accordance with the Listing Standards; or
(ii)
recoupment of the applicable Recoverable Incentive Compensation would likely cause an otherwise tax-
qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the
requirements of Code Section 401(a)(13) or Code Section 411(a) and regulations thereunder.
(d)
Sources of Recoupment. To the extent permitted by applicable law, the Administrator shall, in its sole discretion,
determine the timing and method for recouping Recoverable Incentive Compensation hereunder, provided that such recoupment is
undertaken reasonably promptly. The Administrator may, in its discretion, seek recoupment from a Covered Officer from any of the
following sources or a combination thereof, whether the applicable compensation was approved, awarded, granted, payable or paid to the
Covered Officer prior to, on or after the Effective Date: (i) direct repayment of Recoverable Incentive Compensation previously paid to
the Covered Officer; (ii) cancelling prior cash or equity-based awards (whether vested or unvested and whether paid or unpaid); (iii)
cancelling or offsetting against any planned future cash or equity-based awards; (iv) forfeiture of deferred compensation, subject to
compliance with Code Section 409A; and (v) any other method authorized by applicable law or contract. Subject to compliance with any
applicable law, the Administrator may effectuate recoupment under this Policy from any amount otherwise payable to the Covered
Officer, including amounts payable to such individual under any otherwise applicable Company plan or program, e.g., base salary,
bonuses or commissions and compensation previously deferred by the Covered Officer. The Administrator need not utilize the same
method of recovery for all Covered Officers or with respect to all types of Recoverable Incentive Compensation.
(e)
No Indemnification of Covered Officers. Notwithstanding any indemnification agreement, applicable insurance
policy or any other agreement or provision of the Company’s certificate of incorporation or bylaws to the contrary, no Covered Officer
shall be entitled to indemnification or advancement of expenses in connection with any enforcement of this Policy by the Company,
including paying or reimbursing such Covered Officer for insurance premiums to cover potential obligations to the
1
Note to Draft: A non-independent compensation committee (e.g., in the case of reliance on a phase-in or controlled company exception) would not be eligible under
the Listing Standards to make the determination as to whether recoupment is impracticable.
3
Company under this Policy.
(f)
Indemnification of Administrator. Any members of the Administrator, and any other members of the Board who
assist in the administration of this Policy, shall not be personally liable for any action, determination or interpretation made with respect
to this Policy and shall be indemnified by the Company to the fullest extent under applicable law and Company policy with respect to
any such action, determination or interpretation. The foregoing sentence shall not limit any other rights to indemnification of the
members of the Board under applicable law or Company policy.
(g)
No “Good Reason” for Covered Officers. Any action by the Company to recoup or any recoupment of Recoverable
Incentive Compensation under this Policy from a Covered Officer shall not be deemed (i) “good reason” for resignation or to serve as a
basis for a claim of constructive termination under any benefits or compensation arrangement applicable to such Covered Officer, or (ii)
to constitute a breach of a contract or other arrangement to which such Covered Officer is party.
5.
ADMINISTRATION
Except as specifically set forth herein, this Policy shall be administered by the Administrator. The Administrator shall have full
and final authority to make any and all determinations required under this Policy. Any determination by the Administrator with respect
to this Policy shall be final, conclusive and binding on all interested parties and need not be uniform with respect to each individual
covered by this Policy. In carrying out the administration of this Policy, the Administrator is authorized and directed to consult with the
full Board or such other committees of the Board as may be necessary or appropriate as to matters within the scope of such other
committee’s responsibility and authority. Subject to applicable law, the Administrator may authorize and empower any officer or
employee of the Company to take any and all actions that the Administrator, in its sole discretion, deems necessary or appropriate to
carry out the purpose and intent of this Policy (other than with respect to any recovery under this Policy involving such officer or
employee).
6.
SEVERABILITY
If any provision of this Policy or the application of any such provision to a Covered Officer shall be adjudicated to be invalid,
illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Policy,
and the invalid, illegal or unenforceable provisions shall be deemed amended to the minimum extent necessary to render any such
provision or application enforceable.
7.
NO IMPAIRMENT OF OTHER REMEDIES
Nothing contained in this Policy, and no recoupment or recovery as contemplated herein, shall limit any claims, damages or
other legal remedies the Company or any of its affiliates may have against a Covered Officer arising out of or resulting from any actions
or omissions by the Covered Officer. This Policy does not preclude the Company from taking any other action to enforce a Covered
Officer’s obligations to the Company, including, without limitation, termination of employment and/or institution of civil proceedings.
This Policy is in addition to the requirements of Section 304 of the Sarbanes-Oxley Act of 2002 (“SOX 304”) that are applicable to the
Company’s Chief Executive Officer and Chief Financial Officer and to any other compensation recoupment policy and/or similar
provisions in any employment, equity plan, equity award, or other individual agreement, to which the Company is a party or which the
Company has adopted or may adopt and maintain from time to time; provided, however, that compensation recouped pursuant to this
Policy shall not be duplicative of compensation recouped pursuant to SOX 304 or any such compensation recoupment policy and/or
similar provisions in any such employment, equity plan, equity award, or other individual agreement except as may be required by law.
4
8.
AMENDMENT; TERMINATION
The Administrator may amend, terminate or replace this Policy or any portion of this Policy at any time and from time to time
in its sole discretion. The Administrator shall amend this Policy as it deems necessary to comply with applicable law or any Listing
Standard.
9.
SUCCESSORS
This Policy shall be binding and enforceable against all Covered Officers and, to the extent required by Rule 10D-1 and/or the
applicable Listing Standards, their beneficiaries, heirs, executors, administrators or other legal representatives.
10.
REQUIRED FILINGS
The Company shall make any disclosures and filings with respect to this Policy that are required by law, including as required
by the SEC.
*
*
*
*
*
5
CARA THERAPEUTICS, INC.
INCENTIVE COMPENSATION RECOUPMENT POLICY
FORM OF EXECUTIVE ACKNOWLEDGMENT
I, the undersigned, agree and acknowledge that I am bound by, and subject to, the Cara Therapeutics, Inc. Incentive Compensation
Recoupment Policy, as may be amended, restated, supplemented or otherwise modified from time to time (the “Policy”). In the event of
any inconsistency between the Policy and the terms of any employment agreement, offer letter or other individual agreement with Cara
Therapeutics, Inc. (the “Company”) to which I am a party, or the terms of any compensation plan, program or agreement, whether or not
written, under which any compensation has been granted, awarded, earned or paid to me, the terms of the Policy shall govern.
In the event that the Administrator (as defined in the Policy) determines that any compensation granted, awarded, earned or paid to me
must be forfeited or reimbursed to the Company pursuant to the Policy, I will promptly take any action necessary to effectuate such
forfeiture and/or reimbursement. I further agree and acknowledge that I am not entitled to indemnification, and hereby waive any right to
advancement of expenses, in connection with any enforcement of the Policy by the Company.
Agreed and Acknowledged:
Name:
Title:
Date: